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ZUSAMMENFASSUNG FÜR LAIEN 
Wenn einem Patienten Medikamente, zum Beispiel für eine Krebstherapie, in die Blutbahn injiziert 
werden, verteilen sie sich im ganzen Körper. Da hierbei allerdings nicht nur Krebszellen, sondern auch 
gesunde Zellen angegriffen werden, können zum Teil schwere Nebenwirkungen entstehen. Um dieses 
Problem zu lösen, versucht man mithilfe von Nanopartikeln die Medikamente gezielt zu ihrem 
Wirkungsort, z.B. dem Tumor, zu dirigieren. Die Kunst dabei ist es, die Nanopartikel so herzustellen, 
dass sie nicht sofort vom Immunsystem als fremdartig erkannt und zerstört werden oder von 
Filtrationsorganen wie der Leber und Niere ausgeschieden werden. Die grundlegende Idee für 
zielgerichtete Medikamente wurde schon vor über hundert Jahren von Paul Ehrlich beschrieben. Nach 
einer langen Zeit der intensiven Grundlagenforschung wurde dann Ende der 90er Jahre das erste auf 
Nanopartikeln basierende Krebsmedikament, namentlich Doxil, von den Behörden zugelassen. Nicht 
erst durch diesen Erfolg erfuhr das Feld der Nanomedizin einen riesigen Aufschwung. Unsummen an 
Forschungsgeldern wurden investiert auf der Suche nach einer neuen und besseren Generation von 
Krebsmedikamenten. Verglichen mit der Anzahl der wissenschaftlichen Publikationen und der darin 
enthaltenen Versprechungen schafften es leider nur relativ wenige Nanomedikamente bis zur 
definitiven Anwendung im Patienten. Dies hat in den letzten Jahren dazu geführt, dass kritische 
Stimmen laut wurden und einige zweifelten bereits an der allgemeinen Anwendbarkeit solcher 
Medikamente. Trotz der zum Teil berechtigten Kritik gibt es immer mehr auf Nanopartikeln basierende 
Medikamente in klinischen Studien (also kurz vor der Zulassung) oder solche, welche bereits 
zugelassen sind. Es wäre also falsch zu behaupten, dass sich das Forschungsfeld in einer grundlegenden 
Krise befände. Nichtsdestotrotz stimmt es, dass die Entwicklung der genauen Zusammensetzung eines 
solchen Nanopartikels extrem schwierig und mühsam ist. Dies hat auch damit zu tun, dass neue 
Nanopartikel in Zellkulturen getestet werden müssen, da eine grosse Anzahl von Tierversuchen in 
Ratten und Mäusen teuer, aufwändig und nicht zuletzt ethisch fragwürdig sind. Allerdings sind 
Zellkulturen nicht fähig, komplexe biologische Vorgänge eines Lebewesens genau darzustellen. Darum 
passiert es oft, dass, basierend auf den Ergebnissen aus Zellkulturstudien, Nanopartikel für weitere 
Experimente in Nagern ausgewählt werden, welche nicht genügend unter realistischen biologischen 
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Bedingungen optimiert werden konnten. Das Ziel dieser Doktorarbeit war es, diese Lücke zwischen 
Zellkultur und Nagetieren zu schliessen. Dafür wurden frühe Entwicklungsstadien des Zebrafisches als 
ideale Lösung identifiziert, da sie gegenüber Versuchen in Nagetieren zahlreiche Vorteile aufweisen. 
Die verwendeten Zebrafischjungtiere sind klein, günstig in der Haltung, extrem gut verfügbar (ca. 200 
Stück pro Zebrafischpaar und Woche) und durchsichtig. Zudem ist keine ausführliche Bewilligung durch 
die Tierversuchsbehörden nötig, da Experimente in diesem Entwicklungsstadium nicht offiziell als 
Tierversuche gelten. In einem ersten Teil dieser Arbeit wurde das neue Zebrafischmodell getestet und 
mit bekannten Daten aus Nagetieren wie Mäusen oder Ratten verglichen. Es wurde gezeigt, dass 
aufgrund der Resultate aus einem Zebrafischversuch tatsächlich Vorhersagen über das Verhalten von 
Nanopartikeln in Wirbeltieren gemacht werden können. Im zweiten Teil dieser Arbeit wurden dann 
direkte Anwendungen am Zebrafischmodell getestet. Dabei war es möglich, neu entwickelte 
Nanopartikel mithilfe des Zebrafisches zu optimieren und unter realistischen biologischen 
Bedingungen zu testen. Aufgrund der erzielten Erfolge werden in Zukunft einige dieser Projekte 
weitergeführt werden, welche unter anderem die Entwicklung eines neuen Nanopartikel basierten 
Medikamentes zur Behandlung von Infektionskrankheiten einschliessen. Zusammenfassend konnte 
gezeigt werden, dass der Zebrafisch vielversprechende Möglichkeiten für die Optimierung von 
Nanopartikeln bietet und hoffentlich in der Lage sein wird, die Anzahl der erfolgreich in Patienten 
eingesetzten Nanomedikamente zu erhöhen. 
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SUMMARY 
Nanomedicines are a valuable option to achieve drug accumulation specifically in diseased cells or 
tissues and therefore reduce side effects. Since the introduction of the revolutionary concept called 
the magic bullet for such sophisticated treatments more than 100 years ago, a lot of hope and 
expectations were placed into the field of nanoparticulate drug delivery. Initial forms of nanoparticles 
such as liposomes were described and extensively characterized which finally resulted in the FDA 
approval of the first cancer nanomedicine, namely Doxil, in 1996. This early success fueled the already 
gold-rush like atmosphere and resulted in a huge amount of time and money invested in nanomedicine 
research and development. As it is often the case for such a much-noticed field of medicinal research, 
the number of approved and clinically applied nanomedicines was not able to keep up with the 
unrealistic expectations resulting from the exponential increase of nanomedicine related publications. 
This triggered a lot of criticism questioning basic principles such as the enhanced permeability and 
retention effect or even the general use of nanomedicines. Despite the fact that the raised points are 
legitimate to a certain degree, the field of nanomedicine is far away from suffering from a general 
crisis, underlined by the steadily (but slowly) increasing number of approved formulations. 
Nevertheless, it cannot be denied that nanomedicine development is a cumbersome process suffering 
from a lot of drop-outs during very early phases of clinical trials. Among other things, this is due to the 
fact that formulation design and optimization is mainly based on in vitro studies, which are not able to 
fully mimic complex biological conditions. Moreover, only a selected number of formulations can 
subsequently be assessed in rodent in vivo experiments, since such studies are expensive, time 
consuming and suffer from ethical concerns. Obviously, there is a huge gap between in vitro cell culture 
and rodent in vivo studies, which makes the selection of potentially successful nanomedicine 
formulations extremely difficult. In addition, this situation does not allow a thorough formulation 
design and optimization under complex biological conditions and hampers a detailed understanding 
of basic nanomedicine interactions with biological environments at a macromolecular level. Therefore, 
this PhD thesis aimed to introduce the zebrafish as a complementary and easy accessible in vivo model 
in order to bridge the gap between in vitro and rodent in vivo studies during nanomedicine 
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development. In the first part (Chapters I-I to III-I), the current nanomedicine development process 
prior to rodent in vivo studies was reviewed and the zebrafish model was set-up, validated, and further 
characterized. Briefly, already described formulation effects on nanomedicine pharmacokinetics were 
reproduced and the predictive power of the zebrafish model system was verified. Thereby, a special 
focus was put on two main nanomedicine clearance mechanisms, namely phagocytosis by 
macrophages as a part of the mononuclear phagocytic system and scavenger receptors expressed on 
cells, which belong to the reticuloendothelial system. Based on the successful completion of the first 
part, the zebrafish model was used for the development of sophisticated nanoparticulate delivery 
systems (Chapter IV). For example, the optimal ligand density for an actively targeted nanoparticle was 
established in the zebrafish model and verified in a subsequent rodent biodistribution experiment. In 
addition, two different nanoparticle-enzyme systems were tested regarding their stability, 
biocompatibility, and functionality in this living biological system, i.e. zebrafish. During this thesis, 
general advantages of the zebrafish model such as large clutch size, optical transparency, availability 
of many transgenic lines, the possibility to screen a large number of formulations, and relatively low 
regulatory requirements became evident. All parameters were adapted to the purpose of 
nanomedicine formulation design and optimization. The promising findings will be further pursued in 
detailed follow-up studies regarding the development of an accurate and quantitative 
pharmacokinetic model, the elucidation of exact formulation dependent nanomedicine cell uptake and 
trafficking mechanisms under in vivo conditions, or to support the formulation design and optimization 
of nanomedicines for infectious diseases. Altogether, the presented zebrafish model showed to be a 
valuable and promising tool for several applications in the field of nanomedicine development and will 
hopefully foster the successful translation of further nanomedicines from bench to bedside. 
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INTRODUCTION 
In 1907, Paul Ehrlich introduced the visionary concept of the magic bullet [1] which marked the 
beginning of a new medicinal concept called targeted drug delivery. In the following decades, drug 
loaded nanoparticles (nanomedicines) made of different materials [2,3] were investigated as 
therapeutic options for several diseases [4], but mainly cancer treatment [5,6]. Based on the discovery 
of liposomes in the early 60’s by Bangham et al. [7], liposomal formulated doxorubicin (Doxil) became 
the first commercially available nanomedicine formulation approved by the FDA in 1995 [8]. Inspired 
by this early success, a lot of hope and expectations were placed into this revolutionary therapeutic 
concept and huge investments in the field of nanomedicine were made. This gold-rush like atmosphere 
resulted in a vast amount of publications, describing the synthesis and characterization of increasingly 
sophisticated nanomedicines. Nevertheless, only a very limited number of these systems showed to 
be useful for any clinical application [9]. In parallel, the enhanced permeability and retention effect 
(EPR), which served as a rational for almost every cancer targeted nanomedicine, was found to be less 
conserved between different cancer types as generally assumed [10]. To this end, a lot of studies were 
able to demonstrate passive accumulation of various long circulating nanomedicines in rodent tumor 
models, but again, only a minority of these formulations were successful in later clinical trials [11,12]. 
Moreover, Wilhelm et al. questioned the general validity of targeted nanomedicines by underlining 
that less than 0.7 % of the administered dose can be found in the targeted tumor [13]. Altogether, 
nanomedicines seem to suffer from a very poor translation from bench to bedside, which affects the 
trust of patients, the healthcare systems, and investors in the research field. On the other hand, the 
picture changes looking at the described concerns from a different angle. Lately, various forms of 
complex targeted or stimuli-responsive nanoparticles for controlled drug release were published in 
increasing numbers of articles [14,15]. However, these systems are highly sophisticated and often 
prepared and characterized under very controlled conditions, which do not reflect any biological 
environment [9]. Being realistic, such systems are often designed and promoted to attract funding and 
to be published in high impact journals rather than to be clinically applied in the near future. This 
negatively affects overall nanomedicine translation to clinics at the first glance. For example, to 
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overcome the issue of heterogenic EPR effect, patient stratification would increase the clinical success. 
This is already done for other therapies such as HER2 receptor positive breast cancer therapy [16]. The 
emerging field of nanoparticle based theranostics could further help to select patients, which will really 
benefit from nanomedicines [17]. Regarding the low targeting efficiency, one could argue that 
antibodies for cancer treatment, which are commercially very successful, do not target tumors more 
efficiently [18]. Interestingly, a slightly increased accumulation in target tissue in parallel to a 
decreased accumulation in off-target tissue can already result in patients’ benefit which justifies the 
application of a nanomedicine formulation. In addition, considering the raising number of 
nanomedicines which are already approved or tested in clinical trials [19] indicates a lot of progress 
which has been made during the last years and does not confirm the picture of a research field 
suffering from a general crisis.  
Nevertheless, progressing to clinical trials is a cumbersome and often difficult venture also originating 
from the up to date unsatisfying nanomedicine development process. Nanomedicines interact 
differently with biological environments such as cells or whole organisms, depending on their 
formulation (i.e. material, surface modifications) and their physicochemical properties (i.e. size, 
surface charge) [20]. Due to the high number of possible combinations, formulation design and 
optimization is usually performed based on empirical knowledge and by using in vitro systems which 
are suitable for screening approaches. Subsequently, a smaller number of formulations is selected and 
subjected to further rodent in vivo studies. This procedure represents a classical drug development 
process and has also become standard for the development process of nanomedicines [21], without 
reflecting their inherent complexity. Obviously, there is a huge gap between cell culture and living 
animals, which makes the selection of promising lead formulations difficult, leading to a lot of 
drop-outs during these early development phases [22]. Altogether, a cost- and time-effective in vivo 
model which can be used to screen large numbers of nanomedicine formulations prior to rodent in 
vivo studies is desperately needed in order to facilitate the optimization and selection of potentially 
successful formulations under complex biological conditions.  
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Caenorhabditis elegans (nematode), Drosophila melanogaster (fruit fly), and Danio rerio (zebrafish) 
are among the most extensively characterized animal models in life sciences. Nematodes and fruit flies 
(invertebrates) can be considered as initial models for developmental biology while zebrafish entered 
this field at a later stage due to the desire to study fundamental biological processes in a vertebrate 
animal model sharing more similarities with mammalians [23,24]. Moreover, chicken embryos 
featuring the relatively easy accessible chorioallontoic membrane (CAM) have been applied in 
biomedical research as tumor models [25], to investigate drug delivery [26], and to assess the toxicity 
of anti-cancer drugs [27]. However, the zebrafish model has many advantageous properties such as 
large clutch size and low husbandry costs making it applicable for screening processes. Furthermore, a 
broad spectrum of established and characterized genetic tools is available [28], allowing the generation 
of transgenic zebrafish lines expressing fluorescent proteins in specific cell types. Combined with its 
optical transparency at early developmental stages (embryo/larvae), this offers the possibility to 
observe physiological processes at a cellular or even macromolecular level using high-resolution 
imaging techniques such as fluorescent confocal microscopy. Consequently, the zebrafish became an 
emerging animal model for biomedical research and is widely applied as a tool for drug discovery [29], 
as a cancer [30] or disease model [31], and recently also for nanomedicine development [32]. 
Introducing the zebrafish model as a complementary tool to design, optimize, and preselect 
nanomedicine formulations for subsequent rodent in vivo experiments raises the question about the 
conservation and predictive value of such experimental results. Therefore, a detailed validation and 
characterization of the emerging zebrafish model is heavily required. Importantly, formulation effects 
which have already been described in established in vivo models (i.e. rats, mice) have to be confirmed. 
In this regard, liposomes are the best characterized and clinically most successful form of 
nanomedicines [5]. Already from the beginning, rodent models have extensively been used to describe 
liposome formulation effects such as size [33], lipid composition [34], PEGylation [35] amount of 
cholesterol [36], or injected dose [37] on pharmacokinetic parameters such as clearance, area under 
the curve (AUC), or half-life (t1/2) [38]. Using liposomes as a reference offers the possibility to assess 
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the zebrafish model regarding its ability to predict correctly the influence of minor formulation changes 
on later in vivo experiments in mice and rats. Once validated and characterized, the zebrafish model 
can also be used to assess the in vivo behavior (i.e. biodistribution, functionality, stability) of novel 
nanoparticulate systems as well as the optimization of sophisticated drug delivery systems such as 
targeted nanomedicines.  
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AIM OF THE THESIS 
As outlined above, nanomedicine formulation design and optimization is mainly based on 
physicochemical characterization and in vitro studies which are not able to fully reflect the complex 
biological conditions as they are present in vivo. As a consequence, the design, optimization and 
selection of promising nanomedicine lead formulations for subsequent rodent in vivo studies 
represents a major bottleneck in nanomedicine development. Therefore, the aim of this PhD thesis 
was to establish and validate the zebrafish as an early and easy accessible in vivo tool for nanomedicine 
formulation design and optimization, finally bridging the gap between in vitro and rodent in vivo 
studies. To achieve this objective, four major work packages were defined as followed: 
 Evaluation of current zebrafish applications during nanomedicine formulation design and 
optimization (Chapter I) 
 How can advantageous zebrafish features be optimally exploited during nanomedicine 
formulation design and optimization in order to close the in vitro – in vivo gap? 
 Set-up and validation of the zebrafish model for nanomedicine development (Chapter II) 
 Is it possible to reproduce already known nanomedicine formulation effects in the 
zebrafish model? 
 Are findings from zebrafish studies predictable for rodent in vivo studies? 
 Mechanistic studies on cellular nanoparticle clearance in the zebrafish model (Chapter III) 
 Which are the receptors involved in nanomedicine clearance in zebrafish? 
 What is the corresponding mechanism in mammalians? 
 Application of the established zebrafish model (Chapter IV) 
 Can the zebrafish model be applied during the development of active targeted 
nanomedicines? 
 Is it possible to assess nanoparticle based enzyme systems under in vivo conditions 
using the zebrafish model? 
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RESULTS 
The presented PhD project consist of four major working packages (Chapters I to IV) and has led to 
seven publications. Each of these publications is assigned to one of the four chapters as a subproject, 
which is separately presented. 
Chapter I: 
I) Zebrafish as a preclinical in vivo screening model for nanomedicines 
Chapter II: 
I) Zebrafish as a predictive screening model to assess macrophage clearance of liposomes in vivo 
II) Zebrafish as an early stage screening tool to study the systemic circulation of nanoparticulate drug 
delivery system in vivo 
Chapter III: 
I) Directing Nanoparticle Biodistribution through Evasion and Exploitation of Stab2-Dependent 
Nanoparticle Uptake 
Chapter IV: 
I) Optimization-by-Design of Hepatotropic Lipid Nanoparticles Targeting the Sodium-Taurocholate 
Cotransporting Polypeptide 
II) Immobilization of Enzymes on PLGA Sub-Micrometer Particles by Crosslinked Layer-by-Layer 
Deposition 
III) Biomimetic artificial organelles with in vitro and in vivo activity triggered by reduction in 
microenvironment 
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Chapter I-I 
Zebrafish as a preclinical in vivo screening model for nanomedicines 
 
Sandro Sieber, Philip Grossen, Jeroen Bussmann, Frederick Campbell, Alexander Kros, Dominik 
Witzigmann, Jörg Huwyler 
Manuscript: Advanced Drug Delivery Reviews (2019) [39] 
 
Highlights: The zebrafish as an emerging model in biomedical research is a promising tool to close the 
gap between in vitro experiments and subsequent rodent in vivo studies. This review article 
summarizes current applications of the zebrafish during nanomedicine development (i.e. nanotoxicity, 
biodistribution, cancer targeting). Advantageous zebrafish features in combination with critical 
experimental parameters are discussed in order to further promote the successful application of this 
emerging model system during nanomedicine formulation design and optimization.
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Available online xxxxThe interactions of nanomedicines with biological environments is heavily inﬂuenced by their physicochemical
properties. Formulation design and optimization are therefore key steps towards successful nanomedicine devel-
opment. Unfortunately, detailed assessment of nanomedicine formulations, at amacromolecular level, in rodents
is severely limited by the restricted imaging possibilities within these animals. Moreover, rodent in vivo studies
are time consuming and expensive, limiting the number of formulations that can be practically assessed in any
one study. Consequently, screening and optimisation of nanomedicine formulations is most commonly per-
formed in surrogate biological model systems, such as human-derived cell cultures. However, despite the time
and cost advantages of classical in vitromodels, these artiﬁcial systems fail to reﬂect and mimic the complex bi-
ological situation a nanomedicine will encounter in vivo. This has acutely hampered the selection of potentially
successful nanomedicines for subsequent rodent in vivo studies. Recently, zebraﬁsh have emerged as a promising
in vivo model, within nanomedicine development pipelines, by offering opportunities to quickly screen
nanomedicines under in vivo conditions and in a cost-effective manner so as to bridge the current gap between
in vitro and rodent studies. In this review, we outline several advantageous features of the zebraﬁsh model, such
as biological conservation, imaging modalities, availability of genetic tools and disease models, as well as their
various applications in nanomedicine development. Critical experimental parameters are discussed and the
most beneﬁcial applications of the zebraﬁsh model, in the context of nanomedicine development, are
highlighted.
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Drug delivery using nanoparticulate carrier systems (i.e.
nanomedicines) is an effective way to enhance drug concentrations
within speciﬁc target tissues and minimize side effects in off-target or-
gans [1]. To effectively exploit these unique pharmacokinetic features
of nanomedicines, the physicochemical properties of the underlying
nanoparticles need to be optimized. Ideally nanomedicines should dem-
onstrate low cytotoxicity, stability in biological environments, con-
trolled blood circulation half-life, cell/tissue speciﬁcity and efﬁcacy/
functionality under in vivo conditions. To this end, nanomedicine for-
mulations are designed and optimized according to almost endlessly
tunable parameters. These include chemical composition, size, shape,
surface charge or surface modiﬁcation. Therefore, the preclinical devel-
opment and evaluation of nanomedicines typically follows the same
route taken as for traditional drug development, namely physicochem-
ical characterization, in vitro experiments and ﬁnally rodent in vivo
studies [2]. During this development pipeline, the number of investi-
gated nanomedicine candidates decreases with each step, due to in-
creasing experimental costs and complexity. However, as recently
outlined by Dai et al., nanomedicine performance is heavily affected by
biological features which are mimicked during speciﬁc experimental
set-ups [3]. In particular, the presence of serum and/or extracellularma-
trix proteins, heterogeneous cell populations (including cells of the im-
mune system) and dynamic blood ﬂow, particularly varying levels of
shear stress, have all been shown to be critical to nanomedicine perfor-
mance. Despite the vast battery of well characterized and increasingly
sophisticated in vitro models, there remains a huge gap between cell
culture experiments and rodent in vivo studies in terms of accurately
mimicking the full complexity of a living animal. In light of this, signiﬁ-
cant efforts have been made in recent years to increase the predictive
value of in vitro experiments through the development of 3D cell (co-)
cultures and/or organ-on-a-chip set-ups [4–7]. However, the reproduc-
ible generation and characterization of these sophisticated cell culture
models remains extremely challenging [8]. In the case of organs with a
complex architecture such as the liver, accurate cell culture models
are still missing, among other things due to notoriously difﬁcult cultiva-
tion of liver sinusoidal endothelial cells. Furthermore, cell-based
systems are often more sensitive in terms of nanomedicine toxicity, as
they suffer from poor particle distribution and the inability to compen-
sate stresses via homeostatic balances [9].
The absence of early and easy accessible in vivo screening tools to as-
sess the effects of various nanomedicine formulation parameters under
complex biological conditions has hindered effective nanomedicine for-
mulation design andoptimization (e.g. accurately tailoring the composi-
tion). This has resulted in a high rate of drop-outs during early phases of
nanomedicine development [10] and limited understanding of
nanomedicines' in vivo behaviour [11]. Alternative vertebrate animal
models that are available in large numbers, easy to handle, cheap to
house and maintain, and applicable to nanomedicine formulation
screening approaches, are therefore of great interest to bridge the gap
between in vitro and rodent in vivo studies.
Over time, different in vivo model systems such as nematodes
(Caenorhabditis elegans), frogs (Xenopus laevis), chicken embryos, and
zebraﬁsh1 (Danio rerio) have been introduced to answer various biolog-
ical questions related to nanoparticles and nanomedicines [12–14].1 Developmental stages of zebraﬁsh described as follows: zebraﬁsh=no speciﬁc develop-
mental stage, zebraﬁsh embryo=until 48hpost fertilization (hpf), zebraﬁsh larvae=48hpf
– 3 week post fertilization, adult zebraﬁsh = N3 weeks post fertilization.
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tal biology [15–20], increasingly these organisms are being used as
in vivo models in biomedical research, most prominently as platforms
for high throughput screens of small molecule drug candidates either
in target- or phenotype-based approaches [21–25]. Critical experimen-
tal parameters when using zebraﬁsh for biomedical screening (i.e.
zebraﬁsh age, sample size, concentrations, wild type versus transgenic
lines) have been summarized by Rennkamp et al. [21]. The popularity
of these biomedical screens has been further boosted by the develop-
ment of several partially automated readout technologies (e.g. light/
dark preference test, open ﬁeld test, visual motor response test)[26].
Given the current empirical approach to nanomedicine design and opti-
mization, and the almost endless variations in potential nanomedicine
composition, shape, size, surface charge and surface modiﬁcation,
nanomedicines could potentially beneﬁt signiﬁcantly from this emerg-
ing in vivomodel. Indeed, recent studies have demonstrated the poten-
tial of the zebraﬁsh as an early and easily accessible in vivo tool during
nanomedicine development [27,28].
To this end, this review focuses on applications of the emerging
zebraﬁsh model (Fig. 1) to facilitate nanomedicine formulation design
and optimization prior to rodent studies. Zebraﬁsh characteristics
which are of special interest for biomedical research, such as the conser-
vation of key biological features, imagingmodalities and the availability
of genetic tools and disease models are discussed in detail. Assessment
of important nanomedicine characteristics including toxicity, in vivo
stability and functionality, biodistribution and blood circulation proper-
ties, and targeting efﬁciency within the zebraﬁsh are described and the
most suitable experimental set-ups are emphasized. Since comparabil-
ity and standardization of such experiments are of great importance,
critical experimental parameters are also highlighted and discussed.2. Important zebraﬁsh features for nanomedicine research
Zebraﬁsh larvae have several advantageous properties over adult
zebraﬁsh or rodents, which makes them attractive to screen
nanomedicines. Firstly, the costs of zebraﬁsh husbandry are low (com-
pared to mice or rats) and larvae are available in large numbers and
develop external from the mother. This allows for high-throughput
screening set-ups under in vivo conditions. Secondly, information net-
works such as ZFIN (zﬁn.org), combined with the fact that embryos or
frozen sperm can be easily transferred between labs, guarantee fast
and easy access to speciﬁc transgenic zebraﬁsh lines. Thirdly, the optical
transparency of zebraﬁsh larvae, which can be chemically prolonged up
to several days (e.g. using 1-phenyl-2-thiourea (PTU) to inhibitmelano-
genesis [29]), enables high resolution (ﬂuorescence) imaging of speciﬁc
biological events in real time and across entire the living organism. Al-
ternatively to PTU treatment, a transparent zebraﬁsh line (i.e. Casper)
has been generated which still lacks pigmentation in the adult stage
[30]. Finally, numerous molecular and biological tools are available to
create new genetically modiﬁed zebraﬁsh lines. These include TILLING
[31], morpholino oligonucleotides [32], zinc-ﬁnger nucleases [33],
TALENs [34], and CRISPR/Cas [35], Tol2 transposons combinedwith bac-
terial artiﬁcial chromosomes [36], and in situ hybridization [37]. Using
these tools, many zebraﬁsh lines with particular relevance to
nanomedicine development have been generated and are summarized
in Table 1. The availability of transparent zebraﬁsh larvae, ﬂuorescent
reporter lines and sophisticated imaging techniques, such as confocal
or light sheet microscopy, are key factors that enable the investigation
of nanomedicine behavior in vivo at a macromolecular level.as a preclinical in vivo screeningmodel for nanomedicines, Adv. Drug
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Fig. 1. Schematic representation of nanomedicine formulation design and optimization including the emerging zebraﬁsh model. The complementary application of classical in vitro
systems and the zebraﬁsh model offers the possibility to screen the effects of varying nanomedicine formulations and physicochemical properties under complex biological conditions.
This facilitates the selection of promising lead formulations for subsequent rodent in vivo studies.
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terisation raises immediate questions regarding the conservation of rel-
evant biological features and the accuracy of translating ﬁndings to
mammals. At the genomic level, 76% of human genes (82% of disease-
related genes) have orthologues in zebraﬁsh, compared to 80% and
84% in chicken and mice, respectively [47]. Epigenetic markers, which
regulate conserved genes between these species, are highly consistent
[48]. Zebraﬁsh anatomy and physiology are well described [49–52]
and physiological parameters and organ systems of particular interest
in terms of nanomedicine toxicity and biodistribution, such as the vas-
cular system [53–55], blood composition [56,57], immune system
[58,59] including a lymphatic system [60], blood-brain barrier [61–63]
and liver [64,65] have been extensively studied and share many impor-
tant physiological homologies with their mammalian equivalents [66].
The rapid development of the zebraﬁsh embryo results in a compart-
mentalized brain and the presence of eyes, ears and internal organs
after one day post fertilization (dpf) [29,67,68]. However, maturation
of some key organs, particularly the adaptive immune systems, occurs
at later developmental stages. When considering a zebraﬁsh study, de-
velopmental stage is therefore a critical experimental parameter as
discussed in Section 3.
As a key cell type of themononuclear phagocyte system (MPS),mac-
rophages are among the ﬁrst cell types that respond to administered
nanomedicines [9]. Importantly, early embryonic macrophages have
been found to be present and functional at very early stages of zebraﬁsh
development (30 h post fertilization, hpf) [69]. In addition, other key
cell types deﬁning the mammalianMPS, including monocytes and den-
dritic cells, are present in adult zebraﬁsh [70]. Macrophage polarization
is reported to change fromM1 toM2 upon tumor tissue inﬁltration. This
is an important feature of tumor growth and progression [71] and con-
version of M1 to M2 macrophages has been demonstrated in larval
zebraﬁsh to highlight the diversity and plasticity of zebraﬁsh macro-
phages as well as similarities to their human counterparts [42]. The
rapid development of zebraﬁsh immune cells again highlights the im-
portance of choosing an appropriate zebraﬁsh developmental stage.Table 1
Overview of zebraﬁsh lines with particular value for the in vivo characterization of nanomedic
way. An exemplary selection of existing zebraﬁsh lines is highlighted here togetherwith their sp
and optimization.
Zebraﬁsh line Reference Speciﬁc characteristic
Casper [30] Transparent adults
Tg(ﬂk1:EGFP) [38] Fluorescent vasculature
Tg(lyve1:EGFP) [39] Fluorescent lymphatic system
Tg(zmpo:GFP) [40] Fluorescent neutrophils
Tg(mpeg1:mCherry) [41] Fluorescent macrophages
Tg(tnfa:EGFP-F) [42] Fluorescent M1 macrophages
Tg(l-fabp:DBP-EGFP) [43] Fluorescent Vitamin D binding prote
TgBAC(cldn5a:EGFP) [44] Fluorescent brain endothelial cells
Stab2 mutant [28] No stabilin 2 receptors
LDLR mutant [45] Low density lipoprotein receptor de
Apoc2 mutant [46] Apolipoprotein loss of function
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on the adsorbed protein corona. In the case of intravenously (i.v.) ad-
ministered nanomedicines, the protein corona comprises blood
serum components [72]. In general, zebraﬁsh and human plasma
proteomes share striking similarities, in particular regarding the con-
servation of apolipoproteins and complement factors [73]. Surface
opsonization via complement factors C3, C4, and C5 is an important
initial step towards nanoparticle recognition by macrophages [74]
and these proteins are highly conserved in zebraﬁsh, including con-
servation of respective signalling pathways [75]. Likewise immuno-
globulins (Igs), such as IgG and IgM, are known to tag nanoparticles
as “foreign” material in the body, again initiating nanomedicine
clearance by macrophages [76,77]. As in humans, zebraﬁsh Igs are
composed of a light- and heavy-chains, bearing variable V, D, and J
segments that are generated through recombination. Junctional di-
versity and hypermutation further amplify variety of the antibody
repertoire. In contrast to humans, where ﬁve classes of Igs are
known, zebraﬁsh possess only three different Ig isotypes: IgM, IgZ
and IgD [78]. Moreover, different cells express varying types of apo-
lipoprotein receptors, which greatly affects the biodistribution of
apolipoprotein coated nanoparticles [79–81]. Otis et al. characterised
the zebraﬁsh as a suitable model for apolipoprotein biology [82],
ﬁnding a generally conserved physiological role of apolipoproteins
despite low genetic sequence similarity. Abundant serum proteins
such as albumin, ﬁbrinogen, and transferrin [83] are major compo-
nents of the characterized protein corona of nanoparticles in mam-
mals [77]. Whereas ﬁbrinogen and transferrin are present in
zebraﬁsh [73], a coding gene for the albumin- paralogue, vitamin D
binding protein, but not albumin itself, has been found [84].
Regarding the investigation of organ pathology the zebraﬁsh has
shown to be a valid tool [85–88]. Zebraﬁsh disease models at varying
developmental stages for the cardiovascular system [89–91], liver
[92,93], kidney [94,95] and immune system, including the spleen
[96–99], are available. Notably, all these organs can signiﬁcantly inﬂu-
ence nanomedicine biodistribution and clearance.ines. Various promoters and ﬂuorescent reporter proteins can be combined in almost any
eciﬁc characteristics and possible applications in nanomedicine formulation development
Possible application
Long term tumor models, ﬂuorescence imaging of adult zebraﬁsh
Blood circulation behavior
Lymphatic uptake and distribution
Immune systems interaction
Immune systems interaction
Immune systems interaction
in Binding to albumin paralogue
Brain delivery
Scavenger receptor interactions
ﬁciency LDLR dependent biodistribution, hepatocyte or brain targeting
Apoc2 dependent biodistribution
as a preclinical in vivo screeningmodel for nanomedicines, Adv. Drug
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model, there are practical limitations, primarily due to the small size
of the experimental system. Firstly, blood sampling from zebraﬁsh lar-
vae and even adult zebraﬁsh is difﬁcult. Secondly, only low amounts
of biomolecules, e.g. proteins, are available for further analysis due to
the small size of zebraﬁsh larvae or respective tumor burden (see
Section 4.5). These challenges often require pooling several zebraﬁsh
larvae for analysis, which excludes the possibility to observe differences
between individual animals, as it is for example possible in rodent
in vivo studies. However, analysis of high numbers of zebraﬁsh larvae in-
creases the statistical power. In addition, there are technical limitations
compared to in vitromodels. Protocols including the inhibition andﬂuo-
rescent staining of speciﬁc cellular uptake and trafﬁcking mechanisms
aremostly designed for in vitro set-ups [100,101] and still need to be op-
timized in order to routinely apply them in zebraﬁsh. Furthermore, gen-
erating stable transgenic zebraﬁsh lines expressing ﬂuorescent proteins
or speciﬁc targeting receptors requires severalmonths, which can be an
experimental constraint, especially when compared to simply
transfecting cells ex vivo. Overall, zebraﬁsh-based test systems have to
be validated carefully by comparing them to established protocols.
This will ultimately increase acceptance in the scientiﬁc community
and facilitate the use of the zebraﬁshmodel during preclinical screening
of nanomedicine formulations.
3. Critical parameters of zebraﬁsh experiments
The success and reproducibility of nanomedicine zebraﬁsh studies is
affected by several experimental parameters which are discussed in the
following section (Fig. 2). Developmental stage and experimental timing
are the ﬁrst parameters that must be carefully deﬁned when planning a
zebraﬁsh study. The stages of zebraﬁsh embryonic development and the
presence of major vertebrate organ systems are well described and easy
to predict [67,102]. As already indicated, zebraﬁsh development includ-
ing the gradual loss of transparency, organ maturation and the develop-
ment of the immune system occurs over relatively short time frames
(hours to days) and may inﬂuence experimental outcomes. Depending
on the study objective, different stages of development are recom-
mended as start point. For example, generation of genetically modiﬁed
zebraﬁsh lines using mutagens, such as N-Ethylnitrosourea (ENU), are
performed on adult zebraﬁsh whereas genetic constructs/systems, such
as capped mRNA, expression plasmids or CRISPR-Cas, are preferentially
injected at the single-cell stage [103]. Exploiting the optical transparency
of the zebraﬁsh larvae, ﬂuorescently labeled nanomedicine injections
are often coupled with ﬂuorescence-based imaging. Importantly, theFig. 2. Critical experimental parameters affecting the results of nanomedicine zebraﬁsh studies.
line is crucial. In addition, the route of administration of nanomedicines, such as incubation
husbandry and maintenance dictates many factors, such as water conductivity, pH, feedin
experimental conditions.
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controls and replicates should be planed carefully to ensure consistent
intervals between injection and imaging.
Various administration routes of nanomedicines into the zebraﬁsh
have been used. These include, for example, oral administration, simple
addition to the zebraﬁshmedia and both i.v. and intraperitoneal (i.p.) in-
jections. Choosing a suitable administration route is partly dependent
on the required dosing accuracy and zebraﬁsh developmental stage.
Oral administration by gavage has been performed in adult zebraﬁsh
[104,105], as well as in larvae [106], but will not be further discussed
given the very few reports of orally administered nanomedicines.
Injecting nanomedicines into blood circulation is often performed via
the easily accessible duct of Cuvier, a comparatively large blood vessel
of the embryonic zebraﬁsh that continuously remodels and reduces in
size until 120 hpf [107]. Alternatively, local CNS (i.e. brain ventricle)
[108], retro-orbital [109] or i.p. injections [110] have been described.
These injections are generally performed at later developmental stages.
Finally, direct injection into the blood island/caudal hematopoietic tis-
sue (CHT) is often used in infection models within the embryonic ﬁsh.
Using a microinjector-system, precise injections of samples can be
achieved. By adjusting air pressure and volume, injection volumes can
be calibrated by injecting samples into mineral oil followed by drop
size measurements with a scale included in the microscope ocular, the
injection base [111] or usingmicroscopy calibration slides. For injections
via the duct of Cuvier, special care must be taken to avoid injection into
the yolk sac. Material injected into the yolk will not enter circulation,
leaving an unknown sample volume in circulation. The blood volume
of a zebraﬁsh larvae at 2 dpf is around 60nl, therefore i.v. injected sample
volumes should not exceed low nanoliter ranges (i.e. up to 3 nl) [112].
Experimental temperature is another critical factor. Incubation tem-
perature, during early zebraﬁsh developmental stages, affects the rate of
development and the innate immune response of zebraﬁsh larvae [113].
In general, it is known that zebraﬁsh cope with stress (i.e. chemical ex-
posure, pain) by choosing regions of higher water temperatures. Tem-
perature dependent physiological processes (e.g. immune response)
can in turn affect experimental results [114–116], meaning experimen-
tal temperature must be carefully selected and standardized, especially
when assessing processes involving the zebraﬁsh immune system (e.g.
nanomedicine clearance bymacrophages). Furthermore, physicochem-
ical nanoparticle properties can also vary dependent on body tempera-
ture thereby inﬂuencing nanomedicine pharmacokinetics [27]. Of
particular note here are lipids (e.g. DMPC) with phase transition tem-
peratures between 28°C (zebraﬁsh) and 37°C (mammalian) for which
small variations in experimental temperature can become critical.The appropriate selection of zebraﬁsh developmental stage and themost suitable zebraﬁsh
in media or intravenous injection, strongly inﬂuences experimental results. Zebraﬁsh
g, and ﬁsh density. They should be considered and controlled to guarantee consistent
as a preclinical in vivo screeningmodel for nanomedicines, Adv. Drug
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16Notably, elevated temperatures over longer periods of time can af-
fect physiological processes of the zebraﬁsh, mediated by the presence
of heat shock proteins [117,118]. Therefore, performing experiments
under varying temperature conditions should be considered carefully,
strictly controlled and exact conditions should be reported.
4. Applications of the zebraﬁsh in nanomedicine development
Given the many advantages over rodent counterparts, zebraﬁsh lar-
vae are increasingly used as model systems during nanomedicine for-
mulation development and optimization. Nanomedicine toxicity,
biodistribution and systemic circulation, stability, functionality and
targeting efﬁciency have all been successfully assessed within the com-
plex biological, in vivo environment of a living zebraﬁsh larvae (Fig. 3).
Table 2 summarizes the experimental details of various nanomedicine
studies using the zebraﬁsh model. Since nanomedicines are most fre-
quently developed as potential cancer therapies, the generation, com-
patibility (with well characterized mouse models [119–122]) and use
of zebraﬁsh cancer models will be discussed in Section 4.5 of this
review.
4.1. Toxicity assessment of nanoparticulate drug delivery systems
Toxicological assessment of nanomedicines was one of the ﬁrst ap-
plications to combine nanomedicines and zebraﬁsh and is covered in
several reviews [123–125]. In general, nanotoxicity studies involve ex-
posing zebraﬁsh embryos to nanoformulations via addition to the
zebraﬁsh media. This approach is, at the very least, questionable
with respect to dosing accuracy, actual exposure and the stability of
nanoparticles in zebraﬁsh media. In testing the overall toxicity of
nanomedicines, properties of the encapsulated drug will also affect ex-
perimental outcomes. Based on varying logP values, drugs permeate dif-
ferently into zebraﬁsh skin, a factor that will signiﬁcantly affect the
ability to control and standardize dosage and exposure [23]. Henn
et al. showed that results of toxicological assays or drug screenings
(i.e. chemical exposure), were differentially affected by the chorion sur-
rounding the zebraﬁsh embryo [126]. In a related study, Paatero et al.
tested toxic effects of different nanoparticles following incubation
with normal and dechorionated embryos, as well as injection of the
same samples into 4 hpf embryos [127]. This study revealed differingFig. 3.Complementary application of in vitro and zebraﬁshmodel experimental set-ups for nano
2-D (bottom left) and sophisticated 3-D (top left) in vitro systems and the zebraﬁsh model (
environments under complex biological conditions. The availability of an optimized preclin
nanomedicine formulations prior to translation into rodent in vivo studies.
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cantly inﬂuenced toxicological proﬁles. To overcome this variable, the
chorion can be removed by either enzyme supported- or mechanical
dechorionation [126]. To standardize exposure of single zebraﬁsh em-
bryos in toxicological screens, the presence or absence of the chorion,
assay volume, nanoparticle concentration and number of zebraﬁsh/
well has to be clearly stated. Going one step further, Pan et al. quantiﬁed
nanoparticle uptake in individual zebraﬁsh embryos through induc-
tively coupled plasma mass spectrometry of digested zebraﬁsh em-
bryos/larvae obtained via an aqua regia-based microwave digestion
protocol [128]. Although rigorous, this approach is time consuming
which hampers its use for the screening of large nanomedicine libraries.
Taken everything together, direct injection of nanomedicines into
zebraﬁsh larvae allows for a precise control of zebraﬁsh exposure and
should therefore be the method of choice. As an example, Vibe et al.
assessed the toxicity of free and nanoparticle formulated drug upon in-
jection into zebraﬁsh larvae [129]. Thus, uncertainties regarding the ac-
tual drug exposure were excluded enabling the observation and
analysis focused solely on nanoformulation effects. In contrast, simple
addition of formulations to the ﬁsh water should be avoided since the
amount of test substance taken up by the animal cannot be controlled.
An exception are long-term exposure studies in the ﬁeld of eco-
nanotoxicology.
Nanoparticle aggregation and sedimentation are heavily affected by
the suspensionmedia. In contrast to cell culturemedia containing bicar-
bonate/CO2 and buffering agents, sample addition to un- or only slightly
buffered zebraﬁsh media can induce pH changes (possibly resulting in
false positive results) and should therefore be carefully monitored
[128]. If nanoparticle toxicity is tested via addition to the zebraﬁsh
media, colloidal stability should also be assessed in that same media
(i.e. E3 medium [130]) to ensure uniform exposure. Along these lines,
Kiene et al. ﬁrst determined the highest non-toxic nanoparticle concen-
tration in vitro before proceeding to test their nanoparticles in a
zebraﬁsh embryo toxicology assay (mortality, morphology, hatching
rate) with accompanying size and polydispersity measurements [131].
Toxicological readouts, such as survival or malformations, can be
assessed in a controlled and relatively fast manner [132]. However,
given the degree and severity of malformations is often subjective. In
an attempt to improve comparability and reproducibility of these ex-
perimental outcomes semi-quantitative scoring systems have beenmedicine formulation design and optimization. The complementary application of classical
middle right) offers the possibility to assess nanomedicine interactions with biological
ical, in vivo screening platform increases the chance to identify potentially successful
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Table 2
Summary of nanomedicine studies using zebraﬁsh to investigate toxicity, biodistribution, functionality and tumor treatment.
Application Experimental readouts Administration
(nanomedicine/cancer cells)
Zebraﬁsh line Developmental
stage
Reference
Nanotoxicology Mortality, Blood ﬂow, Tissue
penetration
Incubation*/Injection Tg(kdrl:EGFP s843) 6–24 hpf [127]
Morphology, Hatching,
Mortality, Induction of
Heat-Shock Protein
Incubation* Wild-type, Tg(hsp70:GFP) 0 hpf [128]
Mortality, Swim bladder
inﬂation, Yolk discoloration,
Pericardial edemas
Injection Tg(nacre-/-;roy-/-) 72 hpf [129]
Mortality, Morphology,
Hatching
Incubation* Wild-type (AB) 4 hpf [131]
Mortality Injection N.A. 1-cell stage [132]
Development, Morphology,
Mortality
Incubation* Wild-type (AB) 2 hpf [133]
Morphology, Mortality Incubation* Wild-type (AB) 0–2 hpf [134]
Development, Morphology,
Apoptotic cell death, Heart
functionality
Incubation* Wild-type (AB), Tg(cmlc2:EGFP) 6–30 hpf [136]
Gill injury, Biochemical liver
and kidney toxicity, Mortality
Incubation* Wild-type Adult [138]
Mortality, Morphology, Heart
rate, Apoptotic cell death,
Tissue distribution
Incubation* N.A. 0 hpf [139]
Locomotion, Hatching,
Morphology, Mortality, Body
weight, Thyroid hormone
levels
Incubation* Wild-type (AB) 2 hpf [140]
Mortality, Morphology,
Locomotion, Neuronal cell
volume
Incubation* Wild-type (AB), Tg(lsl1:EGFP) 48–96 hpf [141]
Biodistribution NP extravasation and blood
circulation behavior
Injection via duct of Cuvier Tg(kdrl:GFP) 48 hpf [27]
Scavenging receptor,
macrophage and neutrophil
mediated nanoparticle
clearance
Injection via duct of Cuvier Tg(kdrl:GFP)s843, Tg(kdrl:RFP-CAAX)s916, Tg(mpeg:GFP)gl22,
Tg(mpeg:RFP-CAAX)ump2, TG(ﬂt1enh:RFP)hu5333, Tg(ﬂt4BAC:
YFP)hu7135, Tg(mpx:GFP)uwm1, CRISPR/Cas9 mutants
52–56 hpf [28]
Macrophage clearance Injection via duct of Cuvier Tg(kdrl:EGFP), Tg(mpeg1:Gal4;UAS:Kaede) 48 hpf (Sieber et al.,
manuscript in
preparation)
NP localization in blood
vessels
Injection via heart Tg(kdrl:GFP), Tg(gata1:DsRed) 52 hpf [149]
Endothelial cell association,
Tissue penetration
Injection via duct of Cuvier Tg(kdrl:GFP) 52 hpf [150]
Endocytosis and stability Injection via duct of Cuvier Tg(kdrl:GFP) 52–56 hpf [151]
Transport across biological
barriers
Incubation* Wild-type Embryo,
Larvae, Adult
[153]
Presence in whole body,
brain, eye, and intestine,
Intestinal absorption
Incubation*, Oral
administration (gavage),
Injection into intestine
Wild-type 24–168 hpf,
Adult
[154]
Ability to cross the BBB Injection via heart Wild-type 144 hpf [155]
Presence in brain, blood
stream, and spinal cord
Injection via caudal vein,
spinal cord, and brain
Tg(-3mnxl:TagBFP), Tg(isl1:GFP), Tg(GFAP:EGFP), Tg(ﬂi1a:
EGFP)
96–144 hpf [156]
Uptake into infected and
uninfected macrophages
Injection via caudal vein Casper, Tg(mpeg1:mcherry), Tg(lyz:DsRed2), Tg(ﬂi1:EGFP) 72–120 hpf [163]
Accumulation in tuberculosis
granulomas
Injection via posterior caudal
vein
Tg(ﬂi1a:EGFP),
Wild-type
48-52hpf [164]
Functionality Photothermal triggered drug
release
Injection via brain ventricle N.A. 120 hpf [170]
Photothermal induction of
ROS generation
Injection of cancer cell/NP
mixture via duct of Cuvier
Casper 30 hpf [171]
Reduction of xenograft cell
viability upon singlet oxygen
generation
Injection via cardinal vein N.A. 48 hpf [172]
Laser induced formation of
plasmonic nanobubbles
N.A. N.A. Blastula stage [173]
Enzyme activity, Stability Injection via duct of Cuvier Wild-type (ABC/TU) 48 hpf [174]
Enzyme activity, Stability Injection via duct of Cuvier Wild-type (ABC/TU), Tg(mpeg1:Gal4;UAS:Kaede) 48 hpf [175]
Transfection efﬁciency Injection into embryo
interlayer
N.A. 1-cell stage [180]
mRNA delivery Injection into yolk, via
hindbrain ventricle, caudal
vein, trunk, and pericardial
cavity
Wild-type (AB) 1-cell stage,
24–48 hpf
[181]
Gene silencing Injection Tg(ﬂi:EGFP) Sphere stage [182]
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Table 2 (continued)
Application Experimental readouts Administration
(nanomedicine/cancer cells)
Zebraﬁsh line Developmental
stage
Reference
Tumor
Treatment
Tumor proliferation analysis Cancer cell injection via the
perivitelline space, NP via
yolk
N.A 48–144 hpf [229]
Cancer cell targeting Cancer cell injection via duct
of Cuvier, NP via the caudal
vein
Tg(ﬂi1:EGFP) 48–53 hpf [230]
Tumor growth inhibition Cancer cell injection via the
perivitelline space, NP
incubation*
Tg(FLK-1:EGFP), Tg(FLK-1:mCherry) 48 hpf [231]
Tumor growth inhibition,
Tumor spreading
Injection of cancer cell/NP
mixture into yolk
N.A. 96 hpf [232]
Tumor vascularization Injection of cancer cell/NP
mixture via perivitelline
space
Tg(ﬂi1a:EGFP), Wild-type 48 hpf [233]
Tumor vascularization Injection of cancer cell/NP
mixture into yolk
Wild-type (AB) 48 hpf [234]
Metastasis Pretreated cancer cell
injection into yolk
Tg(kdrl:mCherry) 48 hpf [235]
NP tumor accumulation,
Tumor growth, NP
circulation, NP macrophage
uptake
Cancer cell injection via duct
of Cuvier, NP injection via
caudal vein
Wild-type (AB), Tg(ﬂi1:EGFP)y1, Tg(mpeg1:
mCherry)UMSF001
48–96 hpf [236]
Angiogenesis, Tumor growth,
Metastasis
Cancer cell injection via
perivitelline space, NP
incubation*
Tg(FLK-1:EGFP) 48 hpf [238]
Tumor cell
migration/invasion
Cancer cell via hindbrain
ventricle, NP incubation*
5D tropical strain 48–96 hpf [239]
PCR analysis of VEGF RNA as
a marker of cancer cell
growth
Injection via common
cardinal vein
Tg(ﬂi1:GFP) 120 hpf [240]
PCR analysis of cancer cell
speciﬁc RNA
Cancer cell injection into
yolk,
Tübingen Wild-type 48–144 hpf [241]
Evaluation of optimal
targeting ligand density
Cancer cell and NP injection
via duct of Cuvier
Tg(kdrl:EGFP), Tg(mpeg1:Gal4;UAS:Kaede) 48 hpf (Witzigmann
et al.,
manuscript in
preparation)
For each study, experimental readouts are included. Administration routes of nanomedicines and/or cancer cells (for the generation of zebraﬁsh tumor models) are indicated as well as
transgenic zebraﬁsh lines used and zebraﬁsh development stage during the course of experiments. References are sorted according to their application and listed in order of their appear-
ance in themanuscript. It has to be noted that simple incubation of zebraﬁshwith nanomedicines (*) is not recommended as exposure and dose cannot be controlled. NP= nanoparticle,
hpf = hours post fertilization, N.A. = information not available.
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18proposed by different experts [133,134]. Accompanying these scoring
systems are newly developed nanotoxicity readouts focusing on behav-
ioral aspects of zebraﬁsh larvae and aimed at greater automation and
sample throughput. These include automated procedures for studying
locomotion parameters such as swimming speed and depth [135].
Interestingly, nanomedicine toxicity can been visualized at a cellular
level within zebraﬁsh embryos/larvae [136]. For example, acridine or-
ange staining of apoptotic cells and tissues is possible [137]. Further-
more, toxicological endpoints such as disruption of gill [138], skin
[139], and the endocrine system [140], as well as complex toxicity
mechanisms (e.g. immunotoxicity, genotoxicity, neurotoxicity, or repro-
ductive toxicity) have all been reported [123]. Nasrallah et al. performed
a locomotion assay in Tg(Isl1:EGFP) zebraﬁsh larvae, stably expressing
green ﬂuorescent protein in motor neurons, following nanoparticle in-
cubation [141]. Finally, a highly sensitive analysis of nanoparticle toxic-
ity was recently proposed by Pan et al. [128], that takes advantage of the
endogenous expression of heat shock proteins in response to toxic com-
pounds [142]. Using a newly generated transgenic zebraﬁsh line, ex-
pressing green ﬂuorescent protein (GFP) under the control of a heat
shock protein promoter, the authors were able to show nanoparticle
toxicity induced GFP expressionwith 20-fold greater sensitivity as com-
pared to a classical toxicology analysis in wild type zebraﬁsh [128].
4.2. Biodistribution and systemic circulation of nanomedicines
Most i.v. administered nanomedicines aim to alter the biodistribution
of their drug payload, prolong blood circulation lifetimes of drugs and/or
promote passive accumulation of drugs in fenestrated solid tumors.Please cite this article as: S. Sieber, P. Grossen, J. Bussmann, et al., Zebraﬁsh
Deliv. Rev., https://doi.org/10.1016/j.addr.2019.01.001Organ biodistribution, circulation half-life (t1/2) and area under the
curve (AUC) are therefore important pharmacokinetic parameters of
nanomedicines that have been traditionally assessed in mice, rats or
dogs [143,144]. These dynamic parameters can be assessed in zebraﬁsh
larvae, with the accompanying advantage of being able to extensively
optimize nanomedicine formulations under realistic and complex
in vivo conditions early in the development process and prior to ﬁrst tri-
als in higher animals.
Biodistribution is heavily affected by nanoparticles' propensity to be
recognized and cleared by cells of the reticuloendothelial system (RES
or MPS) [145–147]. By screening nanoparticles in zebraﬁsh larvae,
both the systemic circulation and the clearance of nanoparticles, pri-
marily by macrophages and scavenger receptor expressing cells, can
easily be assessed [27,28]. Correlating data ascertained in zebraﬁsh em-
bryos to higher order mammals. We recently demonstrated that
zebraﬁsh larvae are an accurate in vivo model to predict pharmacoki-
netic properties in rodents [27]. In this study, different lipid-based
nanoparticle formulations demonstrated different binding afﬁnities to
venous tissues of the zebraﬁsh larvae. Based on the analyzes of acquired
confocal images, zebraﬁsh extravasation and circulation factors were
deﬁned to enable semi-quantitative descriptions of nanoparticles'
blood circulation.With this approach, investigational nanomedicine for-
mulations can be compared to established and well-deﬁned formula-
tions (e.g. long circulating PEGylated liposomes). Here it is important
to note that predictions of absolute pharmacokinetic parameters (allo-
metric scaling from zebraﬁsh to mice), such as t1/2 or AUC, are not yet
possible but are the subject of current investigations. To further eluci-
date the underlying biological mechanisms of nanoparticle clearance,as a preclinical in vivo screeningmodel for nanomedicines, Adv. Drug
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expressed exclusively in the caudal vein (CV) and caudal hematopoietic
tissue (CHT) of the zebraﬁsh larvae [28]. Highly expressed on mamma-
lian liver sinusoidal endothelial cells (LSECs) and other clearance organs
[148], stabilin-2 is primarily responsible for the removal ofmacromolec-
ular and colloidal waste from blood circulation. By injecting different
nanoparticles in zebraﬁsh larvae, we showed a preference of this recep-
tor for all anionic nanoparticles, a ﬁnding which was veriﬁed in mice.
Nanoparticle uptake by macrophages represents another important
clearance mechanism of nanomedicines. Transgenic zebraﬁsh express-
ing ﬂuorescent proteins in all macrophages [41] are therefore a valuable
tool to assess this important pharmacokinetic parameter. Our group has
recently investigated macrophage clearance of liposomes of various
sizes and surface modiﬁcations (i.e. PEGylation) in zebraﬁsh embryos.
Importantly, a good correlation between macrophage uptake in
zebraﬁsh larvae and liposome accumulation in the spleen of rats, a
main reservoir of mammalian macrophages, was found (Sieber et al.,
manuscript in preparation).
To assess the ability to accurately mimic dynamic ﬂow, Garcia et al.
assessed various parameters including blood ﬂow velocity, shear stress
and ﬂow disturbances in zebraﬁsh larvae. It was found that depending
on the vasculature architecture (i.e. branch points, curvature), and con-
comitant changes in velocity and shear stress, nanoparticle accumula-
tion was strikingly altered. This study further highlights the value of
the zebraﬁsh larvae model when it comes to nanoparticle studies
under dynamic conditions [149], a parameter which cannot be mim-
icked in vitro in such a detailed manner. Jiang et al. investigated the im-
pact of surface charge on nanoparticle interactions with endothelial
cells, under ﬂow, in zebraﬁsh larvae [150]. In this case, vessel diameter
dependent changes of blood ﬂow velocity as well as nanoparticle sur-
face charge was found to inﬂuence nanoparticle binding to endothelial
cells and penetration into surrounding tissue. Askes et al. investigated
cellular uptake and trafﬁcking of nanoparticles in cell culture and
zebraﬁsh larvae at various timepoints [151]. Here, nanoparticle endocy-
tosis and lysosomal accumulation, including long-term stability in these
cellular compartments, was demonstrated both in vitro and in vivo.
Biological barriers, such as the blood brain barrier (BBB), prevent
nanomedicines reaching their site of action. The BBB is of particular in-
terest, as effective drug delivery to the brain remains a major challenge
in terms of drug delivery. Active targeting of nanomedicines to recep-
tors (over-)expressed at the BBB is one popular approach taken to try
and breach this biological barrier [152]. Li et al. successfully demon-
strated this approach in larval zebraﬁsh envisioned based on already de-
scribed zebraﬁsh features such as a functional BBB and the expression of
tight junctions, transferrin receptors, and efﬂux transporters [153–155].
Furthermore, transgenic zebraﬁsh lines expressing ﬂuorescent proteins
in neuronal cells or astrocytes have been used to examine brain accu-
mulation of nanoparticles upon injection at different sites within
zebraﬁsh embryos [156]. However, it is important to note that current
information on BBB development in the zebraﬁsh is scarce and this
topic remains controversial. Accurate descriptions of the functional de-
velopment of the BBB in zebraﬁsh larvae, determined using established
protocols [157,158] and with appropriate control experiments, will be
of great value to the zebraﬁsh community. In the context of
nanomedicines, BBB permeability is relevant and can be assessed
using ﬂuorescent dyes with different molecular weights [159].
4.3. Nanomedicines targeting macrophage resident pathogens
Nanomedicines are a promising therapeutic option to treat infec-
tious diseases. Ideally, this should involve the preferential
biodistribution of nanomedicines, and subsequent targeted drug deliv-
ery, to niches formed by bacteria. Interestingly, zebraﬁsh larvae have
emerged as more accurate model system for many infectious diseases.
Mice often fail to replicate important features of human pathology
which is particularly striking in the case of tuberculosis (TB) wherePlease cite this article as: S. Sieber, P. Grossen, J. Bussmann, et al., Zebraﬁsh
Deliv. Rev., https://doi.org/10.1016/j.addr.2019.01.001compact granulomas, characteristic of human tuberculosis infections,
are present in zebraﬁsh embryo TB models [160,161] but absent from
the most widely used mouse models [162]. Taking advantage of the
high persistency of TB in macrophages, Fenaroli et al. were able to
show rifampicin loaded nanoparticles, administered to zebraﬁsh larvae
and targeted to macrophages, resulted in increased survival rates and
decreased bacterial load, whereas free rifampicin showed only a re-
duced efﬁcacy [163]. Complementary to the transgenic macrophage
ﬂuorescent line, the authors also exploited established transgenic
zebraﬁsh lines expressing ﬂuorescent proteins in neutrophils or in vas-
cular endothelial cells, to precisely describe both the infection status
and nanomedicine treatment process. In a follow up study, the authors
investigated the possibility of macrophage independent nanomedicine-
based delivery strategies to tuberculosis granulomas via an enhanced
permeability and retention (EPR)-like process. Here, the versatility in
experimental set-ups of zebraﬁsh larvae enabled injection ofMycobac-
terium marinum into the neural tube of zebraﬁsh larvae, resulting in
the formation of tissue granuloma (i.e.model organism to study tuber-
culosis infection). Subsequent injection of PEGylated nanoparticles re-
sulted in reduced clearance by macrophages and accumulation of
nanoparticles within granulomas, supporting the authors’ hypothesis
[164].
4.4. In vivo evaluation of advanced functional nanomedicines
Nanomaterials are used in a broad range of applications including
stimuli responsive systems, enzyme/protein delivery, and gene thera-
peutics [165–169]. Successfully developing such complex and sophisti-
cated systems is heavily dependent on their stability and functionality
under in vivo conditions. These parameters can often be ideally assessed
in zebraﬁsh.
4.4.1. Stimuli responsive nanomedicines
Nanoparticle drug delivery systems can be designed to release their
cargo upon a speciﬁc trigger (e.g. pH changes, redox changes,
photoirradiation). Yan et al. injected photo-responsive, curcumin loaded
nanoparticles in zebraﬁsh larvae [170] to demonstrate triggered drug re-
lease upon light irradiation or temperature increase (37 °C). Here, the in-
herent ﬂuorescence of curcumin could be used as a reporter within the
living embryo. In addition, curcumin released in the zebraﬁsh larvae
heart was able to improve heart function (i.e. heartbeat rate and cardio
muscular contractility). Photoirradiation, in combination with nanopar-
ticles, has also been used to generate reactive oxygen species (ROS) to
kill tumor cells within zebraﬁsh larvae [171,172]. Nanomedicines are
also ideal candidates for combined diagnostic and therapeutic function,
so-called theranostics. In zebraﬁsh larvae, theranostic plasmonic
nanobubbles, generated around gold nanoparticles, have been success-
fully used to both identify and kill xenografted cancer cells upon focused
laser illumination and without harming surrounding tissue [173]. As a
more general comment here, the small and transparent zebraﬁsh larvae
are, of course, an ideal proof-of-concept in vivo system to validate and
optimize photo-responsive systems. However, the micrometer thick tis-
sue of a transparent zebraﬁsh larvae does not resemble clinically relevant
tissue and, in taking these technologies forward into the clinic, signiﬁcant
challenges to efﬁciently deliver light into deep and opaque tissue must
be additionally met.
4.4.2. Enzyme and protein delivery
For nanoparticle-mediated enzyme delivery, enzyme activity upon
immobilization is a key question to be assessed. An important parame-
ter for enzymatic activity is access to substrates and co-factors. This pro-
cess can be affected bymany factors in vivo, including blood ﬂow, shear
stress, cell interactions (e.g. immune cells) and protein adsorption.
Using classical enzymatic activity assays, it is simply not possible to
mimic all these complex and intertwined determinants.as a preclinical in vivo screeningmodel for nanomedicines, Adv. Drug
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20Transparent zebraﬁsh larvae are an ideal platform for initial in vivo
assessment of enzyme delivery systems since many enzymes can
process colorimetric or ﬂuorescent substrates (a requirement for
image-based analysis). Recently, enzyme loaded nanoparticles and
free enzyme were injected into the blood circulation of zebraﬁsh larvae
followed by an enzyme activity assay [174]. Both enzyme preparations
were shown to be active and neither elicited acute toxicity (i.e. seizures,
heart failure, signs of denaturation). Interestingly, immobilized en-
zymes remained associated with particles after injection (distinct local-
ized areas) in contrast to the very diffuse distribution of free enzyme
throughout the zebraﬁsh larvae. Qualitative analysis of staining patterns
enabled assessment of both the stability and functionality of enzyme
loaded particles in vivo. In this example, zebraﬁsh larvae had to be eu-
thanized prior to the enzyme activity assay, however this limitation
can be overcome by choosing a suitable enzyme reaction, preferably
one producing a ﬂuorescent product, as demonstrated by Einfalt et al.
[175]. In this study, polymer-based artiﬁcial organelles, containing pro-
tein gates and a model enzyme, were developed. After demonstrating
functionality in vitro, zebraﬁsh larvae were then used to demonstrate
activity in vivo. In this case, ﬂuorescently labeled artiﬁcial enzyme-
containing organelles were injected into the blood circulation of
zebraﬁsh larvae. After successful uptake of artiﬁcial organelles by mac-
rophages in the caudal region of the zebraﬁsh larvae, the enzyme sub-
strate was injected. Importantly, the formation of a ﬂuorescent
product demonstrated the intracellular functionality of the designed
system in a complex in vivo environment.
4.4.3. Gene therapy
The past decades have seen signiﬁcant progress in the development
of non-viral vectors for gene therapy [169,176]. Typically, an excess of
positively charged or ionizable lipids or polymers is required to efﬁ-
ciently complex polyanionic nucleic acids within discrete nanoparticle
formulations. Since cationic nanoparticles are often highly cytotoxicity
in vitro [177], much effort has been made to optimize formulation de-
sign, e.g. screening polymer/lipid to nucleic acid ratios, use of ionizable
cationic lipids (with optimized pKa values) and/or including helper
lipids, to minimize cytotoxicity and other detrimental features (e.g. ag-
gregation in serum) associated with cationic particles. These efforts
have recently resulted in the clinical translation of the ﬁrst non-viral
RNAi therapeutic [178]. Many challenges however remain, perhaps
most signiﬁcant being the ability to efﬁciently target genes to cells be-
yond the liver. Once again, the ability to quickly screenmany and varied
gene delivery systems within realistic in vivo situations would hugely
beneﬁt theﬁeld [179]. Encouragingly, zebraﬁsh embryos/larvae have al-
ready been used to show successful nanoparticle-mediated gene trans-
fection [171,180,181] and gene silencing [182], highlighting the
suitability of this model organism for the design and optimization of
gene delivery systems.
4.5. Nanomedicines for cancer therapy
In the past 30+ years, very few nanomedicines have been granted
market approval for the targeted treatment of solid tumors, although
several are currently in clinical trials [183]. Successful translation of
nanomedicines, from the preclinical setting to the clinic, therefore re-
mains a persistent and major hurdle. The development of new in vivo
platforms to quickly screen, analyse, and optimize large numbers of can-
cer nanomedicines has the potential to facilitate the selection of lead
formulations and to accelerate their preclinical development. However,
in vivo cancermodelsmust be designed and appliedwith utmost care to
avoidmisleading conclusions as to the nanomedicines' efﬁcacy, particu-
larly given cancer is a pathophysiologically heterogeneous disease (e.g.
varying tumor size, presence and extent of the extracellularmatrix, spe-
ciﬁc cell types, location). In the following sections, existing zebraﬁsh
cancer models are described including comparisons to their rodentPlease cite this article as: S. Sieber, P. Grossen, J. Bussmann, et al., Zebraﬁsh
Deliv. Rev., https://doi.org/10.1016/j.addr.2019.01.001counterparts and their applications during nanomedicine development
are discussed.
4.5.1. Zebraﬁsh cancer models
Zebraﬁsh can be used to study the pathophysiology of various can-
cers including melanoma, rhabdomyosarcoma and hepatoma
[184–186]. Most tumormodels generated in zebraﬁsh are histologically
comparable to human tumors and possess important hallmarks of can-
cer, such as genomic instability, invasiveness, transplantability, exis-
tence of cancer stem cells and conservation of tumor suppressor genes
and oncogenes [185,187–189]. Furthermore, the availability of various
genetically modiﬁed zebraﬁsh lines such as Casper [30] (transparent
at adult stage), Tg(kdrl:eGFP) [38] (ﬂuorescent embryonic and early lar-
vae vasculature), Tg(mpx:eGFP) [190] (ﬂuorescent neutrophils), Tg
(mpeg1:eGFP) [41] (ﬂuorescent macrophages) and Tg(cd41:eGFP)
[191] (ﬂuorescent thrombocytes) facilitates detailed investigation of
important cancer features such as angiogenesis, neutrophil-mediated
metastasis, and immune responses, at a cellular level and in living or-
ganisms [192–194]. For example, Nicoli et al. injected cancer cells,
loaded with ﬂuorescent dye, into zebraﬁsh larvae expressing GFP in
their vascular endothelial cells, to dynamically assess tumor angiogene-
sis in vivo [195,196]. In another study, Feng et al. investigated host in-
ﬂammatory response, upon cancer cell transplantation, making use of
various transgenic ﬂuorescent zebraﬁsh lines [197].
Zebraﬁsh cancermodels can be created through embryo exposure to
carcinogens, forward genetic screens, reverse genetic knockouts, trans-
gene expression or xenotransplantation of mammalian cancer cells
[185]. Carcinogenic chemicals, such as N-nitrosodimethylamine [198],
7,12-dimethylbenz(a)anthracene [199] or N-ethyl-N-nitrosourea
[200], can be directly dissolved or dispersed into the zebraﬁsh media,
making this approach straightforward. Since many oncogenes and
tumor suppressor genes are also important for tumor development,
new cancer-related genes can be identiﬁed through forward genetic
screens, including the selection of phenotypeswith proliferation defects
[201,202]. The creation of reverse genetic knockout enables creation of
human-like cancer mutations through speciﬁc knockout of a gene
known to be linked to cancer development, for example the tumor sup-
pressor, TP53 [203]. Here it is important to note that these methods are
affected by an evolutionary gene duplication event in zebraﬁsh [204],
resulting in the presence of redundant genes that can compensate for
engineered genetic mutations. Therefore, induction of tumors by trans-
genic expression of mammalian oncogenes, within single cell zebraﬁsh
embryos, is a frequently used approach. This also allows for the combi-
nation of human oncogenes and ﬂuorescentmarkers to be co-expressed
in speciﬁc tissues [205]. However, transgene expression is time con-
suming and laborious. As an alternative, zebraﬁsh cancer models can
be generated by xenografting human cancer cell lines or patient-
derived tumor cells within zebraﬁsh embryos [206,207]. The success
and reproducibility of this approach is however strongly affected by dif-
ferent experimental parameters, such as developmental stage, site of in-
jection and experimental temperature, and care must therefore be
taken to ensure these parameters are strictly controlled. Most studies
involving the generation of zebraﬁsh xenografts report cancer cell injec-
tion at 2 dpf, as highlighted in different reviews [192,208–210]. At this
time point, gastrulation is complete, the main anatomical organization
of the zebraﬁsh body is established, larvae are fully transparent and
have not yet developed an adaptive immune system. As a result, injec-
tion of human cancer cells into zebraﬁsh embryos does not require im-
munosuppression. Furthermore, zebraﬁsh, at this developmental stage,
feed exclusively from their yolk, minimizing ﬁsh-to-ﬁsh variations
caused by differential diet.
The site of xenograft injection is critical in determining resultant
tumor access to blood and/or vascularization. The yolk is commonly
preferred as xenograft injection site, given its large size, the ability to
carry large tumor burdens and the naturally nutrient rich environment
that promotes tumor proliferation. The main limitation of xenograftas a preclinical in vivo screeningmodel for nanomedicines, Adv. Drug
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which limits tumor vascularization (i.e. blood vessels do not sprout
to xenograft). Alternatively, cancer cells can be injected into the
perivitelline space, resulting in spontaneous tumor vascularization via
the ingrowing subintestinal vessels [196]. This approach is often used
to test novel angiogenesis inhibiting compounds [211].
Direct cancer cell injections into blood circulation, via the duct of Cu-
vier [212] or the cardinal vein [213], have also been demonstrated. This
approach gives less control over the ultimate site of tumor formation,
however most i.v. administered cancer cells will tend to accumulate in
the caudal part of the zebraﬁsh larvae vasculature, due to the narrowed
blood vessels and reduced bloodﬂowvelocity of this tissue,which guar-
antees blood access of the established xenograft.
In general, injecting mammalian cancer cells into zebraﬁsh larvae
presumes an accurate control of experimental temperature givenmam-
malian cells require an optimal temperature of 37 °C whereas the opti-
mal temperature for zebraﬁsh husbandry is 28 °C. Fortunately, zebraﬁsh
larvae, from 2 dpf onwards, are able to survive and develop at temper-
atures up to 35 °C [214] for several days, while adult zebraﬁsh canwith-
standwater temperatures up to 38 °C [215]. Asmentioned previously, in
carrying out zebraﬁsh experiments at elevated temperatures, the po-
tential activation of heat shock protein pathways should also be care-
fully considered.
4.5.2. Zebraﬁsh and rodents as complementary model organisms in cancer
research
As stated previously, most tumor models generated in zebraﬁsh are
histologically comparable to human tumors and possess many impor-
tant hallmarks of cancer. For both mice and zebraﬁsh, genetic cancer
models and xenotransplants are available. Each has its own advantages
and disadvantages. Genetically induced tumors (i.e. gene knockout or
knock-in) in zebraﬁsh, for instance, suffer from later onset and lower in-
cidence rates (close to 30%) compared to orthologue mouse models
[185]. This can be somewhat compensated byworkingwith larger num-
bers of zebraﬁsh, given the fecundity and comparably cheap husbandry
costs of zebraﬁsh. In addition, most cancer models can be effectively
exploited in zebraﬁsh larvae as observed larval phenotypes are strongly
predictive of adult phenotypes. Nevertheless, some zebraﬁsh organs are
anatomically less complex (e.g. kidney, pancreas) than their mamma-
lian counterparts or indeed absent all together (e.g.mammary and pros-
tate glands and lungs) [189]. This clearly hampers, or prevents, the
generation of representative tumormodelswithin these organs. In addi-
tion, tumor classiﬁcation and characterization of zebraﬁsh cancer
models is often difﬁcult given the lack of zebraﬁsh-speciﬁc antibodies
required for tissue staining, ﬂow cytometry or western blots. Regarding
the conservation of oncogenic pathways, for example high conservation
of BRAF and NRAS oncogenes and absence of BRCA1 and INK4α/ARF
tumor suppressors, the inability to accurately characterize tumor pa-
thology can be critical [47,216]. Upon cancer cell xenotransplantation,
successful tumor formation often requires the addition of supplemen-
tary cytokines, such as growth factors. The use of solubilized tissue base-
ment membrane matrices (e.g. Matrigel® or Cultrex®), containing
transforming growth factor and ﬁbroblast growth factor, has been
shown to support tumor growth in both rodents and zebraﬁsh xeno-
graft models [196,217]. Addition of tissue-speciﬁc growth factors to
the zebraﬁsh media is possible but has yet to be established as standard
protocol. Regarding xenograft rejection, the adaptive immune system of
zebraﬁsh is not fully functional until 1 month post fertilization, making
common immunosuppression protocols used in rodents, redundant in
zebraﬁsh embryos [218]. For xenotransplantation in adult zebraﬁsh, im-
munosuppression through irradiation or dexamethasone treatment is
effective [30,219].
In general, xenograft cancermodels in zebraﬁsh have several advan-
tageous features over their rodent counterparts. Due to the small size of
zebraﬁsh embryos, zebraﬁsh xenografts require a relatively small num-
ber of transplanted tumor cells (max. 2000 cells/zebraﬁsh compared toPlease cite this article as: S. Sieber, P. Grossen, J. Bussmann, et al., Zebraﬁsh
Deliv. Rev., https://doi.org/10.1016/j.addr.2019.01.001up to 1 million cells/mouse) [192,220]. This is particularly relevant in
cases where human primary cells are to be xenografted, given these
cells are difﬁcult to obtain in large numbers. As such, the potential use
of zebraﬁsh cancer models towards personalized cancer therapy has
not gone unnoticed [221]. Indeed, given the relatively short amount of
time needed to generate patient-derived xenografts in zebraﬁsh larvae,
it is possible to assess the effectiveness of various patient treatment op-
tions under more realistic and predictive biological conditions in
zebraﬁsh larvae [222].
Assessment of tumor growth and tumor cellmigration in zebraﬁsh is
generally done before and after treatment. By transplanting ﬂuores-
cently labeled cancer cells, these two parameters can be determined dy-
namically in living organisms at cellular resolution and can even be
quantiﬁed [214,223]. In contrast, imaging of transplanted cancer cells
in rodents generally relies on luminescence measurements, which suf-
fer from limited resolution [189]. High resolution live imaging of tumors
is possible in rodents by intravital microscopy [224]. However, this pro-
cedure requires invasive surgical procedures.
4.5.3. Screening of cancer nanomedicines
Various xenograft cancermodels used in rodents can be successfully
translated to zebraﬁsh, including models for metastasis [225]. At pres-
ent, xenografting remains the method of choice for zebraﬁsh-based
drug discovery and development of cancer nanomedicines, as empha-
sized in speciﬁc reviews [209,226]. Key advantages of this approach in-
clude the ability to transplant hundreds of larvae a day, the ability of
zebraﬁsh to support relatively large tumor burdens, the observed
rapid onset of cancer, transparent larvae (for live ﬂuorescence imaging)
and the use of human cancer cell lines, which are stained or genetically
modiﬁed to express ﬂuorescentmarkers [185,209]. In addition, Stoletov
et al. were able to observe characteristic fenestrations in the tumor vas-
culature following transplantation of cancer cells overexpressing vascu-
lar endothelial growth factor into zebraﬁsh embryos [219,227]. This
may prove a valuable model for the characterization of nanomedicines
designed to passively accumulatewithin solid tumors via the EPR effect.
However, the generation of such an ‘EPR zebraﬁsh model’ will require
thorough characterization given the developing vasculature of zebraﬁsh
larvae is intrinsically leaky, as evidenced by the increased observed ex-
travasation of long circulating nanoparticles into the tissues of healthy
larvae [27]. In addition, the size of the xenografted tumor is a potentially
critical parameter. On the one hand, tumors in zebraﬁsh larvae are in-
herently limited in size, raising questions over the conservation of key
characteristics of large tumors, such as functional tumor microenviron-
ment or the presence of a hypoxic/necrotic core. On the other hand, as
observed in rodent tumormodels, the use of adult zebraﬁsh to generate
larger tumors could result in the overestimation of nanomedicine per-
formance due to exaggerated tumor growth rates and disproportionally
large tumors [228]. Moreover, by using adult zebraﬁsh, the many ad-
vantages of zebraﬁsh larvae, such as optical transparency and availabil-
ity, are lost.
If carefully implemented, zebraﬁsh larvae xenograft models can be a
valuable tool to optimize speciﬁc aspects of nanomedicine performance
under in vivo conditions. Gao et al. successfully used zebraﬁsh larvae to
generate tumor models using multidrug resistant cancer cells, since
comparable models in mice often lose drug resistance over long exper-
imental time periods [229]. Making use of the optical transparency of
zebraﬁsh larvae, injected cells can be pre-treated (with membrane
dyes or genetically modiﬁed) to obtain ﬂuorescent cancer cells or cells
expressing speciﬁc proteins/receptors. Going one step further, Yang
et al. injected transfected cancer cells, expressing a coiled coil forming
peptide, into zebraﬁsh larvae [230]. Through subsequent injection of
nanoparticles decorated with a complementary coiled coil peptide, se-
lective cancer cell delivery of ﬂuorescent nanoparticle cargos, viamem-
brane fusion, was demonstrated.
Several ways of applying nanomedicine formulations to zebraﬁsh
xenografts have been demonstrated, including addition to the zebraﬁshas a preclinical in vivo screeningmodel for nanomedicines, Adv. Drug
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22media [231], direct co-injection of a nanomedicine/cancer cell mixture
[232–234] or injection of pre-treated cancer cells [235]. While issues
surrounding the addition of nanomedicines to zebraﬁsh media have
already been discussed in this review, as potential cancer therapies, nei-
ther co-injection nor pre-treatment of cancer cells with nanomedicines
accurately reﬂect any realistic course of treatment. Moreover, these ad-
ministration routes do not exploit a key advantage of using zebraﬁsh
larvae, namely the ability to assess blood circulation behavior, a key pa-
rameter of all clinically approved cancer nanomedicines. Ideally,
zebraﬁsh larvae xenografts should be established and characterized be-
fore nanomedicine injection into blood circulation, as described by
Evensen et al. [236]. To the best of our knowledge, this latter study is
the most extensive application of zebraﬁsh xenografts with regards to
nanoparticle characterization. In a separate study, Zhou et al. exploited
an established zebraﬁsh model of cancer metastasis [225,237] to inves-
tigate the role of TGF-β during cancer metastasis and demonstrated cy-
tokine function in both zebraﬁsh and human cancer cells. Based on
these ﬁndings and extensive characterization of this cancer model,
Zhou et al. were subsequently able to develop a nanomedicine formula-
tion for the co-delivery of two drugs to cancer cells [235]. This study
highlights the importance of using well-established zebraﬁsh cancer
models during nanomedicine development.
Various readouts to assess cancer nanomedicine efﬁcacy in zebraﬁsh
cancer models are available. Many studies report antiangiogenic prop-
erties of nanomedicines [233,234,238] following reported protocols
[196]. In addition, evaluation of tumor growth or metastasis have been
reported, to various degrees of detail [229,231,232,238]. However,
assessing such experimental readouts in a reproducible, robust, and
representative way remains a major issue. To address this, Wehmas
et al. developed imaging software protocols to reproducibly measure
glioblastoma cell migration and invasion in zebraﬁsh larvae following
nanomedicine treatment [239]. Other groups have reported polymerase
chain reaction (PCR) procedures to assess RNA levels of speciﬁc tumor
markers, such as vascular endothelial growth factor (VEGF) [240,241],
as a quantitative assessment of nanomedicine treatment efﬁcacy.5. Discussion and conclusion
The potential value of the zebraﬁsh model for nanomedicine devel-
opment has beendemonstrated bymany studies. In particular, zebraﬁsh
larvae are uniquely placed to bridge the gap between in vitro models
and rodent in vivo studies given their availability in large numbers,
their optical transparency, the availability of numerous transgenic ﬂuo-
rescent lines and the relatively low costs of husbandry and experimen-
tal set-ups. These features facilitate the rapid and cost-effective
assessment of nanomedicines, under in vivo conditions and down to
themacromolecular level. Nanomedicine assessment inwhole living or-
ganisms is particularly important as nanomedicine-bio interactions are
determined by a combination of biological processes, anatomical fea-
tures and molecular mechanisms. Up to date, this dynamism and com-
plexity simply cannot be accurately mimicked in vitro [242].
Zebraﬁsh models can be used for formulation screening using re-
ported experimental set-ups and conventional imaging technologies.
Screening of up to 20 nanomedicine formulations per day, researcher,
and microscope is feasible. Nevertheless, to reach high-throughput
screening capabilities, fully automated injection, imaging, and analysis
protocols will need to be developed. Towards this goal, signiﬁcant prog-
ress has been made to fully automate zebraﬁsh injections [243-247]
using organ-targetedmicroinjection systems [248]. However, these sys-
tems remain highly customized and are not widely available. Further-
more, automated injection into zebraﬁsh blood circulation, given the
precision required, remains a major unmet challenge. Nevertheless,
given the zebraﬁshmodel for biomedical applications is rapidly gaining
interest, further technical developments to improve screening speed
and accuracy are anticipated.Please cite this article as: S. Sieber, P. Grossen, J. Bussmann, et al., Zebraﬁsh
Deliv. Rev., https://doi.org/10.1016/j.addr.2019.01.001Zebraﬁsh are not yet considered a standardmodel for nanomedicine
research. Further studies are necessary to fully characterize the model,
evaluate potential applications, and assess its predictive value for stud-
ies in higher animals. Prediction of therapeutic efﬁcacy or exact phar-
macokinetics requires precise characterisation of physiological
features. As highlighted above, the protein corona has a strong effect
on nanoparticle behavior in biological environments [249,250]. Several
publications have demonstrated the source of serum proteins (i.e.
sheep, rat, human, rabbit) differentially inﬂuences the extent to which
nanoparticles aggregate as well as their targeting efﬁciencies
[249,251]. Nevertheless, the importance of assessing nanoparticle for-
mulations in vivo, with respect to the adsorbed protein corona, have
been highlighted by Hadjidemetriou et al. Here, striking differences be-
tween protein corona compositions formed in vitro (plasma incubation)
and those formed in vivo (rodent injection and recovery)were observed
resulting in markedly different proﬁles of both nanoparticle receptor
binding and cellular uptake [252].
Further research is therefore needed to investigate the protein com-
position of zebraﬁsh plasma, which has not yet been fully characterized
[73]. Similarly, there are still several fundamental biological unknowns
of the zebraﬁsh that need to be fully characterized, including presence
or absence of Kupffer cells and blood-brain barrier integrity. In terms
of experimental parameters, both the route of nanomedicine adminis-
tration and the developmental stage of the zebraﬁsh are critical. Nano-
particles should always be administered to zebraﬁsh larvae via the
same anticipated route used in higher order animals and ultimately pa-
tients. For example, incubation of nanoparticles in zebraﬁshmedia does
not reveal toxicological information of the same formulation adminis-
tered into blood circulation. With respect to development stage, it is
critical to appreciate that zebraﬁsh development is a very rapid process,
especially during early developmental stages (up to larvae). The pres-
ence andmaturation of different cells and organs during early develop-
ment can change in the timeframe of hours and must be considered
carefully, particularly with respect to timing of nanomedicine adminis-
tration and imaging over different experimental days.
Despite these open questions and challenges, zebraﬁsh models are
highly predictive when it comes to the characterization of pharmacoki-
netic properties of nanoformulations. For example, disparities between
in vitro and in vivo results have been demonstrated when determining
the optimal ligand density of receptor targeted nanomedicines. In
vitro, higher ligand densities often result in an increased cellular uptake.
However, this often does not translate to rodent in vivo studies, where
intermediate ligand densities are often optimal so as to balance circula-
tion, targeting, and clearance proﬁles [253]. Witzigmann et al. used a
zebraﬁsh larvae xenograft model to optimize nanoparticle targeting li-
gand density. As expected, optimal ligand densities in vitro did not cor-
relate with in zebraﬁsh larvae studies. However, the latterwas precisely
predictive of subsequent rodent in vivo experiments (Witzigmann et al.,
manuscript in preparation).
The vast majority of nanomedicine research in zebraﬁsh is per-
formed in zebraﬁsh larvae (see footnote1). This is primarily due to
their easy availability and favorable imaging properties (dimension
and transparency). These advantages diminish at later developmental
stages. Zebraﬁsh larvae are therefore ideal tools to assess nano-bio in-
teractions occurring over short timeframes. This includes cell speciﬁc
binding, clearance by cells of the innate immune system and functional-
ity of advanced nanosystems (i.e. enzyme/gene delivery). Zebraﬁsh
models might not be well suited to assess long-term effects of
nanomedicines (e.g. evaluation of chronic toxicity of nanomedicines fol-
lowing repeated administration).
In conclusion, formulation design andoptimization of nanomedicines
in complex biological environments are key steps prior to ﬁrst
rodent in vivo experiments. Due to the inherent complexity and
diversity of physicochemical parameters of nanomedicines, selection
of appropriate biologicalmodel systems during preclinical development
of nanomedicines is crucial (Fig. 4). Several factors inﬂuence thisas a preclinical in vivo screeningmodel for nanomedicines, Adv. Drug
Fig. 4. Comparison of different preclinical models for nanomedicine development. Factors affecting the appropriate selection of a model system during nanomedicine formulation design
and optimization are represented. Depending on the experimental complexity and rationale, each model system has its speciﬁc advantages and disadvantages. An optimized screening
strategy relies on a smart combination of several available model systems and is key to success during clinical translation.
12 S. Sieber et al. / Advanced Drug Delivery Reviews xxx (2019) xxxselection, including the extent to which complex biological conditions
are mimicked, user control over experimental parameters, ability to
screen appropriate numbers of samples, time, and costs. To this end,
every available (e.g. 2D/3D cell culture) or emerging model system
(zebraﬁsh, organ-on-a-chip) has its own advantages and disadvantages.
Ultimately, both in vitro and in vivo model systems (i.e. zebraﬁsh)
should be used to complement, enrich, and inform the design and opti-
mization of nanomedicines prior to ﬁrst injections in rodents. An ap-
proach, which aligns with reduce, replace and reﬁne (3Rs) legislative
guidelines concerning the ethical use of animals in research. With this
arsenal of techniques, we may ﬁnally see the long awaited advance of
many new nanomedicines from bench to bedside.
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Highlights: Recognition and uptake by cells of the immune system (i.e. macrophages) is one of the 
major nanomedicine clearing mechanism and mainly affected by nanomedicine size and surface 
modification (i.e. PEGylation). In this study, differently sized liposomes modified with varying amounts 
and molecular weights of PEG were assessed regarding their clearance by macrophages following the 
traditional drug development process (preparation and physicochemical characterization, in vitro, 
in vivo). In addition, the zebrafish was used as a complementary in vivo screening model in order to 
design and optimize nanomedicine formulations under complex biological conditions. Finally, selected 
and most interesting findings were verified in a biodistribution study in rats, demonstrating the 
predictive power of the zebrafish model.
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Macrophage recognition of nanoparticles is highly influenced by particle size and surface modification. Due to the lack of appropriate
in vivo screening models, it is still challenging and time-consuming to characterize and optimize nanomedicines regarding this undesired
clearance mechanism. Therefore, we validate zebrafish embryos as an emerging vertebrate screening tool to assess the macrophage
sequestration of surface modified particulate formulations with varying particle size under realistic biological conditions. Liposomes with
different PEG molecular weights (PEG350-PEG5000) at different PEG densities (3.0-10.0 mol%) and particle sizes between 60 and 120 nm
were used as a well-established reference system showing various degrees of macrophage uptake. The results of in vitro experiments,
zebrafish embryos, and in vivo rodent biodistribution studies were consistent, highlighting the validity of the newly introduced zebrafish
macrophage clearance model. We hereby present a strategy for efficient, systematic and rapid nanomedicine optimization in order to facilitate
the preclinical development of nanotherapeutics.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Key words: Nanoparticles; Liposomes; PEG; Cell uptake; Zebrafish screening model; Systemic clearance; Macrophage accumulationNanomedicines offer valuable therapeutic options by delivering
drugs of interest to diseased tissues or organs. By modifying their
physicochemical properties, interactions of nanomedicines with
macrophages and other cells of the mononuclear phagocyte system
(MPS) can be tailored to the intended application. On one hand,
this can be exploited to treat various diseases. During inflammation
and cancer for example, nanomedicines can be used to alter the
polarization state of macrophages (i.e. M1, M2).1–3 Furthermore,
several infectious pathogens such as tuberculosis persist in
macrophages and thus targeting these microbial reservoirs canConflicts of Interest: The authors declare no conflict of interest regarding th
Acknowledgments: DW and JH have equally contributed to the present public
pharmazeutischen Nachwuchses in Basel”, the “Freiwillige Akademische Gesellsc
and No. 173057) and the EU Horizon 2020 project “NanoReg2”. Prof. Dr. M. A
zebrafish eggs and sharing their expertise.
⁎Corresponding authors at: Division of Pharmaceutical Technology, Departme
E-mail addresses: dominik.witzigmann@unibas.ch, (D. Witzigmann), joerg.h
1 These authors contributed equally to this work.
https://doi.org/10.1016/j.nano.2018.11.017
1549-9634/© 2019 The Authors. Published by Elsevier Inc. This is an open acc
licenses/by-nc-nd/4.0/).dramatically decrease the disease progression.4,5 On the other
hand, most nanomedicine applications require a low uptake by the
MPS to increase circulation half-life and ultimately enhance
accumulation in target tissues.
In this regard, size and surface modification have been identified
as crucial physicochemical characteristics of nanomedicines.6
Consequently, the most advanced systems in clinics are based on
liposomal formulations with long circulating properties, achieved
by hydrophilic surface modification and a mean diameter of
approximately 100 nm.6,7 The state-of-the-art strategy to prevente publication of this paper.
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liposome surface with polyethylene glycol (PEG), i.e. a hydrophilic
polymer coating. In recent decades, various groups have analyzed
the effect of key PEG characteristics such as chain length
(i.e.molecular weight) and PEG concentration (i.e. surface density)
on pharmacokinetics of nanoparticles in vitro and in vivo.8–10
However, whereas some research groups report that circulation
times are relatively independent of changes in PEG modifications,
others report a PEG molecular weight and surface density
dependent influence on liposome circulation.8–10 Similarly, size
differences of liposomes may have a major impact on their
pharmacokinetics and clearance rate. For example, an upper particle
size limit of 150 nm was proposed to avoid rapid hepatosplenic
clearance whereas the lower size limit is set by the glomerular
filtration size cut-off of around 6 nm to avoid renal elimination.11
Nevertheless, many studies include particles with a large size range
up to micrometer scale,12 which is therefore in disagreement with
the generally accepted size range for biomedical applications.13,14
A major challenge in the design of novel nanomedicines is the
lack of appropriate screening models to optimize physicochemical
properties of nanoparticles. So far, in vitromodels can be used only
to study cellular interactions with nanoparticles. It is not possible to
predict from in vitro experiments to which degree small variations
in physicochemical properties and surface modifications influence
nanoparticle circulation properties in vivo and their accumulation
in macrophage rich organs such as the spleen. Furthermore, novel
nanomedicine components substituting PEG such as a broad range
of various polymers,15 polysarcosines,16 hyperbranched polyether
chains,17 or polyglycerol derivatives18 are continuously synthe-
sized and require a thorough analysis. Such novel nanomedicine
formulations have to be tested in vivo to account for the full
complexity of a living animal including the presence of blood flow,
shear stress, and serum proteins. In view of ethical considerations,
high costs and limited throughput of animal experiments in higher
vertebrates, zebrafish embryos have been proposed as a vertebrate
screening model for nanomedicines. Recent studies show that the
systemic circulation of nanoparticles can be assessed in a time-
effective manner using this novel screening tool.19–21
Since the evolution of the adaptive immune system took place
before the divergence of fish from other vertebrates, the innate and
adaptive immune system of teleost (zebrafish) and mammals is
highly conserved.22 Early embryonic macrophages are present in
zebrafish embryos already at 30 h post fertilization.23 Furthermore,
additional cells such as monocytes and dendritic cells, which define
the mammalian MPS can be found in adult zebrafish.24 Notably,
polarized macrophages (M1, M2) are present in zebrafish
embryos,25 which are of special importance for nanomedicines
intended to treat cancer or inflammatory disorders. Conclusively,
the zebrafish offers the possibility to assess nanomedicine clearance
by macrophages in a living animal under physiological conditions.
It was therefore the aim of the present study to validate the use of
the zebrafish model to investigate nanoparticle clearance by
macrophages. PEGylated liposomes were used as a well-
established model system. The influence of various parameters
such as PEG molecular weight (PEG350-PEG5000), PEG density
(3 mol%-10 mol%) and liposome size (60-120 nm) on zebrafish
macrophage clearance was assessed in a systematic zebrafish
screening approach under live in vivo conditions.Monodisperse liposome formulations with a physiologically
relevant and well defined size range and different PEG
modifications were prepared by a microfluidics Design-of-
Experiment (DoE) approach, followed by physicochemical and
in vitro characterization. Liposome clearance by macrophages
was studied using transgenic zebrafish embryos with fluorescent
macrophages in combination with fluorescently labeled liposomal
formulations. The effects observed for the variation of liposome
size and PEGylation were confirmed in vivo in rats using tissue
distribution studies with a focus on unwanted nanoparticle
accumulation in the spleen, i.e. the largest blood filter organ of
the body.26Methods
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy
(polyethylene glycol)-5000] (PEG5000) were purchased from
Corden Pharma (Liestal, Switzerland). 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]
(PEG2000) was obtained from Lipoid (Steinhausen, Switzerland).
Cholesterol and 1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbo-
cyanine perchlorate sterol (DiI) were purchased from Sigma-
Aldrich (Buchs, Switzerland). 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-[methoxy(polyethylene glycol)-350]
(PEG350), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-750] (PEG750), and 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic
acid (DSPE-DTPA) were obtained from Avanti Polar Lipids
(Alabaster, USA). 111InCl3 was purchased from Mallinckrodt
Pharmaceuticals (Hennef, Germany).
Preparation of fluorescent liposomes for zebrafish injections
using a full factorial Design-of-Experiments (DoE)
Liposomes were prepared using microfluidics (NanoAssemblr
Benchtop Instrument, Precision NanoSystems Inc., Vancouver,
Canada) as described previously.27 Briefly, microfluidics car-
tridges contained two separate inlets for the solvent (lipids in
ethanol) and the aqueous (Dulbecco's phosphate buffered saline
without calcium chloride and magnesium chloride, DPBS) phase.
The herringbone mixing structure ensured optimal mixing of the
two phases, resulting in liposome formation. To control liposome
size, the flow rate ratio (FRR, ratio of aqueous and organic phase)
of the two liquid phases was varied thereby influencing the speed
of polarity change. To finally identify the optimal FRR for each
lipid composition and to analyze the effects of PEG molecular
weight and PEG density on liposome size and PDI, a full factorial
DoE was used as described previously for various clinically
approved liposome formulations.28 Analysis of results and model
fitting of the statistical DoE were performed using Stavex 5.2
software (Aicos Technologies AG, Basel, Switzerland). Lipids
were dissolved in ethanol while the aqueous phase consisted of
DPBS. The total flow rate (TFR) was kept constant at 10 mL/min
while the flow rate ratio (FRR) between the solvent and aqueous
stream was adjusted for each formulation. The liposome
formulation was dialyzed overnight against H2O using a dialysis
membrane with a molecular weight cut-off of 12-14 kDa.31
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32Preparation of radiolabeled liposomes for rat in vivo studies
Radioactive labeling of liposomes with 111In was performed as
described previously.29 Liposomes with different sizes were
prepared in citrate buffered saline pH 5.4 at a total lipid
concentration of 60 mM including 3 mol% DSPE-DTPA. Lipo-
somes were incubated immediately before injection with 111InCl3 at
37°C for 45 min and purified using gel filtration chromatography
(NAP® 5 columns, Pharmacia Biotech AB, Uppsala, Sweden). The
outer buffer was exchanged to sterile saline.Dynamic light scattering measurements
Size and polydispersity index (PDI) of liposome samples were
determined by dynamic light scattering (DLS) using a Delsa Nano
C Particle Analyzer (Beckman Coulter, Nyon, Switzerland) as
described previously.30 All measurements were performed at
10 mM lipid concentration in H2O at room temperature.Cell culture
Liver cancer-derived cell lines HepG2 and Sk-Hep1 were
kindly provided by the cell depository of the Institute of Pathology,
University Hospital of Basel, Switzerland. Cells were maintained
in DMEM high glucose (4.5 g/L) containing 10% fetal calf serum
(FCS) and 1% penicillin–streptomycin (P/S). THP-1 cells (ATCC,
TIB-202) were cultured in Roswell Park Memorial Institute
(RPMI-1640) medium containing 10% FCS, 1% P/S, 10 mM
HEPES, 1% sodium pyruvate and 0.05 mM mercaptoethanol. All
cells were cultured at 37 °C under 5% CO2.
31,32Flow cytometry
In vitro uptake experiments were performed according to
published protocols.33,34 In brief, HepG2, Sk-Hep1 and THP1 cells
were seeded at a density of 1 × 105 cells/cm2 in a 12-well plate
(TPP, Trasadingen, Switzerland). In order to induce differentiation
of THP1 monocytes into macrophages, phorbol 12-myristate 13-
acetate (PMA) at a final concentration of 100 nM was added to
seeded THP-1 cells 72 h prior to the actual uptake experiment. For
uptake experiments, cells (80% confluence) were washed with
37 °C DPBS and incubated with cell culture media at final lipid
concentrations of 50, 100, and 200 mM, or corresponding volumes
of DPBS as negative control. Uptake experiments were terminated
3 or 24 h post incubation by removal of liposome or DPBS
containing cell medium and washing of cells with 1 mL of DPBS.
Cells were detached with 0.25% Trypsin–EDTA at 37 °C for 8
(HepG2, SkHep1) or 10 (THP1) min. The trypsin reaction was
stopped by adding 1 mL of ice-cold cell medium and the cells were
collected by centrifugation for 5 min at 200 ×g and 4 °C. The cell
pellet was washed with 1 mL ice cold DPBS, centrifuged and
suspended in 500 μL FACS buffer (DPBS, 0.05%NaN3, 1% FCS,
2.5 mM EDTA). Flow cytometry analysis was performed using a
FACSCanto II (BDBioscience, California, USA). DiI fluorescence
was excited at 561 nm and detected using a 586/15 bandpass filter.
Signals of 20,000 cells were analyzed using FlowJo analysis
software version V9/X (Tree-Star, Oregon, USA). Cell doublets
were excluded from analysis.Zebrafish embryo culture and injection
Zebrafish embryos/larvae from adult Tg(kdrl:EGFP)35 and Tg
(mpeg1:Gal4;UAS:Kaede)36,37 were raised at standard conditions
at 28 °C in zebrafish culture media38 containing 1-phenyl-2-
thiourea (PTU) and in accordance with Swiss animal welfare
regulations. Injections of liposome samples (10 mM) in zebrafish
embryos (2 dpf) were performed as described previously.19,39
Calibrated volumes of 1 nL were injected into the blood circulation
via the common cardinal vein using a micromanipulator (Wagner
Instrumentenbau KG, Schöffengrund, Germany), a pneumatic Pico
Pump PV830 (WPI, Sarasota, Florida), and a Leica S8APO
microscope (Leica, Wetzlar, Germany). Imaging of successful
injected zebrafish embryoswas performed 3 and 24 h post injection
(hpi) using an Olympus FV-1000 inverted confocal laser scanning
microscope (Olympus Ltd., Tokyo, Japan) equipped with a 10×
UPlanSApo (NA 0.4) and 20× UPlanSApo (NA 0.75) objective.
Macrophage colocalization analysis
To analyze macrophage clearance of liposomes, transgenic
zebrafish embryos were imaged using an Olympus FV-1000
inverted confocal laser scanning microscope equipped with a
20× UPlanSApo (NA 0.75) objective. For colocalization analysis
of liposomes with macrophages, the overlap coefficient was used
as implemented by the JaCoP plugin from Fiji ImageJ.40,41
Overlap coefficients are given as fold change in colocalization as
compared to PEG350 modified liposomes with a size of 90 nm.
Pharmacokinetic study in rats
Organ and tissue distribution profile of PEG350 and PEG2000
liposomes was analyzed in female Wistar rats (225-275 g body
weight; Janvier Labs, Saint-Berthevin Cedex, France). Animal
experiments were approved and carried out in accordance with
local animal welfare regulations. 111In-labeled liposomes, pre-
pared using a chelating strategy based on DSPE-DTPA, were
injected intravenously via the tail vein. The injection volume was
100-150 μL, the total activity was 10 MBq per rat, and the total
lipid concentration was 30 mM. After 24 h, animals were
euthanized, organs were collected and radioactivity associated
with organs was measured with a Berthold LB 951G gamma
counter (Berthold Technologies, Bad Wildbad, Germany) and
expressed in terms of injected dose (%ID) per g tissue.Results
Liposome preparation and physicochemical characterization
Since liposome PEGylation and particle size heavily influence
liposome interactionswith cells, a microfluidics-based formulation
approach was selected to obtain liposomes of comparable sizes
independent of PEG modification. Depending on the liposome
composition, increasing FRR can result in larger or smaller
liposomes. In order to accurately investigate the interplay between
FRR and each liposome composition (i.e. PEG molecular weight,
PEG density), a full factorial DoE was performed. At constant
FRRs, increasing PEG molecular weight resulted in smaller
liposomes (Figure 1). The FRR had a significant influence on
Figure 1. Preparation of PEGylated liposomes based on a Design-of-Experiment (DoE) approach. DSPC-cholesterol based liposomes with different PEG
molecular weights and PEG densities were prepared using a microfluidics technology. Different flow rate ratios (FRRs) were used to adjust liposome size. The
contour plots for each PEG chain length show the effect of different flow rate ratios and PEG densities on liposome size. r2 of model fits = 0.988-0.998. Specific
color legends represent liposome size (nm).
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density (mol%) had a variable influence on liposome size
depending on PEG type (0.001 ≤ P ≤ 0.259). The size model
fit for all PEG molecular weights was very good (r2 = 0.988-
0.998). Based on these findings, different types of PEGylated
liposomes with a defined size and a narrow, monodisperse particle
size distribution (i.e. a PDI b 0.15) were prepared by specifically
adjusting FRR for each formulation. The exact size and PDI
for each lipid composition using optimized FRRs are shown in
Table 1. Fluorescent and radiolabeled liposome samples, which
were injected into zebrafish or rats, were analyzed regarding their
stability upon storage at 4 °C (Supplementary Tables S1 and S2).
No significant changes of liposome size or PDI were observed forradiolabeled liposomes. One fluorescently labeled formulation
showed a final PDI over 0.250 after one year of storage. Despite the
high colloidal stability of the liposomal preparations, liposomes
were used immediately after preparation.
In vitro characterization
Cellular interactions of the prepared liposome librarywith three
human cell lines representative for hepatosplenic clearance were
studied using a well-established in vitro screening assay (Figure 2,
Supplementary Figure S1). HepG2 cells were used to mimic
hepatocytes, SkHep1 cells are derived from liver sinusoidal
epithelial cells, and THP1 cells represent macrophages. All cell33
Table 1
Size and size distribution of different PEG liposome formulations.
Liposome Modification
(mol% PEG MW)
Optimized FRR Size
(nm)
PDI
3.0 PEG350 2.85 91.6 0.142
6.5 PEG350 2.88 88.5 0.141
10.0 PEG350 3.19 83.7 0.041
3.0 PEG750 2.49 94.4 0.148
6.5 PEG750 2.39 94.2 0.077
10.0 PEG750 3.06 87.4 0.032
3.0 PEG2000 2.88 80.6 0.024
6.5 PEG2000 1.82 85.8 0.100
10.0 PEG2000 1.82 87.8 0.072
3.0 PEG5000 1.88 87.6 0.095
6.5 PEG5000 1.98 97.9 0.045
10.0 PEG5000 2.01 107.2 0.061
Based on a full factorial Design-of-Experiment (Figure 1), liposomes with
various PEG molecular weights (MW) and PEG densities (mol%) were
prepared using microfluidics with optimized flow rate ratios (FRR) to achieve
a uniform size independent of lipid composition. Hydrodynamic size in nm
and polydispersity index (PDI) were determined by dynamic light scattering.
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34lines were incubated for 3 and 24 hwith DiI labeled liposomes and
analyzed by flow cytometry to determine the fraction of DiI
positive (DiI+) cells (surface binding and/or internalization) and
mean fluorescence intensity (MFI). Thus, the degree liposome
interactions with cells characterized by a phagocytic or enhanced
endocytic potential could be determined. After 3 h of incubation,
phagocytic macrophages (THP1) showed a remarkably high
liposome cell interaction compared to hepatocytes (HepG2) and
liver sinusoidal epithelial cells (SkHep1). Notably, cellular
interactions of liposomes increased over time for all cell lines. At
both time points (i.e. 3 h and 24 h of incubation), an increased
PEG molecular weight and PEG density resulted in a decreased
liposome clearance. Liposomes modified with 3 mol% PEG
showed a higher clearance as compared to liposomes with 6.5 mol
%or 10 mol%PEG. PEG5000 decreased liposome clearancemore
efficiently than smaller PEG molecular weights.Influence of PEGylation on liposome clearance in the
zebrafish model
To assess the general clearance mechanisms of liposomes in the
zebrafish model, two different non-pegylated liposome formula-
tions (DSPC:cholesterol, 60:40 mol% and POPC:cholesterol
55:45 mol%) were initially injected into transgenic zebrafish
lines expressing a green fluorescent protein in its vasculature
(Supplementary Figure S2). As reported previously, liposome
formulations composed of the high transition temperature lipid
DSPC were mainly cleared via a scavenger receptor mediated
mechanism.19,20 However, this strong staining pattern does not
allow a parallel assessment of liposome accumulation in
macrophages, since the two signals are overlapping. To overcome
this issue, low transition temperature lipids (i.e.POPC) can be used,
as shown by a liposome formulation based on the clinically
approved Myocet. The Myocet-based formulation was not cleared
via scavenger receptors but resulted in distinct localized accumu-
lations in the vasculature. Further investigations demonstrated that
macrophages, but not neutrophils, were responsible for thisclearance (Supplementary Figure S3). An alternative approach to
decrease scavenger receptor clearance is the modification of
liposomes using PEG. Since PEGylation can be varied regarding its
molecular weight and density, this offers interesting perspectives
for a library screening and was therefore further investigated. To
this end, PEGylated liposomes were injected into blood circulation
of 2-day-old zebrafish using a micro-injector device (Figure 3, A).
A representative confocal image of a living zebrafish for
each liposome formulation 24 h post injection (hpi) is shown in
Figure 3,B. Fluorescent signal of DiI labeled PEGylated liposomes
in the caudal vein and the caudal hematopoietic tissue was heavily
influenced by variations of PEGmolecular weight and PEG density
on the liposome surface. To facilitate data evaluation, zebrafish
embryos were analyzed 24 hpi since the number of liposome
accumulations (representingmacrophage clearance) increased over
time. Consistent with the in vitro data shown above, an increase of
liposomes accumulation in the posterior caudal vein was observed
for liposomes with lower PEG density and lower PEG molecular
weight. Semi-quantitative visual scores for liposome accumulation
indicate that PEG5000 reduced the systemic clearance twofold as
compared to PEG350.
Influence of PEGylation on macrophage blood clearance in
transgenic zebrafish
Liposomes with a low degree of PEGylation showed and
extensive uptake into THP1 in vitro as well as a high degree of
agglomeration, most probably in macrophages, in the initial
zebrafish screening. In order to verify this hypothesis, fluorescent
(i.e. DiI labeled) liposomes containing 6.5 mol% of each PEG
molecular weight were injected into geneticallymodified zebrafish,
expressing green fluorescentKAEDEprotein in theirmacrophages.
Liposome clearance by macrophages was assessed qualitatively
and quantitatively by confocal laser scanning microscopy followed
by a colocalization analysis. With decreasing PEG molecular
weight, we observed an increased colocalization of liposomes with
macrophages resulting in a yellow signal, i.e. clearance of red
fluorescent liposomes by green fluorescent macrophages (Figure 4,
Supplementary Figure S4). In addition to the qualitative analysis,
macrophage uptake was quantified by calculating the overlap
colocalization coefficient of KAEDE (i.e. macrophages) and DiI
(i.e. PEGylated liposomes). Macrophage clearance of liposomes
decreased with increasing PEGmolecular weight at both 3 hpi and
24 hpi leading to statistically significant differences between low
and high PEG molecular weight formulations.
Influence of liposome size on macrophage clearance in
the zebrafish
After successfully demonstrating PEGylation effects in the
presented zebrafishmodel, the additional influence of liposome size
was investigated. Based on in vitro and zebrafish data, liposomes
modified with PEG5000 showed very little macrophage clearance
irrespective of the PEGdensity. Therefore, the smaller and clinically
used PEG2000 was used and compared to PEG350 in further
studies. Consequently, liposomes containing either 6.5 mol%
PEG2000 or 6.5 mol% PEG350 with sizes of 60, 90, and 120 nm
were prepared and injected into zebrafish. After 24 h, confocal laser
scanning microscopy was used to assess the systemic clearance of
Figure 2. In vitro clearance of liposomes with different PEG modification. Hepatocytes (HepG2), liver sinusoidal endothelial cells (SkHep1) and macrophages
(THP1) were incubated with DiI labeled liposomes with a uniform size (Table 1). Different modifications (i.e. variation in PEG molecular weights and PEG
densities) were tested for 3 and 24 h at different total lipid concentrations (50 mM: low, 100 mM: medium, and 200 mM: high). The percentage of DiI positive
(DiI+) cells is indicated and highlighted using a color code shown in the right panel from low clearance (green) to high clearance (red).
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As shown in Figure 5, PEG2000 modified liposomes showed a
higher shielding effect as compared to PEG350 for all liposome
sizes (i.e. normalized overlap coefficient always below 1 as
compared to 90 nm sized PEG350 liposomes). Interestingly,
PEG350 modified liposomes with a size above 90 nm showed a
significantly higher macrophage clearance as compared to smaller
liposomes. In sharp contrast, surface modification of liposomes
using PEG2000 successfully decreased macrophage uptake of all
liposomes independent of size. Even for liposomes with a size of
120 nm, no statistically significant difference in systemic macro-
phage clearance was observed. Thus, the zebrafish screening
revealed a clear correlation between liposome size and PEG
molecular weight on liposome shielding. Importantly, two groups
have been identified by analyzing macrophage clearance: Lipo-
somes with a size of 60-90 nm were shielded independent of PEG
molecular weight whereas for liposomes with a size of 120 nm
PEG2000 was needed to prevent macrophage clearance.
Influence of liposome size and PEGylation on splenic clearance
in rats
To verify the combined influence of small changes in liposome
size and PEGylation identified in the zebrafish model, a selection
of two liposome sizes (70 nm vs. 120 nm) was injected into rats
(Figure 6). Organ biodistribution was analyzed 24 hpi with a focus
on clearance by the spleen, which contains a large number of
tissue-resident macrophages.42 As observed during our zebrafish
experiments, liposome size strongly correlated with macrophage
clearance (high accumulation in spleen). Systemic splenic
clearance of 70 nm liposomes was low and increased PEG
molecular weight (i.e. 6.5 mol% PEG2000) did not result in a
beneficial in vitro biodistribution. Liposomes with an average size
of 120 nm showed increased accumulation in the spleen. Incontrast to small liposomes, surface modification of liposomes
using PEG2000 was almost twice as effective in shielding as
compared to PEG350.Discussion
The physicochemical properties of nanomedicines such as size
and surface charge heavily influence their pharmacokinetics and
biodistribution. Thus, strategies to optimize these nanoparticle
attributes and a valid prediction of these characteristics early in
development under realistic biological conditions could increase
the poor translation of promising preclinical results into effective
therapeutics. Liposomes are the most advanced nanomedicines and
well established in clinics43 and can therefore be used to establish
quantitative relationships between physicochemical characteristics
and behavior in vivo.44 Indeed, it was shown that varying particle
size or single components can potentially affect the circulation
properties of the final formulation.19,45 Considering that advanced
liposomal formulations can easily contain five or more (lipid)
components as well as novel designed components such as PEG
alternatives, optimization of these parameters remains complex.
Therefore, nano-bio interactions should be investigated under
dynamic conditions (i.e. blood flow and shear stress) in presence
of plasma proteins including apolipoproteins or complement
factors,46,47 which are known to strongly influence interactions of
liposomes with macrophages. To this end, Chang et al already
introduced adult zebrafish as an animal model to study nanoparticle
biodistribution prior to rodent in vivo studies. Nanoparticles prepared
from different materials (i.e. polystyrene, titanium dioxide, dextran-
sulfate, hyaluronic acid, and chitosan) were assessed and a high
correlation between in vitromacrophage uptake and adult zebrafish
liver accumulation was found.48 Whereas adult zebrafish allow
analysis of nanoparticle biodistribution and interaction with fully35
Figure 3. Influence of PEG modification on liposome accumulation in the zebrafish. DiI labeled Liposomes with various PEG molecular weights and PEG
densities were injected into blood circulation of zebrafish 2 days post fertilization. (A) The indicated area (dotted box) of injected zebrafish representing part of
the caudal vein and the caudal hematopoietic tissue was analyzed for liposome accumulates (white arrows) 24 h post injection. (B) Representative confocal
images of the tail region for each liposome formulation are shown. The number of red dots (i.e. liposome accumulates) in the caudal vein was counted and is
represented as mean ± SEM (n = 3).
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36matured organs, this approach is not applicable for screening.
However, zebrafish embryos are easily available in large numbers
and offer the possibility for spatio-temporal fluorescence imaging
due to their optical transparency in combination with various
transgenic fluorescent reporter lines. Altogether, we have therefore
evaluated the potential of zebrafish embryos to serve as a vertebrate
screening tool to optimize particulate drug formulations in vivo.19 It
was thus the primary goal of the present study to extend the use of the
zebrafish model and to demonstrate that not only the systemic
circulation but as well clearance of nanoparticles by macrophages
can be evaluated by this tool and predicted for higher animals. A
prerequisite for the present study was the availability of PEGylated
liposomal formulations with a defined composition and preciselycontrolled size distribution as a reference system. As shown
previously, PEG-lipids preferentially deposit on the liposome
surface thereby increasing its relative polarity. The larger the
molecular weight or molar ratio of PEG-lipids is, the smaller the
resulting liposomes (i.e. PEG-lipid dictated liposome size).49,50
Therefore, a systematic optimization of the scalable microfluidics
technology using a DoE approach was used. Compared to extrusion
trough filter membranes, where only a limited number of filter pore
sizes are available, the microfluidics approach allowed a precise
control of liposome size and PDI (independent of PEGmodification)
for the screening process. In agreement with previous studies, the
flow rate ratio (FRR) of ethanolic lipid solution and aqueous buffer
was thereby identified to determine liposome size.28,51 This
Figure 4. Influence of PEG modifications on macrophage clearance in transgenic zebrafish. DiI labeled liposomes modified with the indicated PEG molecular
weights were injected into the blood circulation of zebrafish 2 days post fertilization. Confocal images were acquired 3 and 24 h post injection (hpi).
Colocalization analysis of green fluorescent macrophages (KAEDE) and DiI labeled liposomes was performed based on normalized overlap colocalization
coefficients. Values are means ± SEM, n = 3. *P b 0.1 or **P b 0.05 (multiple comparison using ANOVA assuming equal variance and Bonferroni correction)
as compared to 90 nm sized PEG350 liposomes.
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teristics of liposomal formulations (e.g. PEG molecular weight)
while others remain constant (e.g. size).
Fluorescent labeling of the liposomes (i.e. lipophilic cationic
indocarbocyanine dyes) or incorporation of a metal chelator
(i.e. DSPE-DTPA needed for 111In labeling) impaired neither
size nor their storage stability. The latter observation is confirmed
by studies, which demonstrated excellent in vivo properties of
DSPE-DTPA liposomes.29,52 It should be noted that active loading
of liposomes with [3H]doxorubicin using a pH- or ion-gradient did
induce changes in liposome size, especially pronounced when
small liposomes with a diameter below 90 nm were loaded.
Consequently, protocols established previously by our team for
systemic pharmacokinetics and tissue distribution studies53 could
not be used for the present study to evaluate the effect of small
differences in liposome size on systemic clearance.
The traditional pattern of organization to screen interactions of
nanoparticulate formulations with biological systems starts with
in vitro experiments with cultured cells and progresses to
investigations in vivo in rodents.54 For in vitro experiments,
nanoparticle uptake by cultured cells is analyzed mostly under static
conditions. This experimental set-up allows a first characterization of
nanoparticle interactions with living cells in a fast and controlled
way. However, it has been shown that presence of plasma proteins55
as well as dynamics of fluids and resulting shear stress56,57 heavily
influences the interaction of nanoparticle with cells, e.g. by altering
the protein corona. Based on the design of the in vitro system,aggregation and subsequent sedimentation of liposomes can heavily
influence cellular uptake results.58 Our flow cytometry analysis
revealed the highest clearance rate (number of DiI labeled liposome
positive cells) for differentiated phagocytic THP1 cells, followed by
liver sinusoidal endothelial cells (SkHep1) and hepatocytes
(HepG2). This can be explained by the phagocytic nature of THP1
cells and high endocytic activity of SkHep1 cells.59 Experiments
performed after 24 h showed no or only minor differences between
cell lines and liposomal formulations, probably due to saturation of
liposome uptake and due to static cell culture conditions.
Furthermore, liposomes containing PEG2000 showed a higher
degree of interactions with different cells as compared to liposomes
modified with PEG750. Similar phenomena have already been
described previously and were linked to altered protein binding
resulting in differences in the protein corona during in vitro assays.60
Notably, flow cytometry analysis does not allow to clearly
distinguish between liposomes which were internalized or simply
bound to the cell surface. However, tedious washing steps and
trypsinization of cells at the end of the uptake experiment decrease
the amount of cell surface bound liposomes. In addition, reporting
the number of DiI positive cells instead of the MFI can partially
overcome this issue. Nevertheless, an additional liposome uptake
study by confocal microscopy including a cell membrane staining
would be required to completely answer such a question. This
example demonstrates that a full and systematic assessment of
nanoparticle uptake in vitro using different cell types is time-
consuming and not suitable for a rapid screening process.37
Figure 5. Influence of liposome size and different PEG modification on macrophage clearance in zebrafish. PEG350 or PEG2000 modified and DiI labeled
liposomes with three different sizes (60 nm, 90 nm, and 120 nm) were injected into the blood circulation of zebrafish 2 days post fertilization. Confocal images
were acquired 24 h post injection (hpi). Colocalization of green fluorescent macrophages (KAEDE) and DiI labeled liposomes was quantitated using normalized
overlap colocalization coefficients. Values are means ± SEM, n = 5. not significant (NS) or **P b 0.05 (ANOVA and Bonferroni correction) as compared to
90 nm sized liposomes.
Figure 6. Influence of PEG modification and liposome size on splenic clearance in rats. 111In labeled liposomes with 6.5 mol% of PEG350 or PEG2000 were
injected into blood circulation of rats via the tail vein. Two size groups of liposomes, i.e. smaller liposomes (70 nm) and larger liposomes (120 nm), of each PEG
molecular weight were tested. Organ distribution of radiolabeled liposomes 24 h post injection is shown. Values are means ± SEM, n = 3. ***P b 0.001
(ANOVA and Bonferroni correction).
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experiments, we injected the same lipid formulations into 2 day
old zebrafish and analyzed liposome blood circulation behavior
in vivo by live confocal imaging. This enables an assessment of
PEG molecular weight and PEG density under in vivo conditions
in a cost-effective and time-efficient manner. Analysis of
nanoparticle biodistribution in zebrafish was facilitated using
transgenic lines expressing fluorescent proteins in vasculature or
macrophages. Increasing PEG molecular weights and densities
efficiently decreased liposome clearance by macrophages as
shown by semi-quantitative image analysis (i.e. colocalization
studies). Interestingly, the high cellular uptake in vitro of PEG2000
liposomes was not observed in zebrafish experiments. In zebrafish
embryos, phagocytosis by macrophages was reduced with
increasing PEG chain length and PEG density (as known from
numerous in vivo studies in higher vertebrates including human),
underlining the importance of studying such phenomena under
dynamic conditions in vivo. Encouraged by these results, the
proposed zebrafish model was further validated regarding its
ability to resolve small formulation differences such as size
variations in the range of 30 nm. To this end, liposomes with a size
of 60, 90, and 120 nm and modified with either PEG350 or
PEG2000 were compared. Smaller liposomes with a medium PEG
density (i.e. 6.5 mol%) and a size of 60 and 90 nm showed a
decreased macrophage uptake as compared to their larger
counterparts with a size of 120 nm. Interestingly, increasing the
PEGmolecularweight from350 to 2000 Dawas sufficient tomask
this size dependent phenomenon.
To validate these findings and to analyze whether the data
acquired in zebrafish embryos are predictive for rodents, we
performed control experiments in rats. Previous studies in rodents
have already shown high clearance rates for non- and low-
PEGylated liposomes by the MPS which reached a plateau at
24 hpi.33,61,62 Consequently, the experimental set-up was chosen
accordingly to reduce the number of needed rats. Non-PEGylated
liposomes were excluded from the study due to rapid clearance and
organ biodistribution was analyzed 24 hpi. Liposomes with a size
below and above the cut-off for macrophage uptake observed in
zebrafish (i.e. 70 and 120 nm) modified with either 6.5 mol% of
PEG350 or PEG2000 were radiolabeled with 111In and injected
intravenously. Biodistribution of liposomes was analyzed with a
special focus on accumulation of liposomes in the spleen. This
organ is ideally suited to study cellular clearance of particles (such
as microorganisms but also nanoparticles) by macrophages due to
its high blood filtration capacity, specific anatomical features and a
high concentration of adaptedmacrophages.26,42 Indeed, as shown
in Figure 6, uptake in terms of %ID/g tissue was maximal for this
organ. Liver tissue was not analyzed because this tissue consists of
several cell types able to clear liposomes from blood circulation,
i.e. parenchymal (i.e., hepatocytes, 70%-80% of all liver cells)63
and non-parenchymal liver cells including sinusoidal endothelial
cells (LSEC, 10%-20%)59 and hepatic macrophages (Kupffer
cells, 10%-15% of the total liver cell population).64 In fact, a recent
publication by our team emphasized the cellular sequestration of
nanoparticles by liver sinusoidal endothelial cells via the Stabilin-2
scavenger receptor.20 These factors limit the reliable assessment
of nanomedicine clearance by liver-resident macrophages
(i.e. Kupffer cells). Thus, further studies are warranted focusingon the contribution of different liver cell types towards the
clearance of nanomedicines. As demonstrated in zebrafish,
liposome size was an important determinant for phagocytosis
and modification of liposomes with high molecular weight PEG
(i.e. PEG2000) was able to shield 120 nm liposomes and
decrease macrophage uptake in the spleen. Thus, analysis of
liposome clearance by macrophages in the zebrafish showed a
high correlation with accumulation of liposomes in the spleen
when injected intravenously in rats.
The development of nanomedicines from the preclinical
situation to the human application is a time-consuming and
challenging process, especially if novel nanomedicine components
have to be tested. Thus, new strategies are needed to select
promising nanoformulations and optimize their characteristics
early in drug development. In this study, the zebrafish was
successfully used and validated to assess macrophage clearance of
nanoparticles using PEGylated liposomes as a reference system.
Data obtained in zebrafish experiments correlated with in vivo
experiments in rodents. Importantly, the zebrafish may serve as a
bridging tool to mimic the complex situation in vivo with the
advantage to screen a large number of nanoparticle samples in a
time- and cost-effective manner. As a consequence, the presented
zebrafish model could also be used for the optimization of
nanomedicine-based therapies which take advantage of macro-
phage uptake (i.e. cancer, inflammation, infections). Notably, not
all pharmacokinetic parameters such as metabolism or renal
filtration can be assessed in zebrafish embryos. However, this
vertebrate screening model has the potential to reduce the number
of formulations needed to be tested in mammals and to serve as a
predictive in vivo tool in early phases of the nanomedicine
development process.Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.nano.2018.11.017.References
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Highlights: Liposomes are the clinically most successful form of nanomedicines and therefore well 
characterized. However, liposomes can be composed of various lipids and different amounts of 
cholesterol, both influencing their pharmacokinetic behavior in vivo. In this study, different liposome 
formulations with reported pharmacokinetics in rodents were injected into the blood circulation of 
zebrafish embryos and investigated regarding their circulation and extravasation behavior. Qualitative 
and semi-quantitative zebrafish findings were evaluated and linked to known pharmacokinetic 
properties in rodents (i.e. long versus short circulating). Finally, the predictive power of the presented 
zebrafish model was demonstrated by assessing the so far unknown pharmacokinetic behavior of a 
specific liposome formulation first in zebrafish and finally in rats.
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A B S T R A C T
Nanomedicines have gained much attention for the delivery of small molecules or nucleic acids as treatment
options for many diseases. However, the transfer from experimental systems to in vivo applications remains a
challenge since it is diﬃcult to assess their circulation behavior in the body at an early stage of drug discovery.
Thus, innovative and improved concepts are urgently needed to overcome this issue and to close the gap be-
tween empiric nanoparticle design, in vitro assessment, and ﬁrst in vivo experiments using rodent animal
models.
This study was focused on the zebraﬁsh as a vertebrate screening model to assess the circulation in blood and
extravasation behavior of nanoparticulate drug delivery systems in vivo. To validate this novel approach,
monodisperse preparations of ﬂuorescently labeled liposomes with similar size and zeta potential were injected
into transgenic zebraﬁsh lines expressing green ﬂuorescent protein in their vasculature. Phosphatidylcholine-
based lipids diﬀered by fatty acid chain length and saturation. Circulation behavior and vascular distribution
pattern were evaluated qualitatively and semi-quantitatively using image analysis. Liposomes composed of lipids
with lower transition temperature (< 28 °C) as well as PEGylated liposomes showed longer circulation times and
extravasation. In contrast, liposomes composed of lipids with transition temperatures > 28 °C bound to venous
parts of the vasculature. This circulation patterns in the zebraﬁsh model did correlate with published and ex-
perimental pharmacokinetic data from mice and rats.
Our ﬁndings indicate that the zebraﬁsh model is a useful vertebrate screening tool for nanoparticulate drug
delivery systems to predict their in vivo circulation behavior with respect to systemic circulation time and
exposure.
1. Introduction
During the last decades, great expectations were placed on passively
and actively targeted nanoparticles for the treatment of severe diseases
including solid and metastatic tumors. The visionary concept of the
magic bullet, introduced by Paul Ehrlich in 1907 [1], laid the founda-
tion for a new age of cancer treatment. Liposomes, ﬁrst described by
Bangham et al. in 1965 [2], can be considered to be the by far most
successfully used nanoparticles in clinical cancer care. Since the ﬁrst
approval of a liposomal anticancer product, namely Doxil/Caelyx in
1995, several lipid-based formulations have reached the market [3,4].
This milestone generated much hope for oncology-based nanoparticu-
late therapeutics resulting in an increased interest in cancer nanome-
dicines and a rapid growth of this research ﬁeld [5].
Importantly, the physico-chemical properties of liposomal formulations
have a direct impact on their pharmacokinetics and tissue distribution.
Correspondingly, the eﬃcacy and safety of the encapsulated drugs heavily
depend on the used nanoparticulate drug delivery system. Recently,
Lammers et al. highlighted that shifting the balance between oﬀ- and on-
target accumulation is the most rational point for clinical use of nanome-
dicines [6]. Therefore, optimization of pharmacokinetics and biodistribu-
tion is of utmost importance for the success of nanomedicines. Unique na-
noparticle properties combined with prolonged blood circulation
characteristics result in decreased oﬀ-target eﬀects and increased prob-
ability to reach the target side, e.g. via enhanced permeability and retention
eﬀect (EPR) in solid tumors.
The predictability of in vivo performance, however, remains a critical
bottleneck in the development of nanoparticles and hampers the translation
from in vitro to in vivo applications [3,7]. For example, the pharmacoki-
netic proﬁle of liposomes can be inﬂuenced by multiple parameters
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including lipid composition, amount of cholesterol, PEGylation, or for-
mulation methods as it is described in excellent reviews [8,9,4,10]. These
parameters oﬀer virtually endless possibilities for the optimization of na-
noparticle formulations. Thus, liposome formulations are often designed
empirically and based on physico-chemical properties but rarely optimized
after the ﬁrst in vivo experiments in mice and rats due to high costs and
time consumption of in vivo studies. To overcome this issue and to advance
the correlation between nanoparticle properties and in vivo performance,
diﬀerent attempts and suggestions have been described [3,7,11,12]. How-
ever, there is still an urgent need to incorporate improved pre-clinical test
models for the assessment of nano-bio-interactions (e.g. with proteins,
membranes, cells) in an early stage of development. This could help to
predict the performance in higher animals, systematically pre-select pro-
mising nanomedicine formulations and thus facilitate the liposome for-
mulation and development process.
In this study, we focused on the zebraﬁsh as an early and easy ac-
cessible vertebrate model to evaluate the circulation behavior of lipid-
based nanomedicines in vivo, thus bridging the gap between in vitro
cell-based models and in vivo mammalian models. As compared to
rodent in vivo models, the zebraﬁsh oﬀers unique advantages including
high reproducibility, low husbandry and experimental costs, ethical
considerations (3R principle), high level of genetic homology to hu-
mans, availability of transgenic lines, and most importantly optical
transparency [13,14]. This enables in vivo imaging at spatio-temporal
resolution (i.e. down to a cellular level and at various time points) [15].
Consequently, we combined a transgenic zebraﬁsh line expressing
green ﬂuorescent protein (GFP) speciﬁcally in their vasculature with
ﬂuorescently labeled nanoparticles. This oﬀers the possibility to gain
advanced insights into the circulation behavior of nanoparticulate drug
delivery systems [16]. In order to investigate the predictability of our
approach, we have chosen the most established nanoparticulate drug
delivery systems, i.e. liposomes. We have used a comprehensive and
pioneering work by Semple et al., describing eﬀects of fatty acid chain
length, saturation of phosphatidylcholine-based lipids, and cholesterol
content on liposome pharmacokinetics in mice [17]. First, we aimed to
reproduce the results obtained in mice by Semple et al. in zebraﬁsh
embryos, in order to validate the zebraﬁsh model as a sophisticated and
early in vivo tool for nanoparticle screening and characterization.
Second, we predicted the circulation behavior of a lipid formulation in
rats after assessment in our zebraﬁsh model. Finally, we analyzed the
eﬀect of cholesterol and PEGylation on the circulation behavior of li-
posomes in the zebraﬁsh model in vivo.
This comprehensive study can provide the basis for a high-
throughput screening platform to assess the circulation behavior of
diverse nanoparticulate drug delivery approaches, thus oﬀering a novel
concept for nanomedicines development.
2. Material and methods
2.1. Material
1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2 dioleoyl-3-trimethylammonium-propane
(DOTAP), and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) were
purchased from Corden Pharma Switzerland LLC (Liestal, Switzerland).
1,2-diarachidonoyl-sn-glycero-3-phosphocholine (DAPC 20:4), 1,2-dia-
rachidoyl-sn-glycero-3-phosphocholine (DAPC 20:0), and 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl)
(ammonium salt) (Rhod-PE) were obtained from Avanti Polar Lipids
(Alabaster, AL, USA). 1,2-distearoyl-sn-glycero-3-phosphoethanola-
mine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) was
provided by Lipoid (Steinhausen, Switzerland). Cholesterol, branched
polyethylenimine Mw 25′000 (PEI), and Sulforhodamine B were pur-
chased from Sigma-Aldrich (Buchs, Switzerland). 1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) and 1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine (Texas red) were
purchased from Invitrogen (Basel, Switzerland). SolvableTM and
Ultima GoldTM XR were purchased from PerkinElmer (Schwerzenbach,
Switzerland).
2.2. Preparation of ﬂuorescent liposomes
Liposomes were prepared as described previously [18]. Lipid and
cholesterol stock solutions were prepared in chloroform/methanol (2:1,
v/v). For the preparation of liposomes either pure phosphatidylcholine-
based phospholipids, a combination of DSPC and an indicated mol% of
cholesterol or a combination of DSPC/cholesterol and an indicated mol
% of DSPE-PEG2000 were used [19]. Desired ratios of stock solutions
were mixed at a total lipid concentration of 10 mM and dried overnight
using nitrogen. Liposomes were ﬂuorescently labeled using 1 mol% of
ﬂuorescent dye (as indicated). Dry lipid ﬁlms were re-hydrated for
10 min at Tm + 10 °C using 0.4 mL of H2O. For passive encapsulation of
a hydrophilic ﬂuorescent dye (i.e. sulforhodamine B), H2O was replaced
by a 1 mM aqueous solution of sulforhodamine B. The resulting mul-
tilamellar vesicles were equilibrated for 10 min at Tm + 10 °C and ﬁ-
nally extruded 17 times through a polycarbonate membrane with a pore
size of 100 nm (Avanti Polar-Lipids). Free hydrophilic dye was removed
by size exclusion chromatography using a Sepharose CL-4B column
(Sigma-Aldrich) and concentrated using a Millipore Amicon tube
(Sigma-Aldrich) with a molecular cut oﬀ of 10 kDa (10 min, 4000 rcf).
2.3. Preparation of radioactive liposomes
Tritium labeled doxorubicin ([3H]-doxorubicin) (Campro Scientiﬁc,
Veenendaal, Netherlands) was encapsulated into DAPC 20:0- and DAPC
20:4-based liposomes using an active loading strategy (i.e. a pH gra-
dient) as follows: Lipid ﬁlms were re-hydrated using acetate buﬀer
(0.3 M, pH 4.0) and extruded as described before. The external buﬀer
phase was exchanged by PBS (0.01 M, pH 7.8) using gel ﬁltration
chromatography (Econo-Pac 10DG, Bio-Rad Laboratories AG, Cressier,
Switzerland). [3H]-doxorubicin in EtOH (15 μCi) was placed into a glass
vial and EtOH was removed under nitrogen. Subsequently, [3H]-dox-
orubicin was rehydrated in H2O (20 μL) and liposome formulations
were added. The mixtures were incubated at> Tm for 10 min. Free
[3H]-doxorubicin was removed by gel ﬁltration chromatography using
PBS (0.001 M, pH 7.4) as a mobile phase. Liposomes were immediately
used for pharmacokinetic experiments in vivo in rats.
2.4. Dynamic and electrophoretic light scattering measurements
Dynamic and electrophoretic light scattering measurements for the de-
termination of liposome size and zeta potential were conducted using a
Delsa Nano C Particle Analyzer (Beckman Coulter, Nyon, Switzerland) as
described previously [20,21]. All measurements were carried out at room
temperature (RT) at a lipid concentration of 1 mM in H2O. For size dis-
tribution analysis, the laser was adjusted to 658 nm and scattered light was
detected at a 165° angle. Data was converted using CONTIN particle size
distribution analysis. For zeta potential analysis, the measurement angle
was 15° and data were converted using the Smoluchowski equation (Delsa
Nano V3.73/2.30, Beckman Coulter Inc., Brea, CA).
2.5. Cryo transmission electron microscopy (Cryo-TEM)
Size and shape of liposomes were analyzed by Cryo-TEM using a Philips
CM200-FEG electron microscope operated at an acceleration voltage of
200 kV as described previously [20]. In brief, liposomes were deposited
onto glow-discharged carbon grids (Quantifoil, Jena, Germany), blotted
with Whatman 1 ﬁlter papers, and vitriﬁed in liquid nitrogen-cooled liquid
ethane using a Vitrobot IV plunge-freezing device (FEI Company, Eind-
hoven, Netherland). Micrographs were recorded with a 4 k× 4 k TemCam-
F416 CMOS camera (TVIPS, Gauting, Germany).
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2.6. Zebraﬁsh embryo nanotoxicity screening
Time and concentration dependent in vivo toxicity (i.e. viability) of
injected liposome formulations was assessed following an adapted
protocol [22–24]. In brief, fertilized zebraﬁsh eggs at 4 h post fertili-
zation were incubated in 24-well plates (5 zebraﬁsh eggs/well) with
diﬀerent nanoparticle formulations at concentrations of 1 μM, 10 μM,
100 μM, and 1000 μM in zebraﬁsh culture media. Standard liposomes
(i.e. DOPC, DMPC, DPPS, DSPC, DAPC 20:0) were compared to DOTAP-
based liposomes and PEI (polymeric nanomaterial) as positive controls.
Viable embryos were counted after 24, 48, and 72 h post incubation
using a Leica S8APO microscope (Leica Microsystems, Heerbrugg,
Switzerland). Representative images at 24 h post incubation (i.e.
timescale of pharmacokinetics experiments) were taken using an
Olympus CKX41 microscope (Olympus Ltd., Tokyo, Japan).
2.7. Zebraﬁsh embryo culture and injections
Zebraﬁsh (Danio rerio) were maintained at standard conditions and
in accordance with Swiss animal welfare regulations. Eggs from adult
transgenic kdrl:EGFPs843 [25] zebraﬁshes were collected and kept in
zebraﬁsh culture media at 28 °C. In order to suppress pigment cell
formation, 1-phenyl 2-thiourea (PTU) was added to the culture media
1-day post fertilization (dpf). Liposome samples were injected into
zebraﬁsh embryos (2 dpf) at a concentration of 1 mM. Injections were
performed following an adapted protocol as described previously [26].
Anesthetized zebraﬁsh embryos (0.01% tricaine, w/v) were embedded
in 0.3% (w/v) agarose containing tricaine. Calibrated volumes of 1 nL
were injected into the duct of Cuvier. Injections were performed using a
micromanipulator (Wagner Instrumentenbau KG, Schöﬀengrund, Ger-
many), a pneumatic Pico Pump PV830 (WPI, Sarasota, Florida), and a
Leica S8APO microscope (Leica, Wetzlar, Germany). After successful
liposome injection (i.e. exclusion of zebraﬁsh embryos characterized by
ﬂuorescence accumulation in the yolk) zebraﬁsh embryos were imaged
using an Olympus FV-1000 inverted confocal laser scanning microscope
equipped with a 10× UPlanSApo (NA 0.4) and 20× UPlanSApo (NA
0.75) objective. In addition to experiments at 28 °C, control injections
at 37 °C were performed to relate the experiments to mammalian body
temperature. Detailed procedures are provided in the Supplementary
data.
2.8. Semi-quantitative image analysis
Image stacks were processed and analyzed using FIJI/ImageJ soft-
ware 1.51 g [27,28]. For each z-stack a maximum intensity projection
was created and a constant background was subtracted. For calculation
of the circulation factor (CF), a mask of the vascular region was used
and the mean intensity of bound (IBound ) from free particles (IFree ) were
discriminated by using the analyze particle function with a constant
threshold. The mean ﬂuorescence intensity of free particles was nor-
malized by the vascular area (AVasc ) after subtraction of the back-
ground (Eqs. (1) and (2)).
= −I I IFree Vasc Bound (1)
=CF I
A
Free
Vasc (2)
For calculation of the extravasation factor (EF), mean ﬂuorescence
intensity of the vascular region (IVasc ) was divided by mean ﬂuores-
cence intensity in the non-vascular region (INon Vasc ) after normalization
by the corresponding area (Eq. 3).
=EF I
A
A
I
Vasc
Vasc
Non Vasc
Non Vasc (3)
It is important to note that EF values are ﬂuorescence intensity ra-
tios (i.e. absolute values) and therefore independent of instrument
settings. In contrast, CF values are relative values and have been
compared to a reference formulation in the same set.
2.9. Pharmacokinetic study in rats
Pharmacokinetic proﬁles of DAPC 20:0 or DAPC 20:4 liposomes
were analyzed in female Wistar rats [250–280 g] (Janvier Labs, Saint-
Berthevin Cedex, France) using [3H]-doxorubicin as described earlier
[29,30]. The protocol for animal experiments was approved by Swiss
animal welfare authorities (authorization No. 2836) and all experi-
ments were conducted in accordance with Swiss animal welfare reg-
ulations. Rats were anesthetized (isoﬂurane) and the jugular vein was
cannulated. [3H]-doxorubicin (4 μCi) encapsulated in DAPC 20:0 or
DAPC 20:4 was injected via the catheter. Blood samples (200 μL) were
collected at various time points via the catheter, mixed with EDTA
(0.5 M, 10 μL), and centrifuged for 5 min at 1000 rcf and 4 °C to obtain
plasma. The blood volume collected was replaced by saline containing
heparin (100 U/mL). After 1 h, animals were sacriﬁced. Plasma aliquots
(40 μL) were mixed with Solvable™ (200 μL) and solubilized by in-
cubation for 4 h at 50 °C. Samples were bleached using 30% H2O2,
mixed with 10 mL of Ultima-Gold™ XR scintillation cocktail and ana-
lyzed using liquid scintillation counting using a TriCarb 4910 TR Liquid
Scintillation Analyzer (PerkinElmer, Schwerzenbach, Switzerland).
Plasma-concentration time proﬁles were analyzed using PK solver [31].
Appropriate compartmental curve ﬁtting models were chosen according
to Akaike Information Criterion and Schwarz Criterion as described
previously [32].
2.10. Statistical analysis
Statistical analysis was performed by one-way analysis of variance
(ANOVA) followed by Bonferroni or Tukey post-hoc test using
OriginPro 9.1 software (OriginLab Corporation; Northampton, MA). All
zebraﬁsh data represent at least n≥ 4 independent sets of experiments.
Diﬀerences between groups were considered to be statistically sig-
niﬁcant at the indicated p-values (*p < 0.05, **p < 0.01 and
***p < 0.001).
3. Results
3.1. Physicochemical properties of liposomes
To validate the zebraﬁsh as a screening tool, ﬁve diﬀerent liposome
formulations consisting of one single phosphatidylcholine-based lipid
only were prepared. Vesicles had diﬀerent main phase transition tem-
peratures (Tm) depending on fatty acid chain length (DMPC 14:0, DPPC
16:0, DSPC 18:0, DAPC 20:0) or fatty acid saturation (DOPC 18:1) of
the phospholipids (Table 1). Morphology, size, polydispersity index
(PDI), and zeta potential of the diﬀerent liposomal formulations were
analyzed by Cryo-TEM or dynamic and electrophoretic light scattering
analysis, respectively, as summarized in Fig. 1 and Table 1.
Table 1
Physico-chemical characteristics of diﬀerent liposome formulations. Lipid transition
temperature (Tm) was taken from Semple et al. [17]. Hydrodynamic size, polydispersity
index (PDI), and zeta potential of diﬀerent liposomes were analyzed using dynamic and
electrophoretic light scattering. n= 3 independent experiments; values are means ± SD.
Liposome Lipid Tm
(°C)
Size (nm) PDI Zeta potential (mV)
DAPC 20:4 −70 106.1 ± 3.4 0.096 ± 0.043 −26.5 ± 5.8
DOPC −22 116.8 ± 4.4 0.105 ± 0.031 −25.4 ± 7.7
DMPC 23 113.7 ± 3.2 0.075 ± 0.035 −19.6 ± 9.7
DPPC 41 105.9 ± 2.4 0.076 ± 0.015 −16.9 ± 4.0
DSPC 55 104.6 ± 2.3 0.062 ± 0.029 −16.6 ± 5.6
DAPC 20:0 66 110.7 ± 4.7 0.110 ± 0.037 −17.1 ± 6.6
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Each type of liposome showed an uniform and spherical vesicle
morphology with an unilamellar lipid bilayer (Fig. 1). Liposomes
composed of phospholipids with Tm < 28 °C (DOPC, DMPC) showed
spherical geometries (Fig. 1A and B) whereas liposomes with
Tm > 28 °C (DPPC, DSPC, DAPC 20:0) displayed irregular spherical
shapes (Fig. 1C-E) on electron micrographs. Dynamic light scattering
measurements conﬁrmed the monodisperse size distribution of diﬀerent
liposome formulations (as indicated by a polydispersity index < 0.2)
with an average hydrodynamic diameter of around 110 nm (Fig. 1 and
Table 1). Zeta potential measurements revealed a negative zeta po-
tential of all liposome formulations around −20 mV.
Fig. 1. Physico-chemical characterization of diﬀerent liposome formulations. Liposomes were prepared using diﬀerent phosphatidylcholine-based lipids and analyzed by Cryo-TEM and
dynamic light scattering. Liposomes are selected based on Semple et al. [17] and ordered according to ascending main phase transition temperature Tm (Table 1), namely (A) DOPC, (B)
DMPC, (C) DPPC, (D) DSPC, and (E) DAPC 20:0. A representative electron micrograph and intensity-based size distribution is shown for each liposome formulation. Scale bars represent
100 nm.
Fig. 2. Schematic representation of transgenic zebraﬁsh
embryo and inﬂuence of diﬀerent ﬂuorescent dyes on li-
posome circulation behavior. (A) Transgenic zebraﬁsh
embryo with ﬂuorescent vasculature including the tail re-
gion which was used for imaging. Schematic representation
of zebraﬁsh vasculature with anatomical nomenclature.
DLAV: dorsal longitudinal anastomotic vessel, ISV: inter-
segmental vessels, DA: dorsal aorta, PCV: posterior (caudal)
cardinal vein. Scale bars represent 500 μm (overview) and
100 μm (insert). (B) Fluorescence distribution patterns of
DSPC-based liposomes were analyzed 1 hpi using confocal
microscopy. Liposomes contained either 1 mol% of a lipo-
philic dye, i.e. Rhod-PE, DiI, and Texas Red-DHPE, or 1 mM
sulforhodamine B (SRB) as a hydrophilic payload.
Representative images are shown for each setting.
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3.2. Nanotoxicity screening of liposomes
To investigate if the diﬀerent liposome formulations exhibit toxic
eﬀects in vivo, we performed a nanotoxicity testing using the zebraﬁsh
embryo assay (Supp. Fig. 1). All single phosphatidylcholine-based li-
posomes were biocompatible and did not show any apparent toxic ef-
fects. In sharp contrast, positively charged lipid- (i.e. DOTAP) or
polymer- (i.e. PEI) based nanomaterials showed strong toxic eﬀects in
zebraﬁsh embryos.
3.3. Labeling strategy to study liposome circulation behavior
Fluorescently labeled liposomes were injected into the duct of
Cuvier of 2 days old zebraﬁsh embryos. After speciﬁc time points, the
circulation behavior of diﬀerent lipid formulations were imaged in the
tail region using confocal laser scanning microscopy. A schematic re-
presentation of the zebraﬁsh tail region including its vasculature no-
menclature [33] is shown in Fig. 2A. To exclude an eﬀect of the
ﬂuorescent dye on liposome circulation behavior, diﬀerent labeling
strategies were evaluated. Thereby, diﬀerent ﬂuorescent dyes were in-
corporated into DSPC-based liposomes (Fig. 2B). Three diﬀerent lipo-
philic dyes and one hydrophilic dye were tested. Lipophilic dyes were
used to label the phospholipid bilayer, i.e. the nanocarrier. Lipophilic
Rhod-PE and Texas Red-DHPE were chosen as a head group-modiﬁed
phospholipid analogs with large chromophore structures. The lipophilic
and cationic indocarbocyanine dye DiI was chosen due to deep in-
corporation into the lipid bilayer and small chromophore structure. In
order to investigate a hydrophilic payload, sulforhodamine B was en-
capsulated into the core of liposomes. As shown in Fig. 2B, diﬀerent
dyes did not inﬂuence the circulation behavior (i.e. ﬂuorescence dis-
tribution patterns) of the DSPC-based lipid formulation. Therefore,
Rhod-PE was chosen as ﬂuorescent dye for all further experiments, due
to its stable incorporation properties into the lipid bilayer, similar
structure to phosphatidylcholine-based lipids used for the diﬀerent
formulations, and relatively small chromophore as compared to Texas
Red.
3.4. Liposome circulation behavior in zebraﬁsh embryos
In a next step, diﬀerent liposome formulations consisting of speciﬁc
phosphatidylcholine-based lipids were injected into the duct of Cuvier
of zebraﬁsh embryos and ﬂuorescence signals in the tail region were
analyzed at 1 h post injection (hpi) and 24 hpi (Fig. 3). Experiments
were carried out at 28 °C. Confocal images revealed a diﬀerent circu-
lation behavior and staining pattern dependent on fatty acid chain
length or saturation of phospholipids. Liposomes composed of DMPC
(Tm 23 °C) or DOPC (Tm −22 °C), which exist in the liquid crystalline
state at experimental conditions, were evenly distributed in the whole
vasculature at 1 hpi. In sharp contrast, liposomes containing lipids in
the gel state, i.e. DPPC (Tm 41 °C), DSPC (Tm 55 °C), or DAPC 20:0 (Tm
66 °C), were mainly attached to the venous part of the vasculature (i.e.
posterior cardinal vein, PCV). In addition, these lipid formulations
showed a dotted staining pattern. In agreement to the observations at
1 hpi, a clear diﬀerence between the two groups, i.e. Tm < 28 °C or
Tm > 28 °C, was also observed 24 hpi. Whereas lipids with a high
transition temperature (DPPC, DSPC, DAPC 20:0) still mainly attached
to the PCV, lipids with a low transition temperature (DOPC, DMPC)
showed an evenly distributed staining pattern which was not restricted
to the vascular structure, demonstrating extravasation into surrounding
tissue (Fig. 3). Control experiments performed at 37 °C (i.e. mammalian
body temperature) using a lipid formulation from each group (DSPC vs.
DOPC) conﬁrmed these results (Supp. Fig. 2). We observed the same
staining patterns. In addition, zebraﬁsh embryos developed normally
and no change in zebraﬁsh morphology could be detected up to 24 hpi.
Semi-quantitative parameters were calculated using computer-as-
sisted image analysis to compare diﬀerent lipid formulations. Two
Fig. 3. Qualitative evaluation of liposome circulation behavior in vivo in the zebraﬁsh model. Diﬀerent liposome formulations composed of speciﬁc phosphatidylcholine-based lipids
were injected into transgenic zebraﬁsh embryo expressing green ﬂuorescent protein in the vasculature endothelial cells. All liposome formulations contained 1 mol% Rhod-PE as a
ﬂuorescent marker. Confocal images were taken 1 and 24 hpi in the tail region (see Fig. 2A).
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diﬀerent factors characterizing the circulation behavior of liposomes in
zebraﬁshes were deﬁned (Fig. 4). First, ﬂuorescence intensity of cir-
culating liposomes was calculated and represented as circulation factor
(CF). In this experiment, higher CF values (> 200) 24 hpi represent
liposome formulations, which show an extended circulation time and
reduced binding to vascular structures, i.e. PCV. Second, an extra-
vasation factor (EF) was determined. The EF represents the ratio be-
tween liposomes located outside the vasculature and liposomes located
inside the vasculature. Long circulating liposomes showed a higher
tendency to extravasate 24 hpi (EF > 270), whereas short circulating
lipid formulations had low extravasation values (EF < 70). As shown
in Fig. 4, liposomes can be clearly diﬀerentiated into two groups (i.e.
long and short circulating), based on their transition temperature, CF,
and EF values. Table 2 shows the comparison of the plasma half-life (t1/
2) in mice reported by Semple et al. [17] and the calculated zebraﬁsh
factors for all used lipid formulations.
3.5. Eﬀect of cholesterol on circulation behavior
To further verify the zebraﬁsh model as eﬃcient screening tool to
assess multicomponent lipid formulations with minor diﬀerences and to
conﬁrm that the phase transition temperature Tm of phospholipid
Fig. 4. Semi-quantitative analysis of liposome circulation behavior in vivo in the zebraﬁsh model. Circulation (CF) and extravasation factors (EF) of each lipid composition were
calculated 1 and 24 hpi based on ﬂuorescence signal intensities of liposomes in speciﬁc regions as indicated by the respective colour coding. CF values correspond to freely circulating
liposomes and represent the diﬀerence between total vascular (Vasc) and bound (Bound) liposome signals. EF values are based on ratios between vascular (Vasc) and nonvascular
(NonVasc) signals. n≥ 5 experiments. Box plots represent median, third and ﬁrst quantiles, minima and maxima, asterisks indicate statistically signiﬁcant diﬀerences between phos-
pholipids with a Tm < 28 °C (grey boxes) and a Tm > 28 °C (white boxes) (see Table 1). *p > 0.05 or **p > 0.01.
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bilayers has a strong impact on systemic circulation of phosphati-
dylcholine-based liposomes, control experiments with DSPC liposomes
containing increasing amounts of cholesterol (i.e. 10 to 50 mol%) were
performed (Fig. 5). Cholesterol has been reported to have a strong
impact on Tm in saturated phosphatidylcholine-based liposomes, sub-
sequent protein binding and circulation lifetimes [17]. Indeed, an in-
crease of circulating liposomes was observed with increasing amounts
of cholesterol in the zebraﬁsh model (Fig. 5A). The typical dotted and
non-circulating staining pattern of pure DSPC liposomes in the PCV
gradually changed towards the circulation behavior of circulating li-
posomes. Semi-quantitative image analysis conﬁrmed the inﬂuence of
cholesterol content on CF and EF (Fig. 5B). At 24 hpi striking
Table 2
Circulation behavior of diﬀerent liposome formulations in vivo in mice and zebraﬁshes.
Plasma circulation half-life of liposomes in mice (t1/2) were taken from Semple et al. [17].
Zebraﬁsh circulation (CF) and extravasation factor (EF) are based on semi-quantitative
image processing of ﬂuorescence intensities 24 hpi. n≥ 5 independent zebraﬁsh ex-
periments; values are means ± SD.
Liposome t1/2 mice (min) CFzebraﬁsh EFzebraﬁsh (×103)
DOPC > 120 217.3 ± 25.1 334.5 ± 117.4
DMPC 74.0 243.3 ± 69.9 270.0 ± 81.7
DPPC 1.2 148.3 ± 28.8 56.3 ± 23.4
DSPC 0.9 159.0 ± 10.2 61.2 ± 25.2
DAPC 20:0 0.9 128.8 ± 14.4 24.7 ± 7.3
Fig. 5. Eﬀect of cholesterol on circulation behavior of
DSPC-based liposomes in vivo in the zebraﬁsh model.
(A) DSPC-based liposome formulations with in-
creasing amounts of cholesterol were injected into
transgenic zebraﬁsh embryos and images were taken
1 hpi from the tail region. (B) Liposome circulation
behavior was assessed semi-quantitatively. Circulation
(CF) and extravasation factors (EF) of each lipid
composition 1 and 24 hpi are given. n≥ 4 experi-
ments. Box plots represent median, third and ﬁrst
quantiles, minima and maxima. *p > 0.05 as com-
pared to control (10 mol% cholesterol).
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diﬀerences in CF and EF for formulations containing higher amounts of
cholesterol diﬀerences were observed.
3.6. Comparison of circulation behavior in the zebraﬁsh model and rats
In a next step, a lipid formulation with unknown pharmacokinetic
behavior was assessed in the zebraﬁsh model and in rats as a proof-of-
concept experiment to underline the validity of our proposed screening
tool. Liposomes composed of the unsaturated DAPC 20:4 lipid were
injected into zebraﬁsh embryos and compared with already described
DAPC 20:0-based liposomes (Fig. 6A). In contrast to non-circulating
DAPC 20:0-based liposomes, the staining pattern of DAPC 20:4 matched
to long-circulating liposomes consisting of lipids in the liquid crystal-
line state such as DMPC or DOPC. A statistically signiﬁcant increased CF
and EF for DAPC 20:4-based liposomes as compared to DAPC 20:0-
based liposomes conﬁrmed the qualitative observations. Subsequently,
both lipid formulations were injected into rats and blood sampling was
performed for 60 min (Fig. 6B). The predictive CF and EF (1 hpi) and
the pharmacokinetic parameters from rat experiments are summarized
in Table 3. As expected from the zebraﬁsh experiments, DAPC 20:4-
based liposomes injected into rats showed an approximately 5-fold in-
creased circulation half-life (t1/2) as well as a 10-fold increased area
under the curve (AUC) as compared to DAPC 20:0-based liposomes.
3.7. Inﬂuence of PEGylation on liposome circulation
As a ﬁnal proof-of-concept experiment to validate the zebraﬁsh
model, we assessed the eﬀect of PEGylation on liposome circulation in
the zebraﬁsh model. Therefore, PEGylated liposomes containing in-
creasing amounts of DSPE-PEG2000 were injected into zebraﬁsh. As
shown in Fig. 7, a clear correlation between increasing amounts of
DSPE-PEG2000 and enhanced circulation behavior can be observed in
the presented zebraﬁsh model.
4. Discussion
Optimization of physicochemical and pharmacokinetic properties of
liposomal formulations (or any other type of nanoparticulate drug de-
livery system) remains a challenge. Many factors including lipid com-
position, size, PDI, or surface charge can inﬂuence the pharmacoki-
netics of liposomes in vivo. Estimation or even prediction of liposome
circulation behavior in vivo due to changes in lipid composition or
physico-chemical characteristics is diﬃcult and often based on empiric
data. Therefore, the aim of the present study was to introduce and
validate the zebraﬁsh as an early stage vertebrate screening model
closing the gap between in vitro and in vivo experiments in rodents.
This could oﬀer a possibility to change the predictable pattern of or-
ganization in nanoparticle research [11]. Interestingly, the zebraﬁsh is
an emerging model to study human diseases and some research groups
have started to test the therapeutic eﬃcacy of nanocarriers in these
models [34–36]. The prediction value of the zebraﬁsh model to study
the circulation behavior of lipid-based nanoparticles in vivo was as-
sessed in three steps. First, we compared the circulation behavior of
liposomes in zebraﬁshes with data reported from mice experiments by
Semple et al. Second, we evaluated a lipid formulation with unknown
circulation properties in zebraﬁsh embryos and compared these results
to pharmacokinetic experiments which we have performed in rats. Fi-
nally, we investigated the eﬀects of cholesterol or PEGylation as most
widely used enhancer of liposome circulation [37,38] in the zebraﬁsh
model.
Inspired by the early publication of Semple et al., ﬁve diﬀerent lipid
formulations were chosen. Thus, the inﬂuence of lipid composition
(length of fatty acid chain, saturation, amount of cholesterol, and
consequently phase transition temperature) on liposome circulation
behavior was assessed in vivo in zebraﬁshes and compared to reported
ﬁndings in mice. All liposomes had comparable nanoparticle
characteristics, i.e. size, PDI, and zeta potential, to increase compar-
ability of diﬀerent lipid formulations and thus minimize size-related
eﬀects. Importantly, the zebraﬁsh model was also used to investigate
the toxicological eﬀects with respect to viability of the diﬀerent lipo-
somes in vivo. Estimating that a zebraﬁsh embryo has a total blood
volume of 60nL [39], the ﬁnal lipid concentration in blood circulation
after injection of 1 nL liposomes is around 16 μM. Thus, none of the
tested liposome formulations exhibited toxic eﬀects in the concentra-
tion range used for zebraﬁsh injections.
In a next step, diﬀerent ﬂuorescent dyes were incorporated into li-
posomes to validate our ﬂuorescence microscopy-based approach. No
inﬂuence on liposome circulation behavior was observed using low
amounts of ﬂuorescent label (i.e. 1 mol% of the ﬁnal lipid composition
for lipophilic dyes). The compatibility of lipophilic and hydrophilic
dyes is an important prerequisite for further studies using the zebraﬁsh
model. Lipophilic dyes oﬀer the possibility to exclusively follow the
nanocarrier circulation in vivo, whereas the circulation of en-
capsulated, hydrophilic dyes is also inﬂuenced by the nanocarrier sta-
bility (i.e. encapsulated vs. free drug). Since the focus of the present
study was to analyze the inﬂuence of lipid characteristics on nano-
carrier circulation behavior, the ﬂuorescent phospholipid analog Rhod-
PE was used for all further experiments. After assessment of liposome
circulation behavior at various time points post injection (data not
shown), 1 and 24 hpi were chosen as suitable time points for image
analysis. It has been shown that the 1 hpi time point oﬀers the possi-
bility of an almost immediate ﬁrst assessment of blood circulation
patterns. In addition, there is a good correlation with later (i.e. 24 hpi)
time points. The 24 hpi time point is optimal to assess the extravasation
factor of long circulating nanocarriers (i.e. evaluation of extravasation
into vascular surrounding tissue). Furthermore, CF and EF show less
variability for the same formulation 24 hpi due to smaller deviations in
developmental stage of zebraﬁsh.
Based on the qualitative observations and semi-quantitative image
analysis, we propose following strategy for the assessment of diﬀerent
formulations: (I) Injection of reference samples with known pharma-
cokinetic properties and test samples of interest into the duct of Cuvier
of zebraﬁsh embryos 48 h post fertilization, (II) qualitative image
analysis 1 hpi, and (III) qualitative and semi-quantitative image ana-
lysis 24 hpi. Following this strategy, the circulation behavior of novel
nanocarriers can be determined relative to reference samples with
known pharmacokinetic properties or due to gradual changes in the
nanoparticle formulation (e.g. cholesterol amount). In our study using
phosphatidylcholine-based lipids, the classiﬁcation seems to be de-
pendent on individual transition temperatures (which most probably
inﬂuences subsequent protein binding in circulation) as reported by
Semple et al. in mice [17]. It is therefore advisable to carefully control
temperature (i.e. 28 °C) during the experiment. Interestingly, higher
temperatures (e.g. 37 °C) can be used to extend the zebraﬁsh model to
temperature-sensitive drug delivery systems. However, it has to be kept
in mind that in zebraﬁsh embryos heat-shock proteins such as hsp70 are
activated at 37 °C [40,41]. In addition, Haldi et al. observed necrosis in
the yolk after incubation for 2 days at 37 °C [42].
We observed that liposomes composed of lipids with lower transi-
tion temperature (i.e. DAPC 20:4 Tm −70 °C, DOPC Tm −22 °C, and
DMPC Tm 23 °C) resulted in comparably higher CF and EF. In contrast,
liposomes composed of lipids with higher transition temperatures (i.e.
DPPC Tm 41 °C, DSPC Tm 55 °C, and DAPC 20:0 Tm 66 °C) resulted in
low circulation factors and reduced extravasation.
Qualitatively, two main circulation patterns were observed in a
deﬁned tissue segment of the tail region of injected zebraﬁsh embryos
1 hpi. Long circulating formulations evenly distributed into the whole
vasculature whereas short circulating formulations attached to venous
structures (e.g. PCV) almost immediately after injection.
Importantly, a clear distinction between ﬂuorescent liposomes and
endothelial structures was possible by using transgenic zebraﬁsh em-
bryos expressing GFP in endothelia cells. Thus, the unique properties of
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the zebraﬁsh embryo (i.e. transparency and availability of transgenic
lines) allow for a clear distinction between nanoparticles located within
or outside the vasculature. This feature was of special importance
analyzing liposomes made of DOPC. Qualitatively, DOPC-based lipo-
somes showed an intermediate circulation behavior (i.e. high ﬂuores-
cence in circulation and strong signals in the PCV). However, long
circulating properties should be observed for DOPC-based liposomes
according to pharmacokinetic data reported in mice. Notably, an in-
teresting phenomenon was observed for DOPC-based liposomes as
compared to short circulating liposomes such as DSPC. Indeed, after
injection, short circulating liposomes are attached to venous capillaries
Fig. 6. Comparison of liposome circulation in zebraﬁshes
and rats. Liposomes were prepared from saturated (DAPC
20:0) and unsaturated (DAPC 20:4) lipids. (A)
Representative images of liposome distribution pattern and
zebraﬁsh circulation factor (CF) and extravasation factor
(EF) 1 hpi are shown. n≥ 5 experiments. Box plots re-
present median, third and ﬁrst quantiles, minima and
maxima. **p > 0.01 or ***p > 0.001. (B) Radiolabeled
liposomes were intravenously injected into rats and plasma
concentrations of encapsulated [3H]-doxorubicin were
analyzed at various time points over 1 h. n≥ 3 in-
dependent experiments. Values are means ± SD. Black
triangles indicate DAPC 20:0-based liposomes. White
open circles indicate DAPC 20:4-based liposomes.
Pharmacokinetic parameters are summarized in Table 3.
Table 3
Summary of liposome circulation characteristics in vivo in zebraﬁshes and rats. DAPC
20:0- and DAPC 20:4-based liposomes were injected into zebraﬁshes and rats. The zeb-
raﬁsh circulation factor (CF), extravasation factor (EF), and pharmacokinetic factors in
rats (terminal t1/2, AUC∞0) were determined 1 hpi. n≥ 3 independent rat experiments;
values are means ± SD. Data were evaluated using a 2-compartmental pharmacokinetic
model.
Liposome CFzebraﬁsh EFzebraﬁsh (×103) t1/2 ratterminal
(min)
AUC∞0 rat (%
ID ∗mL/min)
DAPC 20:0 233.8 ± 38.2 7.0 ± 6.1 12.5 ± 10.1 19.6 ± 6.1
DAPC 20:4 398.2 ± 61.6 77.9 ± 49.4 54.4 ± 21.5 120.4 ± 31.9
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inside the vasculature as can been visualized in merged ﬂuorescence
images of vasculature and liposomes. In sharp contrast, the strong
ﬂuorescence signals obtained for DOPC-based liposomes are located
outside the vasculature. It is tempting to speculate that these extra-
vascular signals result from extravasated liposomes accumulating in the
perivascular space. DOPC-based liposomes have a low transition tem-
perature (−22 °C) which results in a ﬂuid lipid bilayer at experimental
conditions (28 °C). This characteristic might lead to an increased ability
to diﬀuse through nanosized pores in the young and freshly formed
vasculature of zebraﬁsh embryos. The semi-quantitative assessment
clearly showed, that DOPC-based liposomes belong to the group of long
circulating formulations conﬁrming published data in rodents.
In general, long circulating liposome formulations (DAPC 20:4,
DOPC, DMPC) were still present in circulation 24 hpi and in addition
showed a high degree of extravasation. In strong contrast, the circula-
tion patter of short circulating liposomes (DPPC, DSPC, DAPC 20:0) was
unaltered 24 hpi compared to 1 hpi. Therefore, obvious qualitative
diﬀerences at speciﬁc time points allowed for a fast estimation of sys-
temic circulation behavior, even without the proposed semi-quantita-
tive analysis. However, if minor changes in the lipid composition have
to be assessed and compared, qualitative diﬀerences of circulation be-
havior become less obvious.
To proof the validity of the zebraﬁsh screening model to study such
subtle phenomena, increasing amounts of cholesterol (up to 50 mol%)
where incorporated into DSPC-based liposomes. It has been reported
that incorporation of cholesterol increases liposome circulation half-life
Fig. 7. Inﬂuence of PEGylation on liposome circula-
tion in vivo in the zebraﬁsh model. (A) Liposome
formulations (DSPC/cholesterol with increasing
amounts of DSPE-PEG2000) were injected into trans-
genic zebraﬁsh embryos and images were taken 1 and
24 hpi. (B) Circulation (CF) and extravasation factors
(EF) of each lipid composition were calculated. n≥ 5
experiments. Box plots represent median, third and
ﬁrst quantiles, minima and maxima. *p > 0.05 as
compared to control (0 mol% PEG).
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and nanocarrier stability in mice [17,43]. In addition, cholesterol in-
ﬂuences phospholipid dynamics and structure within bilayers and
thereby has a strong impact on their phase transition temperature
[44,45]. In agreement with our observation, concentration dependent
modulation of phospholipid phase transition behavior led to a longer
circulation time of liposomes containing cholesterol. It is tempting to
speculate that cholesterol mediated eﬀects such as membrane “ﬂuidi-
zation” and reduced plasma protein binding [17] were responsible for
the observed eﬀect. Interestingly, the highest circulation factor was
determined for DSPC-based liposomes with 30 mol% cholesterol. This
plateau phenomenon was also observed by Semple et al. in mice. Suc-
cessful assessment of these small changes in circulation behavior due to
minor changes in liposome composition highlights the validity of the
zebraﬁsh model as sensitive and predictive screening tool.
After successful correlation and conﬁrmation of published data from
mice experiments in the zebraﬁsh model, the zebraﬁsh model was va-
lidated using a liposome formulation with unknown pharmacokinetic
properties. Based on our previous ﬁndings in zebraﬁsh embryos, that
phosphatidylcholine-based lipids with a Tm < 28 °C show increased
circulation properties, the unsaturated phospholipid DAPC 20:4 was
selected. Liposomes composed of the previously tested long-chain sa-
turated phospholipid DAPC 20:0 were selected as reference formula-
tion. We expected that DAPC 20:4, which exists in the liquid crystalline
state at 28 °C, increases the CF of liposomes in zebraﬁsh embryos and
ﬁnally circulation half-life in rodents as compared to DAPC 20:0.
Indeed, based on the evaluation in zebraﬁsh embryos, the pharmaco-
kinetic properties of DAPC 20:4-based liposomes were successfully
predicted in the rat using [3H]-doxorubicin labeled formulations. In a
ﬁnal set of experiments, the eﬀect of PEGylation was evaluated in the
zebraﬁsh model. In clinic, the encapsulation of doxorubicin into con-
ventional (i.e. Myocet) or PEGylated liposomes (i.e. Doxil) increases the
area under the curve (AUC) from 3.5 mg·h/L (free doxorubicin) to
19.4 mg·h/L or even 4082 mg·h/L, respectively and thus results in an
improved therapeutic index [46]. As expected, Doxil-based formula-
tions showed a signiﬁcantly increased circulation behavior in the zeb-
raﬁsh. In addition, the zebraﬁsh EF (i.e. extravasation of liposomes into
adjacent tissue) was enhanced by PEGylation. All eﬀects were con-
centration dependent and a function of the used amount of DSPE-
PEG2000.
Notably, ongoing experiments (manuscript in preparation) indicate
that the proposed screening strategy can be applied to other types of
nanoparticulate drug delivery systems such as polymer-based nano-
particles or super paramagnetic iron oxide nanoparticles (SPIONs). For
example, a direct comparison of PEGylated liposomes and poly(ethy-
lene glycol)-b-poly(ε-caprolactone) [PEG-PCL] micelles revealed similar
circulation patterns in the zebraﬁsh. Subsequent experiments in rats
conﬁrmed a long circulation behavior of these delivery systems. PEG-
liposomes as well as PEG-PCL micelles increased the circulation half-life
of the model drug doxorubicin by a factor of 42 and 60, respectively.
Conclusively, pharmacokinetic properties of investigational as well as
clinically approved nanoparticulate drug delivery systems can suc-
cessfully be screened and veriﬁed in the zebraﬁsh model.
5. Conclusion
In summary, a statistically signiﬁcant diﬀerence in circulation be-
havior was observed for several diﬀerent formulations starting from
single- to multi-component lipid formulations. Furthermore, it was
possible to study the eﬀects of cholesterol and PEGylation and to pre-
dict the circulation behavior in mice and rats. Obtained results were
indicative of a direct link between Tm, phospholipid bilayer ﬂuidity,
incorporation of surface coating and systemic circulation and extra-
vasation. We conclude that the zebraﬁsh model is a suitable screening
tool to assess the inﬂuence of various parameters such as size, surface
charge, encapsulation eﬃciency, targeting properties, and composition
of nanoparticles on their circulation characteristics in vivo. Our
proposed screening strategy is time- and cost-eﬀective and can be used
to optimize the circulation behavior of nanoparticulate drug delivery
systems in a simple vertebrate model before moving to more complex
pharmacokinetic studies in rodents. As compared to standard in vitro
assays, nanoparticle formulations can be optimized under in vivo con-
ditions including multiple factors simultaneously such as blood circu-
lation, presence of various cell types, plasma protein binding and
macrophage uptake. Its use as a screening model for the assessment of
in vivo circulation behavior and toxicological eﬀects during very early
stages of drug discovery might therefore drastically reduce the amount
of higher vertebrates needed for the pre-clinical assessment of nano-
particulate drug delivery systems in accordance to the 3R principle of
animal welfare. In conclusion, this approach has the possibility to ad-
dress an unmet pre-clinical need in the ﬁeld of drug delivery and might
facilitate the translation of the classical nanoparticle development
process from an empirical approach, which is mainly based on opti-
mization of physico-chemical characteristics, to an “optimization-by-
design” concept.
Acknowledgements
DW and JH have equally contributed as senior authors. The authors
are thankful for the ﬁnancial support of the “Stiftung zur Förderung des
pharmazeutischen Nachwuchses in Basel”, “Freiwillige Akademische
Gesellschaft Basel”, “Novartis University Basel Excellence Scholarship
for Life Sciences”, the EU Horizon 2020 project “NanoReg2” (Swiss SBFI
Nr. 15.0200-3) and the Swiss National Science Foundation (SNF grant
No. 31003A_173057). The authors declare no conﬂicts of interests. Dr.
M. Chami from the University of Basel, C-CINA, is acknowledged for
Cryo-TEM experiments. We also thank Prof. Dr. M. Aﬀolter, Dr. H.G.
Belting and N. Schellinx for providing zebraﬁsh eggs. Furthermore, we
thank Prof. Dr. A. Kros, Dr. J. Bussmann, and Dr. F. Campbell from the
University of Leiden for fruitful discussions and training regarding the
handling of zebraﬁsh embryos.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2017.08.023.
References
[1] P. Ehrlich, Experimental Researches on Speciﬁc Therapy, on Immunity with Special
Relationship between Distribution and Action of Antigens, Harben Lect., 1908.
[2] A.D. Bangham, M.M. Standish, J.C. Watkins, Diﬀusion of univalent ions across the
lamellae of swollen phospholipids, J. Mol. Biol. 13 (1965) 238-IN27 http://dx.doi.
org/10.1016/S0022-2836(65)80093-6.
[3] J.I. Hare, T. Lammers, M.B. Ashford, S. Puri, G. Storm, S.T. Barry, Challenges and
strategies in anti-cancer nanomedicine development: an industry perspective, Adv.
Drug Deliv. Rev. (n.d.). doi:http://dx.doi.org/10.1016/j.addr.2016.04.025.
[4] T.M. Allen, P.R. Cullis, Liposomal drug delivery systems: from concept to clinical
applications, Adv. Drug Deliv. Rev. 65 (2013) 36–48, http://dx.doi.org/10.1016/j.
addr.2012.09.037.
[5] A. Wicki, D. Witzigmann, V. Balasubramanian, J. Huwyler, Nanomedicine in cancer
therapy: challenges, opportunities, and clinical applications, J. Control. Release
200C (2015) 138–157, http://dx.doi.org/10.1016/j.jconrel.2014.12.030.
[6] T. Lammers, F. Kiessling, M. Ashford, W. Hennink, D. Crommelin, G. Storm, Cancer
nanomedicine: is targeting our target? Nat. Rev. Mater. 1 (2016), http://dx.doi.org/
10.1038/natrevmats.2016.69.
[7] K.A. Whitehead, J. Matthews, P.H. Chang, F. Niroui, J.R. Dorkin, M. Severgnini,
et al., In vitro–in vivo translation of lipid nanoparticles for hepatocellular siRNA
delivery, ACS Nano 6 (2012) 6922–6929, http://dx.doi.org/10.1021/nn301922x.
[8] D.C. Drummond, O. Meyer, K. Hong, D.B. Kirpotin, D. Papahadjopoulos, Optimizing
liposomes for delivery of chemotherapeutic agents to solid tumors, Pharmacol. Rev.
51 (1999) 691–744.
[9] D.C. Drummond, C.O. Noble, M.E. Hayes, J.W. Park, D.B. Kirpotin,
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier devel-
opment, J. Pharm. Sci. 97 (2008) 4696–4740, http://dx.doi.org/10.1002/jps.
21358.
[10] B.S. Pattni, V.V. Chupin, V.P. Torchilin, New developments in liposomal drug de-
livery, Chem. Rev. 115 (2015) 10938–10966, http://dx.doi.org/10.1021/acs.
chemrev.5b00046.
[11] S. Mitragotri, T. Lammers, Y.H. Bae, S. Schwendeman, S. De Smedt, J.-C. Leroux,
S. Sieber et al. Journal of Controlled Release 264 (2017) 180–191
190
53
et al., Drug delivery research for the future: expanding the Nano horizons and be-
yond, J. Control. Release 246 (2017) 183–184, http://dx.doi.org/10.1016/j.jconrel.
2017.01.011.
[12] B.J. Crielaard, A. Youseﬁ, J.P. Schillemans, C. Vermehren, K. Buyens,
K. Braeckmans, et al., An in vitro assay based on surface plasmon resonance to
predict the in vivo circulation kinetics of liposomes, J. Control. Release 156 (2011)
307–314, http://dx.doi.org/10.1016/j.jconrel.2011.07.023.
[13] C. Delvecchio, J. Tiefenbach, H.M. Krause, The zebraﬁsh: a powerful platform for in
vivo, HTS drug discovery, Assay Drug Dev. Technol. 9 (2011) 354–361, http://dx.
doi.org/10.1089/adt.2010.0346.
[14] G.J. Lieschke, P.D. Currie, Animal models of human disease: zebraﬁsh swim into
view, Nat. Rev. Genet. 8 (2007) 353–367, http://dx.doi.org/10.1038/nrg2091.
[15] K. Howe, M.D. Clark, C.F. Torroja, J. Torrance, C. Berthelot, M. Muﬀato, et al., The
zebraﬁsh reference genome sequence and its relationship to the human genome,
Nature 496 (2013) 498–503, http://dx.doi.org/10.1038/nature12111.
[16] L. Evensen, P.L. Johansen, G. Koster, K. Zhu, L. Herﬁndal, M. Speth, et al., Zebraﬁsh
as a model system for characterization of nanoparticles against cancer, Nano 8
(2016) 862–877, http://dx.doi.org/10.1039/c5nr07289a.
[17] S.C. Semple, A. Chonn, P.R. Cullis, Inﬂuence of cholesterol on the association of
plasma proteins with liposomes, Biochemistry (Mosc) 35 (1996) 2521–2525,
http://dx.doi.org/10.1021/bi950414i.
[18] P. Detampel, D. Witzigmann, S. Krähenbühl, J. Huwyler, Hepatocyte targeting using
pegylated asialofetuin-conjugated liposomes, J. Drug Target. 22 (2014) 232–241,
http://dx.doi.org/10.3109/1061186X.2013.860982.
[19] A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, et al., Prolonged
circulation time and enhanced accumulation in malignant exudates of doxorubicin
encapsulated in polyethylene-glycol coated liposomes, Cancer Res. 54 (1994)
987–992.
[20] D. Witzigmann, S. Sieber, F. Porta, P. Grossen, A. Bieri, N. Strelnikova, et al.,
Formation of lipid and polymer based gold nanohybrids using a nanoreactor ap-
proach, RSC Adv. 5 (2015) 74320–74328, http://dx.doi.org/10.1039/
C5RA13967H.
[21] D. Witzigmann, D. Wu, S.H. Schenk, V. Balasubramanian, W. Meier, J. Huwyler,
Biocompatible polymer-peptide hybrid-based DNA nanoparticles for gene delivery,
ACS Appl. Mater. Interfaces 7 (2015) 10446–10456, http://dx.doi.org/10.1021/
acsami.5b01684.
[22] L.Y. Rizzo, S.K. Golombek, M.E. Mertens, Y. Pan, D. Laaf, J. Broda, et al., Vivo
Nanotoxicity testing using the zebraﬁsh embryo assay, J. Mater. Chem 1 (2013),
http://dx.doi.org/10.1039/C3TB20528B.
[23] K. Kiene, S.H. Schenk, F. Porta, A. Ernst, D. Witzigmann, P. Grossen, et al., PDMS-b-
PMOXA polymersomes for hepatocyte targeting and assessment of toxicity, Eur. J.
Pharm. Biopharm. (2017) Verfahrenstechnik EV http://dx.doi.org/10.1016/j.ejpb.
2017.07.002.
[24] Y.-L. Hu, W. Qi, F. Han, J.-Z. Shao, J.-Q. Gao, Toxicity evaluation of biodegradable
chitosan nanoparticles using a zebraﬁsh embryo model, Int. J. Nanomedicine 6
(2011) 3351–3359, http://dx.doi.org/10.2147/IJN.S25853.
[25] S.-W. Jin, D. Beis, T. Mitchell, J.-N. Chen, D.Y.R. Stainier, Cellular and molecular
analyses of vascular tube and lumen formation in zebraﬁsh, Development 132
(2005) 5199–5209, http://dx.doi.org/10.1242/dev.02087.
[26] B.M. Weinstein, D.L. Stemple, W. Driever, M.C. Fishman, Gridlock, a localized
heritable vascular patterning defect in the zebraﬁsh, Nat. Med. 1 (1995)
1143–1147.
[27] J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, et al.,
Fiji: an open-source platform for biological-image analysis, Nat. Methods 9 (2012)
676–682, http://dx.doi.org/10.1038/nmeth.2019.
[28] C.A. Schneider, W.S. Rasband, K.W. Eliceiri, NIH Image to ImageJ: 25 years of
image analysis, Nat. Methods 9 (2012) 671–675.
[29] J. Huwyler, D. Wu, W.M. Pardridge, Brain drug delivery of small molecules using
immunoliposomes, Proc. Natl. Acad. Sci. 93 (1996) 14164–14169.
[30] J. Huwyler, J. Yang, W.M. Pardridge, Receptor mediated delivery of daunomycin
using immunoliposomes: pharmacokinetics and tissue distribution in the rat, J.
Pharmacol. Exp. Ther. 282 (1997) 1541–1546.
[31] Y. Zhang, M. Huo, J. Zhou, S. Xie, PKSolver: an add-in program for pharmacokinetic
and pharmacodynamic data analysis in Microsoft excel, Comput. Methods Prog.
Biomed. 99 (2010) 306–314, http://dx.doi.org/10.1016/j.cmpb.2010.01.007.
[32] T.M. Ludden, S.L. Beal, L.B. Sheiner, Comparison of the Akaike Information
Criterion, the Schwarz criterion and the F test as guides to model selection, J.
Pharmacokinet. Biopharm. 22 (1994) 431–445.
[33] S. Isogai, M. Horiguchi, B.M. Weinstein, The vascular anatomy of the developing
zebraﬁsh: an atlas of embryonic and early larval development, Dev. Biol. 230
(2001) 278–301, http://dx.doi.org/10.1006/dbio. 2000.9995.
[34] S. Ahn, E. Seo, K. Kim, S.J. Lee, Controlled cellular uptake and drug eﬃcacy of
nanotherapeutics, Sci Rep 3 (2013) 1997, http://dx.doi.org/10.1038/srep01997.
[35] F. Fenaroli, D. Westmoreland, J. Benjaminsen, T. Kolstad, F.M. Skjeldal,
A.H. Meijer, et al., Nanoparticles as drug delivery system against tuberculosis in
zebraﬁsh embryos: direct visualization and treatment, ACS Nano 8 (2014)
7014–7026, http://dx.doi.org/10.1021/nn5019126.
[36] C.B. Vibe, F. Fenaroli, D. Pires, S.R. Wilson, V. Bogoeva, R. Kalluru, et al.,
Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin
therapy against mycobacterial infection in zebraﬁsh, Nanotoxicology 10 (2016)
680–688, http://dx.doi.org/10.3109/17435390.2015.1107146.
[37] A. Gabizon, F. Martin, Polyethylene glycol-coated (pegylated) liposomal doxor-
ubicin, Drugs 54 (1997) 15–21, http://dx.doi.org/10.2165/00003495-199700544-
00005.
[38] A.A. Gabizon, Y. Barenholz, M. Bialer, Prolongation of the circulation time of
doxorubicin encapsulated in liposomes containing a polyethylene glycol-deriva-
tized phospholipid: pharmacokinetic studies in rodents and dogs, Pharm. Res. 10
(1993) 703–708, http://dx.doi.org/10.1023/A:1018907715905.
[39] M.P. Craig, S.D. Gilday, D. Dabiri, J.R. Hove, An optimized method for delivering
ﬂow tracer particles to intravital ﬂuid environments in the developing zebraﬁsh,
Zebraﬁsh 9 (2012) 108–119, http://dx.doi.org/10.1089/zeb.2012.0740.
[40] S.R. Blechinger, T.G. Evans, P.T. Tang, J.Y. Kuwada, J.T. Warren, P.H. Krone, The
heat-inducible zebraﬁsh hsp70 gene is expressed during normal lens development
under non-stress conditions, Mech. Dev. 112 (2002) 213–215, http://dx.doi.org/10.
1016/S0925-4773(01)00652-9.
[41] R.J. Duszynski, J. Topczewski, E.E. LeClair, Simple, economical heat-shock devices
for zebraﬁsh housing racks, Zebraﬁsh 8 (2011) 211–219, http://dx.doi.org/10.
1089/zeb.2011.0693.
[42] M. Haldi, C. Ton, W.L. Seng, P. McGrath, Human melanoma cells transplanted into
zebraﬁsh proliferate, migrate, produce melanin, form masses and stimulate angio-
genesis in zebraﬁsh, Angiogenesis 9 (2006) 139–151, http://dx.doi.org/10.1007/
s10456-006-9040-2.
[43] C. Kirby, J. Clarke, G. Gregoriadis, Eﬀect of the cholesterol content of small uni-
lamellar liposomes on their stability in vivo and in vitro, Biochem. J. 186 (1980)
591–598, http://dx.doi.org/10.1042/bj1860591.
[44] C.T. Boughter, V. Monje-Galvan, W. Im, J.B. Klauda, Inﬂuence of cholesterol on
phospholipid bilayer structure and dynamics, J. Phys. Chem. B 120 (2016)
11761–11772, http://dx.doi.org/10.1021/acs.jpcb.6b08574.
[45] L. Redondo-Morata, M.I. Giannotti, F. Sanz, Inﬂuence of cholesterol on the phase
transition of lipid bilayers: a temperature-controlled force spectroscopy study,
Langmuir 28 (2012) 12851–12860, http://dx.doi.org/10.1021/la302620t.
[46] J. Huwyler, J. Drewe, S. Krähenbuhl, Tumor targeting using liposomal anti-
neoplastic drugs, Int. J. Nanomedicine 3 (2008) 21–29.
S. Sieber et al. Journal of Controlled Release 264 (2017) 180–191
191
54
Chapter III-I 
Directing Nanoparticle Biodistribution through Evasion and Exploitation of Stab2-Dependent 
Nanoparticle Uptake 
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Highlights: In mammalians, macromolecular and colloidal waste is removed from blood circulation by 
scavenging receptors on liver sinusoidal endothelial cells, which are part of the reticuloendothelial 
system (RES). Interestingly, various nanoparticles were also found to bind to the caudal vein of 
zebrafish embryos resulting in their clearance from blood circulation. This article describes the 
identification and characterization of a specific orthologue zebrafish receptor, which is responsible for 
the observed nanoparticle binding pattern in zebrafish embryos. Different fluorescently labelled 
nanoparticles and various specific receptor binding molecules were injected in zebrafish and mice. As 
a result, the Stabilin-2 receptor has been discovered to scavenge nanoparticles from blood circulation 
in the caudal vein of zebrafish embryos/larvae and in the mammalian liver lined with liver sinusoidal 
endothelial cells. A zebrafish line lacking the Stabilin-2 receptor was generated via CRISPR/Cas9 
mutagenesis in order to validate these findings. Finally, selective and functional nanoparticulate drug 
delivery via this receptor has been performed to demonstrate receptor mediated cellular uptake of 
bound nanomedicines.
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ABSTRACT: Up to 99% of systemically administered
nanoparticles are cleared through the liver. Within the
liver, most nanoparticles are thought to be sequestered by
macrophages (Kupﬀer cells), although signiﬁcant nano-
particle interactions with other hepatic cells have also been
observed. To achieve eﬀective cell-speciﬁc targeting of
drugs through nanoparticle encapsulation, improved mech-
anistic understanding of nanoparticle−liver interactions is
required. Here, we show the caudal vein of the embryonic
zebraﬁsh (Danio rerio) can be used as a model for assessing
nanoparticle interactions with mammalian liver sinusoidal
(or scavenger) endothelial cells (SECs) and macrophages.
We observe that anionic nanoparticles are primarily taken up by SECs and identify an essential requirement for the
scavenger receptor, stabilin-2 (stab2) in this process. Importantly, nanoparticle−SEC interactions can be blocked by
dextran sulfate, a competitive inhibitor of stab2 and other scavenger receptors. Finally, we exploit nanoparticle−SEC
interactions to demonstrate targeted intracellular drug delivery resulting in the selective deletion of a single blood vessel in
the zebraﬁsh embryo. Together, we propose stab2 inhibition or targeting as a general approach for modifying
nanoparticle−liver interactions of a wide range of nanomedicines.
KEYWORDS: endothelial cells, scavenger receptor, nanomedicine, liposomes, stabilin, zebraﬁsh, targeted drug delivery
Cell-type speciﬁc targeting is a common goal innanoparticle drug delivery. However, the inability toeﬃciently target subpopulations of cells, beyond the
macrophages and monocytes of the mononuclear phagocyte
system (MPS), has stymied progress of these technologies into
clinical use.1−4 Up to 99% of systemically administered
nanoparticles, of all shapes, sizes, and chemical compositions
are cleared through the liver.5 While it is generally accepted that
nanoparticles are taken up by liver-resident macrophages
(Kupﬀer cells (KCs)),6 the principal cell type of the MPS in
the liver, signiﬁcant nanoparticle interactions with other hepatic
cells, including liver sinusoidal endothelial cells (LSECs),
hepatocytes, and hepatic B-cells, have also been observed.7−10
In these instances however, the cell-speciﬁc mechanisms
underpinning these interactions have not been elucidated. A
detailed understanding of exactly where and how nanoparticles
are sequestered and cleared within the liver is crucial for the
eﬀective optimization of nanoparticle-mediated drug delivery.
The principle function of the liver is to maintain homeostasis.
This includes the removal (“scavenging”) of macromolecular
and colloidal waste and pathogens from the blood. Within the
liver, scavenging function is primarily associated with the
hepatic sinusoids,11 specialized blood vessels connecting the
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Figure 1. A zebraﬁsh model for liposome biodistribution. (a) Schematic of liposome injection and quantiﬁcation in zebraﬁsh. Fluorescently
labeled liposomes (1 mM total lipids containing 1 mol % Rhod-PE) were injected into the duct of Cuvier at 54 hpf. Confocal microscopy is
performed in a deﬁned region (boxed) caudal to the yolk extension at 1, 8, 24, and 48 h after injection. (b) Whole-embryo view of liposome
distribution in kdrl:GFP transgenic embryos, 1 hpi with three diﬀerent liposome formulations (AmBisome, EndoTAG-1, and Myocet). (c)
High-resolution imaging allows quantiﬁcation of liposomes in circulation (measured in the lumen of the dorsal aorta (white box)) and
liposome association with diﬀerent blood vessel types (see Supporting Information). CHT-EC: caudal hematopoietic tissue endothelial cells,
DLAV: dorsal longitudinal anastomotic vessel. ISV: intersegmental vessel. (d) Tissue level view of liposome distribution in kdrl:gfp transgenic
embryos, 1 h and 8 h after injection with three diﬀerent liposome formulations and a single confocal section through the dorsal aorta (DA) at
1 h after injection. (e) Quantiﬁcation of liposome levels in circulation based on mean rhodamine ﬂuorescence intensity in the lumen of the
dorsal aorta at 1, 8, 24, and 48 h after injection (error bars: standard deviation.) n = 6 individually injected embryos per formulation per time
point (in two experiments). (f) Quantiﬁcation of liposome levels associated with venous vs arterial endothelial cells based on rhodamine
ﬂuorescence intensity associated with caudal vein (CV) vs DA at 8 h after injection. (g) Quantiﬁcation of extravascular liposome levels based
on rhodamine ﬂuorescence intensity outside of the vasculature between the DLAV and DA at 8 h after injection. (h) Quantiﬁcation of
liposome levels associated with the vessel wall based on rhodamine ﬂuorescence intensity associated with all endothelial cells relative to
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hepatic artery and portal vein (incoming blood ﬂow) with the
central vein (outgoing blood ﬂow). In these vessels, scavenging
function is facilitated by a >10-fold decrease in blood ﬂow
velocity.12 Hepatic sinusoids are primarily composed of LSECs
(∼70%) and KCs (∼20%).13 Together these cells comprise the
hepatic reticuloendothelial system (RES), a term originally
proposed in the early 20th century by Aschoﬀ14 to include
specialized cells that accumulated vital stains. Since then, the
term RES has been largely superseded by the MPS, which in
the liver sinusoid includes KCs but not LSECs.
Cells with a scavenging function similar to mammalian
LSECs have been identiﬁed in all vertebrates examined.
However, in teleost ﬁsh, sharks, and lampreys these cells have
not been found in the liver, but are identiﬁed in various other
organs.15 Collectively, these cells are known as scavenger
endothelial cells (SECs), a specialized endothelial cell type
functionally deﬁned as the major clearance site of endogenous
macromolecules such as oxidized low-density lipoprotein
(oxLDL) and hyaluronic acid (HA) from the blood.11
Mammalian LSECs have also been implicated in clearance of
blood-borne viruses from circulation16−18 and are important
cell-types of both the innate and adaptive immune system.19,20
In LSECs, clearance function is mediated through a relatively
small number of pattern-recognition endocytosis receptors.11
Given the wide variety of macromolecules, colloids, and
pathogens sequestered by LSECs, these receptors are clearly
promiscuous with respect to potential binding partners.
However, what general physicochemical properties direct
materials to LSECs, to what extent are individual endocytosis
receptors involved, and the signiﬁcance of these interactions in
the clearance of nanoparticles from circulation are not clearly
deﬁned.
Here, we show a speciﬁc part of the zebraﬁsh embryonic
vasculature displays functional homology to the mammalian
liver sinusoid and includes macrophages/monocytes and
functional SECs. Using this model, we are able to study
which general properties of nanoparticles result in their uptake
by each of these cell types after intravenous injection. For
SECs, we reveal an important molecular mechanism required
for nanoparticle clearance, involving the transmembrane
receptor stabilin-2, which can be both inhibited and exploited
to guide cell-speciﬁc nanoparticle-mediated drug delivery.
RESULTS AND DISCUSSION
A Zebraﬁsh Model for Liposome Biodistribution. Of
the myriad nanoparticles reported as potential drug delivery
vectors, liposomes are the most widely investigated and the
major class of nanoparticles approved for clinical use.21,22 So
far, the ability to predict the fate of liposomes following
intravenous injection based on lipid composition alone has
been limited. Furthermore, the opacity of mammalian models
precludes comprehensive assessment of the dynamic behavior
of liposomes in vivo. Recent studies have shown that the small
and transparent zebraﬁsh embryo allows for the direct
observation of circulating nanoparticles, including liposomes,
and their interactions with cells.23−26 These studies show key
aspects of nanoparticle behavior, including uptake by the MPS,
are conserved between zebraﬁsh and mammals. We therefore
selected this model to identify the inﬂuence of lipid
composition on liposome biodistribution and the mechanisms
of liposome uptake by cells.
Three liposome formulations, either approved for clinical use
or under development (Myocet, EndoTAG-1, and AmBi-
some),27−29 were initially selected for intravenous injection into
zebraﬁsh embryos. These formulations were speciﬁcally chosen
to assess the inﬂuence of contrasting nanoparticle surface
charge. Myocet is a neutral liposomal-doxorubicin formulation
showing extravasation in tumors.27 EndoTAG-1 is a positively
charged liposomal-paclitaxel formulation targeting actively
growing tumor blood vessels.28 AmBisome is a negatively
charged liposomal-amphotericin B formulation used to treat
severe fungal infections.29 Fluorescently labeled liposomes
(∼100 nm in diameter and without encapsulated drugs) based
on the lipid composition of these formulations (Table S1) were
injected intravenously into the duct of Cuvier of zebraﬁsh
embryos at 54 h post-fertilization (hpf), a stage at which most
organ systems are established. Injected embryos were imaged
using confocal microscopy at 1, 8, 24, and 48 h post-injection
(hpi) (Figure 1a), and confocal micrographs were generated for
the entire embryo (whole organism level) as well as from a
region caudal to the cloaca (tissue level) (Figure 1b,d and
Figure S1). We developed a quantiﬁcation method to compare
levels of circulating liposomes, extravasation, and accumulation
in diﬀerent blood vessel types between formulations (Figure
1c,e−h and Figure S2).
At 1 hpi, on a whole organism level, all three liposome
formulations were found associated with the blood vasculature
and over time, the ﬂuorescence associated with freely
circulating liposomes within the lumen of the dorsal aorta,
decayed exponentially (Figure 1b,e). At the tissue level
however, clear diﬀerences in liposome biodistribution were
observed (Figure 1d). Consistent with their behavior in
mammals, neutral Myocet liposomes were mostly seen
circulating within the blood vessel lumen. At 1 hpi, liposome
translocation through the vessel wall (extravasation) was
already evident, and between 1 and 8 hpi, co-localization with
plasma-exposed macrophages was observed (Figure 1d,g,
Figure S3). Increasing the size of Myocet liposomes resulted
in enhanced uptake by macrophages, whereas surface
PEGylationa strategy widely employed to limit nanoparticle
clearance in vivo30eﬀectively inhibited phagocytotic uptake as
described previously (Figure S3).23,26
For EndoTAG-1 and AmBisome, a large fraction of the
injected dose was removed from circulation by 1 hpi and 8 hpi
respectively, and these formulations were found associated with
the vessel wall (Figure 1e,h). Strikingly however, anionic
Figure 1. continued
rhodamine ﬂuorescence intensity in circulation at 1h after injection. (f−h) Bar height represents median values, dots represent individual data
points, brackets indicate signiﬁcantly diﬀerent values (*: p < 0.05, **: p < 0.01, ***: p < 0.001) based on Kruskal−Wallis and Dunn’s tests
with Bonferroni correction for multiple testing. n = 12 individually injected embryos per group (in 2 experiments). (i) Whole-embryo view of
liposome distribution in kdrl:GFP transgenic embryos, 1 h after injection with DOPG and DSPC liposomes. Liposome accumulation for both
formulations is observed in the primitive head sinus (PHS), common cardinal vein (CCV), posterior cardinal vein (PCV), and caudal vein
(CV). (j) Tissue level view of liposome distribution in kdrl:GFP transgenic embryos, 1 h after injection with DOPG and DSPC liposomes at
102 hpf. Liposome accumulation is observed in the entire caudal vein (CV), but only on the dorsal side of the PCV (dPCV, arrows).
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AmBisome liposomes associated only with ECs of a subset of
blood vessels, namely the caudal vein (CV), the posterior and
common cardinal veins (PCV and CCV), and the primary head
sinus (PHS) as well as ECs within the caudal hematopoietic
tissue (CHT-ECs) (Figure 1d,f−h).31 These comprise the
majority of venous ECs within the zebraﬁsh embryo at this
developmental stage.32 Cationic EndoTAG-1 liposomes at 1
hpi associated with all ECs as expected33 but at later time
points remain associated only with venous ECs.
AmBisome, EndoTAG-1, and Myocet are each composed of
various mixtures of (phospho)lipids and cholesterol. In these
cases, lipid headgroup chemistries, fatty acid chain saturation
and cholesterol content, will together combine to aﬀect the
overall physicochemical character of the formulated liposomes
and consequently their in vivo fate. To limit potential variation
in liposome membrane composition, we next formulated and
injected ∼100 nm liposomes composed of the individual
(phospho)lipids constituting AmBisome, EndoTAG-1, and
Myocet (Figure S4 and Table S1). We also included liposomes
composed of 1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycer-
ol) (DOPG) and 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC). In these experiments, injected cationic liposomes
(measured zeta potential; >30 mV) initially associated with
both arterial and venous ECs of the embryonic ﬁsh. All anionic
liposomes (<−30 mV) associated with venous ECs alone, and
the behavior of neutral liposomes was dependent on lipid fatty
acid chain saturation, whereby “ﬂuid” liposome membranes (for
example, DOPC), rich in unsaturated lipids, are freely
circulating, whereas those composed of ‘rigid’, saturated lipids
(for example, 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC)) associated with venous ECs. Of these, liposomes
composed of DSPC and DOPG associated with venous ECs of
the CCV, PHS, PCV, CHT, and CV most strongly (Figure 1i,
Figure S4a,d). Both these liposomes also accumulated in
macrophages within the CHT and along the CCV (Figure S5).
Diﬀerential distribution of nanoparticles over blood vessel
networks has previously been attributed to diﬀerences in ﬂow
patterns.7,25 However, when injections were performed in 4
Figure 2. Identiﬁcation of scavenger endothelial cells (SECs) in zebraﬁsh embryos. (a, b) Ex vivo imaging of adult Tie2:GFP transgenic mouse
organs, 1 h after injection with DOPG liposomes. (a) Liposome accumulation is observed in liver, but not in the ear skin or heart muscle. (b)
Within the liver, DOPG liposomes are observed as punctae within Tie2:GFP+ sinusoidal ECs (arrows) as well as sinusoid-associated cells
which based on shape and position were identiﬁed as KCs (arrowheads). (c) Tissue level view of lithium carmine distribution in kdrl:GFP and
mpeg:GFP transgenic zebraﬁsh embryos, 1 h after injection. Lithium carmine (carminic acid) ﬂuorescence co-localizes both with kdrl:GFP+
endothelial cells in the caudal vein and mpeg:GFP+ monocytes/macrophages (arrowheads) within the CHT. (d) Whole-embryo view of
ﬂuorescent oxLDL distribution in kdrl:GFP transgenic embryos, 1 h after injection. Accumulation of oxLDL is observed in the PHS, CCV,
PCV, and CV. (e) Whole-embryo view of ﬂuoHA distribution in kdrl:RFP transgenic embryos, 1 h after injection. Accumulation of ﬂuoHA is
observed in the PHS, CCV, PCV, and CV. (f) Tissue level view of ﬂuoHA distribution in kdrl:RFP transgenic embryos, 1 h after injection at
102 hpf. FluoHA accumulation is observed in the entire caudal vein (CV), but only on the dorsal side of the PCV (dPCV, arrows). (g) Tissue
level view of ﬂuoHA in kdrl:RFP and mpeg:RFP transgenic embryos. Co-localization of RFP expression and ﬂuoHA is observed only within
kdrl:RFP endothelial cells, but not mpeg:RFP monocytes/macrophages. (h) Tissue level view of co-injected ﬂuoHA and DOPG liposomes, 1 h
after injection reveals co-localization in SECs. Monocytes/macrophages (arrowheads) take up DOPG but not ﬂuoHA. (i) Ex vivo imaging of
adult mouse liver, 1 h after injection with ﬂuoHA and DOPG liposomes reveals widespread co-localization within sinusoidal ECs (arrows).
KCs (arrowheads) take up DOPG liposomes only.
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day-old zebraﬁsh embryos, both DOPG and DSPC liposomes
preferentially associated with only a subset of venous ECs along
the dorsal side of the PCV (dPCV) (Figure 1j). Liposome
association with a subset of ECs in a single, straight blood
vessel (where ﬂow patterns are expected to be similar
throughout) indicated dPCV ECs are a cell type distinct from
ventral PCV (vPCV) ECs. Indeed, diﬀerentiation of dPCV and
vPCV ECs has previously been observed during the induction
of lymphatic diﬀerentiation and subintestinal vein angio-
genesis,34,35 suggesting dPCV diﬀerentiation may lead to the
expression of speciﬁc receptors by these ECs which in turn
Figure 3. stab2 is required for anionic liposome uptake by SECs. (a, b) Tissue level view of DOPG (a) and DSPC (b) liposome distribution at
1 hpi in control and dextran sulfate injected embryos, with quantiﬁcation of liposome levels associated with venous vs arterial endothelial cells
based on rhodamine ﬂuorescence intensity associated with CV vs DA. (c) stab2 domain structure predicted to be expressed from the wild-type
stab2 and the stab2ibl2 allele. (d) Whole-embryo view of f lt1:RFP, f lt4:YFP double transgenic embryos at 5 dpf to visualize blood vascular and
lymphatic development. No defects were identiﬁed during (lymph)angiogenesis and vascular patterning in stab2ibl2 homozygous embryos
compared to sibling controls. (e) Fertile adult females (stab2ibl2 homozygous and sibling controls) at 3 months post-fertilization. (f−k) Tissue
level view of ﬂuoHA (f) and DOPG (g), DSPC (h), AmBisome (i), EndoTAG-1 (j), and Myocet (k) liposome distribution at 1 hpi in stab2ibl2
and sibling control embryos, with quantiﬁcation of liposome levels associated with venous vs arterial endothelial cells based on rhodamine
ﬂuorescence intensity associated with CV vs DA. (a, b, f−k) Bar height represents median values, dots represent individual data points, and
brackets indicate signiﬁcantly diﬀerent values (*: p < 0.05, **: p < 0.01, ***: p < 0.001, N.S.: not signiﬁcant) based on Mann−Whitney test. n
= 6−10 per group (in two experiments).
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could mediate the selective binding of DOPG and DSPC
liposomes.
Identiﬁcation of a Zebraﬁsh EC Type Homologous to
Mammalian LSECs. Selective association of liposomes with
most venous ECs has not been observed in adult mammals.
However, we hypothesized a more restricted subset of ECs in
mammals could be functionally related to venous ECs of the
embryonic zebraﬁsh. To test this hypothesis, DOPG liposomes
were injected intravenously into Tie2:GFP+ adult mice. In
these mice, liposomes were removed from circulation within 1
hpi, and a striking accumulation was observed in the liver
(Figure 2a). Within the liver, liposomes associated with
Tie2:GFP+ sinusoidal ECs and with cells identiﬁed as KCs
based on cell shape and intravascular localization (Figure 2b).
No liposome accumulation was observed in hepatocytes or
other analyzed organs. This suggested venous ECs and
macrophages within the CHT and CV of the embryonic
zebraﬁsh were functionally homologous to LSECs and KCs of
the mammalian liver and comprise the RES in zebraﬁsh
embryos. To conﬁrm this, we injected colloidal lithium carmine
(Li-Car), the most prominent vital stain originally used to
deﬁne the mammalian RES, into zebraﬁsh embryos. Making use
of the inherent ﬂuorescence of carminic acid,36 we observed
accumulation of this colloid in the same blood vessels (CV,
CHT, PCV, and PHS) and subcellular structures within venous
ECs and macrophages, in which DOPG and DSPC liposomes
also accumulate (Figure 2c).
A small number of transmembrane receptors are selectively
expressed in mammalian LSECs compared to other blood
vascular ECs.11 These include the scavenger receptors Stabilin-
1 and -237 and the mannose receptor Mrc1. Analysis of the
expression patterns of their orthologs (stab1, stab2 and mrc1a)
in zebraﬁsh embryos conﬁrmed their restricted expression in
venous ECs of the PHS, PCV, CHT, and CV as described
previously.38,39 Importantly, expression of these genes becomes
enriched in the dPCV, matching observed EC binding
speciﬁcities of both DOPG and DSPC liposomes (Figure S6).
LSECs mediate the scavenging of macromolecular waste
including oxLDL and HA through receptor-mediated endocy-
tosis.40 Therefore, we injected ﬂuorescently labeled oxLDL and
HA (ﬂuoHA) and observed their rapid endocytosis, within the
same subset of venous ECs (within the PHS, CCV, (d)PCV,
and CV) (Figure 2d−f). Based on the conserved uptake of
DOPG liposome, oxLDL, ﬂuoHA, and Li-Car from circulation
and expression of known LSEC markers by this venous EC
subset in zebraﬁsh embryos, we deﬁne them as SECs -
homologous to mammalian LSECs.
In contrast to DSPC and DOPG liposomes and to oxLDL,
ﬂuoHA uptake was speciﬁc to SECs, and no uptake was
observed in macrophages (Figure 2g). We next used ﬂuoHA as
a marker for endocytosis in SECs. Co-injection of ﬂuoHA with
DSPC or DOPG liposomes resulted in precise intracellular co-
localization in all SECs of the embryonic ﬁsh, while in
macrophages only liposome internalization was observed
(Figure 2h, Figure S7). Intracellular co-localization in LSECs
(but not KCs) of ﬂuoHA and DOPG liposomes was conserved
in the adult mouse liver (Figure 2i). These results
demonstrated ﬂuoHA endocytosis is a selective vital marker
for SECs in vertebrates and oﬀered a convenient method to
study SEC diﬀerentiation in the developing zebraﬁsh embryo
(Figure S8). Importantly, we found SECs were present at the
earliest time point at which intravenous injection is possible (28
hpf). During embryonic and larval stages, SECs were
maintained within the CV, but starting at 52 hpf became
gradually restricted to the dPCV. No ﬂuoHA uptake was
observed in embryonic veins that develop during later stages,
such as in the brain and subintestinal vasculature. These results
show that SECs are one of the ﬁrst EC subtypes to emerge
during embryonic development and provide the ﬁrst analysis of
early embryonic SEC diﬀerentiation in any vertebrate.
Stabilin-2 Is Required for Uptake of Liposomes and
Other Nanoparticles by SECs. The precise intracellular co-
localization of ﬂuoHA with DOPG and DSPC liposomes in
SECs indicated the use of a shared receptor for endocytosis.
Importantly, one of the markers for SECs in zebraﬁsh embryos
and adult mammals, Stabilin-2, has been identiﬁed as the main
HA clearance receptor in the mouse liver.40 In vitro, Stabilin-2
and its paralog Stabilin-1 have been shown to bind to a large
variety of endogenous (mostly anionic) macromolecules41 as
well as phosphothiorate-modiﬁed antisense oligonucleotides
(PS-ASO),42 apoptotic cell bodies,43 biotinylated albumin,44
and carbon nanotubes.45 In vivo, Stabilin-1 and Stabilin-2 were
shown to mediate sequestration (but not uptake) by LSECs of
aged erythrocytes in a phosphatidylserine-dependent manner.46
Stabilin-1 and Stabilin-2 are both nonessential genes for
development and normal physiology in mice, with mice lacking
both Stabilin-1 and Stabilin-2 displaying deﬁcient removal of
nephrotoxic macromolecules from circulation.37 To test if
stabilins were involved in liposome uptake by SECs, embryos
were ﬁrst pretreated with dextran sulfate - a competitive
inhibitor of scavenger receptors, including stab1 and stab2.47,48
Subsequent liposome injection (or co-injection) resulted in a
striking loss of liposome uptake by SECs, oﬀset by an increase
in circulating liposomes, and particularly in the case of DOPG
liposomes, an increase in macrophage uptake (Figure 3a,b). In
contrast, injection of mannan, a competitive inhibitor of
mrc1a,49 did not inhibit liposome uptake by SECs (data not
shown).
To identify the speciﬁc role of stab1 and stab2 in liposome
uptake, mutants for both genes were generated through
CRISPR/Cas9-mediated mutagenesis. Here, we report the
analysis of a stab2 mutant line, in which we identiﬁed a 4nt
deletion (stab2ibl2), leading to a frameshift in the stab2 coding
sequence and a premature stop codon (C233X) (Figure 3c,
Figure S9). This mutation is predicted to remove most
conserved stab2 domains including all fasiclin domains, the
HA binding Link domain, and the transmembrane and
cytoplasmic segments. Homozygous stab2ibl2 mutants displayed
a strong reduction of stab2, but not of stab1 or mrc1a, mRNA
expression indicating normal SEC diﬀerentiation and nonsense-
mediated decay of stab2ibl2 mRNA (Figure S10). Stab2ibl2
mutants survived throughout embryonic development without
defects in either blood or lymphatic vascular systems, which
were described previously for stab2 morphants,50,51 and fertile
adults were identiﬁed in normal Mendelian ratios (Figure 3d,e).
Consistent with the increase in circulating HA levels observed
in mouse Stab2 knockouts,52 a complete loss of ﬂuoHA uptake
by SECs was observed in zebraﬁsh stab2ibl2 mutants, showing a
conserved role for stab2 in HA clearance in vertebrates (Figure
3f). Importantly, when either DOPG or DSPC liposomes were
injected in stab2ibl2 mutants, a strong reduction of liposome
endocytosis by SECs was observed, oﬀset by an increase in
circulating liposome levels and an increase in macrophage
uptake (Figure 3g,h). Diﬀerential liposome uptake in
neighboring venous ECs of embryos with a mosaic loss of
stab2 function indicated a cell-autonomous role of stab2
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function in liposome uptake by SECs (Figure S11). For the
original three liposome formulations screened, loss of stab2
function aﬀected AmBisome, but not Myocet or EndoTAG-1
biodistribution (Figure 3i−k). Since both AmBisome and
EndoTAG-1 accumulated within SECs of wild-type embryos,
stab2-mediated uptake by SECs appears dependent on speciﬁc
physicochemical properties of liposomes and stab2 does not
function in the clearance of cationic liposomes.
In vivo, several other scavenger receptors with similar binding
proﬁles to stab2 are expressed,11 not only on SECs but also on
other endothelial cells and macrophages. Given the signiﬁcant
increase in circulating DOPG, DSPC, and AmBisome lip-
osomes in stab2ibl2 mutants, stab2 clearly plays a dominant role
in removal of these liposomes from circulation compared to
other scavenger receptors (including the structurally related
stab1). Similarly, clearance of PS-ASOs was recently shown to
be dominated by Stab2 in the mouse liver.42 To test the
generality of stab2 function, several other polyanionic nano-
particles were injected in wild-type and stab2ibl2 mutant
embryos as well as following dextran sulfate injection (Figure
4a−l). These included endogenous (DOPS liposomes, a model
for apoptotic cell fragments), viral (Cowpea Chlorotic Mottle
Virus-like particles, CCMV VLPs),53 polymeric (polymer-
somes54 and polystyrene beads), and inorganic (quantum
dots, QDs) nanoparticles. All of these particles were
endocytosed selectively by SECs in zebraﬁsh embryos, and in
all cases SEC endocytosis could be inhibited by dextran sulfate.
However, not all nanoparticles were dependent on stab2 for
SEC endocytosis. Although uptake by SECs of DOPS
liposomes, polymersomes, and polystyrene nanoparticles was
Figure 4. stab2-mediated scavenging of anionic nanoparticles in vivo. (a−i) Tissue level view of DOPS liposome (a, b), PIB-PEG polymersome
(c, d), carboxylated polystyrene nanoparticle (e, f), CCMV virus-like particle (g, h), and carboxylated quantum dot (i, j) distribution at 1 hpi
in stab2ibl2 and sibling control embryos (a, c, e, g, i) or control and dextran sulfate injected embryos (b, d, f, h, j). Quantiﬁcation of
nanoparticle levels associated with venous vs arterial endothelial cells based on rhodamine ﬂuorescence intensity associated with caudal vein
vs DA. (a−j) Bar height represents median values, dots represent individual data points, and brackets indicate signiﬁcantly diﬀerent values (*:
p < 0.05, **: p < 0.01, ***: p < 0.001, N.S.: not signiﬁcant) based on Mann−Whitney test. n = 5−12 per group (in two experiments).
ACS Nano Article
DOI: 10.1021/acsnano.7b06995
ACS Nano XXXX, XXX, XXX−XXX
G
62
strongly decreased in stab2ibl2 mutants, uptake of CCMV VLPs
was only partly dependent on stab2 and QD uptake appeared
stab2-independent. Alternatively, QD uptake by SECs is also
mediated in part by stab2, but its function is masked in stab2ibl2
mutants through redundancy with other scavenger receptors
(such as stab1) that can be inhibited by dextran sulfate. CCMV
VLPs (28 nm) and QDs (<10 nm) were the smallest
nanoparticles screened in this study, suggesting size may be
an important determinant of scavenger receptor−nanoparticle
interactions.
Targeted Liposomal Drug Delivery to SECs. Finally, to
demonstrate we could extend the observed interaction of
nanoparticles with SECs to cell-selective drug delivery, we
encapsulated a model drug, clodronic acid, within DSPC
liposomes (Table S2). Clodronic acid requires active transport
(endocytosis or phagocytosis) across the target cell membrane
to illicit a cytotoxic eﬀect.55 Liposome-mediated intracellular
delivery of clodronic acid into monocytes/macrophages is used
extensively as a research tool to selectively remove these cell
populations in vivo.56 After 12−24 hpi, synchronous changes in
the morphology of the CHT and caudal vein ECs were
observed, followed by a gradual loss of kdrl:GFP+ endothelial
cells or cell fragments and ultimately leading to the complete
disappearance of the caudal vein between 24 and 48 hpi (Figure
5a−d, Movie S1 and S2). The PCV and other cell types within
the CHT, including mpeg:GFP+ macrophages (most of which
are not exposed to circulating nanoparticles) as well as
mpx:GFP+ neutrophils, were largely unaﬀected (Figure S12).
Injection of free clodronic acid (a control demonstrating the
requirement of liposomal encapsulation) did not result in any
observable changes to the venous endothelium. Similarly,
injection of freely circulating DOPC-clodronic acid liposomes
(a control demonstrating the requirement of selective nano-
particle uptake by SECs) did not aﬀect the venous
Figure 5. Nanoparticle-mediated SEC deletion. (a) Whole-embryo and tissue level views at 48 hpi of the blood vasculature in kdrl:GFP
transgenic control embryos, embryos injected with 1 mg/mL clodronic acid, or embryos injected with liposomes containing 1 mg/mL
clodronic acid (DSPC or DOPC liposomes). Complete deletion of the caudal vein is observed in embryos injected with DSPC liposomes
containing clodronic acid (brackets and asterisks). (b) Schematic representation of blood ﬂow in control embryos or embryos injected with
DSPC liposomes containing 1 mg/mL clodronic acid. Blue indicates venous or capillary blood vessels, and red indicates arterial blood vessels.
Arrowheads indicate direction of blood ﬂow (based on observations from Movie S1). The removal of the CV (dashed lines) leads to a
rerouting of blood ﬂow through the DLAV. (c) Quantiﬁcation of PCV length in injected embryos. Bar height represents median values, dots
represent individual data points, and brackets indicate signiﬁcant values (**: p < 0.01, ***: p < 0.001) based on Kruskal−Wallis and Dunn’s
tests with Bonferroni correction for multiple testing. n = 6 individually injected embryos per group (in two experiments). (d) Progression of
SEC deletion. Individual frames from Movie S2 at indicated time points after injection of DSPC liposomes containing 1 mg/mL clodronic
acid, injected into kdrl:GFP transgenic embryos. SEC fragmentation in this case is observed mostly between 12 hpi and 16 hpi, followed by a
gradual loss of ﬂuorescence or removal of cellular debris. (e) Tissue level view of distribution of DSPC liposomes containing 1 mg/mL
clodronic acid at 1 hpi in stab2ibl2 and sibling control embryos. (f) Whole-embryo and tissue level views at 48 hpi of the blood vasculature in
kdrl:GFP transgenic stab2ibl2 and sibling embryos. Embryos were injected with DSPC liposomes containing 1 mg/mL clodronic acid.
Complete deletion of the caudal vein is observed in sibling control (brackets and asterisks), but not stab2ibl2 mutant embryos. (g) Schematic
representation of blood ﬂow in sibling control embryos or stab2ibl2 homozygous mutants, both injected with DSPC liposomes containing
approximately 1 mg/mL clodronic acid. Blue indicates venous or capillary blood vessels, and red indicates arterial blood vessels. Arrowheads
indicate direction of blood ﬂow (based on observations from Movie S3). The removal of the CV (dashed lines) leads to a rerouting of blood
ﬂow through the DLAV in control embryos but not in stab2ibl2 homozygous mutants. (h) Quantiﬁcation of PCV length in injected embryos.
Bar height represents median values, dots represent individual data points, and brackets indicate signiﬁcant values (***: p < 0.001) based on
Mann−Whitney test.
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endothelium. The development of the dorsal aorta was
unaﬀected by deletion of the CV and CHT, and blood supply
to the caudal parts of the embryo was maintained through a
rerouting of blood cells into the intersegmental vessels and
dorsal longitudinal anastomotic vessel (DLAV). Embryos with
a complete loss of the CV and CHT endothelial cells were agile
and could survive at least until 6 dpf. Imaging of ﬂuorescent
DSPC-clodronic acid liposomes revealed selective stab2-
dependent uptake by SECs analogous to empty DSPC
liposomes (Figure 5e). Importantly, loss of stab2 function as
observed in stab2ibl2 mutant embryos rescued the CV
phenotype induced by injection of DSPC-clodronic acid
liposomes (Figure 5 f-h, Movie S3). These results identify
stab2-mediated uptake of liposomes by SECs as a simple
strategy for intracellular compound delivery to this cell type in
zebraﬁsh embryos.
CONCLUSION
In summary, we show stab2 is an important (scavenger)
receptor mediating the uptake of circulating nanoparticles by
SECs. In particular, anionic nanoparticles, between 50 and 250
nm in size, are avidly taken up by SECs in a stab2-dependent
fashion. Here, binding and uptake appear independent of
material and functional properties of nanoparticles and are
solely dependent on surface charge. Given the comparable sizes
and surface charge of many blood-borne viruses,16−18,57
clearance of these circulating pathogens by LSECs is also
potentially mediated by stab2. These ﬁndings, combined with
the high expression of stab2 by LSECs within the mammalian
liver,11 implicate SECs as an important cell-type in the binding,
uptake, and clearance of administered nanoparticles. As such,
we support the re-adoption of the RES, over the MPS, as the
most accurate term to describe the specialized cellular
components involved in nanoparticle clearance from circu-
lation.58
The ultimate goal of many nanoparticle-based technologies is
cell-type-speciﬁc targeting. Yet reported targeting eﬃciencies
rarely surpass 1% of the total injected nanoparticle dose.1 A
major contributing factor has been oﬀ-target nanoparticle
interactions within the mammalian liver.5 By revealing the
molecular basis of nanoparticle interactions with speciﬁc cells of
the embryonic zebraﬁsh, we have been able to demonstrate
nanoparticle targeting of, and drug delivery to, speciﬁc cell
types with homologues in the mammalian liver. In addition, we
show these interactions can be eﬀectively inhibited by dextran
sulfate. As stab2 is not essential for normal adult physiology,37
this oﬀers a simple method to extend circulation lifetimes of
nanoparticles by minimizing potential oﬀ-target liver inter-
actions.59 This will likely be particularly beneﬁcial in instances
where active targeting of nanoparticles to cell types beyond the
liver (for example, cancer cells) is desired.
Importantly, the SEC/selective drug delivery we describe has
not resulted from adding further complexity to nanoparticle
designs. Instead, through systematic screening of “simple”
nanoparticles (i.e., liposomes composed of a single phospho-
lipid), we have established what general properties and
molecular mechanisms direct nanoparticles to speciﬁc cell
types. The use of the embryonic zebraﬁsh as a model organism,
and the ability to visualize nanoparticle−cell interactions at high
resolution in living organisms, has been essential in this process.
We therefore propose that the embryonic zebraﬁsh, with its
established extensive genetic toolkit, is a valuable preclinical in
vivo model allowing screening, optimization, and mechanistic
understanding of nanoparticle biodistribution, predictive of
their behavior in mammals.26
MATERIALS AND METHODS
Reagents. Fluorescein-labeled hyaluronic acid (ﬂuoHA) was
prepared through conjugation of hyaluronic acid (100 kDa) with
ﬂuorescein isothiocyanate (Isomer I, Sigma-Aldrich) as previously
described.60 Additional ﬂuoHA was provided as a kind gift from W.
Jiskoot (Leiden University, The Netherlands). Colloidal Li-Car was
prepared as previously described.61 Rhodamine-loaded polymersomes
on polyisobutadiene/polyethylene glycol (PIB/PEG) block copoly-
mers54 were a kind gift from S. Askes and S. Bonnet (Leiden
University, The Netherlands). Atto-647 labeled CCMV-virus-like
particles (t = 3, 28 nm)53 were a kind gift from M. de Ruiter and J.
Cornelissen (Twente University, The Netherlands). Purchased
reagents are described in the Supporting Information.
Liposome Preparation and Characterization. All liposomes
(without encapsulated drugs) were formulated in ddH2O at a total
lipid concentration of 1 mM. Individual lipids, as stock solutions (1−
10 mM) in chloroform, were combined at the desired molar ratios and
dried to a ﬁlm, ﬁrst under a stream of N2 and then >1h under vacuum.
With the exception of Myocet 325 and 464 nm, lipid ﬁlms were
hydrated in 1 mL ddH2O at >65 °C (with gentle vortexing if
necessary) to form large/giant multilamellar vesicles. Large unilamellar
vesicles were formed through extrusion above the Tm of all lipids (>65
°C, Mini-extruder with heating block, Avanti Polar Lipids, Alabaster,
US). Hydrated lipids were passed 11 times through 2 × 400 nm
polycarbonate (PC) membranes (Nucleopore Track-Etch membranes,
Whatman), followed by 11 times through 2 × 100 nm PC pores. All
liposomes were stored at 4 °C. With the exception of DSPC liposomes
(signiﬁcant aggregation after 1 week storage), all liposomes were stable
for at least 1 month. Myocet 325 and 464 nm liposomes were
formulated by gentle hydration of lipid ﬁlms at 35 °C (without
vortexing). In the case of 464 nm Myocet liposomes, hydrated lipids
were passed through a 800 nm PC membrane 7 times at 35 °C. In the
case of 325 nm Myocet liposomes, hydrated lipids were passed
through a 400 nm PC membrane 7 times at 35 °C. See Supporting
Information for nanoparticle characterization methods and Table S1
for all lipid compositions, size, and zeta potentials of nanoparticles
used in this study.
Clodronic Acid Encapsulation and Quantiﬁcation. Lipid ﬁlms
(10 mM total lipids) were hydrated with ddH2O containing 200
mgmL−1 clodronic acid (1 mL) and formulated through extrusion as
described for the corresponding “empty” liposomes. Unencapsulated
clodronic acid was removed by size exclusion chromatography (illustra
NAP Sephadex G-25 DNA grade premade columns (GE Healthcare)
used according to the supplier’s instructions). Eluted clodronic acid-
encapsulated liposomes were diluted 2.5× during SEC and injected
without further dilution. Quantiﬁcation of encapsulated clodronic acid
was determined by UV absorbance as previously reported.62 Brieﬂy,
liposomes were ﬁrst destroyed through a 1:1 dilution with 1% v/v
Triton X-100 solution before further dilution into an acidic CuSO4
solution (1:2.25:2.25; Liposome-Triton X-100 mix: 3 mM HNO3: 4
mM CuSO4). The concentration of clodronic acid was determined by
UV absorbance (Cary 3 Bio UV−vis spectrometer) at 240 nm and
quantiﬁed against a predetermined calibration curve (50 μM to 2.5
mM clodronic acid). All UV−vis absorbance measurements were taken
at room temperature. Blanks were made using liposome solutions
without encapsulated clodronic acid but prepared otherwise identically
(including SEC procedure). The ﬁnal encapsulated clodronic acid
concentration varied between 0.9 and 1.7 mg mL−1 (see Supporting
Information Table S2).
Zebraﬁsh Strains, in Situ Hybridization, and CRISPR/Cas9
Mutagenesis. Zebraﬁsh (Danio rerio, strain AB/TL) were maintained
and handled according to the guidelines from the Zebraﬁsh Model
Organism Database (http://zﬁn.org) and in compliance with the
directives of the local animal welfare committee of Leiden University.
Fertilization was performed by natural spawning at the beginning of
the light period, and eggs were raised at 28.5 °C in egg water (60 ug/
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mL Instant Ocean sea salts). The following previously established
zebraﬁsh lines were used Tg(kdrl:GFP)s843,63 Tg(kdrl:RFP-
CAAX)s916,38 Tg(mpeg:GFP)gl22,64 Tg(mpeg:RFP-CAAX)ump2,65 Tg-
(f lt1enh:RFP)hu5333,66 Tg(f lt4BAC:YFP)hu7135,67 and Tg(mpx:GFP)uwm1.68
Whole-mount in situ hybridization was performed as described.69
Supporting Information Table S3 lists primers for probe generation.
Cloning-free sgRNAs for CRISPR/Cas9 mutagenesis were designed
and synthesized as described.70 sgRNAs (125 pg) and cas9 mRNA
(300 pg) were co-injected into single-cell wild-type, albino or f lt4:YFP;
f lt1:RFP transgenic embryos. Mutagenesis eﬃcacy, founder identi-
ﬁcation, and genotyping were performed using CRISPR-STAT.71 The
nucleotide sequences and predicted stab2 amino acid sequences in the
stab2ibl2 line are shown in Figure S11. Table S3 lists guide RNA
sequences and genotyping primers. For mosaic analysis, heterozygous
embryos (stab2ibl/+) obtained from a cross between a stab2ibl2
homozygous parent and a kdrl:GFP (stab2+/+) parent were co-injected
with sgRNAs (125 pg) and cas9 mRNA (300 pg) to create second-hit
mutations in the wild-type allele.
Zebraﬁsh Intravenous Injections. Liposomal formulations were
injected into 2 day old zebraﬁsh embryos (52−56 hpf) using a
modiﬁed microangraphy protocol.72 Embryos were anesthetized in
0.01% tricaine and embedded in 0.4% agarose containing tricaine
before injection. To improve reproducibility of microangiography
experiments, 1 nL volumes were calibrated and injected into the sinus
venosus/duct of Cuvier. We created a small injection space by
penetrating the skin with the injection needle and gently pulling the
needle back, thereby creating a small pyramidal space in which the
liposomes and polymers were injected. Successfully injected embryos
were identiﬁed through the backward translocation of venous
erythrocytes and the absence of damage to the yolk ball, which
would reduce the amount of liposomes in circulation. For injections at
later stages (>80 hpf), 0.5 nL volumes were injected into the CCV.
The following concentrations were injected: dextran sulfate (20 mg/
mL), FluoHA (0.2 mg/mL), oxLDL (1 mg/mL), CCMV-VLP (1 mg/
mL), QDs (1:25 dilution), lithium carmine (1:50 dilution), polymer-
somes (1 mg/mL), latex beads (1:10 dilution). Dextran sulfate was
injected 20 min prior to nanoparticle injection.
Zebraﬁsh Imaging and Quantiﬁcation. For each treatment or
time point, at least six individual embryos (biological replicates) using
at minimum two independently formulated liposome preparations
were imaged using confocal microscopy. Embryos were randomly
picked from a dish of 20−60 successfully injected embryos (exclusion
criteria were: no backward translocation of erythrocytes after injection
and/or damage to the yolk ball). Confocal z-stacks were captured on a
Leica TCS SPE confocal microscope, using a 10× air objective (HCX
PL FLUOTAR) or a 40× water-immersion objective (HCX APO L).
For whole-embryo views, 3−5 overlapping z-stacks were captured to
cover the complete embryo. Laser intensity, gain, and oﬀset settings
were identical between stacks and sessions. Images were processed and
quantiﬁed using the Fiji distribution of ImageJ.73,74 Quantiﬁcation (not
blinded) of liposome biodistribution was performed on 40× confocal
z-stacks (with an optical thickness of 2 μm/slice) as described in the
Supporting Information.
Mouse Injections and Imaging. All experiments were performed
in accordance with the guidelines of the Animal Welfare Committee of
the Royal Netherlands Academy of Arts and Sciences, The
Netherlands. Tg(TIE2GFP)287Sato/J mice were sedated using
isoﬂurane inhalation anesthesia (1.5−2% isoﬂurane/O2 mixture). 100
μL of DOPG liposomes (10 mM DOPG + 1% Rhod-PE) diluted 1:5
in PBS were injected retro-orbitally with an insulin syringe (BD). After
1 h, mice were sacriﬁced, and organs were harvested and imaged ex
vivo on glass bottom dishes. Images were taken with a Leica SP8
multiphoton microscope with a chameleon Vision-S (Coherent Inc.),
equipped with four HyD detectors: HyD1 (<455 nm), HyD2 (455−
490 nm), HyD3 (500−550 nm), and HyD4 (560−650 nm). Diﬀerent
wavelengths between 700 nm and 1150 nm were used for excitation;
HA and Rhod-PE were excited with a wavelength of 960/1050 nm and
detected in HyD3 and HyD4. All images were in 12 bit and acquired
with a 25× (HCX IRAPO N.A. 0.95 WD 2.5 mm) water objective.
Statistical Analysis and Data Availability. Because of small
sample sizes, nonparametric tests were used exclusively. For
comparisons between two groups, two-tailed Mann−Whitney tests
were performed. For comparisons between multiple groups, we used
Kruskal−Wallis tests followed by two-tailed Dunn’s tests with
Bonferroni correction using the PMCMR package in R.75 No
statistical methods were used to predetermine sample size, but
group sizes were >5 in order for the null distribution of the Kruskal−
Wallis statistic to approximate the X2 distribution (with k−1 degrees of
freedom). With the exception of Figure 1e, graphs show all individual
data points and the median. Confocal image stacks (raw data) are
available from the corresponding authors upon reasonable request.
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Movie S1: An uninjected control embryo and three
DSPC-clodronic acid (10mM total lipids) liposome
injected embryos showing blood ﬂow dynamics in the
tail region and normal embryonic development 48 h after
injection. Black arrows indicate the most caudal end of
the PCV that contains bloodﬂow, and white arrows
indicate the most caudal perfused ISV (AVI)
Movie S2: Time lapse confocal imaging of a kdrl:GFP
transgenic embryo injected with DSPC-clodronic acid
(10 mM total lipids) liposome. Imaging started 6 hpi.
Confocal z-stacks were captured every 20 minutes for 24
h (AVI)
Movie S3: Three sibling control embryo and three
stab2ibl2 homozygous mutants DSPC-clodronic acid (10
mM total lipids) liposome injected embryos showing
blood ﬂow dynamics in the tail region and normal
embryonic development 48 h after injection (AVI)
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Highlights: Nanomedicines can be actively targeted to selected cell types expressing specific receptors. 
To this end, complementary targeting ligands are coupled to the nanoparticle surface. In case of 
actively targeted nanomedicines, the identification of the correct type and optimal amount of 
targeting ligand on the surface are key questions which have to be investigated. In this study, a 
Hepatitis B Virus (HBV) derived peptide was identified as a suitable targeting ligand for the 
sodium-taurocholate cotransporting polypeptide (NTCP) expressed on the sinusoidal membrane of 
hepatocytes. In vitro uptake studies were performed and circulation properties of different 
nanoparticle formulations were tested in the zebrafish model. Next, NTCP expressing cells were 
xenotransplanted in zebrafish and the optimal targeting ligand density on the nanoparticle surface was 
assessed. Optimized lead formulations were selected and their targeting properties were analyzed in 
a mouse in vivo study. Interestingly, results obtained in the zebrafish model were highly predictive for 
the effects in mice.
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ABSTRACT  
Active targeting and specific drug delivery to parenchymal liver cells is a promising strategy to treat 
various liver disorders. Here, we modified synthetic lipid-based nanoparticles with targeting peptides 
derived from the hepatitis B virus large envelope protein (HBVpreS) to specifically target the sodium-
taurocholate cotransporting polypeptide (NTCP; SLC10A1) on the sinusoidal membrane of hepatocytes. 
Physicochemical properties of targeted nanoparticles were optimized and NTCP-specific, ligand-
dependent binding and internalization was confirmed in vitro. The pharmacokinetics and targeting 
capacity of selected lead formulations was investigated in vivo using the emerging zebrafish screening 
model. Liposomal nanoparticles modified with 0.25 mol% of a short myristoylated HBV derived peptide, 
i.e. Myr-HBVpreS2-31, showed an optimal balance between systemic circulation, avoidance of blood 
clearance, and targeting capacity. Pronounced liver enrichment, active NTCP-mediated targeting of 
hepatocytes and efficient cellular internalization was confirmed in mice by 111In gamma scintigraphy and 
fluorescence microscopy demonstrating the potential of our hepatotropic, ligand-modified nanoparticles. 
 
 
KEYWORDS: nanoparticles, liposomes, hepatitis B virus (HBV), hepatocyte targeting, NTCP, 
zebrafish, Myrcludex B 
71
TABLE OF CONTENTS GRAPHIC 
 
72
INTRODUCTION  
The design of hepatotropic drug carriers is of great interest for the treatment of various liver 
disorders.(Williams et al., 2014; Poelstra et al., 2012; Reddy and Couvreur, 2011) In particular for the 
cell-type specific delivery of macromolecular therapeutic agents, selective targeting of parenchymal liver 
cells and internalization is needed. Previously, hepatocyte targeted nanoparticles have been developed 
exploiting endogenous and exogenous targeting ligand-based mechanisms using glycan, protein or 
antibody modifications of the nanoparticle surface.(Akinc et al., 2010, 2009; Barrett et al., 2014; 
Detampel et al., 2014; Witzigmann et al., 2016) Most established systems for liver-specific drug delivery 
rely on targeting the hepatic asialoglycoprotein (ASGPR) or low density lipoprotein (LDLR) receptors. 
However, studies investigating alternative targeting strategies based on other hepatocyte-specific 
receptors are limited. In this respect, a promising alternative might be offered by the hepatitis B virus 
(HBV), which shows a pronounced efficacy to infect the human liver due to its strong affinity to 
hepatocytes. Less than 10 virus particles have been shown to be sufficient to efficiently target hepatocytes 
of chimpanzees resulting in a pathogenic HBV infection.(Asabe et al., 2009) The reason for its 
extraordinary liver tropism is a highly specific amino acid sequence in the large HBV envelope protein 
(i.e. HBVpreS1 domain), which is essential for target receptor recognition.(Meier et al., 2013; Schieck 
et al., 2013) For decades, the specific target of HBV on the sinusoidal membrane of hepatocytes was 
unknown until in 2012 the interaction with the human sodium-taurocholate cotransporting polypeptide 
(NTCP/SLC10A1) was identified.(Yan et al., 2012) Subsequently, Urban and colleagues performed a 
fine mapping of the HBVpreS sequence to identify the amino acids responsible for efficient 
binding.(Schulze et al., 2010; Ni et al., 2014; Schieck et al., 2013) As a result, the first HBV/HDV entry 
inhibitor, a myristoylated peptide named Myrcludex B, was developed and successfully introduced in 
clinics (currently phase II clinical trials).(Blank et al., 2016; Urban et al., 2014) Myrcludex B binds with 
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high affinity and specificity to human NTCP on the sinusoidal membrane of hepatocytes thereby 
blocking binding of virus particles to their target cells.  
Based on these findings, the question arises whether Myrcludex B might serve as a targeting ligand to 
design a hepatotropic, NTCP-specific nanoparticle. In recent years, several groups have therefore 
attempted to develop targeting strategies based on HBV envelope proteins, e.g. recombinant HBV 
envelope protein particles (bio-nanocapsules) or HBV preS1-derived functionalized liposomes.(Liu et 
al., 2016; Somiya et al., 2016, 2015; Zhang et al., 2015, 2014) However, the nanoparticulate drug delivery 
systems developed had physicochemical properties (e.g. size, colloidal stability, and immunogenic 
potential), which were sub-optimal for efficient in vivo targeting of hepatocytes. Especially the size of 
the nano-formulations presented a limitation. Most developed formulations had sizes above the average 
diameter of hepatic fenestrations in healthy humans (i.e. 100 nm)(Wisse et al., 2008) thereby limiting the 
passage through liver fenestrations and consequently the access to the space of Disse and the sinusoidal 
membrane of hepatocytes. Notably, the liver fenestrae diameter of rodents show high species and strain 
differences ranging from around 100 nm to 160 nm, possibly explaining positive liver targeting of 
published formulations.(Braet and Wisse, 2002; Steffan et al., 1987; Wisse et al., 2008) In addition, a 
nanoparticle size above 100 nm triggers phagocytosis by cells of the reticuloendothelial system (i.e. 
hepatic Kupffer cells and spleen macrophages) resulting in rapid blood clearance.(Kettiger et al., 2013) 
Both factors significantly decrease the likelihood of reaching the parenchymal liver tissue and increase 
the risk for potential off-target effects in untargeted tissues.  
Surface properties are another important characteristic of nanoparticles. The surface charge (i.e. ζ 
potential) should be slightly negative(Xiao et al., 2011) to prevent sequestration of particles in the lung 
(i.e. due to a positive charge)(Ishiwata et al., 2000) or rapid clearance by cells expressing scavenger 
receptors (i.e. due to an excessive negative charge)(Rothkopf et al., 2005). According to the classical 
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Derjaguin-Landau-Verwey-Overbeek (DLVO) theory of colloids, a neutral charge has to be avoided to 
prevent particle agglomeration. In addition to surface charge, steric stabilization by PEGylation mediates 
long circulating properties and prevents opsonization.(Karmali and Simberg, 2011; Milla et al., 2012) 
It was the aim of the present study to design a nanoparticle based on liposomes combined with derivatives 
of Myrcludex B to efficiently target hepatocytes while minimizing interactions with off-target cell types. 
Optimization of physicochemical properties of the nanoparticles included size and charge optimization 
and steric shielding by PEGylation. Derivatives of Myrcludex B were selected based on target binding, 
cellular uptake and their impact on the colloidal stability of nanoparticles. For the lipid membrane 
composition, we used a FDA and EMA approved multi-component lipid formulation based on Doxil® 
(i.e. liposomal formulation of doxorubicin).(Barenholz, 2012) To design an optimal targeted system, 
several Myrcludex B derivatives with variations in the peptide sequence or fatty acid modification were 
covalently linked to the distal end of PEG-lipids. NTCP-specific and ligand-dependent uptake was 
confirmed in vitro using human liver-derived cell lines. Recently, Shan et al. reported huge discrepancies 
between in vitro systems and rodent experiments during the development of targeted 
nanomedicines.(Shan et al., 2015) Therefore, we used the zebrafish as a complementary in vivo screening 
model based on our previous work. (Sieber et al., 2018; Campbell et al., 2018; Einfalt et al., 2018; Sieber 
et al., 2017) We assessed the effect of nanoparticles` ligand type and ligand density on their 
pharmacokinetics. To this end, human derived cell lines lacking or expressing the human NTCP (hNTCP) 
were xenotransplanted into zebrafish embryos prior to systemic administration of nanoparticles. Finally, 
tissue distribution of dual-labeled nanoparticles was quali- (fluorescence-based) and quantitatively 
(radionuclide-based) investigated in vivo in mice to demonstrate the targeting potential of our 
hepatotropic nanoparticle platform in higher vertebrates. 
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RESULTS AND DISCUSSION  
Design and characterization of a hepatotropic nanoparticle for NTCP-specific targeting 
The aim of our study was the design of a hepatotropic, targeting ligand-modified nanoparticle. To this 
end, the surface of liposomal nanoparticles was modified using targeting peptides or lipopeptides derived 
from the preS1 domain of the HBV large envelope protein (Figure 1A). Based on a previous screening 
of 26 HBVpreS peptide variants, we selected Myrcludex B, the first HBV entry inhibitor (Blank et al., 
2016; Bogomolov et al., 2016), and five additional Myrcludex B derived peptides to evaluate the 
influence of amino acid sequence variations or acyl chain modifications on targeting efficiency and 
thereby optimize our hepatotropic nanoparticle. All Myrcludex B derived (lipo)peptides were 
synthesized in high yields and purity by standard solid phase peptide synthesis using Fmoc-
chemistry.(Schieck et al., 2013, 2010; Müller et al., 2013) Lipopeptides were N-terminally modified 
using the fatty acids myristic acid (saturated C14) or capric acid (saturated C10), since our previous 
studies have shown that fatty acid modification is key for mediating interactions with target cells. 
C-termini of synthesized targeting (lipo)peptides were modified with cysteine residues to allow 
conjugation to the distal end of PEGylated phospholipids (DSPE-PEG2000-Maleimide) integrated into 
sterically stabilized liposomes. Coupling was achieved by a chemically reactive maleimide, giving rise 
to a metabolically stable thioether bond suitable for applications in living organisms (Figure 1A). 
Successful conjugation of Myrcludex B to lipid-based nanoparticles was demonstrated by fluorescence 
correlation spectroscopy using Myrcludex B-Atto488. The autocorrelation curve of nanoparticle 
conjugated peptides showed a significant shift to longer diffusion times as compared to the free peptide, 
with average diffusion times of τd = 1639 μs and τd = 192 μs, respectively (Figure 1–figure 
supplement 1). 
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 Figure 1. Hepatotropic nanoparticles based on liposomes modified with Myrcludex B-derived peptides for NTCP-specific 
targeting. (A) Schematic representation of peptides derived from Hepatitis B virus (HBV) large envelope protein including 
the first entry inhibitor, Myrcludex B. Different peptides were conjugated via thiol function to the distal end of PEG chains 
integrated in the nanoparticle structure using maleimide chemistry. The most important amino acid sequence (9-15) for NTCP-
specific binding is highlighted in green color in each lipopeptide. (B) Representative transmission electron microscopy images 
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of different Myrcludex B-derived lipopeptide conjugated nanoparticles. Scale bar = 100 nm. (C) Uptake of Myrcludex B-
modified nanoparticles into human cells with variable NTCP expression levels. Nanoparticles have a dual fluorescent label, 
i.e. lipophilic membrane label (DiI, red) and hydrophilic payload incorporation (carboxyfluorescein, green). Representative 
confocal laser scanning microscopy maximum intensity projections for Myr-preS2-48 modified nanoparticles after 30 min 
are shown. Dotted lines indicate cell membranes. Blue signal: Hoechst stain of cell nuclei. Scale bar = 10 µm. (D) Flow 
cytometry analysis of uptake rate into non-hepatic HeLa cells, liver-derived HepG2 cells and hNTCP overexpressing HepG2 
cells. Increasing concentrations of nanoparticles (CDiI) modified with different Myrcludex B-derived peptides were evaluated. 
Relative mean fluorescence intensities (MFI) of DiI signals normalized to untreated cells are given. All values are shown as 
mean ± SD of biological replicates (n ≥ 3 independent experiments). Numerical data for all graphs are shown in the Figure 1-
source data. 
 
Liposome membrane partition coefficients of mono fatty acid modifications are orders of magnitudes 
lower as compared to di-lipid anchors.(Sauer et al., 2006) Therefore, the distearoyl anchor of DSPE 
results in a stable incorporation of the PEGylated phospholipid-targeting ligand conjugate in the lipid 
bilayer of liposomes (membrane partition coefficient > 103 mM-1), whereas the PEG linker offers a 
flexibility to the distally tethered lipopeptides to extend away from the liposome surface. In addition, a 
thermodynamically favorable backward bending insertion of the acyl chain into the liposomal membrane 
is possible. A slight change in transition temperature evaluated by pressure perturbation calorimetry and 
differential scanning calorimetry confirmed this hypothesis (data not shown). The formulation yield of 
modified nanoparticles after purification was dependent on the conjugated Myrcludex B derived 
(lipo)peptide with preS2-48 >Myr-preS2-31 >Myr-preS2-48A ≥Myr-preS2-48 >Cap-preS2-48.  
Light scattering and electron microscopy verified that all nanoparticles, i.e. Myrcludex B-derived peptide 
conjugated liposomes (modified without or with C14 acyl moiety) had a spherical morphology with a 
small size around 90 nm, narrow size distribution, i.e. PDI<0.2 and a slightly negative zeta potential 
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(Figure 1B, Table 1). Only a small increase in the hydrodynamic size of about 2 nm was observed after 
conjugation of Myrcludex B-derived peptides (Table 1). The zeta potential of nanoparticles remained 
negative due to a negative net charge of Myrcludex B-derived lipopeptides at physiological pH. Thus, 
the physicochemical properties of nanoparticles were not significantly influenced by the surface 
modification with HBVpreS derived lipopeptides containing C14 acyl chains. An exception were 
nanoparticles modified with Cap-preS2-48, which had an average diameter of 134.28 nm and a PDI of 
0.24 (Figure 1B, Table 1).  
Table 1. Physicochemical characteristics of nanoparticles with different surface modifications. 
Hydrodynamic size [nm], polydispersity index (PDI), and zeta potential [mV] were analyzed using 
dynamic and electrophoretic light scattering. All values are shown as mean ± SD of n ≥ 3 independent 
experiments. Numerical data for all nanoparticles are shown in the Table 1-source data. 
Surface Modification Size [nm] ± SD PDI ± SD Zeta Potential [mV] ± SD 
PEG 88.53 ± 5.89 0.05 ± 0.01 -5.93 ± 0.63 
preS2-48 90.74 ± 5.83 0.06 ± 0.02 -3.34 ± 1.38 
Myr-preS2-48 A 90.77 ± 4.98 0.06 ± 0.04 -13.35 ± 3.08 
Myr-preS2-31 89.10 ± 4.38 0.10 ± 0.02 -9.82 ± 0.87 
Cap-preS2-48 134.28 ± 36.23 0.24 ± 0.04 -8.39 ± 1.13 
Myr-preS2-48 92.21 ± 6.78 0.12 ± 0.08 -10.70 ± 4.25 
 
It is tempting to speculate, that the C10 acyl chain of Cap-preS2-48 interfered with liposome membrane 
stability. As compared to longer acyl chains the backward bending insertion of C10 acyl chains into intra-
liposomal membranes is less stable, thus promoting faster dissociation and possible interactions with 
neighboring liposomes due to re-association with inter-liposomal membranes. This was also indicated 
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by formation of aggregates resulting in shorter storage stability (data not shown). Previously published 
studies reporting a rapid partitioning of shorter lipid anchors from liposomal vesicles support our 
observation of unfavorable liposome interactions for Cap-preS2-48.(Sauer et al., 2006; Webb et al., 
1998) 
Cellular uptake and viability  
Next, we investigated the biocompatibility and targeting capacity of our ligand-modified nanoparticles 
in a panel of three different cell lines in vitro, i.e. non-hepatic HeLa cells devoid of hNTCP (negative 
control), liver-derived wild type HepG2 cells (HepG2 WT, hepatocyte control cell line with no detectable 
hNTCP expression based on PCR) and HepG2 cells overexpressing the human NTCP (HepG2 hNTCP). 
We used lentiviral transduced cells overexpressing hNTCP as a positive control to confirm the specificity 
of our system since human liver derived cell lines such as HepG2 and HuH7 down-regulated NTCP 
during oncogenic transformation (i.e. NTCP expression levels are significantly decreased in 
hepatocellular carcinoma).(Lempp et al., 2016) In all cell lines, nanoparticles showed a high 
cytocompatibility up to the highest tested lipid concentration of 8 mM, which is far beyond liposome 
blood concentrations achievable in a clinical setting (Figure 1–figure supplement 2 demonstrating no 
decrease of cell viability using the MTT assay).(Barpe et al., 2010)  
In vitro uptake studies revealed that Myrcludex B-modified nanoparticles were rapidly internalized 
within 30 min into liver-derived HepG2 cell lines whereas no binding or cellular uptake was observed in 
non-hepatic HeLa cells (Figure 1C, representative confocal laser scanning microscopy images for Myr-
preS2-48 modified nanoparticles). Both the liposomal nanoparticle (DiI signal) and the encapsulated 
payload (carboxyfluorescein (CF) signal), were detected intracellularly. Notably, CF was encapsulated 
into our nanoparticles at a fluorescence self-quenching concentration (i.e. 60 mM, Figure 1–figure 
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supplement 3). Thus, CF fluorescence increases significantly after overcoming the Förster critical 
transfer distances, i.e. release of CF from nanoparticles into surrounding environment.(Chen and 
Knutson, 1988) Specific uptake of nanoparticles with NTCP-binding component preS-peptide was 
enhanced with increasing hNTCP expression levels (Figures 1C, D and Figure 1–figure supplement 4) 
demonstrating a high target specificity (i.e. HeLa WT < HepG2 hNTCP). Surprisingly, the highest DiI 
signal (and not CF signal) in HeLa cells was observed with PEGylated nanoparticles. It is tempting to 
speculate that nanoparticle modification with Myrcludex B-derived lipopeptides decreases the interaction 
with negatively charged cell membranes of hNTCP deficient cells (e.g. HeLa) due to a negative net 
charge of lipopeptides at physiological pH and thus increased electrostatic repulsion. Uptake studies with 
a different liver-derived cell line (HuH7) comparing wild type and hNTCP overexpressing cells 
confirmed the hNTCP specific interaction. Overexpression of hNTCP again resulted in a strong 
enrichment of cellular uptake ruling out an involvement of cell-line specific artefacts (Figure 1–figure 
supplement 5).  
Time-dependent uptake studies of nanoparticles with different payloads (i.e. FITC-labeled peptide, 
propidium iodide, and doxorubicin) confirmed the rapid binding and internalization process of Myr-
preS2-31 modified nanoparticles (Figure 1–figure supplement 6, 7, and 8). Conclusively, small 
molecular payloads as well as larger compounds could be successfully incorporated into nanoparticles to 
enhance their internalization into NTCP expressing cells. Interestingly, Myr-preS2-31 modification 
enhanced the cytotoxic effects of propidium iodide and doxorubicin as compared to PEGylated 
nanoparticles (Figure 1–figure supplement 7 and 8) demonstrating that the payload is active and reaches 
the cytosol. Of note, propidium iodide is a cell membrane impermeable drug. Thus, NTCP-targeted 
nanoparticles enabled internalization into cells and successful release into cytosol indicated by enhanced 
cytotoxic effects and nuclear counterstain. 
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Competition of NTCP-specific cellular binding and uptake of targeting ligand-modified 
nanoparticles   
To confirm specificity of NTCP interactions with Myrcludex B derived ligands, we used pre-incubations 
with free Myrcludex B-Atto565 to competitively inhibit nanoparticle binding and cellular uptake 
(Figure 2A). Fluorescently labeled Myrcludex B can be considered to be a suitable blocking agent since 
its binding to NTCP expressing HepG2 hNTCP cells results in a significant shift in fluorescence signal 
as compared to control cells (data not shown). Uptake inhibition of nanoparticles modified with Myr-
preS2-31, Cap-preS2-48, and Myr-preS2-48 by free Myrcludex B-fluorescein was confirmed by flow 
cytometry (Figure 2B). In contrast, the uptake of Myr-preS2-48A modified nanoparticles was not 
significantly inhibited by free Myrcludex B, most probably due to differences in the amino acid sequence 
(see difference in essential amino acid sequence highlighted in Figure 1A). By incubation of cells in 
presence of NaN3 or at low temperature (i.e. 4°C), we confirmed that the uptake of NTCP targeted 
nanoparticles is an energy-dependent process (Figure 2A). These results demonstrate that hepatotropism 
of nanoparticles is mediated by NTCP and that the cellular uptake of the carrier is an active and energy-
dependent process. 
Selection of the optimal hepatotropic Myrcludex B-derived lipopeptide 
After evaluating the formulation yield, physicochemical characteristics (i.e. storage/colloidal stability, 
hydrodynamic diameter, size distribution, zeta potential) and the targeting capacity of our NTCP-specific 
nanoparticles in vitro, we identified Myr-preS2-48 and Myr-preS2-31 as lead structures and used these 
for further investigations. This choice was based on the following observations:  
First, only nanoparticles modified with lipopeptides but not peptides without conjugated fatty acid (e.g. 
preS2-48) can bind to NTCP. This set of experiments confirmed that the acyl modification of peptides 
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on nanoparticles` surface is a crucial prerequisite for hepatocyte binding as reported recently for free 
peptides.(Meier et al., 2013; Schieck et al., 2013) Only acyl modified peptides increased nanoparticle 
binding and internalization. Second, liposomes decorated with peptides conjugated to capric acid had a 
reduced colloidal stability. Their storage stability was limited due to particle aggregation. Furthermore, 
their size of around 134 nm exceeds the diameter of liver sinusoid fenestrations presumably limiting their 
access to the space of Disse. Third, Myr-preS2-48A modified nanoparticles were excluded due to poor 
NTCP specificity as demonstrated by the lack of binding competition by free Myrcludex B. In addition, 
the uptake of these nanoparticles was independent of NTCP expression levels and even higher in HepG2 
wild type cells (Figure 1D).  
Mechanistic studies on NTCP mediated cellular binding and internalization 
In order to demonstrate the importance of covalent peptide attachment, we used a triple fluorescence 
labeling strategy (Figure 2C). The targeting ligand Myrcludex B was labeled with Atto633, the liposomal 
phospholipid bilayer was labeled with DiI, and the aqueous cargo payload of nanoparticles consisted of 
CF. Myr-preS2-31-K-Atto633 was labeled at an additionally introduced lysine at position 2, in order to 
still allow conjugation to the nanoparticle surface by the terminal cysteine. Recently, we have shown that 
additional N-terminal amino acids do not interfere with specific liver enrichment (for comparison Myr-
preS -11-48).(Schieck et al., 2013)  
First, CF-loaded, DiI-labeled nanoparticles were incubated with Myr-preS2-31-K-Atto633 and 
purified using size exclusion chromatography to remove free targeting ligand. Cell experiments 
confirmed successful removal of free Myr-preS2-31-K-Atto633 (no signal on cell membrane) and as 
expected no uptake of PEGylated nanoparticles. As a control, we added a mixture of free Myr-preS2-31-
K-Atto633 and PEGylated nanoparticles to HepG2 hNTCP cells without prior purification. Notably, a 
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strong fluorescence signal on the cell membrane was observed due to specific binding of free Myr-preS2-
31-K-Atto633 to hNTCP indicating specific targeting despite an additional N-terminal amino acid. Free 
Myr-preS2-31-K-Atto633 did not interact with PEGylated nanoparticles and thus did not trigger 
nanoparticle entry into HepG2 hNTCP cells. Finally, we covalently linked the Myr-preS2-31-K-Atto633 
to the nanoparticle surface by Michael addition of the distal cysteine residue to maleimide-functionalized 
pegylated phospholipids integrated in the nanoparticle structure. A strong cellular binding and uptake of 
Myr-preS2-31-K-Atto633 modified nanoparticles was observed already within one hour.  
 
Figure 2. NTCP-specific and ligand-dependent uptake of Myrcludex B-derived lipopeptide conjugated nanoparticles into 
liver-derived cells in vitro. (A) Competitive inhibition study of Myrcludex B (MyrB)-conjugated nanoparticle uptake 
(carboxyfluorescein payload, green signal) into HepG2-hNTCP already after 30 min. Free Atto-565 labeled Myrcludex B (red 
signal) was added after (left panel) or before (middle panel) nanoparticle. Uptake studies at lower temperature (T↓, 4°C, right 
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panel) were performed to demonstrate energy-dependent process of nanoparticle internalization. Representative confocal laser 
scanning microscopy images are shown. Blue signal: Hoechst stain of cell nuclei. Scale bar = 10 µm. (B) Quantification of 
nanoparticle uptake in absence or presence of free Myrcludex B dependent on different Myrcludex B derived peptide 
modification. All values are shown as mean ± SD of biological replicates (n = 3 independent experiments). **p < 0.01. 
(C) Uptake study of nanoparticles (membrane dye, DiI, red signal) loaded with carboxyfluorescein (green signal) into HepG2-
hNTCP without, mixed or covalently modified with Atto-633 conjugated Myr-preS2-31 (yellow signal). Myr-preS2-31-K-
Atto633 is covalently linked to surface via stable thioether bond (right panel). Representative confocal laser scanning 
microscopy images are shown. Blue signal: Hoechst stain of cell nuclei. Scale bar = 10 µm. (D) Concentration (CLipid) 
dependent uptake of nanoparticles modified with different amounts of Myr-preS2-31 analyzed by flow cytometry and based 
on CF signal. All values are shown as mean ± SD of biological replicates (n = 4 independent experiments). *p < 0.05, **p < 
0.01, ***p < 0.001. Numerical data for all graphs are shown in the Figure 2-source data. 
Interestingly, nanoparticles including their payload entered the target cell whereas the targeting ligand 
remained on the cell surface. Since Myrcludex B has a remarkably high affinity to the NTCP (KD of 
67 nM),(Meier et al., 2013) it is tempting to speculate that the targeting ligand is retained by NTCP on 
the cell surface while the dissociated liposome payload is internalized and further processed by a yet 
unknown mechanism. Of note, intracellular CF signals were considerably higher as compared to DiI 
signals. This might also indicate liposome dissociation and perhaps loss of DiI during the internalization 
process. Uptake experiments using pharmacological pathway inhibitors suggested a partially clathrin-
dependent and caveolin-independent mechanism which differs from the process of phagocytosis and 
micropinocytosis (Figure 2–figure supplement 1). Intriguingly, additional factors besides NTCP binding 
seem to contribute to this process. Non-hepatic HeLa cells transduced with mouse NTCP (mNtcp) or 
hNTCP can bind Myrcludex B-modified nanoparticles. However, binding is reduced as compared to 
binding in hepatic cell lines and no uptake is observed (Figure 2–figure supplement 2). Thus, additional 
hepatic cell dependent factors seem to play a role for efficient binding and internalization. Indeed, Verrier 
et al. reported recently that glypican 5 expression is an important co-factor for HBV entry.(Verrier et al., 
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2016) Notably, uptake experiments using psgA745 cells (CHO xylosyltransferase mutants) 
overexpressing NTCP showed that binding of Myrcludex B alone is not influenced by 
glycosaminoglycans (Figure 2–figure supplement 3). In sharp contrast, binding of nanoparticles could 
be partially inhibited in HepG2 WT cells using heparan sulfate suggesting an involvement of 
glycosaminoglycans in the binding and subsequent internalization process of nanoparticles for hepatic 
cells (Figure 2–figure supplement 4). Therefore, it will be an important step for the design of 
next-generation carrier systems to elucidate such co-factors in detail and adapt the nano-sized delivery 
system accordingly. 
To demonstrate concentration-dependent nanoparticle uptake of Myr-preS2-31 and investigate the effect 
of ligand density, qualitative and quantitative fluorescence techniques were used (Figure 2D). Therefore, 
we performed in vitro experiments using nanoparticles with variable amounts of coupled Myr-preS2-31 
(0 mol% - 0.5 mol% initial maleimide functionalities on nanoparticle surface). With increasing targeting 
ligand concentration, a significant increase in cellular uptake was observed (Figure 2D, Figure 2–figure 
supplement 5). Notably, we identified a threshold value of at least 0.25 mol% for efficient cell binding 
by qualitative confocal imaging as well as quantitative flow cytometry experiments (Figure 2D, Figure 2–
figure supplement 5). Below this value, no uptake was observed, whereas above 0.25 mol% cellular 
binding was improved. Stoichiometric estimations assuming a bilayer thickness of 5 nm, a 
phosphatidylcholine headgroup area of 0.71 nm2 and an equal distribution of DSPE-PEG in the outer and 
inner nanoparticle membrane result in 157±16, 79±8, or 39±4 maleimide moieties per liposome capable 
for lipopeptide conjugation corresponding to 0.5 mol%, 0.25 mol%, or 0.125 mol%, 
respectively.(Maurer et al., 2001) Thus, a minimum of 80 functional maleimide moieties per nanoparticle 
is necessary for efficient cellular targeting after Myr-preS2-31 conjugation.  
86
In vivo systemic circulation in the zebrafish vertebrate model 
Since in vitro experimental models are not able to mimic the physiological complexity of nano-bio 
interactions at an organ level, we screened in the next step the effect of ligand density on 
pharmacokinetics of nanoparticles in vivo for Myr-preS2-48 and Myr-preS2-31 (Figure 3). Recently, we 
have reported that the zebrafish is a valuable pre-clinical tool to assess the systemic circulation and blood 
clearance of nanoparticulate drug delivery systems in vivo.(Sieber et al., 2017; Campbell et al., 2018; 
Sieber et al., 2018; Park, 2017; Yin et al., 2018)  
Thus, we injected DiI labeled nanoparticles modified with different amounts of targeting ligand 
(0.125 mol% - 1.0 mol%) into the duct of Cuvier of transgenic kdrl:EGFPs843 zebrafish embryos which 
express GFP in the vasculature endothelial cells. Already one hour post injection, a clear qualitative 
difference in circulation characteristics of tested nanoparticles was detected. With increasing ligand 
density on the nanoparticle surface, the systemic circulation of nanoparticles decreased for both peptides 
(Figure 3) indicating that ligand modification of nanoparticles interferes with the shielding properties of 
PEG. Increased blood clearance was thereby paralleled by accumulation in the posterior caudal vein 
region. The observed binding pattern did not match a stabilin-2 scavenger receptor dependent 
nanoparticle clearance which would be indicative for interactions with mammalian liver sinusoidal 
endothelial cells (LSECs).(Campbell et al., 2018) More likely a sequestration by macrophages is 
responsible for this clearance mechanism corresponding to an accumulation in the spleen of 
rodents.(Sieber et al., 2018)  
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 Figure 3. Systemic circulation of Myrcludex B-derived lipopeptide conjugated nanoparticles in vivo in the zebrafish model. 
Nanoparticles were modified with different amounts of (A) Myr-preS2-48 or (B) short Myr-preS2-31 and injected into 
transgenic zebrafish embryos expressing green fluorescent protein in their vasculature endothelial cells (green signal). 
Membrane of nanoparticles was fluorescently labeled using DiI (red signal). Representative confocal laser scanning 
microscopy images of tail region one hour post injection.  
Interestingly, nanoparticles modified with the shorter targeting peptide, i.e. Myr-preS2-31, showed 
increased systemic circulation (Figure 3B) as compared to Myr-preS2-48 modified nanoparticles (Figure 
3A) at similar ligand densities. Thus, Myr-preS2-31 modified nanoparticles were selected for further 
investigations. However, nanoparticles modified with more than 0.5 mol% Myr-preS2-31 were as well 
excluded from further evaluation due to their poor systemic circulation and high clearance rate. 
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In vivo targeting ability in the zebrafish vertebrate model 
In a next step, we investigated the targeting capacity of Myr-preS2-31 modified nanoparticles to human 
cells in vivo in the zebrafish model (Figure 4). For this approach, we used HEK293 cells stably expressing 
GFP for further genetic modification and establishment of xenotransplants.(Witzigmann et al., 2015b) 
HEK293-GFP cells were transiently transfected with hNTCP to express the targeting factor for our 
hepatotropic nanoparticles. Wild type HEK293-GFP without hNTCP served as control. Both cell lines 
were injected into ABC/TU wild type zebrafish embryos to create human xenotranplants. The different 
nanoparticles were injected as soon as transgenic human cells stopped circulating and remained in the 
caudal vasculature tail region (i.e. after approximately one hour). Interestingly, a clear difference in 
targeting capacity dependent on hNTCP expression and ligand density was revealed. Whereas there was 
no significant difference in targeting capacity at different ligand densities for hNTCP deficient HEK293-
GFP cells (Figure 4A), a significant increase in binding to HEK293-GFP cells was observed if hNTCP 
was overexpressed as the nanoparticles could bind specifically and be readily internalized (Figure 4B). 
Most importantly, this was only valid for nanoparticles modified with 0.25mol% Myr-preS2-31 (Figure 
4, quantitative analysis). This illustrates that ligand density highly influences the balance between 
systemic circulation, systemic clearance rate and targeting efficiency of our liposome-based 
nanoparticles: 
Nanoparticles modified with ligand densities below 0.25 mol% show a favorable systemic circulation 
but have an insufficient targeting ability. This also confirms our observations in vitro, where 
nanoparticles with a ligand density below 0.25mol% did not significantly bind to HepG2 hNTCP cells. 
In sharp contrast, nanoparticles modified with higher Myr-preS2-31 targeting ligand densities (i.e. 
0.5 mol%) have increased targeting ability in vitro. However, decreased systemic circulation and a high 
clearance rate under in vivo conditions counteract the advantage of higher ligand densities. Nanoparticles 
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modified with 0.25 mol% Myr-preS2-31 have the highest targeting efficiency due to an ideal balance 
between target affinity and long circulation time in vivo. It should be noted that nanoparticles are 
internalized by target cells (Figure 4B) whereas free Myrcludex B apparently binds with high affinity to 
target cells but is not internalized (Figure 4–figure supplement 1). This phenomenon was recently 
observed by our team in rodents (data not shown) and was also reported from clinical trials in humans. 
 
Figure 4. Targeting ability of Myr-preS2-31 conjugated nanoparticles in vivo in xenotransplanted zebrafish embryos. 
Nanoparticles were modified with different amounts of Myr-preS2-31 and injected into wild type zebrafish embryos 
xenotransplanted with human, GFP expressing HEK293 cells (green signal), (A) deficient or (B) expressing hNTCP. 
Membrane of nanoparticles was fluorescently labeled using DiI (red signal). Yellow signals demonstrate colocalization (i.e. 
binding and internalization) of nanoparticles with HEK293-GFP cells. Representative brightfield and fluorescence images of 
tail region one hour post injection are shown. Quantitative analysis of nanoparticle binding to HEK293-GFP cells is 
represented by Pearson´s Correlation Coefficient (PCC). All values are shown as box plots of biological replicates (n ≥ 2 
independent experiments). *p < 0.05. Numerical data for all graphs are shown in the Figure 4-source data. 
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In vivo liver targeting of Myr-preS2-31 conjugated nanoparticles in mice 
To elucidate the influence of ligand density on hepatotropism of our nanoparticles in vivo in mammals, 
we evaluated the pharmacokinetic properties of Myr-preS2-31 conjugated nanoparticles in mice. For this 
set of experiments, we used a dual labeling approach. The radioactive nuclide indium-111 (111In) was 
used for whole-body imaging and biodistribution studies whereas fluorescence labeling with DiI was 
used to evaluate intra-organ nanoparticle distribution. Importantly, we incorporated DTPA-conjugated 
DSPE into the lipid bilayer to chelate 111In on the surface of nanoparticles. This radiolabeling strategy 
has distinct advantages as compared to other labeling techniques or loading of 111In-oxine into 
nanoparticles.(van der Geest et al., 2015) First, this radiolabeling method is robust, fast (within 45 min) 
and efficient with labeling efficiencies above 90%. Notably, free 111In was easily removed from 
nanoparticle formulations prior to injection using size exclusion chromatography (NAP-5 columns). 
Second, DTPA-DSPE enables retention of 111In in serum for at least 48 h at 37 °C (>98% label retention) 
demonstrating the high stability necessary for in vivo studies of nanoparticulate drug delivery 
systems.(van der Geest et al., 2015) Third, free 111In is rapidly eliminated via kidneys and excreted in the 
urine as shown previously.(Harrington et al., 2000; Shih et al., 2017) This offers an easy assessment to 
differentiate between non-bound and nanoparticle bound 111In.  
Four different lipid-based nanoparticles were prepared and injected intravenously into the tail vein of 
mice, i.e. PEGylated liposomes (negative control) and nanoparticles modified with 0.125 mol%, 
0.25 mol% and 0.5 mol% Myr-preS2-31. One-hour post injection, plasma and organs were harvested to 
perform a quantitative biodistribution analysis ex vivo (Figure 5A).  PEGylated nanoparticles showed the 
typical biodistribution of sterically stabilized nanoparticles with a strong signal in the blood (Figure 5A). 
Myr-preS2-31 conjugated liposomes demonstrated different biodistribution patterns depending on ligand 
density (Figure 5A). Modification of nanoparticles with 0.125 mol% Myr-preS2-31 did not alter the 
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systemic circulation significantly (i.e. high blood pool signal). Only a minor increase in liver 
accumulation was observed as compared to ligand-lacking PEGylated nanoparticles (Figure 5A).  
Figure 5. In vivo biodistribution and liver targeting of Myr-preS2-31 conjugated nanoparticles in mice. Nanoparticles were 
modified with different amounts of Myr-preS2-31 and labeled with radioactive 111In and fluorescent membrane dye (DiI, red 
signal). (A) Quantitative biodistribution studies were performed 1 hour post injection. Radioactivity of each organ was 
determined with a γ-counter and the percentage of injected dose (%ID) per organ was calculated. B=blood, H=heart, Lu=lung, 
Li=liver, S=spleen, K=kidney. All values are shown as mean ± SD of biological replicates (n = 3 independent experiments). 
Numerical data for all graphs are shown in the Figure 5-source data. (B) Fluorescence imaging (FI) of nanoparticles (DiI, red 
signal) in liver cryo-sections. Blue signal: Hoechst stain of cell nuclei. Scale bar = 100 µm. (C) Immunohistochemistry (IHC) 
of Myr-preS2-31 (red signal) in the liver sections 1 hour after intravenous injection. Mice liver sections were stained with 
anti-Myr-preS2-31 antibody (MA18/7). Blue signals represent cell nuclei. Arrows indicate distinct localized accumulations.  
Interestingly, nanoparticles modified with 0.25 mol% Myr-preS2-31 significantly enriched binding to 
the liver (Figure 5A). Further increase in ligand density (0.5 mol%) resulted in an increase in spleen 
accumulation, i.e. enhanced clearance by cells of the reticuloendothelial system (Figure 5A). Of note, 
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none of the nanoparticle formulation resulted in an elimination via kidneys demonstrating the high 
stability and retention of the DTPA-DSPE chelated 111In. In order to highlight the ligand-density 
dependent hepatotropism, we calculated ratios between the blood pool and important organs, i.e. liver 
(i.e. target organ), spleen (i.e. clearance organ), and kidney (i.e. control organ since nanoparticle bound 
111In should not show renal excretion) (Figure 5–figure supplement 1). Indeed, Myr-preS2-31 
modification ≥ 0.25 mol% resulted in increased liver/spleen-to-blood ratios. Strikingly, nanoparticles 
modified with 0.25 mol% Myr-preS2-31 demonstrated a significant increase in the liver-to-kidney ratio 
confirming our conclusions from the zebrafish model, i.e. 0.25 mol% Myr-preS2-31 as an optimal ligand 
density (Figure 4B). Planar gamma scintigraphy imaging of injected mice confirmed these observations 
(Figure 5–figure supplement 2).  
The biodistribution studies were combined with fluorescence imaging of nanoparticle distribution 
(Figure 5B, Figure 5–figure supplement 3) and immunohistochemistry of Myr-preS2-31 distribution 
(Figure 5C, Figure 5–figure supplement 3-6) in liver, spleen, and kidney (i.e. nanoparticles and 
Myr-preS2-31 should not show renal excretion). PEGylated nanoparticles showed a weak fluorescent 
signal in the liver (Figure 5B). Importantly, these signals were not associated with the sinusoidal 
membrane of hepatocytes but arose from the high hepatic blood supply (Figure 5–figure supplement 5). 
No signals were observed in spleen and kidney (Figure 5–figure supplement 3). Modification of 
nanoparticles with 0.125 mol% Myr-preS2-31 did not result in significantly increased liver levels. A 
marginal binding of nanoparticles to hepatocyte membrane was visually observed (Figure 5B, C). This 
supports our hypothesis that a threshold level of targeting ligand density present on the nanoparticle 
surface is necessary for successful targeting. Importantly, strong signals for nanoparticles modified with 
0.25 mol% Myr-preS2-31 were observed on the basolateral membrane of parenchymal liver cells 
(Figure 5B, C) demonstrating the strong hepatotropism of our nanoparticles. Further increasing the 
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ligand density (i.e. 0.5 mol%) was detrimental and resulted in a diffuse hepatic staining pattern. 
Nanoparticles and their payload were detected as punctuated signals in the whole liver and did not show 
a specific membrane staining (Figure 5B, Figure 5–figure supplement 6). Myr-preS2-31 was detected in 
distinct localized areas only (Figure 5C). We conclude that nanoparticles modified with excessive Myr-
preS2-31 densities (0.5mol%) are rapidly cleared by and liver resident macrophages, i.e. Kupffer cells. 
Subsequent re-distribution phenomena result in an unspecific nanoparticle signal in the whole liver. 
Competition of NTCP-specific uptake into mouse hepatocytes in vivo 
Since nanoparticles modified with 0.25 mol% Myr-preS2-31 allowed highly efficient liver targeting, we 
next investigated the NTCP specificity and the internalization process (Figure 6A). Therefore, we 
injected either labeled nanoparticles alone or together with free unlabeled Myrcludex B into mice 
(Figure 6B). Co-injection of Myrcludex B resulted in a clear decrease in liver enrichment by competitive 
inhibition of NTCP-binding as demonstrated by a change of signal.  
To reveal the localization of nanoparticles, we performed a confocal microscopy analysis of liver cryo-
sections (Figure 6C). We stained liver cryo-sections using antibodies against mNtcp and Myr-preS2-31 
(MA 18/7). Interestingly, nanoparticles that were internalized into parenchymal liver cells did not co-
localize with mNtcp fluorescent signals. Myr-preS2-31 still colocalized with mNtcp suggesting that the 
targeting ligand was separated from the nanoparticle during cellular internalization as already observed 
in in vitro experiments. This phenomenon was confirmed by a colocalization analysis (Figure 6C). The 
observed cellular uptake is a surprising finding since HBV possesses pronounced host species specificity 
with regard to binding and infectivity. HBV binds to murine hepatocytes but cannot infect mice due to 
the lack of host cell dependency factors.(Lempp et al., 2016) Therefore, chimeric mice transplanted with 
primary human hepatocytes have been developed to study anti-HBV drugs.(Petersen et al., 2008; 
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Lütgehetmann et al., 2012) In humans or chimpanzees only, HBV specifically binds to hepatocytes and 
subsequently infects the host.  
 
Figure 6. NTCP-specific uptake of Myr-preS2-31 conjugated nanoparticles into hepatocytes in vivo in mice. (A) Schematic 
representation of NTCP-targeted nanoparticle binding to hepatocytes. Circulating nanoparticles pass the fenestrae of liver 
sinusoidal endothelial cells (LSEC) and subsequently bind to the NTCP in the basolateral membrane of hepatocytes facing 
the space of Disse. Prior to Myr-preS2-31 mediated NTCP binding, the myristoyl chain is inserted into the lipid bilayer. In 
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close proximity to hepatocytes, acyl chain switches into cellular membrane due to high affinity of essential peptide sequence 
to NTCP binding site, thereby consolidating target transporter binding. (B) Nanoparticles were modified with 0.25mol% of 
Myr-preS2-31 and labeled with radioactive 111In and fluorescent membrane dye (DiI, red signal). Planar imaging of mice one 
hour post-injection. Competitive inhibition of liver binding by co-injection of free Myrcludex B clearly demonstrates NTCP-
specific binding. Positions of liver and spleen are indicated by small circles. (C) Immunfluorescence staining of nanoparticles 
(red signal), targeting ligand (Myr-preS2-31, green signal, antibody staining), and mNtcp (cyan signal, antibody staining) in 
liver cryosections. Nuclei staining (blue signal) served as control for complete internalization; no overlap with mNtcp. Scale 
bar = 20 µm. Colocalization analysis with mNtcp is represented by Pearson´s Correlation Coefficient (PCC). All values are 
shown as box plots of biological replicates (n = 3 independent experiments). *p < 0.05. Numerical data for all graphs are 
shown in the Figure 6-source data.  
Importantly, our NTCP-targeted nanoparticles apparently lack this species specificity. In contrast to 
HBV, our hepatotropic nanoparticles specifically bind to mouse hepatocytes in a mNtcp-dependent 
manner and are subsequently internalized. The exact molecular interactions behind this internalization 
process will require additional studies to elucidate structural determinants important for cellular uptake 
and to better understand viral entry mechanisms, which are still unknown.(Glebe and Urban, 2007)  
 
CONCLUSIONS  
In conclusion, the combination of in vitro investigations, the zebrafish model and in vivo experiments in 
rodents offered a unique approach to optimize our targeting ligand modified nanoparticles. The zebrafish 
model demonstrated to be an excellent tool to pre-screen various nanoparticle formulations, to assess the 
effect of Myrcludex B modifications on their pharmacokinetics and biodistribution, and thus increase the 
accuracy of predictions for experiments in rodents. The proposed NTCP targeted delivery platform is an 
alternative and promising approach to current liver targeting strategies. These delivery systems can 
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increase liver uptake levels, decrease accumulation in off-target tissues and at the same time avoid 
clearance by the reticuloendothelial system by mimicking HBV targeting properties. For future clinical 
applications, small molecule drugs, nucleic acids or proteins need to be encapsulated and studied in 
appropriate disease models. In particular, we see a great potential for our nanoparticle targeting strategy 
in the field of metabolic diseases of the liver.  
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MATERIALS AND METHODS  
Synthesis of Myrcludex B-derived peptides. Different peptides were produced by 
fluorenylmethoxycarbonyl/t-butyl (Fmoc/tBu) solid-phase synthesis using an Applied Biosystems 433A 
peptide synthesizer and modified with acyl chains as described previously.(Schieck et al., 2013) Atto 
fluorescence dyes were either linked to the distal cysteine residue by maleimide chemistry or to the 
ε-amino group of an additionally introduced D-lysine at position 2 by NHS chemistry for mechanistic 
studies based on a triple fluorescence labeling strategy. In contrast to all other amino acids of Mycludex 
B-derived lipopeptides, a D-amino acid was introduced in the latter case due to the chemical synthesis 
strategy used. Peptides were purified using preparative reverse-phase high performance liquid 
chromatography (HPLC, LaPrep P110, VWR International GmbH) with a Reprosil-Gold 120 C18 4 µm 
column (Dr. Maisch GmbH) and a variable gradient adapted to the peptides properties in a range of 100% 
H2O to 100% acetonitrile, both containing 0.1% TFA. Peptide identity was verified using an analytical 
Agilent 1100 HPLC system equipped with a Chromolith Performance RP-C18e column (Merck KGaA) 
coupled to a mass spectrometer (Exactive, Thermo Fisher Scientific). 
Preparation of hepatotropic nanoparticles. Hepatotropic nanoparticles based on liposomes were 
prepared using the film rehydration extrusion method as described previously.(Detampel et al., 2014) 
The lipid membrane composition of nanoparticles consisted of DSPC (Lipoid AG), cholesterol (Sigma-
Aldrich), DSPE-PEG2000 (Lipoid AG) at a molar ratio of 52.7:42.3:5. For the conjugation of HBV-
derived peptides, DSPE-PEG2000 was replaced by DSPE-PEG2000-maleimide (Avanti Polar Lipids) at 
indicated molar ratios. For fluorescence labeling of lipid membrane, 1mol% DiI (Thermo Fisher 
Scientific) was added to the lipid composition replacing DSPC. For radioactive labeling with 111In, DSPC 
was replaced by 3 mol% DSPE-DTPA (Avanti Polar Lipids). Desired ratios of lipids were mixed; a 
homogenous thin film was prepared and dried using a Rotavapor A-134 (Büchi). Lipid films were 
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rehydrated using 0.01 M PBS pH 7.2 containing 1 mM EDTA (Sigma-Aldrich) to prevent metal ion 
catalyzed maleimide oxidation. For passive loading and fluorescence labeling of inner core, a 60 mM 
5(6)-carboxyfluorescein (Sigma-Aldrich) solution (pH 7.4) was used for the rehydration step. At this 
concentration >98% of the fluorescence is self-quenched (Figure 1–figure supplement 3). Resulting 
multilamellar vesicles were subjected to five freeze-thaw cycles and extruded 11 times through a 
polycarbonate membrane (Avanti Polar Lipids) with a pore size of 100 nm followed by 11 times through 
a polycarbonate membrane with a 50 nm pore size 10°C above transition temperature (i.e. 65°C for 
DSPC-based formulations). For functionalization with HBV-derived peptides, nanoparticles were mixed 
with peptides at molar maleimide-to-cysteine ratio of 1:1 and incubated at RT overnight. To remove non-
conjugated peptides and/or free hydrophilic dye, size exclusion chromatography using a Sephadex G50 
column (GE Healthcare) eluted with 0.01 M PBS pH 7.4 was performed. The size exclusion 
chromatography column was coupled to an UV detector to analyze recovery of nanoparticles based on 
peak areas. Hepatotropic nanoparticles were concentrated to a final lipid concentration of 10 mM using 
Amicon Ultra-4 centrifugal filter units with a 100 kDa molecular weight cut-off (Millipore). DiI and 
cholesterol were used as marker lipids to quantify total lipid content. DiI content was quantified based 
on relative fluorescence signals as compared to liposome standards and in combination with Triton X-100 
treatment to account for potential DiI self-quenching. Samples were excited at 561 nm and fluorescence 
signals were recorded using a Spectramax M2 microplate reader (Molecular Devices). The cholesterol 
content was determined using the Cholesterol E cholesterol assay kit from Wako following the 
manufacturer’s protocol. 
Loading of compounds into hepatotropic nanoparticles.  
FITC-peptide loading. For passive loading of FITC-Ahx-yKKEEEK into nanoparticles, a 2 mg/mL 
FITC-peptide solution in a mixture of PBS/DMSO/EtOH at pH 7.0 was used for the rehydration step of 
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the homogenous lipid film. Resulting multilamellar vesicles were processed as described in the methods 
section. 
Propidium iodide loading. For passive loading of propidium iodide into nanoparticles, a 10 mg/mL 
propidium iodide solution in PBS was used for the rehydration step of the homogenous lipid film. 
Resulting multilamellar vesicles were processed as described in the methods section including a final 
purification step.  
Doxorubicin loading. For loading of doxorubicin, an active drug loading strategy based on a citrate 
gradient was used as previously described.(Mayer et al., 1990) The homogenous lipid film was 
rehydrated using a 300 mM citrate buffer at pH 4.0 and multilamellar vesicles were processed as 
described in the methods section. The pH of the external buffer solution was adjusted to pH 7.0 and 
nanoparticles were incubated with 2 mg/mL doxorubicin at 65°C for 15 min. Free doxorubicin was 
removed by size exclusion chromatography.  
Physicochemical characterization of hepatotropic nanoparticles.  
Dynamic light scattering. Size and size distribution (polydispersity index, PDI) of nanoparticles were 
analyzed using a Delsa Nano C Particle Analyzer (Beckman Coulter) equipped with a 658 nm laser. 
Samples were measured in D-PBS at RT and a measurement angle of 165°. Data were converted using 
the CONTIN particle size distribution analysis (Delsa Nano V3.73/2.30, Beckman Coulter Inc.). 
Electrophoretic light scattering. Zeta potential of nanoparticles was analyzed using a Delsa Nano C 
Particle Analyzer. Samples were measured in D-PBS at RT and a measurement angle of 15°. Data were 
converted using the Smoluchowski equation (Delsa Nano V3.73/2.30). 
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Transmission electron microscopy. Size and morphology of nanoparticles were analyzed using 
transmission electron microscopy (TEM) as described previously.(Witzigmann et al., 2015a) In brief, 
samples were deposited on a 400-mesh carbon-coated copper grid, negatively stained with 2% 
uranylacetate, and analyzed using a CM-100 electron microscope operating at 80 kV (Philips). 
Fluorescence correlation spectroscopy. Fluorescence correlation spectroscopy (FCS) analysis of 
nanoparticles was performed as described previously.(Uhl et al., 2017) In brief, Atto488, Myr-preS2-48-
Atto488 and Myr-preS2-48-Atto488 conjugated nanoparticles were analyzed using an inverted confocal 
fluorescence laser scanning microscope (Zeiss LSM 510-META/Confocor 2) equipped with a 40× water 
immersion objective lens (Zeiss C-Apochromat 40×, numerical aperture 1.2). Fluorescence intensity 
fluctuations were measured for three independent samples and each measurement was repeated 20-30 
times. Autocorrelation functions were fitted using a two-component model and diffusion times were 
calculated. 
Cell Culture. All human cell lines were cultured at 37 °C under 5% CO2 and saturated humidity in 
Dulbecco’s modified Eagle’s culture medium high glucose (DMEM, Sigma-Aldrich) supplemented with 
10% fetal calf serum (Amimed), penicillin (100 units/mL, Sigma-Aldrich), and streptomycin 
(100 μg/mL, Sigma-Aldrich). Stable NTCP expressing liver derived cell lines, i.e. HepG2 hNTCP and 
HuH7 hNTCP, were created by lentiviral transduction as published previously.(Ni et al., 2014) For 
uptake experiments, different cell lines were seeded at a density of 2.5 × 104 cells/cm2 and allowed to 
adhere for 24 h. For confocal laser scanning microscopy experiments, cells were grown on poly-D-lysine 
(Sigma-Aldrich) coated glass cover slips (#1.5, Menzel) or well plates (TPP). 
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Transfection of cell lines. For transient expression of the transporter, plasmids encoding for mNtcp 
(Slc10a1) or hNTCP (SLC10A1) were generated, amplifying the coding sequence from commercially 
obtained mRNA (Amsbio) by PCR. The following primers were used:  
hNTCP_for: 5′-ATGGAGGCCCACAACGCGTCT-3′,  
hNTCP_rev 5′-CTAGGCTGTGCAAGGGGA-3′;  
mNtcp_for 5`-GTGTTCACTGGGTCGGAGGATG-‘3,  
mNtcp_rev1 5`-CAGGTCCAGAGCAAATACTCATAGGAG-‘3.  
Subsequently the amplicons were ligated into pEF6-V5/HIS (Invitrogen), followed by sequence 
verification (Microsynth). The resulting plasmids mNtcp-pEF6 and hNTCP-pEF6 and Lipofectamine 
3000 (Sigma-Aldrich) were used for transfection of human cell lines. A standard transfection protocol 
was developed as follows: Plasmid DNA and P3000 reagent were diluted in Opti-MEM (Sigma-Aldrich) 
and rapidly mixed with Lipofectamine 3000 diluted Opti-MEM using a DNA-to-Lipofectamine 3000 
w/V ratio of 3. After 5 min incubation, the transfection mix was added to adhered cells at a plasmid DNA 
concentration of 1 μg/mL. Control cells were either transfected with empty pEF6 vector or treated with 
Opti-MEM alone.  
Assessment of cytocompatibility of nanoparticles. To assess the cytocompatibility of nanoparticles 
modified with different Myrcludex B derived peptides a MTT cell viability assay was performed. Wild 
type HeLa cells, liver-derived wild type HepG2 cells and HepG2 hNTCP were seeded and cultured as 
described above. Nanoparticles were added to cells at final concentrations of 0.25 mM – 8 mM. After 
24 h, MTT reagent (Sigma-Aldrich) was added to cells for 4 h. Formazan dye crystals were solubilized 
for 2 h using a mixture containing 3% (v/v) sodium dodecyl sulfate (Sigma-Aldrich) and 40 mM 
hydrochloric acid in isopropanol (Sigma-Aldrich). Absorption of reduced MTT and background signals 
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were measured using a Spectramax M2 microplate reader at 570 nm and 670 nm, respectively. Control 
cells treated with buffer were used to calculate relative cell viability. 
Uptake of nanoparticles in vitro. To assess the uptake rate and intracellular localization of 
nanoparticles, cell lines were incubated with different concentrations of nanoparticles at 37°C or 4°C. 
Nanoparticles were loaded with 5(6)-carboxyfluorescein (payload) and/or incorporated DiI in their 
phospholipid-membrane. Myrcludex B derived peptides were fluorescently labeled if necessary as 
indicated above. At the indicated time points, confocal laser scanning microscopy or flow cytometry 
were used for qualitative and quantitative analysis, respectively.  
Competitive inhibition experiments in vitro. NTCP-specific uptake of nanoparticles was investigated by 
pre-incubation with 400 nM free Myrcludex B fluorescently labeled with Atto-565 or Atto-488 as 
indicated. 
Binding mechanism studies in vitro. The hepatic cell dependent binding mechanism of nanoparticles was 
investigated by pre-incubation with 300 µg/mL heparin sulfate. 
Uptake mechanism studies on NTCP mediated internalization in vitro. The uptake mechanism of 
nanoparticles into HepG2 hNTCP cells was investigated using different pharmacological pathway 
inhibitors as described previously.(Lunov et al., 2011) Cells were pre-incubated using 100 µg/mL 
colchicine (micropinocytosis inhibitor), 10 µg/mL chlorpromazine (inhibitor of clathrin-mediated 
endocytosis), or 25 µg/mL nystatine (inhibitor of caveolin-mediated endocytosis) for 30 min before 
addition of nanoparticles. 
Confocal laser scanning microscopy. At indicated time points, cell nuclei were counterstained for 
5 min using 1.0 μg/mL Hoechst 33342 (Sigma-Aldrich), washed with PBS and embedded using ProLong 
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Gold antifading reagent (Invitrogen Life Technologies). For live cell imaging, cell nuclei were 
counterstained with Hoechst 33342, and if indicated cell membranes were stained with Cell Mask Deep 
Red Plasma Membrane Stain (1.0 μg/mL, Thermo Fisher Scientific) and NTCP was stained using 
fluorescently labeled Myrcludex B. Confocal laser scanning microscopy analysis was performed using 
an Olympus FV-1000 inverted microscope (Olympus Ltd.), equipped with a 60× PlanApo N oil-
immersion objective (numerical aperture 1.40).  
Flow cytometry analysis. To quantify the uptake rate of nanoparticles into non-hepatic and hepatic 
cell lines with different NTCP expression levels, flow cytometry analysis was performed. Cells were 
detached using 0.25% trypsin/EDTA (Sigma-Aldrich), washed twice with PBS and re-suspended in PBS 
containing 1% fetal calf serum, 0.05% NaN3, and 2.5 mM EDTA. At least 10,000 cells per setting were 
analyzed using a FACS Canto II flow cytometer (Becton Dickinson). Doublets were excluded and DiI 
or CF signals were measured. Relative mean fluorescence intensities (MFI) of DiI or CF signals 
normalized to untreated cells were calculated using Flow Jo VX software (TreeStar). 
Zebrafish embryo culture. Zebrafish embryos (Danio rerio) are a well-established vertebrate 
screening model for engineered nanomaterials.(Campbell et al., 2018; Einfalt et al., 2018; Sieber et al., 
2017) They were maintained in accordance with Swiss animal welfare regulations as described 
previously.(Sieber et al., 2017) In brief, eggs from wild type ABC/TU and transgenic kdrl:EGFPs843 
adult zebrafish were maintained in media at 28°C. Formation of pigment cells was prevented by 1-phenyl 
2-thiourea (PTU, Sigma-Aldrich). 
Injection of nanoparticles into zebrafish embryos. To assess the systemic circulation of 
nanoparticles, samples were injected into transgenic kdrl:EGFPs843 zebrafish embryos (2 dpf) as 
described previously.(Sieber et al., 2017) In brief, calibrated volumes of 1 nL were injected into the duct 
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of Cuvier of anesthetized and agarose-embedded zebrafish embryos using a micromanipulator (Wagner 
Instrumentenbau KG), a pneumatic Pico Pump PV830 (WPI), and a Leica S8APO microscope (Leica). 
The tail region of zebrafish embryos was imaged 1 hour post injection (hpi) using an Olympus FV-1000 
inverted confocal laser scanning microscope equipped with a 20× UPlanSApo (numerical aperture 0.75) 
objective. 
Targeting of xenotransplanted human cells in the zebrafish model. Human HEK293 cells deficient 
or overexpressing hNTCP were detached from 6-well cell culture dishes using 1 mL pre-warmed 
DMEM, washed (5 min at 200 g) and resuspended in 10 µL DMEM. Human cells (3 nL) were injected 
into the duct of Cuvier of ABC/TU zebrafish embryos. As soon as transgenic human cells stopped 
circulating and remained in the caudal vasculature tail region (after approximately 2 hpi), nanoparticles 
(1 nL) were injected as described above. Brightfield and fluorescence images of the tail region were 
taken 1 hpi of nanoparticles.  
Colocalization analysis. Binding of nanoparticles to HEK293 cells was analyzed using the JaCoP plug-
in in Fiji. Therefore, Pearson´s Correlation Coefficient (PCC) was determined to assess the extent of 
colocalization.(Bolte and Cordelières, 2006) 
Radioactive labeling of nanoparticles with 111In. Labeling of nanoparticles with 111In was performed 
with modifications as described previously.(van der Geest et al., 2015) Nanoparticles were prepared as 
described above in PBS at a total lipid concentration of 60 mM (including 3 mol% DSPE-DTPA). Size 
exclusion chromatography was used to exchange the buffer system to citrate buffered saline pH 5.4, 
fractions were pooled and finally concentrated using Amicon Ultra-4 centrifugal filter units (100 kDa 
size exclusion). Nanoparticles (30 µmol) were incubated with 40 µl of 111InCl3 (Mallinckrodt 
Pharmaceuticals) at 37°C for 45 min using a thermocycler. After incubation, 111In labeled nanoparticles 
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were purified using NAP-5 columns (GE Healthcare) by elution with sterile saline (B. Braun Medical 
Inc.). Fractions of 250 µL were collected and activity of each fraction was determined.  
Planar imaging of mice in vivo. All mice experiments were carried out in accordance with German 
legislation on animal welfare. Female NMRI mice (6-8 weeks) were obtained from Janvier Laboratories. 
For planar imaging, mice were anesthetized with Isoflurane (Baxter) and 111In labeled nanoparticles with 
a total activity of 8-10 MBq (corresponding to 100 µL) were intravenously injected into the tail vein. 
Afterwards, the animals were placed in prone position on a planar gamma-imager (Biospace) equipped 
with a high energy collimator as described previously.(Müller et al., 2013; Wischnjow et al., 2016) 
Images were recorded at the indicated time points with 10 min acquisition time. 
Organ biodistribution of nanoparticles in mice in vivo. For biodistribution studies, 111In labeled 
nanoparticles with a total activity of 1-2 MBq (corresponding to 100 µL) were intravenously injected 
into the tail vein of wild type mice. Animals were sacrificed (n = 3 per nanoparticle administration) 
1 hour post injection, organs were harvested and the radioactivity in each organ was measured with a 
Berthold LB 951G gamma counter. Each organ-associated activity was related to the injected dose. The 
percentage of injected dose (%ID) per organ was calculated using standard values for organ 
weights.(Mühlfeld et al., 2003) 
Fluorescence imaging of nanoparticles in tissue cryo-sections. Nanoparticles incorporating 1mol% 
DiI were intravenously injected into the tail vein of wildtype mice. Animals were sacrificed 1 hour post 
injection and organs were snap-frozen in liquid nitrogen. Cryo-sections of 16 µm were mounted on 
Superfrost Plus Ultra microscope slides (Thermo Fisher Scientific) and counterstained with Hoechst 
33342 (2 µg/mL). Slides were embedded in Prolong Gold Antifade Mountant (Thermo Fisher Scientific), 
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sealed with nail polisher and analyzed using an Olympus FV-1000 inverted confocal laser scanning 
microscope equipped with a 40x UPlanFL N oil-immersion objective (numerical aperture 1.30). 
Immunohistochemistry of targeting ligand in tissue sections. After intravenous tail vein injection 
of nanoparticles, the mice were euthanized, organs were harvested, rinsed with PBS and immediately 
placed in a 4% formaldehyde solution in PBS. After fixation for 24 h, organs were dehydrated and 
embedded in paraffin. Sections of 5 µm thicknesses were cut using a microtome MICROM HM 355, 
placed onto a microscope slide and dried at 37°C. After dewaxing and rehydration, epitope retrieval was 
performed. The primary antibody against Myr-preS2-31 (MA18/7, kind gift from Wolfram Gerlich) was 
added overnight at 4°C, before incubation with the secondary antibody. Finally, slides were 
counterstained with hemalum (Merck KGaA) for 10 min, blued with tap water and mounted using 
Aquatex (Merck Millipore). 
Immunofluorescence imaging of liver cryo-sections. Animals were sacrificed 3 hour post injection 
of nanoparticles and liver cryo-sections (16 µm) were prepared as described above. Slides were stained 
using primary antibodies against Myr-preS2-31 (MA18/7, 1:100 dilution) and mNtcp (provided by Prof. 
Bruno Stieger, University Zürich, 1:100 dilution). Finally, cell nuclei were counterstained with Hoechst 
33342 (2 µg/mL) and analyzed by confocal microscopy as described above. 
Statistical analysis. Statistical analysis for all experiments was performed by one-way analysis of 
variance (ANOVA) followed by Bonferroni post-hoc test using OriginPro 9.1 software (OriginLab 
Corporation). Differences between groups were considered to be statistically significant at the indicated 
p-values. 
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Figure Supplements 
 
Figure 1–figure supplement 1. Characterization of hepatotropic nanoparticles based on liposomes 
modified with Myrcludex B (Myr-preS2-48) using fluorescence correlation spectroscopy. 
Autocorrelation curves of Atto488 (black cross), Myr-preS2-48 Atto488 (grey triangle), and Myr-preS2-
48-Atto488 conjugated nanoparticles (black square). For comparison curves are normalized to 1 (n = 3 
independent samples). Numerical data is shown in the Figure 1-source data. 
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Figure 1–figure supplement 2. Assessment of cytocompatibility of nanoparticles modified with 
different Myrcludex B derived peptides using non-hepatic HeLa cells (HeLa WT), liver-derived wildtype 
HepG2 cells (HepG2 WT) and HepG2 cells overexpressing the human NTCP (HepG2 hNTCP) by MTT 
assay. All values are shown as mean ± SD of biological replicates (n = 3 independent experiments). 
Numerical data for all graphs are shown in the Figure 1-source data. 
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 Figure 1–figure supplement 3. Concentration dependent fluorescence self-quenching of 5(6)-
carboxyfluorescein. Fluorescence (arbitrary units, a.u.) of carboxyfluorescein in phosphate buffered 
saline (PBS, pH 7.4) at different concentrations (n = 1). Numerical data is shown in the Figure 1-source 
data. 
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 Figure 1–figure supplement 4. Flow cytometry analysis of nanoparticle uptake rate into non-hepatic 
HeLa cells, liver-derived HepG2 cells and hNTCP overexpressing HepG2 cells. Increasing 
concentrations of nanoparticles (CLipid) modified with different Myrcludex B-derived peptides were 
evaluated. Relative mean fluorescence intensities (MFI) of CF signals normalized to untreated cells are 
given. All values are shown as mean ± SD of biological replicates (n ≥ 3 independent experiments). 
Numerical data for all graphs are shown in the Figure 1-source data. 
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 Figure 1–figure supplement 5. Uptake of Myrcludex B-modified nanoparticles into HuH7 liver-derived 
cells deficient (HuH7 WT) or overexpressing hNTCP (HuH7 hNTCP). Nanoparticles have a dual 
fluorescent label, i.e. lipophilic membrane label (DiI, red) and hydrophilic payload incorporation 
(carboxyfluorescein, green). Representative confocal laser scanning microscopy maximum intensity 
projections 30 min after liposome addition are shown. Blue signal: Hoechst stain of cell nuclei. 
Scale bar = 10 µm. Single fluorescent channels are presented as small images. Dotted lines indicate cell 
membranes. 
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 Figure 1–figure supplement 6. Time-dependent internalization of Myr-preS2-31 modified 
nanoparticles into hNTCP overexpressing HepG2 cells. Nanoparticles have a dual fluorescent label, i.e. 
lipophilic membrane label (DiI, red) and hydrophilic payload incorporation (FITC-peptide, green). 
Representative confocal laser images for Myr-preS2-31 modified nanoparticles after specific time points 
are shown. Inserts represent confocal laser images for PEG nanoparticles at the same time point. Blue 
signal: Hoechst stain of cell nuclei.  
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 Figure 1–figure supplement 7. Time-dependent internalization and toxicity of propidium iodide loaded 
nanoparticles into hNTCP overexpressing HepG2 cells. Nanoparticles were passively loaded with 
propidium iodide (red signal). Representative confocal laser images for PEG nanoparticles and Myr-
preS2-31 modified nanoparticles after specific time points are shown. Scale bar = 20 µm. 
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 Figure 1–figure supplement 8. Time-dependent internalization and toxicity of doxorubicin loaded 
nanoparticles into hNTCP overexpressing HepG2 cells. Nanoparticles were actively loaded with 
doxorubicin (red signal) using a citrate buffer gradient. Representative confocal laser images for PEG 
nanoparticles and Myr-preS2-31 modified nanoparticles after specific time points are shown. Arrows 
indicate dead cells. Scale bar = 20 µm. 
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 Figure 2–figure supplement 1. NTCP-dependent uptake mechanism of nanoparticles. Flow cytometry 
analysis of nanoparticle internalization in presence of different pharmacological pathway inhibitors. 
Histograms of HepG2 hNTCP cells incubated with PBS (gray; solid line) and nanoparticles in absence 
(green; solid line) or presence of colchicine (micropinocytosis inhibitor, purple; dotted line), 
chlorpromazine (inhibitor of clathrin-mediated endocytosis, yellow; dotted line), or nystatine (inhibitor 
of caveolin-mediated endocytosis, blue; dotted line).  
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 Figure 2–figure supplement 2. Uptake of Myrcludex B-modified nanoparticles into HeLa cells 
transfected with empty vector (pEF6 Ctrl), mNtcp or hNTCP. (A) Binding of nanoparticles was 
qualitatively assessed using confocal laser scanning microscopy. PBS served as mock control (PBS Ctrl). 
Representative images are shown 1 hour after liposome addition. Blue signal: Hoechst stain of cell nuclei. 
Grey signal: Cell mask stain of plasma membrane. Yellow signal: DiI labeled liposomes loaded with 
carboxyfluorescein. Scale bar = 10 µm. (B) Quantification of liposome binding using flow cytometry 
revealed significant increase of cellular binding by overexpression of mNtcp or hNTCP. All values are 
shown as mean ± SD of biological replicates (n = 3 independent experiments). ****p < 0.001. Numerical 
data for all graphs are shown in the Figure 2-source data.  
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 Figure 2–figure supplement 3. Influence of glycosaminoglycans (GAGs) on Myrcludex B binding. 
Flow cytometry analysis of Myrcludex B binding to CHO or psgA745 cells NTCP deficient (pEF6 
transfected), or overexpressing hNTCP or mNtcp. psgA745 are CHO xylosyltransferase mutants 
deficient of GAGs. Histograms of Myrcludex B binding to cells transfected with empty vector (gray; 
solid line), hNTCP (red; dotted line) or mNtcp (blue; dashed line)  
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 Figure 2–figure supplement 4. Uptake of nanoparticles into HepG2-WT cells in absence or presence of 
heparan sulfate. (A) Binding of PEG, Myr-preS2-48 A and Myr-preS2-48 conjugated nanoparticles was 
quantitatively assessed using flow cytometry. A significant decrease of cellular binding was observed in 
presence of heparan sulfate. All values are shown as mean ± SD of biological replicates (n = 3 
independent experiments). ***p < 0.001, ****p < 0.0001.  Numerical data for all graphs are shown in 
the Figure 2-source data. (B) Representative confocal laser scanning microscopy images of Myr-preS2-
48 A nanoparticles (membrane dye, DiI, red signal) loaded with carboxyfluorescein (payload, green 
signal) internalized into HepG2-hNTCP in absence or presence of heparan sulfate. Blue signal: Hoechst 
stain of cell nuclei. Scale bar = 20 µm. 
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 Figure 2–figure supplement 5. Ligand density dependent uptake of Myrcludex B-modified 
nanoparticles loaded with carboxyfluorescein (payload, green). Representative confocal laser scanning 
microscopy maximum intensity projections are shown. Blue signal: Hoechst stain of cell nuclei. Scale 
bar = 10 µm. 
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 Figure 4–figure supplement 1. Targeting ability of free Myrcludex B in vivo in xenotransplanted 
zebrafish embryos. Atto-565 labeled Myrcludex B (red signal) was injected into wild type zebrafish 
embryos xenotransplanted with human HEK293 cells expressing hNTCP (GFP, green signal). Red 
signals on surface of HEK293 cells demonstrate binding of Myrcludex B. Representative brightfield and 
fluorescence images of tail region including a merge image one hour post injection are shown. 
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 Figure 5–figure supplement 1. Organ ratios of ex vivo biodistribution analysis. Nanoparticles were 
modified with different amounts of Myr-preS2-31 and labeled with radioactive 111In. Quantitative 
biodistribution studies were performed 1 hour post injection. Radioactivity of each organ was determined 
with a γ-counter. Ratios of injected dose (%ID) per organ between the blood pool level and selected 
organs, i.e. liver (i.e. target organ), spleen (i.e. clearance organ), and kidney (i.e. control organ since 
nanoparticle bound 111In should not show renal excretion) were calculated. All values are shown as box 
plots of biological replicates (n = 3 independent experiments). *p < 0.05, **p < 0.01, ***p < 0.001. 
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 Figure 5–figure supplement 2. In vivo biodistribution and liver targeting of Myr-preS2-31 conjugated 
nanoparticles in mice. Nanoparticles were modified with different amounts of Myr-preS2-31. Static 
planar imaging of mice 15 min after intravenous injection of different 111In labeled nanoparticles with 
approximately 8 MBq. 
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 Figure 5–figure supplement 3. Intra-organ distribution of Myr-preS2-31-modified nanoparticles in 
spleen and kidney in vivo in mice dependent on ligand density. (A) Fluorescence imaging (FI) of 
liposomes (DiI, red signal) in spleen and kidney cryo-sections. Blue signal: Hoechst stain of cell nuclei. 
Scale bar = 100 µm. (B) Immunohistochemistry (IHC) of Myr-preS2-31 distribution (red signal) in 
spleen and kidney. Tissue sections from mice were stained with anti-Myr-preS2-31 antibody (MA18/7). 
Blue signals represent cell nuclei. 
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 Figure 5–figure supplement 4. Liver targeting of Myr-preS2-31 conjugated nanoparticles in mice. 
Representative low magnification images of immunohistochemistry (IHC) of Myr-preS2-31 (red signal) 
in liver sections 1 hour after intravenous injection. Mice liver sections were stained with anti-Myr-preS2-
31 antibody (MA18/7). Blue signals represent cell nuclei. Arrows indicate distinct localized 
accumulations. 
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 Figure 5–figure supplement 5. Specific binding of Myr-preS2-31 conjugated nanoparticles to 
sinusoidal membrane of hepatocytes. Immunohistochemistry of FITC-payload (PEG nanoparticles) or 
Myr-preS2-31 (nanoparticles modified with 0.25 mol% Myr-preS2-31) in the liver sections 1 hour after 
intravenous injection (red signals). Mice liver sections were stained with anti-FITC antibody or anti-
Myr-preS2-31 antibody (MA18/7), respectively. Blue signals represent cell nuclei. 
133
 Figure 5–figure supplement 6. Biodistribution of nanoparticles modified with 0.5 mol% Myr-preS2-31 
in mice. Immunohistochemistry of nanoparticles` FITC payload (red signal) in the liver, spleen, kidney 
sections 1 hour after intravenous injection. Tissue sections were stained with anti-FITC antibody. Blue 
signals represent cell nuclei. Arrows indicate distinct localized accumulations. 
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Chapter IV-II 
Immobilization of Enzymes on PLGA Sub-Micrometer Particles by Crosslinked Layer-by-Layer Deposition 
 
Sandro Sieber, Stefan Siegrist, Stéphanie Schwarz, Fabiola Porta, Susanne H. Schenk, Jörg Huwyler 
Manuscript: Macromolecular Bioscience (2017) [43] 
 
Highlights: Enzyme immobilization for therapeutic purposes is a promising branch of nanomedicine 
research. Nevertheless, current immobilization protocols have usually to be tailored and adapted to 
specific enzymes, due to different enzyme molecular weights, active conformations, or stabilities. In 
order to provide a protocol, which is applicable to different enzymes, an enzyme immobilization 
approach only based on enzyme and particle surface charge was developed. Two different model 
enzymes were immobilized on FDA approved poly(lactide-co-glycolide) (PLGA) particles via a 
crosslinked layer-by-layer approach. Enzyme activity and stability under enhanced temperature and 
decreased pH before and after immobilization were investigated. The zebrafish model was used to test 
the biocompatibility, stability, and activity of the designed system under biological conditions.
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to immobilize enzymes on surfaces or particles using 
different techniques. Through enzyme immobilization, 
different characteristics such as biological and chemical 
stability, kinetic properties, solubility and reusability can 
be improved. Today, a continuously growing number of 
immobilization techniques are available. They can mainly 
be divided into the immobilization on supports, entrap-
ment, or crosslinking via the preparation of crosslinked 
enzyme aggregates (CLEAs) or crosslinked enzyme crystals 
(CLECs).[5]
Particles in the sub-micrometer range are ideal candi-
dates for enzyme immobilization due to their high sur-
face to volume ratio and therefore high enzyme loading 
capacity and the broad range of possible applications.[6] 
Despite the in most cases required preliminary activa-
tion of the underlying carrier and the specific reaction 
conditions, covalent attachment is still one of the most 
powerful methods for increasing enzyme stability upon 
immobilization.[4] However, most of these protocols 
require well defined and/or relatively harsh reaction con-
ditions. As an alternative approach, physical adsorption 
Enzyme immobilization is of high interest for industrial applications. However, immobiliza-
tion may compromise enzyme activity or stability due to the harsh conditions which have to 
be applied. The authors therefore present a new and improved crosslinked layer-by-layer (cLbL) 
approach. Two different model enzymes (acid phosphatase and β-galactosidase) are immobi-
lized under mild conditions on biocompatible, monodisperse, sub-micrometer poly(lactide-co-
glycolide) (PLGA) particles. The resulting PLGA enzyme systems are characterized regarding 
their size, surface charge, enzyme activity, storage stability, reusability, and stability under 
various conditions such as changing pH and temperature. The developed and characterized 
cLbL protocol can be easily adapted to different enzymes. 
Potential future uses of the technology for biomedical appli-
cations are discussed. PLGA-enzyme particles are therefore 
injected into the blood circulation of zebrafish embryos in 
order to demonstrate the in vivo stability and activity of the 
designed system.
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1. Introduction
Enzymes are increasingly used in industrial production 
due to their biocatalytic properties and potential. Exam-
ples include enantioselective production of active phar-
maceutical ingredients[1] or the use of enzymes in food 
processing. The enzymatic treatment of milk, for example, 
results in lactose free milk products, which do not con-
tain any residual lactose.[2,3] However, moderate chemical 
stability of many enzymes prevents their recovery from 
technical processes. This leads to high production costs 
and makes enzymes unsuitable for many applications.[4] 
In order to overcome these shortcomings, it was proposed 
Macromol. Biosci. 2017, , 1700015
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based on electrostatic or hydrophobic/hydrophilic interac-
tions can be used allowing enzymes to be adsorbed to the 
particle surface under mild conditions. The layer-by-layer 
(LbL) technique, which was already introduced in 1992 by 
Decher et al.,[7] offers a versatile and adaptable possibility 
to immobilize different enzymes on various carriers 
only based on their opposite electrostatic charge.[8] In 
this case, subsequent layers of polyelectrolytes and 
ionized enzymes are deposited on a solid support. The 
resulting “sandwich” configuration between electrolytes 
and enzymes allows for a high density of immobilized 
enzymes. A major drawback of this approach is the insta-
bility of the resulting carrier-enzyme systems resulting in 
enzyme desorption and the inability to wash and reuse 
enzyme-loaded particles.
In view of the shortcomings of both covalent and 
noncovalent coupling procedures, we present in this pub-
lication a novel crosslinked layer-by-layer (cLbL) immobi-
lization technique. Combining covalent crosslinking and 
layer-by-layer deposition on sub-micrometer particles, the 
benefits of chemical and physical immobilization can both 
be exploited. This improved immobilization technique 
consists of a subsequent deposition of polyelectrolytes 
(PE) and enzymes on the surface of biodegradable 
(poly(lactide-co-glycolide)) (PLGA) particles using the 
layer-by-layer deposition technology. The coiled assembly 
of polyelectrolytes on the carrier facilitates multiple 
enzyme–PE interactions, which finally leads to an efficient 
and reproducible enzyme adsorption. Each PE–enzyme 
layer is subsequently stabilized by covalent crosslinking 
using glutaraldehyde (GA).[9] To this end, a PE with pri-
mary amino groups (i.e., poly(allylamine hydrochloride) 
(PAH)) was selected to allow for covalent crosslinking with 
amine groups present on enzymes. It was the goal of the 
present work to develop a cLBL enzyme immobilization 
technique and to demonstrate its applicability for indus-
trial applications using two model enzymes (acid phos-
phatase and β-galactosidase). The established protocol can 
be adapted to different types of enzymes and allows for a 
fast and highly reproducible enzyme immobilization on 
sub-micrometer particles. Enzyme activity was monitored 
using colorimetric enzyme assays and Michaelis–Menten 
enzyme kinetics. Enzyme stability under stress conditions 
(i.e., storage, pH, and temperature), particle reusability, in 
vivo stability, and biocompatibility were investigated.
2. Experimental Section
2.1. Chemicals and Reagents
Acid phosphatase from potato (0.5–3.0 units mg−1) (AP), 
β-galactosidase from Aspergillus oryzae (13.4 units mg−1) (BGal), 
d-α-tocopherol polyethylene glycol 1000 succinate (DTPG), ethyl 
3-aminobenzoate methane sulfonate (MS 222), halocarbon oil 
27, 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
(HEPES) buffer, paraformaldehyde, poly(allylamine hydrochlo-
ride) (Mw ≈15 000 or ≈17 500) (PAH), ester terminated poly(d,l-
lactide-co-glycolide) (lactide:glycolide 65:35, Mw 40 000–75 000) 
(PLGA), poly(sodium 4-styrene sulfonate) (Mw ≈ 70 000) (PSS), 
N-phenylthiourea (PTU), NP-40, sodium deoxycholate, Tween 20 
(polyoxyethylenesorbitan monolaurate), 2-mercaptoethanol, 
and 4-nitrophenol (4-NP) were purchased from Sigma-Aldrich 
(Sigma-Aldrich, Buchs, Switzerland). Dimethyl sulfoxide 
(DMSO), ethyl acetate, GA 50%, 5-Bromo-4-chlor-3-indoxyl-
β-d-galactoside (X-β-Gal), potassium ferricyanide, potassium 
ferrocyanide, 2-nitrophenol-β-d-galactopyranoside (ONPG), 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), and 4-nitrophenylphosphate (4-NPP) were purchased 
from Carl Roth (Carl Roth GmbH, Karlsruhe, Germany). Agarose 
standard low was purchased from BioRad (BioRad, Hercules, 
CA). All other chemicals were of analytical grade and obtained 
from Merck, Darmstadt, Germany. Deionized water used for all 
experiments had a resistivity of 18.2 MΩ cm (Merck Millipore, 
Darmstadt, Germany). Activity of BGal was determined in cit-
rate buffer (40 × 10−3 m citric acid, 60 × 10−3 m tri-sodium citrate, 
1 × 10−3 m MgCl2, 50 × 10−3 m 2-mercaptoethanol) at the indicated 
pH. If not differently noted, citrate buffers and H2O used for par-
ticle enzyme preparation and enzyme activity assays contained 
0.01% Tween 20 in order to prevent agglomeration and adsorp-
tion of processed PLGA particles on reaction container surfaces.
HEPG2 cells were cultured as described previously.[10] Primary 
human umbilical vein cells (HUVEC) and culture medium were 
from Provitro, Berlin, Germany. Primary HUVEC cells were 
cultured according to protocols of the supplier (Provitro, Berlin, 
Germany) and flasks or plates were coated with a 0.1 mg mL−1 rat 
tail collagen type 1 solution for enhanced monolayer formation. 
HEPG2 and HUVEC were used at passages 25–35 and passages 
4–6 during MTT assays, respectively. 1% (v/v) penicillin/
streptomycin was added to cell culture media.
Zebrafish embryo culture medium was prepared at final 
concentrations of 5 × 10−3 m sodium chloride, 0.25 × 10−3 m potassium 
chloride, 0.5 × 10−3 m magnesium sulfate, 0.15 × 10−3 m potassium 
dihydrogen phosphate, 0.05 × 10−3 m sodium phosphate dibasic, 
0.5 × 10−3 m calcium chloride, 0.71 × 10−3 m sodium bicarbonate, 
0.001% (w/v) methylene blue, pH 7.4.
Phosphate buffer used for all the X-β-Gal buffers was 
prepared at final concentrations of 23 × 10−3 m sodium phosphate 
monobasic, 77 × 10−3 m sodium phosphate dibasic, pH 7.3. X-β-Gal 
fixation buffer was prepared at a final concentration of 2% 
paraformaldehyde and 0.2% glutaraldehyde. X-β-Gal wash buffer 
was prepared at final concentrations of 2 × 10−3 m magnesium 
chloride, 0.02% sodium deoxycholate, and 0.02% NP-40. X-β-Gal 
staining buffer was prepared at final concentrations of 2 × 10−3 m 
magnesium chloride, 5 × 10−3 m potassium ferrocyanide, 5 × 10−3 m 
potassium ferricyanide, 0.02% sodium deoxycholate, 0.02% 
NP-40, and 1 mg mL−1 X-β-Gal.
2.2. PLGA Particle Preparation
PLGA particles were prepared as described previously.[11] Briefly, 
100 mg of PLGA was solubilized in 1 mL of ethyl acetate over-
night. The PLGA solution was added dropwise to 2 mL of a 0.3% 
(w/v) DTPG solution under vigorous agitation using a vortex 
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mixer. The emulsion was sonicated (three times for 10 s) in an 
ice water bath using a probe sonicator Sonifier 250 (Branson, 
Urdorf, Switzerland). The emulsion was diluted with 45 mL of a 
0.3% (w/v) DTPG solution and stirred at 360 rpm for 3 h in order 
to fully evaporate the organic solvent. The resulting particles 
were washed three times by centrifugation using an Optima 
L-90K Ultracentrifuge (Beckman Coulter, Nyon, Switzerland) for
15 min at 17 000 × g and suspended in H2O using a sonication
bath. Particle concentration (mg mL−1) in solution was deter-
mined by lyophilization of an aliquot (500 µL) of PLGA parti-
cles in H2O. Particles were diluted to a final concentration of
2.85 mg mL−1 using H2O.
2.3. Enzyme Immobilization
Following the new developed cLbL protocol, two different 
enzymes were separately immobilized on 0.5 mL of PLGA 
(2.85 mg mL−1) particles. Subsequent layers of PAH, PSS, and GA 
crosslinked enzyme were deposited. In order to reach maximal 
enzyme adsorption, enzymes were always adsorbed onto an 
underlying layer of the opposite charged PE which was PAH in 
case of AP and PSS in case of BGal. For the particle layering with 
PEs, particles were incubated with 1 mL of 10 mg mL−1 PE (PAH 
in H2O, PSS in citrate buffer pH 4.8) for 10 min on an orbital 
shaker using 1.5 mL plastic tubes. The excess of PEs was removed 
by centrifugation for 7 min at 10 000 × g followed by a washing 
step using 1 mL of H2O or citrate buffer pH 4.8. Particles were 
resuspended by gentle sonication using a water bath sonicator 
(Sonorex; Bandelin, Berlin, Germany). For enzyme adsorption, PE 
layered PLGA particles were transferred into 4 mL glass vials and 
incubated with 1 mL of AP or BGal (5 or 20 mg mL−1, respectively) 
in citrate buffer pH 4.8 for 15 min while stirred at 800 rpm. Thus, 
PLGA particles were loaded using an excess of enzyme under 
saturating conditions in order to minimize the time needed for 
enzyme adsorption. Covalent crosslinking of enzyme to PAH was 
performed by suspending a pellet of PE and enzyme layered PLGA 
particles in 1 mL GA (2.5%, v/v) in citrate buffer pH 4.8 followed 
by the same procedure as already described for the enzyme 
immobilization step. The excess of enzyme or GA was removed 
by centrifugation followed by three washing steps using 1 mL of 
citrate buffer pH 4.8. Particles were coated with two layers of GA 
crosslinked enzyme, in order to increase the amount of immo-
bilized enzyme. As a proof of concept and to increased enzyme 
protection, PLGA particles coated with PEs and GA crosslinked 
enzyme were further coated with alternating layers of PEs. Five 
different types of cLbL particles were prepared. The composition 
of the particles is described using the following nomenclature: 
Using the model enzyme AP, PLGA PAH 2(AP GA) x(PAH PSS) par-
ticles were prepared and indicated as PLGA AP xPE, where x may 
adopt a value of 0, 1, or 2. Using BGal, corresponding particles 
were prepared, namely, PLGA PAH PSS 2(BGal GA) x(PAH PSS) and 
indicated as PLGA BGal xPE, where x may adopt a value of 0 or 1.
2.4. Characterization
Particle morphology and size were analyzed using a transmis-
sion electron microscopy (TEM) CM-100 Philips (FEI, Hillsboro, 
OR). Samples were stained on carbon coated copper grids using 
a 2% (w/v) uranyl acetate solution. Size and zeta potential of dif-
ferent PLGA enzyme particles were determined by dynamic light 
scattering (DLS) using a Delsa NanoC Particle Analyzer (Beckmann 
Coulter, Nyon, Switzerland). Size and zeta potential measurements 
of free enzymes at different pH values were carried out using a 
Zetasizer Nano ZSP and MPT-2 Multi-Purpose Titrator (Malvern, 
Herrenberg, Germany). All samples were measured in H2O.
2.5. Michaelis–Menten Enzyme Kinetics
UV/vis spectroscopy was performed using a 96 well plate reader 
Spectramax M2e (Molecular Devices, Sunnyvale, CA). All optical 
density measurements were carried out at a wavelength of 410 nm, 
using transparent 96 well plates and a sample volume of 200 µL.
Enzyme activity was determined according to Cooney.[12] 
One enzyme unit was defined as the amount of enzyme that 
hydrolyzes 1 µmol of its respective substrate per minute. All 
experiments were carried out at pH 4.8 since this represents the 
optimal working pH for both enzymes.
The Michaelis–Menten constant (Km) and the maximum 
velocity (Vmax) were determined as described in the following 
section. For AP, 50 µL of free or immobilized enzyme in citrate 
buffer pH 4.8 were incubated with 50 µL of 4-NPP in citrate 
buffer pH 4.8 with concentrations ranging from 0 to 8.5 × 10−3 m 
for 10 min at 37 °C and 700 rpm. The reaction was terminated 
by adding 100 µL of 1 m NaOH. In parallel, a blank of each 
sample was prepared by adding 50 µL of 4-NPP using the same 
concentration as mentioned above to a mixture of 50 µL free 
or immobilized enzyme in citrate buffer pH 4.8 and 100 µL 1 m 
NaOH. Samples and blanks were transferred to a 96 well plate 
and stored for 60 min at room temperature while slightly shaking 
in order to dissolve the PLGA particles. For BGal, 50 µL of free or 
immobilized enzyme in H2O were incubated with 50 µL of ONPG 
in citrate assay 2× buffer pH 4.8 with concentrations ranging 
from 0 to 22 × 10−3 m for 10 min at 30 °C and 700 rpm. The reaction 
was terminated by adding 150 µL of 1 m sodium carbonate. 
In parallel, a blank of each sample was prepared by adding 
50 µL of ONPG using the same concentration as mentioned 
above to a mixture of 50 µL free or immobilized enzyme in H2O 
and 150 µL 1 m sodium carbonate. Samples and blanks were 
centrifuged for 7 min at 10 000 × g. In order to determine Km and 
Vmax, the model was fitted to the experimental data according to 
Equation (1). We observed an unspecific formation of background 
signal during the incubations due to chemical instability of 
the BGal substrate. This unspecific signal increased linearly 
over time and was subtracted from the experimental data. 
The Michaelis–Menten enzyme kinetics formula, adjusted for 
background signal, was defined as follows
=
×
+
− ×V V SS K m SM
max (1)
where Vmax = maximal velocity [µmol min−1 unit−1], S = substrate
concentration [µm], Km = Michaelis–Menten constant [µm], and 
m = slope of unspecific background signal. Activity of enzymes 
was defined in terms of units, where one unit will hydrolyze 
1.0 µmol of substrate per min under our assay conditions. 
Apparent enzyme efficiency Ecat was defined as Vmax/KM with 
units of [min−1 unit−1].
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2.6. Stress Test and Enzyme Stability
Enzyme activity was determined as described above under dif-
ferent stress conditions. Remaining activities were calculated as 
a percentage of the initial activity from untreated enzyme sam-
ples under the same activity assay conditions. pH sensitivity was 
measured by incubation of free and immobilized enzyme under 
the indicated conditions. Prior to OD measurements, particles were 
removed from solution by centrifugation for 7 min at 10 000 × g.
Temperature stress tests were performed by incubation of 
free and immobilized enzymes at temperatures ranging from 
30 to 80 °C for 10 min. Samples were allowed to cool down to 
room temperature for another 10 min. The temperature treated 
enzyme solution was mixed with its substrate at an enzyme 
saturating concentration. To test storage stability, samples of 
free and immobilized enzymes were stored for 30 d at 4 °C in 
1.5 mL plastic tubes. Remaining activities were calculated as a 
percentage of the initial activity of freshly prepared samples.
2.7. Repeated Use
Samples of immobilized enzymes were tested regarding their 
reusability. Enzyme loaded particles where separated from the 
incubation mix by centrifugation for 7 min at 10 000 × g. The col-
lected pellet was washed with 1 mL of 0.01% Tween 20 in H2O 
(w/v) followed by another activity assay. Remaining activities 
were indicated as percentage of the first activity assay.
2.8. Toxicity
The MTT assay was used to determine cell viability upon nano-
particle incubation. This colorimetric assay monitors NAD(P)
H-dependent oxidoreductase enzyme activity of viable cells. 
The tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide is thereby reduced to a water-insoluble 
and purple colored formazan. 96 well plates were coated with 
a 0.1 mg mL−1 rat tail collagen type 1 solution prior to primary 
HUVEC seeding. HEPG2 and HUVEC cells were transferred to 
96 well plates (20 000 and 10 000 cells per well, respectively) 
and allowed to attach for 24 h prior to incubation for 24 h with 
PLGA AP PE and PLGA BGal PE particles (10 ng mL−1, 100 ng mL−1, 
10 µg mL−1, 50 µg mL−1, 100 µg mL−1, and 250 µg mL−1), 20 × 10−6 m 
terfenadine in 0.1% DMSO (positive control) or blank culture 
medium (negative control). Formazan crystals were dissolved in 
dimethyl sulfoxide and optical density was measured at 570 nm.
2.9. Zebrafish In Vivo Stability
A volume of 2 nL free BGal (5.2 units mL−1) in H2O 0.01% Tween 
20 (w/v), PLGA BGal particles (0.5 units mL−1) in H2O 0.01% 
Tween 20 (w/v), and H2O 0.01% Tween 20 (w/v) as a negative 
control were injected into blood circulation via the Duct of Cuvier 
of zebrafish embryos 2 d post fertilization in order to assess in 
vivo stability of the prepared formulation. Zebrafish embryos 
were kept in zebrafish culture media at 28 °C and bleached with 
PTU 1 d post fertilization. Prior to injection, zebrafish embryos 
were anesthetized using tricaine methanesulfonate (MS222) and 
immobilized in 0.3 % (w/v) agarose followed by injection using 
a micromanipulator (Wagner Instrumentenbau KG, Schöffen-
grund, Germany), a pneumatic Pico Pump PV830 (WPI, Sarasota, 
FL), and a Leica S8AP0 microscope (Leica, Wetzlar, Germany). 
30 min post injection, zebrafish embryos were removed from 
the agarose. They were euthanized, washed with 2 mL X-β-Gal 
wash buffer, and incubated overnight at 4 °C in 2 mL of X-β-Gal 
fixation buffer. Fixed zebrafish embryos were washed three 
times for 5 min using 2 mL X-β-Gal wash buffer followed by 
staining in 2 mL of X-β-Gal staining buffer at 37 °C for 8 h. Active 
β-galactosidase cleaves the β-glycosidic bond of 5-Brom-4-chlor-
3-indoxyl-β-d-galactoside (X-β-Gal), which results in blue precipi-
tates of the insoluble dye. Samples were analyzed using a Leica 
DM6000B microscope using a 10× magnification. Single pictures 
were combined to a composite overview picture using ImageJ 
v1.51 picture processing software (open source software). All 
animal experiments were carried out in accordance with Swiss 
legislation on animal welfare.
2.10. Statistics
Values are means of n ≥ 3 independent sets of experiments ± 
standard deviation (SD). Treatment groups were compared by 
one-way analysis of variance and Tukey’s post hoc test. Statisti-
cally significant differences (p ≤ 0.05) were marked by an asterisk. 
Used software was Origin 9.1 (OriginLab, Northampton, MA).
3. Results
Spherical PLGA microparticles were coated with layers of 
GA crosslinked enzyme and PEs. The resulting PLGA AP xPE 
particles were visualized by transmission electron micros-
copy. Uncoated PLGA particles (Figure 1A1,A2) had a reg-
ular and flat surface. The surface of these PLGA particles 
gradually changed after the addition of one enzyme layer 
and crosslinking using glutaraldehyde (Figure 1B1,B2) fol-
lowed by two layers of opposite charged polyelectrolytes 
(Figure 1C1,C2). Particles had a uniform size and mor-
phology. Enzymes and polyelectrolytes were deposited on 
the particle surface in form of clusters of plaques.
Size and size distribution of PLGA-enzyme particles 
were measured by DLS as summarized in Table 1. A 
hydrodynamic diameter of 494 ± 43 nm of a monodis-
perse particle population (polydispersity index (PDI) 
0.16 ± 0.04) was determined for uncoated PLGA particles. 
Additionally, PLGA particles were analyzed by DLS after 
storage in water at 4 °C for 11 months. No change of par-
ticle size or PDI was observed (size 492.7 nm; PDI 0.155). 
An increase in size was observed after enzyme immobi-
lization and subsequent addition of one or two layers of 
PEs. All PLGA AP PE particle preparations were monodis-
perse as shown by a PDI below 0.2. PLGA BGal PE particles 
showed a slightly increased PDI below 0.3. The change 
of zeta potential (i.e., the electrokinetic potential at the 
slipping/shear plane of a colloid particle) of PLGA parti-
cles after the application of subsequent opposite charged 
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layers via the cLbL approach is presented in Figure 2. Bare 
PLGA particles showed a zeta potential around −40 mV. 
After addition of PAH, the zeta potential was raised to 
positive values. It should be noted that differences in the 
obtained zeta potential can be attributed to differences in 
molecular weight (chain length) of PAH used for the pre-
sent studies (i.e., PAH of 15 000 g mol−1 for AP and PAH of 
17 500 g mol−1 for BGal). Based on DLS measurements at 
different pH, the apparent isoelectric point of AP and BGal 
was estimated to be in the range of pH 4.2 and 6.4 under 
our assay conditions. AP and BGal are therefore negatively 
and positively charged at pH 4.8, respectively. There-
fore, PLGA particles were layered with PAH (positively 
charged) or PSS (negatively charged), 
prior to enzyme immobilization. After 
enzyme immobilization, particles were 
coated with several layers of alternat-
ingly charged polyelectrolytes to protect 
the bound enzymes. Successful layering 
was confirmed by the change of zeta 
potentials (Figure 2).
Free and immobilized enzymes 
were analyzed regarding their kinetic 
properties, which are summarized in 
Figure 3 and Table 2. In addition to the 
standard Michaelis–Menten constants, 
an apparent enzymatic efficiency (Ecat) 
was calculated. Ecat is defined as the 
ratio between Vmax and KM. In con-
trast to all formulations containing 
BGal (Table 2D–F), where no signifi-
cant changes of kinetic properties were 
observed, formulations of AP (Table 2A–C) 
showed different values of Km, Vmax, and 
Ecat. An increased enzyme-substrate 
affinity was observed for both PLGA AP 
and PLGA AP PE as compared with free enzyme (Table 2). 
This was evident by a decreased Km value. Taking into 
account concomitant changes of Vmax, PLGA AP showed a 
1.5 fold increased apparent enzymatic efficiency Ecat.
The different enzyme formulations were tested with 
respect to temperature and pH sensitivity, storage stability, 
and reusability. Immobilized AP did not show any changes 
regarding its temperature sensitivity when compared to 
free AP (Figure 4A). In contrast, immobilization of BGal on 
PLGA particles (Figure 4B) leads to an increased sensitivity 
toward elevated temperatures. Immobilized BGal did not 
show any improved stability against lower pH compared 
to free BGal (data not shown). However, the remaining 
activity of AP formulations increased with advanced states 
of immobilization after the pH of the reaction solution was 
reduced by one log unit. Compared with their activity at pH 
4.8, the remaining activities of free AP, PLGA AP, and PLGA 
AP PE at pH 3.6 were 1.4% ± 0.1, 4.5% ± 0.2, and 13.0% ± 0.3, 
respectively. Comparing storage stability, free and immo-
bilized formulations of AP possessed a remaining activity 
of around 60% after 30 d of storage irrespective of the 
used formulation (Figure 4C). BGal formulations retained 
almost 100% of their initial activity (Figure 4D). Enzymes 
were stored for 30 d at 4 °C. Reusability of enzymes was 
determined in terms of loss of activity during the course of 
five incubation and wash cycles (Figure 4E,F). These experi-
ments were carried out with immobilized enzymes only 
since it is not possible to recover free enzyme from the 
incubation mix after the first activity determination. PLGA 
BGal particles kept around 80% of their initial activity after 
the fifth cycle of activity assays. A comparable result was 
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Figure 1. TEM analysis (negative staining) of uncoated PLGA particles (panels A1, A2), 
PLGA particles coated with acidic phosphatase (panels B1, B2), and PLGA particles coated 
with acid phosphatase and two layers of polyelectrolytes (panels C1, C2). Scale bars cor-
respond to 1 µm (panels A1–C1) and 200 nm (panels A2–C2).
Table 1. Size and polydispersity index (PDI) of different PLGA-
enzyme particles.
Enzyme Particle Size [nm] PDI
– PLGA 494.4 ± 43.2 0.156 ± 0.035
AP PLGA AP 922.6 ± 5.4 0.175 ± 0.016
AP PLGA AP PE 717.6 ± 18.5 0.172 ± 0.015
AP PLGA AP 2 PE 764.9 ± 35.0 0.143 ± 0.069
BGal PLGA BGal 635.8 ± 37.7 0.266 ± 0.017
BGal PLGA BGal PE 648.7 ± 30.1 0.241 ± 0.012
PLGA particles carrying the two different immobilized enzymes 
acid phosphatase (AP) or β-galactosidase (BGal) and the indicated 
number of layers of polyelectrolytes (PE). Particles were analyzed 
using dynamic light scattering (DLS) (n ≥ 3 experiments; values 
are means ± SD).
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obtained for PLGA AP particles, where around 65% of their 
initial activity was recovered.
To exclude a potential cellular toxicity of PLGA-enzyme 
particles, cell viability upon incubation was monitored in 
vitro using the HEPG2 and HUVEC cell lines. In Figure 5, 
the results of a 24 h 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltertrazolium bromide (MTT) reduction assay are shown 
for both HEPG2 (Figure 5A) and HUVEC (Figure 5B). Up to 
a particle concentration of 100 µg mL−1 no statistically sig-
nificant loss in cell viability could be seen. At the highest 
applied doses (250 µg mL−1) of enzyme loaded particles 
only, a significant decrease in cell viability was observed.
The in vivo activity and stability of PLGA BGal particles 
was assessed in zebrafish embryos 2 d post fertilization 
(Figure 6). Two different staining patterns, obtained due 
to enzymatic formation of dark blue precipitates in vivo, 
were observed. Injection of free BGal resulted in a diffuse, 
faint and not localized color distribution 
whereas a dotted and localized staining 
pattern was obtained by injecting PLGA 
BGal particles. Particles seemed to accu-
mulate within the posterior cardinal 
vein and the caudal vein. Zebrafish 
embryos were fixed and stained for 
BGal activity 30 min post intravenous 
injection of free or immobilized BGal 
into the Duct of Cuvier. There were no 
indications of acute toxicity (i.e., sei-
zures, denaturation of tissue fluids or 
yolk, or heart failure) upon injection of 
enzyme or enzyme-loaded particles.
4. Discussion
The aim of this work was to develop and characterize 
an enzyme immobilization protocol (the cLbL protocol), 
which can be adapted to different particulate carriers and 
enzymes. Two our knowledge, this is the first time that dif-
ferent enzymes are immobilized on the surface of particles 
by a combination of both ionic interactions and covalent 
crosslinking using the same protocol. So far, combined cou-
pling procedures were used only for industrial applications 
and coating of extended flat surfaces.[4] Our combined 
approach allowed us to immobilize enzymes by ionic 
interactions on PLGA particle surface and to subsequently 
stabilize the layered enzymes by covalent crosslinking 
under mild and nondestructive conditions. Loss of 
enzyme function (as often observed during crosslinking 
of enzymes using GA[13]) could be avoided, most probably 
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Figure 2. Alternating surface charge based on the cLbL immobilization approach of 
processed PLGA-enzyme particles. 0.15 mg mL−1 AP (panel A) or BGal (panel B) were 
immobilized on PLGA particles and further covered with the polyelectrolytes PAH and 
PSS according to the crosslinked layer-by-layer (cLbL) principle (n ≥ 3 experiments; values 
are means ± SD).
Figure 3. Enzyme kinetics of free and immobilized AP (panels A–C) and BGal (panels D–F). Michaelis–Menten enzyme kinetics of free 
AP (panel A), PLGA AP (panel B), PLGA AP PE (panel C), free BGal (panel D), PLGA BGal (panel E), and PLGA BGal PE (panel F). Solid lines: 
Fitted Michaelis–Menten kinetic model. Dotted lines: Subtracted background signal caused by unspecific conversion of educt. Values are 
means ± SD (n ≥ 3).
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due to stabilization of enzymes in their 
active conformation prior to covalent 
linking. This approach can therefore 
be considered as a good alternative to 
enzyme immobilization via encapsula-
tion, which often leads to unstable pro-
teins.[14] Furthermore, enzyme leakage 
under changing pH conditions, which is 
one of the main drawbacks of physical 
enzyme adsorption,[15,16] did not occur.
The used enzymes acid phosphatase 
(AP) and β-galactosidase (BGal) carry 
opposite electrostatic charges under 
assay conditions demonstrating that 
anionic as well as cationic proteins 
can be immobilized by simple adjust-
ment of the type and order of poly-
electrolyte layers on the particle sur-
face. Based on the isoelectric point 
and the enzymes natural working pH, 
the underlying particle can be layered 
either with an anionic or a cationic 
polyelectrolyte. Embedding the enzyme 
into polyelectrolytes provides a tridi-
mensional network, which results in 
a much stronger enzyme adsorption 
compared to enzyme adsorption onto 
flat surfaces.[9] The extend of coating 
and thus the strength of electrostatic 
interactions was monitored by meas-
uring the zeta potential of the particles. 
The usefulness and convenience of this 
analytical approach has already previ-
ously been recognized, but despite its 
importance there are very few protocols 
making use of it.[17] Adsorption of PSS 
always led to a surface charge of around 
−40 mV. PAH had a dual role: The addi-
tion of PAH to particles resulted in a
strong positive surface charge[18] and
the amino groups of PAH participated
in crosslinking. The apparent isoelectric
point of both enzymes of 4.2 and 6.4,
respectively, was estimated by pH titra-
tion experiments combined with DLS
size and zeta potential measurements
(data not shown). Based on this result,
the actual enzyme immobilization step
was performed at pH 4.8 (activity assay
condition for both enzymes) at which
AP is negatively and BGal positively
charged. The cLbL approach therefore
allowed us to immobilize enzymes at
their natural pH working conditions
Macromol. Biosci. 2017,  ,  1700015
Table 2. Michaelis–Menten kinetic parameters for free and immobilized AP and BGal.
Formulation Km  
[µm]
Vmax  
[µmol min−1 unit−1]
Ecat  
[min−1 unit−1]
Free AP (A) 442.84 ± 28.96 3.73 ± 0.10 42.22 ± 1.62
PLGA AP (B) 165.80 ± 3.48 2.22 ± 0.12 66.84 ± 3.32
PLGA AP PE (C) 269.76 ± 17.66 2.66 ± 0.29 49.16 ± 3.15
Free BGal (D) 1151.36 ± 60.92 3.08 ± 0.07 10.73 ± 0.66
PLGA BGal (E) 1255.71 ± 16.03 3.11 ± 0.23 9.90 ± 0.75
PLGA BGal PE (F) 1361.03 ± 103.55 3.16 ± 0.20 9.33 ± 0.68
Kinetic parameters are calculated based on fitted experimental data (n ≥ 3 experiments; 
values are means ± SD).
Figure 4. Stability tests of free and immobilized enzymes. Enzymatic activity of 
AP (panel A) and BGal (panel B) based formulations, which were kept for 10 min at 
the indicated temperature. Black squares: free enzyme, white circles: PLGA AP/BGal, 
asterisks: PLGA AP/BGal PE. Storage stability of free AP (panel C, black bar), PLGA AP 
(panel C, gray bar), PLGA AP PE (panel C, light gray bar), free BGal (panel D, black bar), 
PLGA BGal (panel D, gray bar), and PLGA BGal PE (panel D, light gray bar) after 30 d of 
storage at 4 °C. Reusability of PLGA AP (panel E) and PLGA BGal (panel F) as shown in 
terms of remaining activity after the indicated number of enzyme incubation and wash 
cycles. n ≥ 3 experiments; values are means ± SD.
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where their active conformation is preserved.[19] In both 
cases, a change of the surface charge of carrier particles 
after enzyme addition was observed. Whereas the immo-
bilization of AP completely changed the surface charge of 
the particle, the binding of BGal to the underlying particle 
was not sufficient to completely invert the zeta potential. 
Therefore, cationic PAH instead of anionic PSS was added 
on top of BGal in order to reach a positive zeta potential, 
which was required for addition of further PE layers.
PLGA, which is an extensively studied and Food and Drug 
Administration (FDA) approved polymer,[20,21] was used as 
the solid carrier for enzyme immobilization. PLGA parti-
cles were nonporous, monodisperse, and had a size in the 
sub-micrometer range. PLGA particle size was determined 
by DLS and TEM and a comparable diam-
eter of around 500 nm was obtained. 
PLGA particle size can be tailored from a 
few to several thousand nanometers and 
therefore be adapted to the specific pre-
requisites of a given application.[22] From 
an industrial point of view, too small 
particles are difficult to recover from the 
reaction.[9] However, too big particles 
suffer from limited mass transport due 
to their decreased Brownian motion.[23] 
For the present study, relatively small 
particles were selected since they are 
characterized by a high surface to 
volume ratio resulting in a high enzyme 
loading capacity.[24] After the layering 
of AP and PEs on PLGA particles, DLS 
and TEM showed slightly different particle sizes. This can 
be explained by the dry state of the samples analyzed by 
TEM compared with the liquid state during DLS measure-
ments. Whereas the solid PLGA particles are not influenced 
by these different states, the usually hydrated and fuzzy 
layers of strongly charged PEs[25] and enzymes dehydrate 
and therefore shrink under dry conditions.
The size of PLGA particles increased upon loading with 
enzymes. This is a consequence of particle aggregation 
due to a decrease in zeta potential from −40 mV to ≈0. 
Thus, the decrease in surface charge reduces electrostatic 
repulsion resulting in the reversible formation of particle 
aggregates.[26] After the addition of polyelectrolytes, how-
ever, the surface charge increased again leading (at least 
in the case of AP) to dismantling of aggregates.
Classic determination of kinetic parameters following the 
standard Michaelis–Menten kinetics was originally defined 
for homogenous systems (“well stirred compartments”), 
which is not necessarily applicable to nanoparticulate 
systems where phenomena such as mass diffusion limi-
tations can occur. As a consequence, calculated Km and 
Vmax values of immobilized enzymes are approximations 
and cannot be compared to the corresponding parameters 
of free enzymes. Nevertheless, due to its simplicity and 
a lack of alternatives, the Michaelis–Menten model is, if 
properly used, still the accepted way for the comparison 
of kinetic parameters.[27] To validate the used enzyme 
assays, the activity of free AP and BGal was determined. 
The measured Km values for both enzymes correspond 
to values published in literature.[28,29] Whereas kinetic 
parameters of free BGal did not change after immobiliza-
tion, an improved catalytic efficiency of immobilized AP 
was observed. After immobilization of AP on PLGA parti-
cles, the affinity (i.e., KM value) of AP toward its substrate 
4-NPP was 2.5 fold increased and its Vmax was slightly 
decreased. This resulted in an overall 1.5 fold increased 
apparent catalytic efficiency (Ecat). After covering the 
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Figure 5. Cellular viability by the MTT assay. 24 h MTT viability testing for HEPG2 (panel 
A) and HUVEC cells (panel B) incubated with different concentrations of PLGA BGal PE 
(dark gray bars) and PLGA AP PE (light gray bars). Untreated cells were used as negative 
control (white bars, 100% viability). Positive control: 20 × 10−6 m terfenadine (black bars). 
Statistically significant differences as compared to 100% control are marked with an 
asterisk (p > 0.05).
Figure 6. Enzymatic activity in vivo of PLGA BGal particles in the 
Zebrafish embryo. Free BGal (panel A) and PLGA BGal particles 
(panel B) were injected into the blood circulation of Zebrafish 
embryos via the Duct of Cuvier 2 d post fertilization. Arrows 
indicate areas of enzyme activity, which are characterized by 
formation of dark blue precipitates. Enzymatic activity was 
determined 30 min post injection.
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immobilized AP with additional layers of PEs, the affinity 
and the Vmax decreased but still remained on a higher 
level as compared to free AP. It is not uncommon to 
observe an increase in enzyme activity after immobiliza-
tion. It has been suggested that stabilization of the active 
conformation or optimized orientation and exposure of 
the substrate binding site may be beneficial.[4,27] Sub-
strate properties are another possible explanation for the 
observed changes of enzyme kinetics. 4-NPP, the substrate 
of AP, is zwitterionic and should therefore interact with 
the charged PE layer surrounding the enzyme. However, 
ONPG, the substrate of BGal, is not charged at assay con-
ditions and therefore should only marginally be affected 
by the enzyme microenvironment.
Increased or unaltered enzyme activity does not have 
to go hand in hand with improved stability against 
elevated temperatures or changed pH conditions. BGal 
showed a decreased thermal stability after immobiliza-
tion, which could be attributed to a decreased enzyme 
flexibility. This has previously been reported to be a key 
factor regarding thermal stability of enzymes.[30] In case 
of AP, an increased stability of the enzyme toward acidic 
reaction conditions was observed. It is tempting to spec-
ulate that PE act as a buffering system and thereby sta-
bilize the pH of the enzyme microenvironment.[31] Both 
immobilized enzymes were, without any loss of activity, 
stored for 30 d at 4 °C and also their reuse with minor loss 
of activity was possible over at least five cycles of activity 
assays. This finding was surprising since previous reports 
by Ratzinger et al. indicated a 75% loss of enzyme activity 
when enzymes were stored under the same conditions as 
presented in this publication.[24] This advantage of high 
storage stability combined with good reusability of our 
novel cLBL approach is of high importance, especially 
regarding industrial applications.
The toxicity of PLGA enzyme PE preparations was 
assessed in two different cell lines. Human liver cancer 
cells (HEPG2) were used in order to represent the liver as 
the main organ of metabolism and nanoparticle accumula-
tion. In order to assess nanoparticle safety upon injection, 
primary endothelial cells (HUVEC) were also incubated 
with increasing particle concentrations. No statistically 
significant effects were observed up to particle concentra-
tions of 100 µg mL−1, a dose which is accepted to represent 
physiologically relevant conditions.[10] Cell viability was 
significantly decreased only at the highest tested particle 
concentration of 250 µg mL−1. Nevertheless, the results 
indicate a weak albeit potential toxicity of the tested for-
mulations, which might be attributed to the two used poly-
electrolytes PAH and PSS[8,32] or the crosslinking agent GA.
To get a first insight into stability and activity of PLGA 
based particles in vivo, zebrafish embryos were used as 
a relatively simple and easily accessible model system. 
Different nanoparticles such as liposomes, polystyrene 
beads, or PLGA have already been successfully tested in 
this vertebrate model.[33–35] There were no visible signs of 
acute toxicity upon injection. The subsequently applied 
staining for enzyme activity resulted in two distinct 
staining pattern. A diffusive blue color was obtained for 
free BGal whereas localized and defined blue dye precipi-
tates resulted from PLGA BGal particles. We conclude that 
our particulate BGal enzyme formulation is active under 
in vivo conditions. The bright blue spots indicate that 
PLGA BGal particles remain stable and intact after injec-
tion for at least 30 min.
5. Conclusion and Outlook
During this study we developed and characterized a 
new and improved approach for enzyme immobiliza-
tion. The described cLbL method is tunable and can be 
adopted to different enzymes based on their charge at 
a desired pH. Kinetic experiments revealed differences 
with respect to the apparent catalytic efficiency of the 
immobilized enzymes as compared to their unbound 
counterparts. While this parameter was unchanged or 
even increased for the tested enzymes, an extrapolation 
to other enzymes is difficult. However, the proposed test 
strategies offer the possibility to rapidly assess the per-
formance of such systems. The present system shows a 
high stability and is therefore suited for industrial appli-
cations. In fact, stability of PLGA based particles can be 
adjusted from weeks to years depending on the ratio of 
lactic and glycolic acid.[20,36] However, future uses might 
as well include biomedical applications such as antigen 
immobilization on nanoparticulate carriers used for vac-
cination or immobilization of digestion enzymes like 
lactases or endopeptidases for the treatment of lactose 
intolerance or celiac disease.[37–39] Preliminary experi-
ments in the zebrafish embryo model indeed demon-
strate enzymatic activity in a biological environment (i.e., 
the blood circulation of a vertebrate). However, for such 
applications, the stability of the particulate carrier has 
to be reduced to ensure biotolerability. In addition, the 
used and potentially toxic crosslinking agent glutaralde-
hyde should be replaced by a biocompatible cross linking 
agent such as genipin.[40] Furthermore, the nonbiode-
gradable polymers PAH and PSS can be replaced by nat-
ural compounds such as alginates or chitosan.[41] Thus, 
the proposed cLbL protocol can be easily adopted for a 
broad range of applications.
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Chapter IV-III 
Biomimetic artificial organelles with in vitro and in vivo activity triggered by reduction in 
microenvironment 
Tomaž Einfalt, Dominik Witzigmann, Christoph Edlinger, Sandro Sieber, Roland Goers, Adrian Najer, 
Ozana Fischer, Mariana Spulber, Jörg Huwyler, Cornelia G. Palivan 
Manuscript: Nature Communications (2018) [44] 
Highlights: In the future, the use of enzyme loaded biomimetic artificial organelles (AO) as cellular 
implants could help to treat metabolic diseases caused by deficient or mutated enzymes. This study 
focused on the generation of such a polymer based AOs including a protein gate to control the access 
of substrate to the enzyme. The stimuli sensitive opening of the protein gate as well as the AO activity 
upon cell uptake were shown in vitro. After testing the AOs under static (in vitro) conditions, live 
zebrafish embryos were used to assess the enzyme’s performance under dynamic biological conditions 
including blood flow and the presence of plasma proteins. Due to its favorable optical properties, the 
zebrafish model allowed to characterize the behavior of enzyme loaded AOs in vivo in a relatively 
simple experimental set-up. This reflects an important step during the development of such 
sophisticated systems, since they are designed to be once used in patients.
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Despite tremendous efforts to develop stimuli-responsive enzyme delivery systems, their
efﬁcacy has been mostly limited to in vitro applications. Here we introduce, by using an
approach of combining biomolecules with artiﬁcial compartments, a biomimetic strategy to
create artiﬁcial organelles (AOs) as cellular implants, with endogenous stimuli-triggered
enzymatic activity. AOs are produced by inserting protein gates in the membrane of poly-
mersomes containing horseradish peroxidase enzymes selected as a model for natures own
enzymes involved in the redox homoeostasis. The inserted protein gates are engineered by
attaching molecular caps to genetically modiﬁed channel porins in order to induce redox-
responsive control of the molecular ﬂow through the membrane. AOs preserve their struc-
ture and are activated by intracellular glutathione levels in vitro. Importantly, our biomimetic
AOs are functional in vivo in zebraﬁsh embryos, which demonstrates the feasibility of using
AOs as cellular implants in living organisms. This opens new perspectives for patient-
oriented protein therapy.
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M imicking biological processes by engineering biomi-metic nanostructures represents an elegant strategyfor addressing problems in various scientiﬁc ﬁelds,
including materials science, chemistry, electronics and medi-
cine1–3. By applying a bottom-up biomimetic design (i.e.
arranging molecules at the nanoscale via self-assembly), it is
possible to combine individual biological units, known for
their sophisticated structure and activity (e.g. proteins, lipids,
DNA), with robust synthetic materials (e.g. polymers, porous
silica surfaces, nanoparticles). This serves to develop nanoscale
biomimics with enhanced properties and functionalities2,4–8
with potential for a wide range of applications (sensitive bio-
sensing, patient tailored therapeutics, detoxiﬁcation of envir-
onmental pollutants, etc.)6,9–12.
Of particular interest are two different concepts that are cur-
rently the main focus in this research ﬁeld: (i) artiﬁcial organelles
(AOs) based on an essential need to offer efﬁcient solutions for
improved therapy and diagnostics13 and (ii) protocell systems
intended to provide simple models of cells for understanding
various internal processes2,14. These concepts are complementary,
one is essential for advancing medical applications (AOs) whereas
the second concept mimics cell behaviour based on very simple
systems (protocells). Similarly, as in nature, the sizes of the
compartments are completely different: while AOs have nano-
metre range sizes, protocells reach the micrometre range. Even
though protocells represent the ﬁrst archetypes of an artiﬁcial cell,
they still inherently lack the material variety and responsiveness
found in the most basic cellular structures, and have not yet been
investigated in vivo to determine whether they preserve their
functionality. AOs are particularly attractive nanoscale biomimics
because they can provide a required compound/signal, detoxify
harmful compounds, or change cellular conditions and reactions.
AOs are based on compartmentalisation of active compounds
(enzymes, proteins, catalysts, mimics) within artiﬁcial nano-
assemblies that reach and function in the intracellular environ-
ment, and thus serve as simpliﬁed mimics of nature’s own
organelles. Various examples of systems with potential to act as
AOs have been developed based on liposomes, porous silica
nanoparticles and polymer compartments (polymersomes) in
combination with biomacromolecules13–16. However, very few
have been evaluated in vitro to assess their in situ cellular func-
tionality6,15–18, and to the best of our knowledge, none has been
assessed in vivo. In vivo functionality of such AOs is a crucial
factor that is necessary to demonstrate that the concept of AOs is
feasible in living organisms, and thus AOs can act as cellular
implants.
Notably, natural organelles have membranes, since inside cells
compartmentalisation is essential to provide conﬁned reaction
spaces for complex metabolic reactions. Therefore, an AO should
preserve the compartmentalisation as a key factor in mimicking
natural organelles. In this respect, polymer compartments, named
polymersomes, are ideal candidates for the creation of AOs,
because of their hollow spherical structure with a membrane
serving as a border for an inner cavity and their greater
mechanical stability than lipid-based compartments, i.e. lipo-
somes19,20. In addition, the chemical nature of the copolymers
provides the possibility of controlling their properties (e.g. size,
stability biocompatibility, ﬂexibility, stimuli-responsiveness)2,21.
Polymersomes have been shown to serve either as carriers for
biomolecules and mimics1,2,21,22, or more recently for develop-
ment of nanoreactors and even the generation of AOs2,6,11,23. A
key factor for supporting in situ reactions20,24 is to render the
polymersome membranes permeable for substrates and products.
An elegant approach bioinspired from the cell membrane is to
incorporate biopores and membrane proteins25–27. Selective
membrane permeability towards protons and ions is achieved by
inserting small pore forming peptides27, while membrane pro-
teins induce size-dependent cut-off permeability26,28–30 or even
mediate the diffusion of speciﬁc molecules10,31. The few reported
AOs exhibit enzymatic reactions either inside porous polymer-
somes6,16,32 or inside polymersomes equipped with channel
porins17, with the aim of emulating cellular pathways (e.g. reac-
tive oxygen species detoxiﬁcation or glucose oxidation).
Another essential factor for tuning AO functionality is a trig-
gered response to its environment, as, for example, the redox state
of the cell, which regulates various processes involved in cellular
signalling pathways33,34. While there are a few reported examples
of polymersomes with a stimuli-responsive permeable membrane
based on the incorporation of genetically or chemically modiﬁed
membrane proteins35, only two of them have served for the
design of catalytic nanocompartments36,37, and none has been
used to control reactions inside AOs. Activation of the AO by a
speciﬁc endogenous stimulus inside cells represents a challenging
step in development of functional AOs in vivo. The design of AOs
with triggered activity and the demonstration of their in vivo
functionality represent necessary steps towards the creation of cell
implants, and the provision of smart solutions for personalised
medicine by a straightforward change of the biomolecules inside
the AOs.
Here, we present a strategy for designing AOs with an in situ
enzymatic reaction that is triggered by the presence of an intra-
cellular stimulus, and demonstrate in vitro and in vivo func-
tionality. Genetically modiﬁed outer membrane protein F
(OmpF) porins were incorporated into polymersomes to induce
redox responsiveness to the membrane, and horseradish perox-
idase (HRP) simultaneously encapsulated inside their cavity to
provide a source of the AO functionality. Such AOs with func-
tionality triggered by intracellular changes represent an advance
in mimicking that of nature’s own organelles, especially those that
are involved in the redox equilibrium of the cellular homo-
eostasis. Amphiphilic block copolymers poly(2-methyloxazoline)-
block-poly(dimethylsiloxane)-block-poly(2-methyloxazoline)
(PMOXAm-PDMSn-PMOXAm) were used to self-assemble into
polymersomes, because such copolymers have already been
shown to form membranes in which biopores and membrane
proteins can be successfully inserted36–38, and to be taken up and
to be non-toxic to various cell lines17. Once inserted in the
polymersome membrane, the modiﬁed OmpF porins act as
protein gates independent of the insertion direction, i.e. orien-
tation in the membrane36,37,39,40, and trigger the in situ HRP
enzymatic reaction when a stimulus is present in the cellular
environment. HRP was selected as model enzyme, because per-
oxidases play a signiﬁcant role in the redox homoeostasis of cells
and cell apoptosis41. This strategy of providing stimuli-
responsiveness to polymersome membranes neither affects the
membrane integrity, as for stimuli-responsive synthetic mem-
branes of compartments42, nor the size and structure of the
polymersomes. Crucial steps were the evaluation of AO toxicity
and functionality in human epithelial tumour cells (HeLa cells),
and once these were established in vivo tolerability, preservation
of the AO structure, and in situ regulation of the activity of the
encapsulated enzyme in the vertebrate zebraﬁsh embryo (ZFE)
model.
Results
Bioengineering protein gates by modiﬁcation of channel por-
ins. The key factors in the design of AOs with activity triggered
by changes in environmental conditions are on-demand perme-
ability of the compartment towards enzymatic substrates/pro-
ducts and structural integrity of the polymersome, which mimics
that of natural organelles. Therefore, our biomimetic strategy
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aimed to equip PMOXA6-PDMS44-PMOXA6 polymersome
membranes with protein gates that are responsive to changes in
glutathione (GSH) concentrations in intracellular environ-
ments, while preserving the structure of the nanocompartment
(Fig. 1a).
It has been shown very recently that chemical modiﬁcations
of amino acid residues at key locations of the OmpF porin
backbone inﬂuence the translocation of substrates through the
pore in a pH-responsive manner36. Here we go one step further
by using a double mutant of OmpF37 to attach molecular caps
to genetically introduced cysteine residues that serve to block/
unblock the OmpF pore upon changes in redox potential, which
occur when the system enters the intracellular microenviron-
ment (Fig. 1b). In contrast to polymersomes with membranes
containing OmpF genetically modiﬁed to release a payload in
reductive conditions35, our system controls the overall func-
tionality of the AOs. We chose a cysteine double mutant of
OmpF (OmpF-M) because cysteine residues, replacing the
amino acids K89 and R270, were expected to form reduction-
sensitive disulphide bonds with molecules selected to serve as
molecular caps. These molecular caps remain attached in mildly
oxidising environments and block substrate diffusion through
the pore, whereas in the presence of reducing agents, such as
intracellular GSH, their cleavage restores normal passage of
small molecular weight molecules (<600 Da) through the OmpF
pores. This approach mimics pathways of metabolism regula-
tion, where proteins within the membranes of natural cell
organelles are irreversibly activated or deactivated on
demand43,44. In addition, we were interested in developing an
irreversible protein gate in order to be able to rapidly evaluate
the functionality of the organelle in vivo.
The ability of the cysteine residues of OmpF-M to form
disulphide bonds with thiol groups of small molecular weight
molecules was examined by two complementary assays, one using
a suitable spin probe (bis-(2,2,5,5-tetramethyl-3-imidazoline-1-
oxyl-4-yl) disulphide) and the second using the ﬂuorescent dye
SAMSA ﬂuorescein (SAMSA-CF) (Fig. 1c, d).
Coupling reaction of the molecular caps with the cysteine
residues of OmpF-M resulted in the formation of OmpF
conjugates (OmpF-S-S-CF for OmpF conjugated with SAMSA-
CF, and OmpF-S-S-NO for OmpF conjugated with bis-(2,2,5,5-
tetramethyl-3-imidazoline-1-oxyl-4-yl) disulphide), respectively.
Binding of the thiol reactive spin probe to the protein was
evaluated by a combination of LC-MS-MS and electron
paramagnetic resonance (EPR). Upon in-gel digestion of the
porin45, LC-MS-MS analysis of the peptide fragments indicated a
very high labelling efﬁciency of the spin probe to cysteine residues
of the OmpF-M (96 ± 4%). Standard deviation is based on three
measurements. The EPR spectrum of the bis-(2,2,5,5-tetramethyl-
3-imidazoline-1-oxyl-4-yl) disulphide in phosphate-buffered sal-
ine (PBS) at 298 K consists of an isotropic triplet pattern
(Supplementary Figure 1) with a hyperﬁne coupling aN value of
15.8 G that is similar to reported values for analogous nitroxide
probes where no aggregation was present46,47. In contrast,
OmpF-S-S-NO gave a broad anisotropic EPR spectrum with no
isotropic component, and is similar to that reported for 5-DSA in
lipid bilayers or cholesterol aqueous solutions48. This EPR
spectrum indicates hindered rotation of the nitroxide probe49
after binding to the OmpF mutant (OmpF-S-S-NO), and
demonstrates successful binding of the bis-(2,2,5,5-tetramethyl-
3-imidazoline-1-oxyl-4-yl) disulphide to the modiﬁed OmpF
mutant (Fig. 2a).
After exposure of OmpF-S-S-NO to 10 mM DTT an isotropic
EPR spectrum (aN value of 15.9 G) characteristic of the freely
rotating spin probe was observed (Fig. 2b). This clearly
demonstrates that the nitroxide spin probe that is bound to thiol
groups of the OmpF-M under oxidative conditions is cleaved in a
reductive environment.
SAMSA-CF (Thermo Fischer Scientiﬁc) was selected as a
molecular cap because its size (molecular weight 521.49 Da) was
expected to block the OmpF-M pore, and because of its ability
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Fig. 1 Engineering stimuli-responsive OmpF. a Schematic representation of modiﬁed OmpF acting as a gate in catalytic nanocompartments. b Molecular
representation of the OmpF-M cysteine mutant37. c Chemical modiﬁcation of OmpF-M cysteine mutant with the spin probe bis-(2,2,5,5-tetramethyl-3-
imidazoline-1-oxyl-4-yl) disulphide. d Chemical modiﬁcation of OmpF-M cysteine mutant with the ﬂuorophore SAMSA-CF
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to form cleavable disulphide bonds50. Thus, attachment of
SAMSA-CF to OmpF-M introduces a stimuli-responsiveness to
the pore, and therefore to the polymersome membrane when
OmpF-S-S-CF is inserted. In addition, the ﬂuorescent proper-
ties of SAMSA-CF allow pore modiﬁcation to be analysed by a
combination of sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and ﬂuorescence correlation
spectroscopy (FCS).
LC-MS-MS analysis of the peptide fragments indicated a high
labelling degree of OmpF-M (81 ± 31%). In addition, a
ﬂuorescent band appeared in the SDS-PAGE gel when
SAMSA-CF was conjugated to OmpF-M, whereas the OmpF
wild type did not interact with the ﬂuorophore; this ﬂuorescent
band supports the formation of OmpF-S-S-CF (Supplementary
Figure 2). To mimic the intracellular reductive environment,
where the GSH concentration is kept at a constantly high level
(10 mM GSH) by cytosolic enzymes51, such as glutathione
reductase, we studied the behaviour of the reduction-responsive
molecular caps in a similar environment. Because of the
absence of a steady-state concentration and constant regenera-
tion of GSH, we used 30 mM GSH to mimic the intracellular
steady state of GSH. In SDS-PAGE the ﬂuorescent band
disappeared when the OmpF-S-S-CF was mixed with GSH,
indicating successful cleavage of the molecular cap under
reductive conditions (Supplementary Figure 2).
The binding of SAMSA-CF to OmpF-M cysteine residues was
also evaluated by FCS, because it allows the determination of
diffusion coefﬁcients, which are correlated to possible interactions
of the ﬂuorescent molecules with supramolecular assemblies, such
as polymersomes, liposomes and nanoparticles in the pico- to
nanomolar concentration region9,21,47–52. We compared the
molecular brightness and diffusion times of SAMSA-CF in PBS
(pH 7.4), SAMSA-CF in 1% OG PBS (pH 7.4) and SAMSA-CF
bound to OmpF (OmpF-S-S-CF) in 1% OG PBS (pH 7.4)
(Fig. 2c). A labelling efﬁciency of an average of two SAMSA-CF
molecules per monomer was calculated by comparing the
molecular brightness (counts per molecule, CPM in kHz) of
SAMSA-CF (2.2 ± 0.7 kHz) with that of protein bound to
SAMSA-CF (4.8 ± 0.6 kHz) (Fig. 2c). Standard deviations in
molecular brightness are based on individual measurements of
the same probe (n= 60). In contrast, wild-type OmpF treated
similarly to the cysteine mutant OmpF-M, did not present any
ﬂuorescence after puriﬁcation, and there was therefore no binding
of SAMSA-CF to OmpF-WT. To determine the kinetics of OmpF
pore opening, we used FCS to evaluate the cleavage of SAMSA-
CF from labelled OmpF-M upon addition of 30 mM GSH at pH
10 mM DTT
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7.4 by FCS, and analysed the results by a two-component ﬁt. Due
to cleavage of the disulphide bonds between the dye and the
OmpF-M, the percentage of the free dye increased over time to
85 ± 9%, with a plateau after 1 h (Fig. 2d, Supplementary
Figure 3). Standard deviations in the percentage of the free dye
are based on individual measurements of the same probe (n= 60)
during a set time point.
Catalytic enzyme-polymersome nanocompartments with pro-
tein gates. The effect of different concentrations of individual
components on the functionality of the ﬁnal system has already
been reported for the insertion of OmpF wild type into
PMOXA-PDMS-PMOXA polymersomes and enzyme encap-
sulation within the inner cavity53. Here we used the optimised
conditions and adapted them for the modiﬁed OmpF and our
AOs. PMOXA6-PDMS44-PMOXA6 copolymers spontaneously
self-assembled in the presence of HRP, HRP and OmpF-S-S-
CF, or HRP and OmpF-S-S-NO, and hollow spherical com-
partments were identiﬁed by cryo-TEM (Fig. 3a, Supplementary
Figure 4). These spherical polymer assemblies were demon-
strated by light scattering to be polymersomes with: RH of 99 ±
2 nm for HRP-loaded polymersomes containing OmpF-S-S-CF,
RH of 89 ± 4 nm for polymersomes loaded with HRP and
equipped with OmpF-SH, and RH of 101 ± 1 nm for HRP-
loaded polymersomes (Supplementary Tables 1 and 2). Stan-
dard deviations were determined based on Pearson’s coefﬁcient
of the correlation function and the Guinier ﬁtted one. The
polymersome architecture was not affected by 30 mM GSH,
with structural parameters ρ (ρ= RG/RH) values in the range
0.90–0.96, which conﬁrmed a hollow sphere morphology54
(Supplementary Tables 1 and 2). HRP-loaded polymersomes,
HRP-loaded polymersomes equipped with OmpF-SH, and
HRP-loaded polymersomes equipped with OmpF-S-S-CF all
preserved their size and did not aggregate after 2 weeks storage
at 4 °C in the dark (Supplementary Figures 5–7).
Insertion of channel proteins into enzyme-loaded PMOXA6-
PDMS44-PMOXA6 polymersomes is critical for in situ activity of
the encapsulated enzyme, because the channels allow substrates
and products of the enzymatic reaction to pass through the
membrane. As OmpF is a pore protein, its functionality is
independent of its orientation inside the membrane, and the
channel porin mediates the ﬂow of molecules up to 600 Da.
We evaluated OmpF-S-S-CF and OmpF-S-S-NO insertion
into the polymersome membrane using FCS and EPR,
respectively. A diffusion time of τd= 2573 ± 960 µs was obtained
by FCS for polymersomes with reconstituted OmpF-S-S-CF,
indicating that the modiﬁed protein gates were successfully
inserted into the polymer membranes (free OmpF-S-S-CF in 1%
OG has τd= 588 ± 261 µs). Standard deviation of the diffusion
times is acquired from individual measurements (n= 60). By
comparing the molecular brightness of the free ﬂuorophore
(CPM= 2.2 ± 0.7 kHz) and the OmpF-S-S-CF equipped poly-
mersomes (CPM= 18.9 ± 11.1 kHz), it was calculated that there
were ﬁve OmpF-S-S-CF porins/polymersome; these values are
similar to those reported previously for wild-type OmpF36
(Fig. 3b).
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Fig. 3 Characterisation of stimuli-responsive catalytic nanocompartments. a Cryo-TEM micrographs of: (left) polymersomes loaded with HRP and
equipped with OmpF-SH, (middle) polymersomes loaded with HRP and equipped with OmpF-S-S-CF, and (right) polymersomes loaded with HRP without
OmpF. Scale bar= 100 nm. b Normalised FCS autocorrelation curves of SAMSA-CF in PBS (black) and OmpF-S-S-CF in the membrane of polymersomes
(blue). Dotted line= experimental autocorrelation curves, solid line= ﬁtted curve. Curves normalised to 1 to facilitate comparison. c Left panel: EPR
spectrum of bis-(2,2,5,5-tetramethyl-3-imidazoline-1-oxyl-4-yl) disulphide-labelled OmpF reconstituted in PMOXA-PDMS-PMOXA polymersomes (black
line). c Right panel: bis-(2,2,5,5-tetramethyl-3-imidazoline-1-oxyl-4-yl) disulphide-labelled OmpF reconstituted in PMOXA-PDMS-PMOXA polymersomes
and incubated with 10 mM DTT experimental (black line) and simulated (blue line). d Amplex Ultra Red conversion of HRP-loaded polymersomes:
immediately after addition of 30mM GSH (left), and 1 h after addition of 30mM GSH (right). OmpF-S-S-CF equipped HRP-loaded polymersomes (green)
and OmpF-SH equipped HRP-loaded polymersomes (blue). Error bars present standard deviations in activity between three separately prepared catalytic
nanocompartments (n= 3)
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HRP-loaded polymersomes containing OmpF-S-S-NO pro-
duced a broad EPR spectrum (Fig. 3c), indicative of low mobility,
a result similar to that reported for 5-DSA and 16-DSA inserted
in polymersomes membranes55. However, when these HRP-
loaded polymersomes containing OmpF-S-S-NO were exposed to
reductive conditions (10 mM DTT), an isotropic EPR spectrum
(aN= 15.9 G) was observed superimposed on the broad peak,
indicating successful cleavage of some of the nitroxide spin probe
from the OmpF (Fig. 3c).
Stimuli-responsiveness of the catalytic nanocompartments. The
effect of an external stimulus on the functionality of the HRP-
loaded polymersomes equipped with OmpF-S-S-CF was eval-
uated by their response to the addition of 30 mM GSH. The
ﬂuorescent signal associated with formation of a resoruﬁn-like
product (RLP) during the in situ enzymatic reaction in the pre-
sence of Amplex Ultra Red (AR) as a substrate for HRP was
measured spectroscopically56. Enzymatic turnover of the AR
substrate was signiﬁcantly lower with HRP-loaded polymersomes
equipped with OmpF-S-S-CF (by up to 36±4%) compared to
HRP-loaded polymersomes equipped with OmpF-SH, suggesting
that the molecular cap is sufﬁcient to reduce the passage of small
molecules through the pore. Note that the very low activity of
HRP-loaded polymersomes without inserted OmpF was taken
into account for background correction. Standard deviation is
based on three measurements of separately prepared catalytic
nanocompartments. Addition of 30 mM GSH to the system
increased the activity of HRP-loaded polymersomes equipped
with OmpF-S-S-CF up to that of HRP-loaded polymersomes
equipped with OmpF-SH. This indicates that reduction of the
disulphide bridge between the attached SAMSA-CF cap and
cysteine residues of the OmpF-M successfully restored the
OmpF-M pore permeability for the substrate of the enzyme by
releasing the molecular cap (Fig. 3d, Supplementary Figures 8
and 9).
Nanocompartments as stimuli-responsive AOs. Here we have
gone a step further by developing stimulus-triggered AOs, whose
functionality is modulated by the responsiveness of modiﬁed
OmpF porins inserted in the membrane of the catalytic nano-
compartments. Previously designed AOs successfully overcame
the ﬁrst barrier of cell membranes and escaped from endo-
somes17. As PMOXA-PDMS-PMOXA polymersomes are stable
at acidic pH27,36, we consider that this will favour a successful
lysosomal/endosomal escape during the recycling of lysosomes
and endosomes.
Possible internalisation mechanisms of various PMOXA-PDMS-
PMOXA-based polymersomes and their high cytocompatibility in
various cell lines have already been reported17,57–59. Here, we
evaluated the cytocompatibility of the biomimetic AOs by testing
their cellular toxicity using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS)
assay before studying their intracellular activation and enzymatic
activity. Notably, their biocompatibility at the cellular level was
shown by the absence of any decrease in viability in HeLa cells even
after 48 h (i.e. polymer concentration ranging from 0.25 to 0.75mg
ml−1) (Supplementary Figure 10).
In order to study cellular internalisation and intracellular
localisation, we ﬁrst conjugated HRP with Atto488 (HRP-
Atto488) and Atto647 (HRP-Atto647), respectively (Supplemen-
tary Figure 11). Then we encapsulated labelled-HRP inside the
cavity of polymersomes, polymersomes equipped with OmpF-S-
S-CF, and polymersomes equipped with OmpF-SH. Cellular
uptake assays in HeLa cells indicated successful internalisation
resulting in a particulate intracellular staining pattern with
increasing intensity in a time-dependent manner from 8 to 24 h
(Fig. 4a, Supplementary Figures 12 and 13). The quantitative
analysis indicates that after 24 h AOs did not co-localise with
early endosomes or lysosomes, conﬁrming successful intracellular
endosomal escape (Supplementary Figure 14)17. Localised HRP-
Atto488 signals conﬁrmed the intracellular integrity of the
polymersomes. In sharp contrast, if cells were treated with a
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membrane disrupting agent (i.e. 0.1% saponin) (Supplementary
Figure 15), polymersome membranes were affected and resulted
in an intracellular cytoplasmic distribution of HRP-Atto488.
The capacity of the AOs to act within target cells in a stimuli-
responsive manner was investigated by using a combination of
confocal laser scanning microscopy (CLSM) and ﬂow cytometry
to evaluate their potential to respond to increased intracellular
GSH levels. HeLa cells were incubated with HRP-loaded
polymersomes without OmpF or with HRP-loaded polymer-
somes equipped with either OmpF-S-S-CF (AOs) or with
OmpF-SH. Extracellular polymersomes were removed by
washing before imaging the intracellular activity of AOs. Cells
were incubated with a 1:1 substrate mixture of H2O2 and AR to
allow the intracellular deposition, and ﬁnally conversion of AR
into its RLP by AOs. Note that both hydrogen peroxide and AR
pass through the cellular membrane via passive partitioning,
while they do not penetrate the membrane of polymersomes
(Supplementary Figure 9). In contrast to untreated cells, or
those incubated with HRP-loaded polymersomes without
OmpF, a signiﬁcant increase of intracellular ﬂuorescence was
observed with AOs equipped with OmpF-S-S-CF or OmpF-SH
(Fig. 4b, Supplementary Figure 16). A similar trend was
observed when AR turnover was quantiﬁed by ﬂow cytometry
(Supplementary Figure 17). The strong ﬂuorescent signal for
AOs based on HRP-loaded polymersomes equipped with
OmpF-S-S-CF conﬁrmed successful intracellular cleavage of
the molecular cap attached to OmpF-M, and subsequent
activation of the AOs within the intracellular environment of
the HeLa cells (Supplementary Figure 17).
In vivo activity of stimuli-responsive AOs. As a step further to
obtaining insight into their safety, tolerability and performance
in vivo, AOs were studied in a ZFE model. ZFEs were selected,
because of their recognition as a complementary vertebrate
animal model for applications, such as compound screening in
drug discovery, toxicological studies and recombinant disease
models60–62. Compared to rodent in vivo models, the ZFE
offers unique advantages: (i) high reproducibility, (ii) low costs,
(iii) high level of genetic homology to humans, (iv) availability
of transgenic lines and (v) most importantly for the evaluation
of AO, optical transparency. Due to their optical transparency,
ZFE provide the possibility of imaging ﬂuorescently-tagged
objects and ﬂuorescent processes in vivo at a high resolution
over time63 (Supplementary Figure 18). Our approach offers
the possibility of gaining detailed insight into the circulation
behaviour of AOs and subsequent enzymatic reactions as we
reported recently for nano-particulate drug delivery systems
in vivo64. In order to follow the biodistribution of AOs, we
injected intravenously via the duct of Cuvier HRP-Atto488-
loaded polymersomes with membranes equipped with OmpF-
S-S-CF or with OmpF-SH, respectively. No acute toxicity, such
as change in behaviour i.e. mobility, seizures, heart failure or
other toxic effects such as malformations, denaturation of tissue
ﬂuids or yolk mass was observed in ZFE injected with AOs after
24 h. ZFE analysed 2 h post intravenous injection of all types of
AOs containing Atto488 conjugated HRP showed a distinct
ﬂuorescent staining pattern (Supplementary Figure 19) in the
posterior cardinal vein region, and we hypothesise that poly-
mersomes are recognised by the ZFE early immune system and
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are subsequently taken up by macrophages65. The remarkable
recognition of polymersome-based AOs by the ZFE immune
system was conﬁrmed by the colocalisation of AOs loaded with
Atto647-conjugated HRP (Atto647-HRP) injected into trans-
genic ZFE speciﬁcally expressing eGFP in macrophages (Fig. 5a,
Supplementary Figure 20). In strong contrast to AOs loaded
with Atto647-HRP, the free Atto647-HRP enzyme did not show
signiﬁcant macrophage colocalisation after 24 h, even when
Atto647-HRP was injected at concentrations of 0.2 mg ml−1
(Supplementary Figure 21). Notably, only macrophages in cir-
culation were targeted and not tissue resident macrophages (i.e.
star shaped).
Once cellular internalisation of AOs by the early immune
system of ZFE was successful in vivo, we explored the uptake
rate, exact intracellular localisation and internalisation mechan-
isms of AOs in immune cells in vitro by using human
macrophage differentiated THP-1 cells. AOs internalisation
started as early as 30 min, and a strong internalisation by
immune cells was achieved after 3 h (Supplementary Figure 22),
with increasing uptake rates at higher time points. As THP-1
cells are immature macrophages with reduced phagocytotic
capacity, a higher uptake rate of AOs is possible for mature
(primary) macrophages in vitro and in vivo.66 Importantly, all
macrophage uptake studies were performed in the presence of
serum proteins to mimic physiological conditions in vivo
because opsonisation of nanoparticles by serum proteins can
highly inﬂuence their interaction with cells.67 To obtain a
mechanistic understanding of the internalisation process, THP-
1 macrophages were pre-treated with different pharmacological
pathway inhibitors.67 We used inhibitors with speciﬁc inhibi-
tion proﬁles: (i) polyinosinic acid to block scavenger receptors,
(ii) colchicine to inhibit pinocytosis, (iii) cytochalasin B as
phagocytosis inhibitor and (iv) sodium azide to inhibit all
energy-dependent uptake processes. Cells not incubated with
Atto488 HRP-loaded AOs served as a control. A 1.28-fold
increase in the mean ﬂuorescence intensity (MFI) was observed
by ﬂow cytometry analysis of the cells incubated with Atto488
HRP-loaded AOs for 6 h, which indicates internalisation of
AOs by THP-1 macrophages. The uptake of AOs by macro-
phages was signiﬁcantly inhibited by cytochalasin B (a 0.13-fold
increase in MFI) and in a lower degree by sodium azide (0.43-
fold increase in MFI), which indicates an energy-dependent
phagocytotic internalisation process (Fig. 5b, c). On the
contrary, polyinosinic acid did not inhibit the AOs uptake,
suggesting little or no involvement of the scavenger receptor in
the internalisation mechanism of AOs (Fig. 5c).
The internalisation process analysed by CLSM using Lyso-
Tracker™ Red DND-99 as a reporter for the lysosomal compart-
ments indicates that AOs co-localise with lysosomal
compartments during their internalisation process (Supplemen-
tary Figure 23). Interestingly, we could not detect a lysosome
signal (lysotracker) 24 h after incubation of macrophages with
AOs, suggesting the presence of an intracellular lysosomal escape
mechanism once the AOs are taken-up by macrophages
(Supplementary Figure 23). After internalisation in macrophages,
the signals associated with Atto488-HRP-loaded AOs in lysoso-
mal compartments changed to larger intracellular vesicular
signals. This suggests an expansion of the AO-bearing lysosomal
compartments before the AOs are released into the cytosol. For
an exact mechanism by which AOs escape the lysosomal
compartment and interact with cellular membranes, further
investigations are planned but they are beyond the scope of this
study.
In order to assess in vivo stability, integrity and functionality of
AOs when exposed to the conditions in the macrophage
microenvironment, we performed a second injection of AOs
together with the enzyme substrate AR. Injection of the co-
substrate H2O2 in combination with AR was not necessary, since
macrophages have the ability to produce H2O2. In addition, co-
injection of H2O2 resulted in a red colouring of the whole blood
volume, presumably due to haemolysis and thus interaction of
AR with erythrocyte enzymes or haemoglobin66 (Supplementary
Figure 24). Distinct colocalisation within macrophages of the
converted AR oxidation product was found only for HRP-
Atto488-loaded AOs equipped with either OmpF-SH or OmpF-S-
S-CF: the molecular cap of OmpF-S-S-CF was cleaved in vivo
leading to activation of the AOs. In sharp contrast, HRP-Atto488-
loaded polymersomes without OmpF remained inactive, demon-
strating that the polymersome membrane is sufﬁciently robust to
remain intact in ZFE macrophages (Fig. 5d).
Discussion
Design and development of AOs able to function inside cells and
support the natural organelles is a necessary step towards the
creation of cellular implants. Complementary as a concept to that
of protocells, AOs respond to an essential need to offer efﬁcient
solutions for improved therapeutic and diagnostic options. Pre-
viously reported examples of AOs were based on conﬁned spaces
for reactions by compartmentalisation of enzymes inside nanos-
cale assemblies, but were not able to function in a stimuli-
responsive manner. Here, we introduce a strategy to develop AOs
with functionality that can be switched on by changes in the
cellular microenvironment. These stimuli-responsive AOs are
created by simultaneous encapsulation of an enzyme involved in
the cellular redox homoeostasis and insertion of a genetically
engineered channel porin to serve as a protein gate that triggers
the enzymatic activity inside AOs.
Our AOs preserved their architecture and were activated after
reaching the cellular microenvironment. More exciting, they are
functional in a vertebrate ZFE model, which proves that the
concept of AOs as cellular implants is feasible in vivo. Further-
more, stability, biocompatibility and low toxicity of AOs repre-
sent real advantages for medical applications compared to
existing solutions for enzyme replacement, such as direct enzyme
delivery and transfection67.
We believe that in the future, the high versatility of our strategy
will allow straightforward development of a large variety of AOs
for speciﬁc medical applications by changing the encapsulated
enzymes and/or of the stimuli-responsive property of the protein
gates. However, a careful selection of substrates is required to
overcome the limited ability to transit through the plasma
membrane of speciﬁc substrates, which are commonly used in
bulk enzymatic reactions.
This example of AOs activated by changes in cellular micro-
environment and that remains functional in vivo, opens the
perspective of complex in situ reactions inside AOs, and repre-
sents an important advance towards the generation of multi-
functional systems that will support the development of
personalised medicine.
Methods
OmpF expression and extraction. The OmpF K89 R270 cysteine mutant and the
OmpF wild type were expressed in BL21 (DE3) Omp8 Escherichia coli cells;
detailed procedure is described in Supplementary Methods.42 The extracted frac-
tion was analysed by a 4–15% Mini-PROTEAN® TGX™ Precast SDS (Bio-Rad
Laboratories, USA) gel to conﬁrm the protein purity and the protein concentration
was determined using a BCA assay kit (Pierce Chemical Co, Rockford, USA).
OmpF was stored at 4 °C in 3% OG at a concentration of 1.2 mgml−1 for several
weeks.
OmpF modiﬁcation with SAMSA ﬂuorescein (OmpF-S-S-CF). The OmpF K89
R270 double cysteine mutant was modiﬁed by disulphide binding of SAMSA
ﬂuorescein to the free cysteine residues. The same reaction was also performed in
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the presence of OmpF wild type in 3% octyl-glucopyranoside (OG) (Anatrace,
USA) and 3% OG in order to serve as controls. Twenty microlitres of 959 µM
SAMSA-CF (5-((2-(and-3)-S-(acetylmercapto) succinoyl) amino) ﬂuorescein)
(Thermo Fischer Scientiﬁc) dissolved in 5% DMSO, 1% OG in PBS buffer was
added to 400 µl of 0.4 mg ml−1 OmpF. The mixture was shaken in dark conditions
for 30 min, when deprotection of SAMSA-CF was initiated by adjusting the pH of
the solution to 8.5 with 0.5 M NaOH. The reaction mixture was incubated and
shaken in the absence of light for 24 h at room temperature, after which another 5
µl of 959 µM SAMA ﬂuorescein was added. Twenty-four hours after the second
addition of SAMSA ﬂuorescein the protein was puriﬁed from the reaction mixture
by washing 25 times with 1% OG in PBS pH 7.4 in Amicon Ultra-0.5 ml centrifugal
ﬁlters for protein puriﬁcation and concentration, molecular cut-off: 30 kDA
(Millipore) (10 min at 13,000 RPM). The volume was adjusted to 475 µl with PBS
pH 7.4, and the protein concentration was determined by UV-Vis spectroscopy.
Forty microlitres of the puriﬁed protein fraction was taken for FCS analysis and
SDS gel electrophoresis. The volume was adjusted to 500 µl and the protein was
dialysed against 1 l of 0.05 % OG in PBS for 16 h and twice against PBS for 2 h
using 14 kDa Membra-CelTM (Carl Roth, Germany) dialysis membranes. The
protein concentration was veriﬁed by UV-VIS (A280) (Thermo Fischer Scientiﬁc,
Switzerland).
OmpF modiﬁcation with (bis-(2,2,5,5-tetramethyl-3-imidazoline-1-oxyl-4-yl)
disulphide) (OmpF-S-S-NO*). The OmpF K89 R270 double cysteine mutant was
modiﬁed by disulphide binding of (bis-(2,2,5,5-tetramethyl-3-imidazoline-1-oxyl-
4-yl) disulphide) (Noxygen, Germany) to the free cysteine residues. The same
reaction was also done in presence of OmpF wild type in 3% OG PBS and 3% OG
PBS in order to serve as controls for unspeciﬁc binding of (bis-(2,2,5,5-tetramethyl-
3-imidazoline-1-oxyl-4-yl) disulphide) to wild-type OmpF and unspeciﬁc inter-
actions with OG micelles. Twenty microlitres of dissolved (bis-(2,2,5,5-tetramethyl-
3-imidazoline-1-oxyl-4-yl) disulphide) (1.4 mM) in 4% DMSO, 1% OG in PBS
buffer were added to 400 µl of 0.4 mg ml−1 OmpF and mixed. The reaction was
performed as described above for OmpF-S-S-CF. Twenty-four hours after the
second addition of (bis-(2,2,5,5-tetramethyl-3-imidazoline-1-oxyl-4-yl) disulphide)
the conjugated protein was puriﬁed from the reaction mixture by washing it 25
times with 1% OG in PBS at pH 7.4 using Amicon Ultra-0.5 ml centrifugal ﬁlters
for protein puriﬁcation and concentration; molecular cut-off: 30kDA (Millipore).
The volume was adjusted to 475 µl using PBS at pH 7.4, and the protein con-
centration was determined by UV-Vis spectroscopy. Forty microlitres of the pur-
iﬁed protein fraction was taken for EPR analysis. The volume was adjusted to 500
µl and the protein dialysed against 1 l of 0.05 % OG in PBS for 16 h and twice
against PBS for 2 h using 14 kDa Membra-CelTM (Carl Roth, Germany) dialysis
membranes. The protein concentration was veriﬁed by UV–VIS (A280) (Thermo
Fischer Scientiﬁc, Switzerland).
Characterisation of SAMSA ﬂuorescein conjugated OmpF. A 4–15% Mini-
PROTEAN® TGX™ Precast SDS (Bio-Rad Laboratories, USA) gel polyacrylamide
gel was used, then samples were mixed with BN-PAGE loading buffer and 15 µl of
the ﬁnal OmpF solution was added to the gel. To show the effect of GSH, separate
probes were incubated with the loading buffer supplemented with 30 mM GSH.
The gels were run at 200 V for 45 min. (Supplementary Figure 2), and scanned
unstained and stained with Coomasie blue.
Fluorescence correlation spectroscopy. All FCS measurements were performed
using a Zeiss LSM 510-META/Confocor2 (Carl Zeiss, Jena, Germany) with an
argon laser (488 nm), and ×40 water immersion C-Apochromat Objective lens.
Measurements were performed at room temperature using a sample volume of 20
µl on a covered Lab-Tek Nunc® Lab-Tek® II chambered cover glass (Nalage Nunc
International). Measurements were recorded over 3 s, and each measurement was
repeated 60 times. The structural parameter and the diffusion time of the free dye
in PBS pH 7.4 (SAMSA-CF) were determined independently. The autocorrelation
function was calculated using a software correlator, and ﬁtted with a one com-
ponent ﬁt (LSM 510 META-ConfoCor2 System). Detailed description of the FCS
measurements and calculations are described in the Supplementary Methods.
Preparation of reduction-triggered catalytic polymersomes. To produce
reduction-triggered catalytic PMOXA-b-PDMS-b-PMOXA nanocompartments,
triblock copolymer ﬁlms with different subsets of Outer membrane protein F
(OmpF) were rehydrated with HRP. The detailed preparation technique and
control experiments are described in the Supplementary Methods.
Characterisation of catalytic nanocompartments. The size and morphology of
the stimuli-responsive catalytic nanocompartments were characterised by a com-
bination of light scattering (SLS, DLS) and cryogenic transmission electron
microscopy (Cryo-TEM). Detailed procedures are described in detail in the Sup-
plementary Methods.
Enzymatic assay. The emission ﬂuorescence intensity was determined using a LS
55 Fluorescence Spectrometer (Perkin Elmer). Samples were incubated with a ﬁnal
concentration of 30 mM GSH in PBS at pH 7.4, and the pH was kept at this value.
For the measurement, 10 µl of the samples mixed with GSH were transferred to
220 µl of the reaction mixture (4.5 µM H2O2 and 3.4 µM AR) in PBS at pH 7.4. The
reaction mixture was excited at 530 nm and the emission intensity was monitored
at 590 nm. Fluorescence was expressed as relative ﬂuorescence units and was
measured at the same instrument setting in all experiments. The detailed procedure
is described in the Supplementary Methods.
Cell toxicity assay. The [3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulphophenyl)-2H-tetrazolium (MTS) assay (Promega) was used to determine
cell viability. HeLa cells were seeded in a triplicate at a density of 2.5 × 103 cells per
well in a 96-well plate. Cells were cultured for 24 h in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) growth medium (supplemented with 10% foetal calf serum,
penicillin (100 units ml−1) and streptomycin (100 µg ml−1)). After 24 h, the
medium 100 μl aliquots containing the corresponding concentration of samples
[0.25, 0.5 and 0.75 mgml−1] were added to the cell medium. Cells incubated only
in medium served as control (100%). After 24 h of incubation 20 µl of MTS
solution was added to each well. The plates were incubated for 1 h at 37 °C, and
absorption was measured at λ= 490 nm. The quantity of formazan product as
measured by absorbance at 490 nm is directly proportional to the number of living
cells in the culture. Absorption of cells where no nanoparticles were added served
as 100%.
24 h uptake of catalytic nanocompartments. HeLa (epitheloid cervix carcinoma,
human; ATCC, CCL-2) cells were cultured at a density of 3 × 104 cells per well in
an eight-well Lab-Tek (NalgeNunc International, USA) for 24 h in DMEM growth
medium supplemented with 10% foetal calf serum, penicillin (100 units ml−1) and
streptomycin (100 µg ml−1) to allow attachment to the surface. After attachment,
the medium was removed and catalytic nanocompartments were added to a ﬁnal
polymer concentration of 0.5 mg ml−1. Cells were washed twice before being
imaged at the respective time points.
Flow cytometry analysis of AO activity. HeLa (epitheloid cervix carcinoma,
human; ATCC, CCL-2) cells were seeded in a well of a 24-well plate (8 × 104 cells
per well) and cultured in DMEM containing 10% foetal calf serum, penicillin (100
units ml−1) and streptomycin (100 µg ml−1)) for 24 h at 37 °C in a humidiﬁed CO2
incubator. Then the medium was exchanged and polymersome solution was added
to a ﬁnal concentration of 0.5 mg ml−1 for another 24 h. Cells were washed three
times with PBS, trypsinised, centrifuged, washed, centrifuged and then suspended
in 1 ml PBS. AR/H2O2 was added to a ﬁnal concentration of 10 µM, and after 2 h,
ﬂow cytometry analysis was performed using a BD FACSCanto II ﬂow cytometer
(BD Bioscience, USA). Doublets were excluded using FSC and SSC detectors, single
cells were excited at 561 nm and the emission was detected in FL5 (586/15;
Resoruﬁn Channel). A total of 10,000 single cells for each sample were analysed,
and data processed using Flow Jo VX software (TreeStar, Ashland, OR).
Intracellular stability of AO. HeLa (epitheloid cervix carcinoma, human; ATCC,
CCL-2) cells were seeded at a density of 3 × 104 cells ml−1 onto poly-D-lysine-
coated glass coverslips. Cells were cultured for 24 h in DMEM growth medium
(supplemented with 10% foetal calf serum, penicillin (100 units ml−1) and strep-
tomycin (100 µg ml−1)). After attachment to the surface, the medium was removed
and catalytic nanocompartments were added to a ﬁnal polymer concentration of
0.5 mg ml−1. Cells were incubated for an additional 24 h in the medium, then
washed three times with PBS and ﬁxed with 4% PFA for 15 min. After a neu-
tralisation step using 50 mM NH4Cl, cells were either treated with PBS (control) or
0.1% saponin for 10 min at room temperature. After additional washing steps, cell
nuclei were counterstained for 10 min using Hoechst 33342 (0.5 µg ml−1). Finally
cells were embedded in Vectashield antifade mounting media. CLSM was per-
formed using an Olympus FV‑1000 inverted microscope (Olympus Ltd, Tokyo,
Japan) equipped with a ×60 UPlanFL N oil‑immersion objective (numerical
aperture 1.40). Cells were excited at 405 nm (Hoechst 33342) and 488 nm
(Atto488-HRP), and the ﬂuorescence signal was collected using Kalman modus
between 425 and 475 nm and 500 and 600 nm, respectively. To minimise spectral
cross talk, the samples were scanned using sequential mode. The laser settings were
adjusted depending on the treatment. Images were processed using the Fiji open
source image processing package of ImageJ.
Intracellular localisation of AO. HeLa (epitheloid cervix carcinoma, human;
ATCC, CCL-2) cells were seeded at a density of 3 × 104 cells per well onto poly-D-
lysine-coated glass coverslips. Cells were cultured for 24 h in DMEM growth
medium (supplemented with 10% foetal calf serum, penicillin (100 units ml−1) and
streptomycin (100 µg ml−1)) to allow attachment to the surface. After attachment,
the medium was removed and catalytic nanocompartments were added to a ﬁnal
polymer concentration of 0.5 mg ml−1. After 24 h cells were washed three times
with PBS and then ﬁxed for 15 min using 4% PFA. After a neutralisation step using
50 mM NH4Cl, cells were incubated with either rabbit polyclonal anti-EEA1
(ab2900, Abcam) (1:1000) or anti-LAMP1 (ab24170, Abcam) antibody (1:1000) for
early endosome or lysosome staining, respectively58. The cells were washed with
PBS, followed by staining with the secondary goat anti-rabbit polyclonal
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Dylight633-labelled antibody (1:1000; #35562, Thermo Fisher Scientiﬁc). Cell
nuclei were counterstained for 10 min using Hoechst 33342 (0.5 µg ml−1). Finally,
cells were embedded in Vectashield antifade mounting media. CLSM was per-
formed using an Olympus FV‑1000 inverted microscope described above. Z-stacks
were taken using Kalman modus and a step size of 450 nm. Cells were excited at
405 nm (Hoechst 33342), 488 nm (Atto488-HRP), and 633 nm (Early Endosome/
Lysosome). The ﬂuorescence signal was collected between 425 and 475, 500 and
600, and 655 and 755 nm, respectively, by scanning in the sequential mode, and
processed as described above.
Colocalisation of polymersomes with markers of early endosome (EEA1) or
lysosome (LAMP1) were carried out using the JaCoP plug-in in the Fiji software.
Pearson’s correlation coefﬁcient (PCC), Mander’s coefﬁcients (M1/M2, using
thresholds of A= 200 and B= 180), and Costes’ randomisation-based
colocalisation (200 randomisation rounds) were used to assess the extent of
colocalisation.
In cellulo activity of AOs by CLSM. HeLa cells (epitheloid cervix carcinoma,
human; ATCC, CCL-2) were cultured at a density of 3 × 104 cells per well in an
eight-well Lab-Tek (NalgeNunc International, USA) for 24 h in DMEM growth
medium (supplemented with 10% foetal calf serum, penicillin (100 units ml−1)
and streptomycin (100 µg ml−1) to allow attachment to the surface. After
attachment, the medium was removed and catalytic nanocompartments were
added to a ﬁnal polymer concentration of 0.25 mg ml−1. Cells were then incu-
bated for an additional 24 h in medium, washed twice with PBS and AR/H2O2
added in the ratio of 1:1 to a ﬁnal concentration of 10 µM in DMEM-based
growth medium. After 30 min, cells were washed three times with PBS and their
nuclei counterstained for 10 min using Hoechst 33342 (0.5 µg ml−1). Cells were
washed twice with D-PBS and cultured in DMEM. CellMask Deep Red Plasma
membrane stain (0.5 µl ml−1) was added and cells were analysed after 5 min.
CLSM was performed as described in the previous section. The laser settings for
RLP, the photomultiplier tube gain and the pinhole settings were kept constant
during the analysis. Images were processed using Olympus FluoView software
(v3.1, Olympus).
In vivo activity of AOs. Standard ZFE culture medium at pH 7.4 was prepared at
ﬁnal concentrations of 5 mM sodium chloride, 0.25 mM potassium chloride, 0.5
mM magnesium sulphate, 0.15 mM potassium dihydrogen phosphate, 0.05 mM
sodium phosphate dibasic, 0.5 mM calcium chloride, 0.71 mM sodium bicarbonate
and 0.001% (w/v) methylene blue.
Collected eggs from adult ABC/TU ZFE (wild type) and EGFPs843 ZFE (GFP-
macrophage line) were kept in ZFE culture medium at 28 °C. PTU (0.03 mgml−1)
was added 1-day post fertilisation (dpf) in order to avoid pigment cell formation.
Three different enzyme-loaded polymersomes were injected into 2-dpf ZFE
according to an adapted protocol originally designed for microangiography. ZFE
were anaesthetised using 0.01% tricaine (w/v) and cast into 0.3% (w/v) agarose
containing the same amount of tricaine. Immobilised ZFE were injected with either
with 3 nl of 0.2 mg ml−1 free HRP or 3 nl AO solution (5 mgml−1), removed from
the agarose and kept in ZFE culture medium containing PTU for 24 h. Then, a
second injection of 1 nl AR (78 µM) was performed following the same procedure.
As control experiments, ZFE were injected with the enzymatic substrate AR and
AR mixed with H2O2 without previous AO injection. Fluorescence imaging of
injected ZFE was performed using an Olympus FV1000 confocal microscope
(Olympus Schweiz AG, Volketswil, Switzerland). ZFE were excited at 488 nm
(Atto488 HRP), 559 nm (Melanocytes) and 635 nm (Resazurin-like product) and
the ﬂuorescence signal was collected between 500 and 530, 575 and 620, and 655
and 755 nm, respectively.
Monocyte cell culture and differentiation to macrophages. THP-1 cells (ATCC,
TIB 202) were cultured at a starting density of 2 × 105 cells ml−1 in Roswell Park
Memorial Institute (RPMI-1640) medium containing 10% FCS, penicillin (100
units ml−1)/streptomycin (100 µg ml−1), 10 mM HEPES, 1% sodium pyruvate and
0.05 mM mercaptoethanol. For uptake studies, THP-1 cells were seeded at a
density of 5.5 × 104 cells per well onto poly-D-lysine-coated Ibidi 8-Well µ-Slides or
2 × 105 cells per ml into a 12-well plate (TPP, Switzerland) for CLSM or ﬂow
cytometry, respectively. Differentiation of human monocytic cell line THP-1 to
macrophages was induced 24 h after seeding using 200 nM phorbol 12-myristate
13-acetate for 72 h.
Uptake study using pathway inhibitors. The uptake mechanism of Atto488-
HRP-loaded polymersomes equipped with OmpF-S-S-CF into THP-1 macro-
phages was investigated using different pharmacological pathway inhibitors67. Cells
were pre-incubated using 10 µg ml−1 cytochalasin B (phagocytosis) for 2 h, 0.1%
sodium azide (energy-dependent uptake process) for 30 min, 100 µg ml−1 colchi-
cine (pinocytosis) for 2 h and 2.5 µg ml−1 polyinosinic acid (scavenger receptor) for
30 min, and then treated with Atto488-HRP-loaded polymersomes.
Qualitative uptake of AOs observed by CLSM. Macrophage differentiated THP-
1 cells were incubated with Atto488-HRP-loaded polymersomes equipped with
OmpF-S-S-CF at a ﬁnal polymer concentration of 0.25 mgml−1 for speciﬁc time
points as indicated. LysoTracker Red DND-99 (Invitrogen) was added to cells 1 h
before imaging at a concentration of 50 nM when indicated. Cell nuclei were
counterstained using Hoechst 33342 (2.5 µg ml−1). Cell membranes were stained
using CellMask Deep Red Plasma membrane stain (0.5 µl ml−1) when indicated
directly before imaging. Live cell imaging was performed as described in the pre-
vious section using an Olympus FV‑1000 inverted microscope (Olympus Ltd,
Tokyo, Japan) equipped with a ×60 UPlanFL N oil‑immersion objective (numerical
aperture 1.40). Orange colour indicated colocalisation of polymersomes with
lysosomes (LysoTracker Red DND-99).
Quantitative uptake studies by ﬂow cytometry. Differentiated THP-1 cells were
incubated with Atto488-HRP-loaded polymersomes equipped with OmpF-S-S-CF
at a ﬁnal polymer concentration of 0.25 mgml−1 for speciﬁc time points as indi-
cated, or in the presence of different pharmacological pathway inhibitors for 6 h.
Flow cytometry analysis was performed using a BD FACSCanto II ﬂow cytometer
(BD Bioscience, USA) as described in the previous section.
Ethical regulations. All procedures on live zebraﬁsh embryos (Danio rerio) were
carried out following the Swiss legislation on animal welfare.
Data availability. The data that support the ﬁndings of this study are included in
the Supplementary Information; the remaining data are available from the corre-
sponding author upon reasonable request.
Received: 25 May 2017 Accepted: 23 February 2018
References
1. Küchler, A., Yoshimoto, M., Luginbühl, S., Mavelli, F. & Walde, P. Enzymatic
reactions in conﬁned environments. Nat. Nanotechnol. 11, 409–420 (2016).
2. Palivan, C. G. et al. Bioinspired polymer vesicles and membranes for biological
and medical applications. Chem. Soc. Rev. 45, 377–411 (2016).
3. Grzybowski, B. A. & Huck, W. T. S. The nanotechnology of life-inspired
systems. Nat. Nanotechnol. 11, 585–592 (2016).
4. Xiao, K., Wen, L. & Jiang, L. Biomimetic solid‐state nanochannels: from
fundamental research to practical applications. Small 12, 2810–2831 (2016).
5. Yoo, J.-W., Irvine, D. J., Discher, D. E. & Mitragotri, S. Bio-inspired,
bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov.
10, 521–535 (2011).
6. Balasubramanian, V. et al. Biomimetic Engineering Using Cancer Cell
Membranes for Designing Compartmentalised Nanoreactors with Organelle‐
Like Functions. Adv. Mater. 29, doi: https://dx.doi.org/10.1002/
adma.201605375 (2017)
7. Parodi, A. et al. Synthetic nanoparticles functionalised with biomimetic
leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 8, 61–68
(2013).
8. Brea, R. J., Rudd, A. K. & Devaraj, N. K. Nonenzymatic biomimetic
remodeling of phospholipids in synthetic liposomes. Proc. Natl. Acad. Sci.
USA 113, 8589–8594 (2016).
9. Najer, A. et al. Nanomimics of host cell membranes block invasion and expose
invasive malaria parasites. ACS Nano 8, 12560–12571 (2014).
10. Zhang, X. et al. Active surfaces engineered by immobilizing protein-polymer
nanoreactors for selectively detecting sugar alcohols. Biomaterials 89, 79–88
(2016).
11. Baumann, P., Balasubramanian, V., Onaca-Fischer, O., Sienkiewicz, A. &
Palivan, C. G. Light-responsive polymer nanoreactors: a source of reactive
oxygen species on demand. Nanoscale 5, 217–224 (2013).
12. Burns, J. R., Seifert, A., Fertig, N. & Howorka, S. A biomimetic DNA-based
channel for the ligand-controlled transport of charged molecular cargo across
a biological membrane. Nat. Nanotechnol. 11, 152–156 (2016).
13. Palivan, C. G., Fischer-Onaca, O., Delcea, M., Itel, F. & Meier, W.
Protein–polymer nanoreactors for medical applications. Chem. Soc. Rev. 41,
2800 (2012).
14. Hammer, D. A. & Kamat, N. P. Towards an artiﬁcial cell. FEBS Lett. 586,
2882–2890 (2012).
15. Thingholm, B., Schattling, P., Zhang, Y. & Städler, B. Subcompartmentalised
nanoreactors as artiﬁcial organelle with intracellular activity. Small 12,
1806–1814 (2016).
16. Godoy Gallardo, M., Labay, C., Jansman, M. M. T., Ek, P. K. & Hosta-Rigau, L.
Intracellular microreactors as artiﬁcial organelles to conduct multiple
enzymatic reactions simultaneously. Adv. Health. Mater. 6, doi: https://dx.doi.
org/10.1002/adhm.201601190 (2017).
17. Tanner, P., Balasubramanian, V. & Palivan, C. G. Aiding nature’s organelles:
artiﬁcial peroxisomes play their role. Nano Lett. 13, 2875–2883 (2013).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03560-x
10 NATURE COMMUNICATIONS |  (2018) 9:1127 | DOI: 10.1038/s41467-018-03560-x | www.nature.com/naturecommunications
156
18. Zhang, Y., Baekgaard Laursen, M. & Städler, B. Small subcompartmentalised
microreactors as support for hepatocytes. Adv. Healthc. Mater. 6, 1601141
(2017).
19. Discher, B. M., Hammer, D. A., Bates, F. S. & Discher, D. E. Polymer vesicles
in various media. Curr. Opin. Colloid Interface Sci. 5, 125–131 (2000).
20. Discher, B. M. et al. Polymerosome: though vesicles made from diblock
copolymers. Science 284, 1143–1146 (1999).
21. Gunkel-Grabole, G. et al. Polymeric 3D nano-architectures for transport and
delivery of therapeutically relevant biomacromolecules. Biomater. Sci. 3, 25–40
(2015).
22. Itel, F. et al. Molecular organisation and dynamics in polymersome
membranes: a lateral diffusion study. Macromolecules 47, 7588–7596 (2014).
23. Baumann, P., Spulber, M., Fischer, O., Car, A. & Meier, W. Investigation of
horseradish peroxidase kinetics in an ‘organelle‐like’ environment. Small 13,
doi: https://doi.org/10.1002/smll.201603943 (2017).
24. Dzieciol, A. J. & Mann, S. Designs for life: protocell models in the laboratory.
Chem. Soc. Rev. 41, 79–85 (2012).
25. Garni, M., Thamboo, S., Schoenenberger, C.-A. & Palivan, C. G. Biopores/
membrane proteins in synthetic polymer membranes. Biochim. Biophys. Acta
1859, 619–638 (2017).
26. Nardin, C., Widmer, J., Winterhalter, M. & Meier, W. Amphiphilic block
copolymer nanocontainers as bioreactors. Eur. Phys. J. E 4, 403–410 (2001).
27. Lomora, M. et al. Polymersomes with engineered ion selective permeability as
stimuli-responsive nanocompartments with preserved architecture.
Biomaterials 53, 406–414 (2015).
28. Graff, A., Sauer, M., Van Gelder, P. & Meier, W. Virus-assisted
loading of polymer nanocontainer. Proc. Natl. Acad. Sci. USA 99, 5064–5068
(2002).
29. Kumar, M., Habel, J. E. O., Shen, Y.-X., Meier, W. P. & Walz, T. High-density
reconstitution of functional water channels into vesicular and planar block
copolymer membranes. J. Am. Chem. Soc. 134, 18631–18637 (2012).
30. Muhammad, N., Dworeck, T., Fioroni, M. & Schwaneberg, U.
Engineering of the E. coli Outer Membrane Protein FhuA to overcome the
hydrophobic mismatch in thick polymeric membranes. J. Nanobiotechnol. 9, 8
(2011).
31. Kumar, M., Grzelakowski, M., Zilles, J., Clark, M. & Meier, W. Highly
permeable polymeric membranes based on the incorporation of the functional
water channel protein Aquaporin Z. Proc. Natl. Acad. Sci. USA 104,
20719–20724 (2007).
32. Peters, R. J. R. W. et al. Cascade reactions in multicompartmentalised
polymersomes. Angew. Chem. Int. Ed. 53, 146–150 (2013).
33. Hatori, Y. et al. Neuronal differentiation is associated with a redox-regulated
increase of copper ﬂow to the secretory pathway. Nat. Commun. 7, 10640
(2016).
34. Dunnill, C. J., Ibraheem, K., Mohamed, A., Southgate, J. & Georgopoulos, N.
T. A redox state-dictated signalling pathway deciphers the malignant cell
speciﬁcity of CD40-mediated apoptosis. Oncogene 36, 2515–2528 (2016).
35. Onaca, O. et al. Functionalised nanocompartments (Synthosomes) with a
reduction-triggered release system. Angew. Chem. Int. Ed. 47, 7029–7031
(2008).
36. Einfalt, T. et al. Stimuli-triggered activity of nanoreactors by biomimetic
engineering polymer membranes. Nano Lett. 15, 7596–7603 (2015).
37. Edlinger, C. et al. Biomimetic strategy to reversibly trigger functionality of
catalytic nanocompartments by the insertion of pH-responsive biovalves.
Nano Lett. 17, 5790–5798 (2017).
38. Itel, F., Najer, A., Palivan, C. G. & Meier, W. Dynamics of membrane proteins
within synthetic polymer membranes with large hydrophobic mismatch. Nano
Lett. 15, 3871–3878 (2015).
39. Nardin, C., Thoeni, S., Widmer, J., Winterhalter, M. & Meier, W.
Nanoreactors based on (polymerised) ABA-triblock copolymer vesicles.
Chem. Commun. 15, 1433–1434 (2000).
40. Xiao, Q. et al. Bioactive cell-like hybrids coassembled from (glyco)
dendrimersomes with bacterial membranes. Proc. Natl. Acad. Sci. USA 113,
E1134–E1141 (2016).
41. Mason, R. P. et al. Glutathione peroxidase activity is neuroprotective in
models of Huntington’s disease. Nat. Genet. 45, 1249–1254 (2013).
42. Sun, H., Meng, F., Cheng, R., Deng, C. & Zhong, Z. Reduction-responsive
polymeric micelles and vesicles for triggered intracellular drug release. Antiox.
Redox Signal 21, 755–767 (2014).
43. Egan, R. W., Paxton, J. & Kuehl, F. A. Mechanism for irreversible self-
deactivation of prostaglandin synthetase. J. Biol. Chem. 251, 7329–7335
(1976).
44. Mailloux, R. J., Jin, X. & Willmore, W. G. Redox regulation of mitochondrial
function with emphasis on cysteine oxidation reactions. Redox Biol. 2,
123–139 (2014).
45. Shevchenko, A., Tomas, H., Havlis, J., Olsen, J. V. & Mann, M. In-gel digestion
for mass spectrometric characterisation of proteins and proteomes. Nat.
Protoc. 1, 2856–2860 (2006).
46. Zhou, L. & Schlick, S. Electron spin resonance (ESR) spectra of amphiphilic
spin probes in the triblock copolymer EO13PO30EO13 (Pluronic L64):
hydration, dynamics and order in the polymer aggregates. Polymer 41,
4679–4689 (2000).
47. Beghein, N. et al. Characterisation of self-assembling copolymers in aqueous
solutions using electron paramagnetic resonance and ﬂuorescence
spectroscopy. J. Control Release 117, 196–203 (2007).
48. Deo, N., Somasundaran, P., Subramanyan, K. & Ananthapadmanabhan, K. P.
Electron paramagnetic resonance study of the structure of lipid bilayers in the
presence of sodium dodecyl sulfate. J. Colloid Interface Sci. 256, 100–105
(2002).
49. Nakagawa, K. Spin-Probe investigations of head group behavior in
aqueous dispersions of a nonionic amphiphilic compound. Lipids 42, 457–462
(2007).
50. Serban, M. A., Yang, G. & Prestwich, G. D. Synthesis, characterisation and
chondroprotective properties of a hyaluronan thioethyl ether derivative.
Biomaterials 29, 1388–1399 (2008).
51. Circu, M. L. & Aw, T. Y. Reactive oxygen species, cellular redox systems, and
apoptosis. Free Radic. Biol. Med. 48, 749–762 (2010).
52. Rigler, R., Mets, Ü., Widengren, J. & Kask, P. Fluorescence correlation
spectroscopy with high count rate and low background: analysis of
translational diffusion. Eur. Biophys. J. 22, 169–175 (1993).
53. Ranquin, A., Versées, W., Meier, W., Steyaert, J. & Van Gelder, P. Therapeutic
nanoreactors: combining chemistry and biology in a novel triblock copolymer
drug delivery system. Nano Lett. 5, 2220–2224 (2005).
54. Stauch, O., Schubert, R., Savin, G. & Burchard, W. Structure of artiﬁcial
cytoskeleton containing liposomes in aqueous solution studied by static and
dynamic light scattering. Biomacromolecules 3, 565–578 (2002).
55. Wu, D. et al. Effect of molecular parameters on the architecture and
membrane properties of 3D assemblies of amphiphilic copolymers.
Macromolecules 47, 5060–5069 (2014).
56. Siti, W. et al. An intercompartmental enzymatic cascade reaction in channel-
equipped polymersome-in-polymersome architectures. J. Mater. Chem. B 2,
2733–2737 (2014).
57. Kiene, K. et al. PDMS-b-PMOXA polymersomes for hepatocyte
targeting and assessment of toxicity. Eur. J. Pharm. Biopharm. 119, 322–332
(2017).
58. Dieu, L.-H., Wu, D., Palivan, C. G., Balasubramanian, V. & Huwyler, J.
Polymersomes conjugated to 83-14 monoclonal antibodies: in vitro targeting
of brain capillary endothelial cells. Eur. J. Pharm. Biopharm. 88, 316–324
(2014).
59. Camblin, M. et al. Polymersomes containing quantum dots for cellular
imaging. Int. J. Nanomed. 9, 2287 (2014).
60. Ali, S., Champagne, D. L., Spaink, H. P. & Richardson, M. K. Zebraﬁsh
embryos and larvae: a new generation of disease models and drug screens.
Birth Defects Res. C Embryo Today 93, 115–133 (2011).
61. Rizzo, L. Y. et al. In vivo nanotoxicity testing using the Zebraﬁsh embryo
assay. J. Mater. Chem. B Mater. Biol. Med. 1, 3918–3925 (2013).
62. MacRae, C. A. & Peterson, R. T. Zebraﬁsh as tools for drug discovery. Nat.
Rev. Drug Discov. 14, 721–731 (2015).
63. Fenaroli, F. et al. Nanoparticles as drug delivery system against tuberculosis in
zebraﬁsh embryos: direct visualisation and treatment. ACS Nano 8, 7014–7026
(2014).
64. Sieber, S. et al. Zebraﬁsh as an early stage screening tool to study the systemic
circulation of nanoparticulate drug delivery systems in vivo. J. Control. Release
264, 180–191 (2017).
65. Torraca, V., Masud, S., Spaink, H. P. & Meijer, A. H. Macrophage-pathogen
interactions in infectious diseases: new therapeutic insights from the zebraﬁsh
host model. Dis. Model Mech. 7, 785–797 (2014).
66. Daigneault, M., Preston, J. A., Marriott, H. M., Whyte, M. K. B. & Dockrell, D.
H. The identiﬁcation of markers of macrophage differentiation in PMA-
stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE 5,
e8668 (2010).
67. Lunov, O. et al. Differential uptake of functionalised polystyrene nanoparticles
by human macrophages and a monocytic cell line. ACS Nano 5, 1657–1669
(2011).
Acknowledgements
We gratefully acknowledge the ﬁnancial support provided by the Swiss Nanoscience Institute,
the Swiss National Science Foundation and the National Centre of Competence in Research—
Molecular Systems Engineering. J.H., D.W. and S.S. acknowledge ﬁnancial support from the
Novartis University Basel Excellence Scholarship for Life Sciences, the NanoReg II research
program of the European Union, the FAG Basel and Stiftung zur Förderung des Pharma-
zeutischen Nachwuchses in Basel. The authors thank Prof. W. Meier (University of Basel) for
providing the polymer and constructive discussions, and Dr. I. A. Dinu (University of Basel)
for synthesising the polymer. “Somersault18:24” is acknowledged for illustration templates. T.
E. thanks M. Garni (University of Basel), Dr. M. Lomora (University of Basel), Dr. G.
Quebatte (University of Basel) for fruitful discussions, and G. Persy (University of Basel) for
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03560-x ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1127 | DOI: 10.1038/s41467-018-03560-x | www.nature.com/naturecommunications 11
157
TEM-measurements. T.E. and D.W. thank Dr. S. Schenk (University of Basel) for providing
valuable scientiﬁc advice in cell culture and support during their studies. We acknowledge Dr.
M. Chami from the University of Basel, C-CINA, for the cryo-TEM experiments and Dr. B.A.
Goodman for editing the manuscript. In addition, the authors thank Prof. Dr. M. Affolter
(University of Basel) for supporting zebraﬁsh breeding.
Author contributions
T.E. contributed to the OmpF modiﬁcation and characterisation, AOs production and
characterisation, in vitro and in vivo assays, and the writing of the manuscript; C.E.
contributed to the double mutant of OmpF and characterisation of the OmpF mod-
iﬁcation; D.W. contributed to the in vitro and in vivo assays; S.S. contributed to the
in vivo assays; R.G. contributed to characterising the enzymatic reactions; A.N. con-
tributed to the FCS experiments; M.S. contributed to the EPR experiments; O.O.-F.
contributed to the OmpF modiﬁcation and characterisation; J.H. contributed to the
in vitro and in vivo experiments and writing of the manuscript; and C.G.P. contributed to
the AOs concept and writing of the manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
018-03560-x.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2018
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03560-x
12 NATURE COMMUNICATIONS |  (2018) 9:1127 | DOI: 10.1038/s41467-018-03560-x | www.nature.com/naturecommunications
158
DISCUSSION AND OUTLOOK 
In the presented PhD thesis, the zebrafish has been validated and applied as a preclinical screening 
model for nanomedicine formulation design and optimization under complex biological conditions. 
The following sections summarize all achievements of this PhD project and puts these into a larger 
context. For this purpose, selected points, which have also been partially discussed in the course of 
Chapter I-I, are mentioned within the discussion of the specific Chapters. Strengths and weaknesses of 
the exploited zebrafish features as well as future perspectives are discussed in each subchapter. 
During nanomedicine development, formulation design and optimization followed by a thorough 
characterization of nanomedicine performance in biological environments is a key step. Due to high 
experimental costs, time consumption, and ethical considerations, a screening of dozens of different 
experimental nanomedicine formulations in rodent in vivo studies is not applicable. To this end, 
different model systems such as in vitro cell culture and the zebrafish are suitable and complementary 
tools to identify potentially successful nanomedicine formulations prior to rodent in vivo studies. Due 
to its unique advantageous features (i.e. optical transparency, availability in large quantities, 
fluorescent transgenic lines), the zebrafish can be used as an early and easy accessible in vivo screening 
model, which is able to mimic complex biological environments. As discussed in Chapter I-I, critical 
experimental parameters and resulting limitations have to be considered in order to promote 
reasonable applications of the newly introduced zebrafish model during nanomedicine formulation 
design and optimization. 
Systemic Clearance Mechanisms 
Upon administration, macrophages as part of the mononuclear phagocytic system (MPS) are among 
the first cells which are involved in the clearance of nanomedicines [45]. Nanoparticle size and surface 
chemistry determine the adsorption of specific plasma proteins (e.g. opsonins) initiating their 
recognition and phagocytosis by immune cells [46,47]. Starting with liposomes, surface modification 
of nanomedicines with PEG has shown to be an effective strategy to prevent this undesired clearance 
mechanism and has therefore become a classical concept in nanomedicine design.  As a result, various 
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forms of PEG are included in many nanomedicine formulations, as it is also the case for the first FDA 
approved formulation, i.e. Doxil [19,48]. In Chapter II-I, the zebrafish model was validated regarding 
its ability to assess the influence of nanomedicine size and PEGylation using (fluorescently labelled) 
liposomes as a model system. Two main advantages of the model, namely its optical transparency in 
combination with the availability of a transgenic zebrafish line expressing Kaede (i.e. a green 
fluorescent protein) specifically in its macrophages were exploited. Importantly, it was possible to 
reproduce PEGylation effects, which have already been described for rodents such as decreased 
macrophage clearance with increasing PEG density and PEG molecular weight in the zebrafish model. 
In addition, zebrafish findings regarding the ability to compensate negative effects of increased 
liposome size by increasing PEG molecular weight were successfully verified in a follow up rodent 
biodistribution study. 
Nevertheless, some questions regarding the full predictive power of this general experimental set-up 
have to be discussed. The used zebrafish line Tg(mpeg1:Gal4/UAS:Kaede) exploits the mpeg1 
promoter to drive fluorescent Kaede expression specifically in macrophages [49]. Assessing 
nanomedicine macrophage clearance using this line does not allow to distinguish between different 
macrophage polarization states (i.e. M1 or M2), which is an important but often neglected factor, as 
shown by MacParland et al. [50]. If desired, this issue can be overcome by using transgenic lines 
expressing fluorescent proteins depending on the polarization state, as presented in a publication 
describing the conservation of macrophage polarization states between zebrafish and mammalians 
[51]. Furthermore, this Gal4;UAS genetic construct showed to be stable in zebrafish embryos/larvae 
but suffers from somatic silencing, resulting in the absence of fluorescent spleen macrophages in adult 
zebrafish [49]. On the one hand, this is an important fact, since the spleen and its macrophages are 
one of the main nanomedicine clearance sites. On the other hand, the applicability of zebrafish 
embryos/larvae in (high-throughput) screenings is a main advantage of the model, which would get 
lost by the application of adult zebrafish. Recently, Schöttler et al. outlined that a much closer look at 
plasma protein adsorption and its effect on macrophage phagocytosis is required since, the presence 
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of specific plasma proteins seems to be necessary for the intended function of nanoparticle PEGylation 
[52]. In addition, protein corona formation around nanoparticles is heavily species dependent, as 
highlighted by Müller et al. [53]. Despite the relatively conserved plasma protein profile between 
zebrafish and human [54], this has to be kept in mind when performing such studies. One might argue 
that nanoparticles pre-incubated in human plasma followed by in vitro cell uptake studies could be the 
better model system to assess such questions. On the other hand, Hadjidemetriou et al. found striking 
differences regarding protein corona composition and in vitro cell uptake between liposomes which 
acquired their protein corona in vivo (mice injection and recovery) or by simple incubation in mouse 
plasma [55]. This indicates the importance of dynamic (blood circulation) instead of static conditions 
as it is present in live zebrafish embryos/larvae. 
Beside its blood circulation time prolonging effect, nanomedicine PEGylation is known to initiate the 
Accelerated Blood Clearance (ABC) phenomenon upon the first injection of such a formulation [56]. 
This leads to an increased clearance of subsequent doses via a still not fully elucidated immune system 
mediated processes [12,57]. Based on the presented extensive validation of the zebrafish model to 
assess PEG formulation effects, the model is currently used to initially assess the in vivo performance 
of chemically synthesized PEG alternatives. In this regard, our group has assessed an alternative 
polymer surface modification in a preliminary study. Surprisingly, injecting this formulation into 
zebrafish blood circulation resulted in a completely unexpected biodistribution pattern. Instead of 
preventing macrophage phagocytosis, the assessed PEG alternative induced nanoparticle 
accumulation in macrophages having direct access to blood circulation (round shape) as well as tissue 
resident macrophages (star shape) (Figure 1). This unexpected result is remarkable since short 
circulating nanoparticles usually accumulate in macrophages which are located inside or in close 
proximity to the blood vasculature. The novel surface modification seems to trigger additional 
nanoparticle phagocytosis by tissue resident macrophages which are usually not reached by 
nanoparticles. Interestingly, macrophages are known to serve as niches for various pathogens such as 
Mycobacterium tuberculosis or Salmonella [58,59]. In addition, Salmonella show increasing resistance 
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against several antibiotics [60] and nanomedicines have shown to be a possible solution to overcome 
such issues [61]. Therefore, these findings will be further pursued in a collaborative project. To this 
end, primary investigations considering the exact targeting mechanism of this macrophage subset as 
well as the development of a nanomedicine based treatment will be investigated in a zebrafish 
infection model [62] followed by further studies in rodent in vivo models. This coincidental but 
promising finding highlights one of the major advantages of the zebrafish (embryo/larvae) model 
compared to rodent in vivo studies, namely the possibility to screen a lot of different nanomedicine 
formulations in a cost- and time effective manner without the need of regulatory approvals at an 
experimental level. In addition, the optical transparency and the availability of many transgenic 
zebrafish lines offer the possibility to observe such effects by straight forward fluorescence (confocal) 
microscopy. 
Figure 1: Targeting of macrophages located in blood circulation and tissue. Double fluorescently labelled liposomes were injected into 
transgenic zebrafish embryos 2 days post fertilization. Accumulation of the liposome (blue) as well as its cargo (red) in macrophages were 
observed 3 hours post injection, indicating the possibility to successfully deliver intact nanomedicines to the whole macrophage population. 
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Blood Circulation Properties 
Beside surface modification (i.e. PEGylation), nanomedicine blood circulation properties can partially 
be controlled by further formulation design. In case of liposomes, this is connected to the transition 
temperature (Tm) of lipids and the amount of cholesterol incorporated into the lipid bilayer. In 
Chapter II-II, multiple (fluorescently labelled) liposome formulations composed of lipids with varying 
Tm and amounts of cholesterol were injected into Tg(kdrl:EGFP) zebrafish embryos expressing 
enhanced green fluorescent protein (EGFP) in their vasculature [63]. Confocal microscopy images 
taken after different time points were compared to published rodent pharmacokinetic data 
representing a classical in vivo study [64]. Doing so, qualitative liposome biodistribution patterns in 
zebrafish, which are characteristic for long or short circulating liposomes, were identified and defined. 
Regarding lipid Tm, short circulating liposomes (high Tm) were observed to almost immediately attach 
to the posterior caudal vein whereas long circulating liposomes (low Tm) showed a diffuse staining 
pattern, indicating their remaining presence in blood circulation. Nevertheless, these qualitative 
observations only allowed an accurate distinction between liposomes altered by using lipids with 
changing Tm. These lipids usually account for the major part of a formulation but liposomes are often 
composed of many additional components (i.e. cholesterol, PEGylation). In order to be able to also 
assess the influence of such minor formulation components, the semi-quantitative zebrafish 
circulation- (CF) and extravasation factor (EF) were introduced. These two zebrafish factors can be 
determined by image analysis using a macro which we have written for FIJI/ImageJ. These zebrafish 
factors subsequently were applied to all investigated nanoparticle formulations. Briefly, higher 
zebrafish EF and CF were observed for long circulating formulations composed of low Tm lipids or 
increased amount of cholesterol. 
Regarding the EF, an enhanced accumulation of liposome formulations with prolonged circulation 
properties outside the zebrafish vasculature was observed. On the one hand, it would be tempting to 
speculate that an increased liposome bilayer fluidity, achieved by low Tm lipids or increased amounts 
of cholesterol, allows such liposome formulations to extravasate more easily in any manner. On the 
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other hand, this characteristic pattern showed to be independent of liposome bilayer fluidity, since 
also liposome surface modification with PEG resulted in the same pattern. In this respect, the zebrafish 
developmental stage at the time of injection (± 48 hours post fertilization (hpf)) could be a possible 
explanation for this observation. The zebrafish vascular morphogenesis including lumen formation is 
still ongoing [65,66] at this time point. Moreover, vasculature tightness during lumen formation seems 
to be temporally impaired, which fosters the extravasation of circulating liposomes (Figure 2). This 
effect is much more pronounced in case of long circulating liposomes, since short circulating liposomes 
are bound by the venous vasculature almost immediately after injection. Performing the zebrafish 
assessment at later time points at which the vasculature is further developed would be one option. On 
the downside, this could also interfere with the diminishing presence of the duct of Cuvier (easy 
accessible site of injection) and increasing regulatory requirements when exceeding developmental 
stages of 5 days post fertilization. Furthermore, varying extravasation patterns of different long 
circulating nanoparticles were observed in extended studies (data not shown). So far, different reasons 
such as altered nanoparticle stability or aggregation in biological environments are discussed but have 
to be further elucidated. With this in mind, the zebrafish extravasation factor should be applied with 
care, especially since the zebrafish CF has been investigated in much more detail (Chapter III-I). 
Figure 2: Time course of long circulating liposome extravasation upon zebrafish vasculature lumen formation. Transgenic zebrafish 
embryos expressing EGFP in their vascular endothelial cells (green) were injected with fluorescently labelled long circulating liposomes (red) 
at 48 hours post fertilization. Images were recorded around 1 hour post injection. Timeframe and sites of lumen formation are indicated 
(white arrows).  
By combining the qualitative and semi-quantitative zebrafish assessment, a successful general 
circulation behavior prediction of a liposome formulation with so far not reported blood circulation 
time was possible and verified in a rodent in vivo study. Nevertheless, this approach always requires 
the comparison of a new nanomedicine formulation with at least one formulation with known 
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pharmacokinetic properties. Moreover, it is not possible to predict exact numerical pharmacokinetic 
parameters such as AUC or t1/2 or to compare results obtained in different experimental series. Being 
able to provide such detailed and comparable information will be the matter of further investigations. 
To this end, fluorescence correlation spectroscopy (FCS) in live zebrafish embryos will be used. By this 
technique, changing fluorescence intensities and size dependent diffusion coefficients of 
nanomedicines in a defined confocal volume are measured. Based on this data and the calibration of 
the whole set-up, normalized pharmacokinetic parameters can be obtained. Initial experiments 
showed a good correlation between liposome pharmacokinetic profiles measured in zebrafish 
embryos by FCS or in rats generated by classical radiolabeling-blood sampling protocols (Figure 3). 
Beside the straightforward and adaptable (i.e. surface, membrane, or hydrophilic core dyes) 
fluorescent labelling, especially the possibility to start recording straight after injection and the short 
time intervals between single measurements can be considered as the main advantage of the 
suggested FCS application. Often, short circulating formulations are almost immediately removed from 
blood circulation after their first passage through large clearance organs such as the liver, spleen, or 
kidneys. Due to the time-consuming injection and blood sampling protocol, such effects can only hardly 
be assessed in rodent in vivo studies. In sharp contrast, injected zebrafish embryos can immediately 
be transferred to a fluorescence microscope which allows the observation of such rapid clearance 
effects as shown by the 10 mol% cholesterol formulation in Figure 3 (top row). 
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Figure 3: Liposome pharmacokinetics in zebrafish and rats. For zebrafish experiments, liposomes were fluorescently labelled and 
pharmacokinetic profiles were recorded by fluorescence correlation spectroscopy in live zebrafish embryos (left column). For rodent in vivo 
studies, liposomes were radiolabeled with the radionuclide 111In followed by blood sampling after indicated time points (right column). All 
blood levels are normalized to starting concentrations. 
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Macromolecular Basis of Nano-Bio-Interactions 
The MPS, which is located in different organs and consists of specialized macrophages (i.e. Liver Kupffer 
cells), is currently described as the main clearing mechanism of nanomedicines [45]. Therefore, a lot 
of effort has been put into the investigation of nanomedicine interactions with macrophages, as 
exemplary shown in Chapter II-I. Beside accumulation in macrophages, a distinct binding pattern 
within the caudal vein of zebrafish embryos has been observed for short circulating liposomes 
(Chapter II-II). As a consequence, an additional nanoparticle clearance mechanism in zebrafish 
embryos has been suspected and further elucidated in Chapter III-I. Already in 1924, Aschoff launched 
the concept of the reticuloendothelial system (RES), a macromolecular waste clearing system in 
mammalians, which not only includes macrophages but also different scavenger endothelial cells 
(SECs) [67]. The biggest portion of SECs are liver sinusoidal endothelial cells (LSECs), which are known 
to selectively express three main receptors compared to other blood vasculature endothelial cells, 
namely Stablilin-1 and -2 and the mannose receptor Mrc1. In the caudal vein of zebrafish 
embryos/larvae, the Stabilin-2 receptor was identified to scavenge nanoparticles from blood 
circulation. To this end, a series of injections, including short circulating liposomes, the RES vital stain 
lithium carmine [68], hyaluronic acid [69], and dextran sulfate [70], as well as the generation of 
Stabilin-2 knockout by CRISPR/Cas9, was performed. Moreover, anionic nanoparticle surface charge 
showed to be the predominant driver behind nanoparticle clearance via this specific receptor. 
Furthermore, the second scavenger receptor Stabilin-1 was shown to be involved in the clearing of 
smaller (< 30 nm) nanoparticles. The identification of the Stabilin-2 scavenger receptor and its localized 
expression was used to demonstrate targeted drug delivery to vascular endothelial cells in the caudal 
vein of zebrafish embryos/larvae. Therefore, a cytotoxic drug (clodronate) was encapsulated into 
fluorescently labelled nanoparticles which were formulated to be cleared by Stabilin-2. This resulted 
in a gradual loss of kdrl:GFP+ endothelial cells in the caudal vein of injected Tg(kdrl:GFP) zebrafish 
embryos/larvae. Injecting clodronate loaded nanoparticles into Tg(mpeg:GFP) or Tg(mpx:GFP) did not 
result in an obvious loss of fluorescent macrophages or neutrophils, respectively (data not shown). 
Since the control injection of free clodronate did not show any effects either, it is most likely that cell 
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uptake via (Stabilin-2) receptor mediated endocytosis of clodronate loaded nanoparticles into 
vasculature endothelial cells is responsible for these observations.  
The zebrafish features identified and described in Chapters II-I to III-I are summarized in Table 1. So 
far, the observed nanomedicine formulation effects in zebrafish and rodents showed to be conserved, 
making zebrafish embryos/larvae a promising model system to test and predict likely nanomedicine 
interactions with the RES/MPS in mammalians. Using a combination of sophisticated imaging 
techniques, transgenic zebrafish lines, their optical transparency, and fluorescently labelled 
nanoparticles allows the investigation of nanomedicine formulation effects in a live animal at a 
macromolecular level. As recently highlighted by Yin et al., this is of special interest for the field of 
nanoparticulate drug delivery [71]. Classical in vivo models (i.e. rodents) are a “conceptual blackbox”, 
which does not offer the possibility to specifically reveal the effects of anatomical features, 
physiological processes, and molecular mechanisms on nanomedicine delivery at such high resolution. 
This often results in a very poor in vitro-in vivo translation, since a proper selection of potentially 
successful nanomedicine formulations under complex biological conditions is hampered [22]. 
Especially for therapeutic nanomedicine approaches, which require a tight control of cellular uptake 
and trafficking mechanisms, having the possibility to assess formulation effects in a detailed manner 
is of utmost importance. 
Gene delivery can be considered as such while being one of the most promising future branches of 
therapeutic nanomedicines. Already available viral gene delivery vectors are questionable regarding 
their immunogenicity and in addition suffer from comparably low loading capacities. Therefore, 
replacing them with biocompatible nanoparticles is of great interest [72]. Nanomedicine formulation 
design and optimization for gene delivery is especially critical as illustrated by the “PEG dilemma” [73]. 
In order to fulfill their therapeutic intention, such systems need to overcome the cellular membrane, 
prevent/escape endosomal/lysosomal degradation, and deliver their intact gene cargo to the cytosol 
or the nucleus [74]. As already described, PEG is often included in nanomedicine formulations to 
prevent their removal from blood circulation by phagocytic cells. On the other hand, PEG is also known 
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to decrease nanomedicine cell uptake and to improve nanoparticle stability leading to poor 
endosomal/lysosomal escape resulting in gene cargo degradation under the acidic conditions in these 
cellular compartments. Expanding the already described features of the zebrafish model (Table 1) with 
in vivo nanomedicine cell internalization and trafficking studies will therefore be a next step which has 
to be well-considered. For this purpose, already available transgenic zebrafish lines expressing 
fluorescent proteins in endosomes [75] and/or lysosomes [76] will be of importance. As an alternative 
method to fluorescence based microscopy, focused ion beam scanning electron microscopy (FIB-SEM), 
which has already been applied on zebrafish embryos [77,78], will be evaluated to generate 3D images 
at isotropic resolutions in the sub-nanometer range. To this end, a nanoreactor approach, which has 
been described in one of our previous research projects [79], will be exploited to load the investigated 
nanomedicine formulations with gold nanoparticles as electron dense contrast agents.  
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Table 1: Zebrafish features and their applicability for nanomedicine formulation design and optimization. Relevant formulation parameters of investigated nanoparticles, time points after nanoparticle zebrafish injection 
or incubation, used zebrafish lines, an overview of discovered key formulation effects, and the original thesis chapter are given. The exact chemical identities of lipids and polymers are listed in the abbreviation section. In 
addition to the indicated compositions, all nanoparticles have been fluorescently labelled using 1 mol% of fluorescent dyes. Nanoparticle size (nm) and surface charge (mV) were measured by dynamic light scattering. 
hpi = hours post injection, Tm = lipid transition temperature. 
Zebrafish Feature Investigated Nanoparticles Assessed Time 
Points  
Zebrafish Line(s) Effects of Formulation Parameters Chapter 
Macrophage 
Clearance 
 
Liposomes: 
- 90 nm PEG350 3.0, 6.5, 10 mol% 
- 90 nm PEG750 3.0, 6.5, 10 mol% 
- 90 nm PEG2000 3.0, 6.5, 10 mol% 
- 90 nm PEG5000 3.0, 6.5, 10 mol% 
- 60 nm PEG350 6.5 mol% 
- 120 nm PEG350 6.5 mol% 
- 60 nm PEG2000 6.5 mol% 
- 120 nm PEG2000 6.5 mol% 
 
 
3, 24 hpi 
 
Tg(kdrl:EGFP), 
Tg(mpeg1:Gal4;UAS:Kaede) 
 
Decreased macrophage clearance by: 
- Increased PEG molecular weight 
- Increased PEG density 
- Decreased nanoparticle size 
 
Higher PEG molecular weight is able to compensate larger 
nanoparticle size. 
 
II-I 
 
Liposomes: 
- 100 nm POPC, Chol (55:45 mol%) 
- 100 nm POPC, Chol, PEG2000 (50:41:9 mol%) 
- 325 nm POPC, Chol (55:45 mol%) 
- 464 nm POPC, Chol (55:45 mol%) 
 
 
2 hpi 
 
Tg(mpeg:GFP) 
 
Decreased macrophage clearance by: 
- Decreased nanoparticle size 
- Addition of PEG 
III-I 
Zebrafish 
Circulation (CF) and 
Extravasation 
Factor (EF) 
 
Liposomes: 
- DAPC 20:4 (Tm -70 °C) 
- DOPC (Tm -22 °C) 
- DMPC (Tm 23 °C) 
- DPPC (Tm 41 °C) 
- DSPC (Tm 55 °C) 
- DAPC 20:0 (Tm 66 °C) 
- DSPC, Chol (90:10 mol%) 
- DSPC, Chol (80:20 mol%) 
- DSPC, Chol (70:30 mol%) 
- DSPC, Chol (60:40 mol%) 
- DSPC, Chol (50:50 mol%) 
- DSPC, Chol, PEG2000 (55:40:5 mol%) 
- DSPC, Chol, PEG2000 (50:40:10 mol%) 
 
 
1, 24 hpi 
 
Tg(kdrl:EGFP) 
 
Prolonged nanoparticle circulation (increased CF and EF) by: 
- Low lipid transition temperature (Tm) 
- Increasing amount of cholesterol (Chol) 
- Increasing amount of PEG2000 
 
II-II 
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Stabilin-1 and -2 
Clearance 
Liposomes (± 110 nm): 
- POPC, Chol (55:45 mol%) (-16 mV) 
- DSPC, DSPG, Chol (53:21:26 mol%) (-34 mV) 
- DOTAP, DOPC (51.5:48.5 mol%) (46 mV) 
- DOPC ± Clodronate (-11 mV) 
- DSPC ± Clodronate (-3 mV) 
- DOPG (-37 mV) 
- DSPG (-46 mV) 
- DOTAP (36 mV) 
- POPC (-17 mV) 
Virus-like (28 nm) 
- 90 CCMV capsid protein dimer (-15 mV) 
Polymersome (83 nm) 
- PIP, PEG (57:43 mol%) (-24 mV) 
Quantum Dots (< 10 nm) (-71 mV) 
Latex beads (121 nm) (-51 mV) 
1, 8, 24, 48 hpi Tg(kdrl:GFP),  
Tg(kdrl:RFP-CAAX), 
Homozygous stab2ibl2 mutants, 
Heterozygous stab2ibl2 mutants, 
Tg(mpx:GFP) 
Stabilin-1 and -2 clearance is independent from nanoparticle 
chemical identity (i.e. lipid, polymer, virus). 
Stabilin-2 nanoparticle clearance is an interplay of: 
- Nanoparticle size > 30 nm
- Pronounced anionic nanoparticle surface charge < -30 mV 
- High transition temperature lipid but neutral nanoparticle surface 
charge (DSPC) 
Nanoparticle binding to Stabilin-2 results in receptor mediated 
endocytosis. 
Stabilin-1 nanoparticle clearance seems to be mediated by: 
- Nanoparticle size < 30 nm
A pronounced cationic surface charge leads to nanoparticle binding 
to the whole zebrafish vasculature. 
III-I 
Toxicity 
Liposomes (1, 10, 100, 1000 µM): 
- DOPC 
- DMPC 
- DPPC 
- DSPC 
- DAPC 20:0 
- DOTAP 
- PEI 
24, 48, 72 hours 
post incubation 
ABC/TU Zebrafish embryo mortality induced by: 
- Increasing dose (1 < 10 < 100 < 1000 µM) 
- Pronounced cationic surface charge 
(DOPC = DMPC = DPPC = DSPC = DAPC 20:0 < DOTAP < PEI) 
II-II 
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Passive and Active Targeting 
After the successful introduction, set-up, and validation of the zebrafish model in Chapters I-I to III-I, 
Chapter IV-I has been dedicated to further applications of the established model. Ligand surface 
modification of nanomedicines is commonly referred as active targeting and triggers the uptake into 
diseased cells which express specific proteins or receptors. This is often used as a complementary 
approach to passive targeting which relies on the EPR effect [80]. After passive accumulation, the main 
purpose of the targeting ligand is to retain the nanomedicine at the site of action and enhance 
internalization [81]. During formulation design and optimization of such actively targeted 
nanomedicines, the optimal ligand density on the nanoparticle surface is a key parameter which is 
normally evaluated in vitro using cells deficient or expressing the target of interest. In general, higher 
ligand densities usually result in increased nanomedicine cell uptake in vitro. Interestingly, optimal 
ligand densities identified in vitro often show poor performance in vivo, as observed by Shan et al. [82] 
and in Chapter IV-I. In order to overcome this issue, the zebrafish model was used as a complementary 
tool to select the nanoparticle formulation carrying the optimal ligand density for subsequent rodent 
in vivo studies. First, Tg(kdrl:EGFP) zebrafish embryos were used to assess the influence of ligand 
density on blood circulation behavior. Higher ligand densities were observed to result in nanoparticle 
aggregation whereas intermediate and lower ligand densities showed gradually increasing blood 
circulation properties (i.e. diffuse staining pattern indicating long circulation properties). Second, a 
comparably simple zebrafish xenograft model was generated [83] by injecting genetically modified 
cells, expressing the receptor of interest and green fluorescent protein (GFP) into wild type zebrafish 
embryos. The nanoparticle formulation modified with a medium ligand density showed the highest 
degree of colocalization with the targeted cells. These findings were confirmed in a subsequent rodent 
in vivo organ distribution study. The highest and medium ligand density nanoparticle formulations 
were observed to accumulate in the target organ (liver). However, nanoparticles bearing a high ligand 
density suffered from a poor liver to spleen ratio. Most probably, this is a result of nanoparticle 
aggregation, as shown in zebrafish studies, leading to nanoparticle phagocytosis by macrophages 
172
expressed in the spleen. Therefore, the potential of using the zebrafish model during formulation 
design and optimization of actively targeted nanomedicines has been shown in this chapter. 
Since decorating the surface of nanoparticle with receptor ligands is one way to increase nanomedicine 
cell uptake via receptor mediated endocytosis [6], the already indicated use of the zebrafish as an in 
vivo model for cell internalization and trafficking could become even more valuable. Further 
approaches are the use of zebrafish tumor models which include the possibility to assess EPR effects 
on targeted nanomedicine delivery. Upon Vascular Endothelial Growth Factor (VEGF) secreting cancer 
cell injection into zebrafish, Stoletov et al. demonstrated vessel remodeling and angiogenesis including 
the formation of vascular holes mediating vascular permeability [84]. Keeping this in mind, the 
generation of a zebrafish xenograft model using the approach published by Nicoli et al. [85], which 
strongly induces angiogenesis resulting in a completely vascularized tumor, could be a possibility to 
generate such an EPR mimicking zebrafish xenograft model. Importantly, a thorough characterization 
of the model will be of utmost importance, since the size of vasculature fenestration (holes) is known 
to vary between organs, tumor types [86] and to be dependent on the secretion of different 
endothelial growth factors by cancer cells [87]. 
Enzyme Activity 
Enzyme immobilization on nanoparticles is envisioned for several therapeutic applications [88]. 
Designing artificial organelles or cells including membrane gates, which control the encapsulated 
enzymes access to its substrates even goes a step further and is an exciting branch of nanomedicine 
[89,90]. Successful delivery and therapeutic application of such systems require specific formulation 
properties which enable cellular internalization, a controlled biodistribution, avoidance of undesired 
clearance, and endosomal escape. In addition, the designed systems have to be nontoxic, 
biocompatible and functional under in vivo conditions [91]. In Chapter IV-II, model enzymes were 
immobilized on PLGA nanoparticles and injected into zebrafish embryos in order to assess their 
biocompatibility and stability under in vivo conditions. Especially the presence of free or unreacted 
glutaraldehyde, which has been used to crosslink enzymes with nanoparticles, was considered as 
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potentially critical. In general, injected zebrafish embryos were observed to be highly vulnerable to 
crosslinking chemicals (i.e. GA) or remaining organic solvents origin from the nanomedicine 
preparation process (data not shown). Nevertheless, injecting PLGA-enzyme particles did not result in 
acute signs of toxicity. Furthermore, performing an enzyme activity assay (formation of a colored 
reaction product) on injected zebrafish embryos was used to evaluate the systems stability and activity 
in a biological environment. As a result, injected PLGA immobilized enzymes showed a dotted and 
bright staining pattern whereas the colored product was diffusely distributed in case of injected free 
enzyme. Based on the dotted and localized staining pattern of immobilized enzymes, the stability and 
functionality of the presented system upon injection into a biological environment was concluded. Due 
to the required experimental conditions of the enzyme activity assay, the injected zebrafish embryos 
had to be euthanized, fixed, and permeabilized prior to the addition of the enzyme substrate. 
Consequently, this protocol does only allow to assess the stability and integrity of nanoparticle-enzyme 
systems but not their actual functionality under live in vivo conditions. Beside its beneficial simplicity, 
this reflects a severe drawback of such an experimental set-up, since the immobilized enzymes access 
to its substrate can be heavily affected by the presence of blood flow. 
Nevertheless, this issue can be overcome by using alternative enzyme activity assays, as demonstrated 
in Chapter IV-III. In this study, polymer based artificial organelles (AO) loaded with a model enzyme 
(i.e. horseradish peroxidase, HRP) were developed and tested in vitro and in vivo using the zebrafish 
model. Importantly, the enzyme loaded nanoparticles were equipped with reduction sensitive protein 
gates controlling the enzyme access to its substrate. In presence of hydrogen peroxide (H2O2), HRP 
converts the enzyme substrate Amplex Ultra Red (AR) into the fluorescent resorufin-like product (RLP). 
In vitro, the designed artificial organelles were taken up by macrophages, an observation which has 
been confirmed by injecting them into Tg(mpeg1:Gal4;UAS:Kaede) zebrafish embryos. In order to 
assess the systems integrity and functionality under live in vivo conditions, the formation of RLP in AO 
injected live zebrafish embryos was successfully observed upon subsequent injection of the enzyme 
substrate AR. Coincidentally, using this specific model enzyme reaction and the accumulation of AOs 
174
in macrophages did not require an additional injection of H2O2, since it is inherently produced by 
macrophages [92].  
On the one hand, using the zebrafish for this purpose allowed an initial assessment of the performance 
of such sophisticated systems under live biological conditions. On the other hand, model enzymes and 
the resulting experimental conditions which are required for the specific enzyme activity assay are 
always defined. Most often, using model enzymes is only valuable during early steps of the formulation 
design and optimization. As soon as the therapeutic efficiency of such as system has to be tested, 
model enzymes have to be exchanged by the therapeutic enzyme. Therefore, model enzymes for such 
studies should not only be chosen based on their price, stability, or easiness to handle. Moreover, the 
actual enzyme properties (i.e. molecular weight, required reaction conditions) should be carefully 
considered. Keeping this in mind, the zebrafish is a valuable complementary tool to test immobilized 
and encapsulated enzyme activity under in vivo conditions.  
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CONCLUSION 
During this PhD thesis, four major objectives (Chapter I to IV) had to be evaluated to set-up and validate 
the zebrafish as an early and easy accessible in vivo tool for nanomedicine development.  
First, the zebrafish has demonstrated advantageous characteristics for nanomedicine formulation 
design and optimization including its optical transparency, the availability of transgenic lines, the 
relatively straight forward in vivo experimental set-up, and the possibility to screen large numbers of 
samples. These features allow an improved selection of potentially successful nanomedicine 
formulations for subsequent rodent in vivo studies under complex biological conditions. Consequently, 
if reasonably applied, this newly introduced model system can serve as an optimal tool to close the 
in vitro - in vivo gap during nanomedicine development (Chapter I).  
Second, the zebrafish model was further characterized and validated as a model system for 
nanomedicine development. Special foci were systemic macrophage clearance (i.e. a main 
nanomedicine clearing mechanisms in mammalians) and the identification of imaging based 
nanomedicine biodistribution patterns indicative for long or short blood circulation behavior. 
Importantly, findings in zebrafish showed a high predictive power for rodent in vivo experiments 
evaluating the effect of various nanomedicine formulation parameters such as size, PEGylation, lipid 
transition temperature, or cholesterol content (Chapter II).  
Third, a detailed follow-up study was performed evaluating additional nanomedicine clearance 
mechanisms. Interestingly, the Stabilin-2 scavenger receptor in the caudal vein of zebrafish 
embryos/larvae was identified, which is the tissue were short circulating nanomedicines accumulate. 
Different formulation parameters such as an anionic surface charge and a defined size range were 
identified to influence this clearance mechanism. Importantly, this nanomedicine scavenging process 
corresponds to an already well-known nanomedicine clearing mechanism by liver sinusoidal 
endothelial cells of mammalians. Thus, the zebrafish has been identified as a suitable and predictive 
model regarding the hepatic clearance of novel nanomedicine formulations (Chapter III).  
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Fourth, further applications of the zebrafish model were evaluated. During the development of actively 
targeted nanomedicines the zebrafish model demonstrated its superior predictive power for 
subsequent rodent in vivo studies when compared to a standard in vitro setting. Additionally, the 
biocompatibility, stability, and functionality of two nanoparticle-enzyme systems under in vivo 
conditions were tested in zebrafish. These findings successfully demonstrated the broad applicability 
of the zebrafish model to assess sophisticated nanomedicines under complex and dynamic biological 
conditions (Chapter IV).  
Conclusively, the findings presented in this PhD thesis will hopefully increase the understanding of 
basic nanomedicine formulation effects and therefore foster a successful translation of further 
nanomedicines from bench to bedside. 
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ABBREVIATIONS 
ABC Accelerated Blood Clearance 
AO artificial organelle 
AR Amplex (Ultra) Red 
AUC area under the curve 
CAM chorioallantoic membrane 
CCMV Cowpea Chlorotic Mottle Virus 
CF (Zebrafish) circulation factor 
Chol cholesterol 
DAPC 20:0 1,2-diarachidoyl-sn-glycero-3-phosphocholine 
DAPC 20:4 1,2-diarachidonoyl-sn-glycero-3-phosphocholine 
DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine 
DOPG 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) 
DOTAP 1,2-dioleoyl-3-trimethylammonium-propane 
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
DSPC 1,2-distearoyl-sn-glycero-3-phosphocholine 
DSPG 1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) 
EGFP enhanced green fluorescent protein 
EPR enhanced permeability and retention effect 
FCS fluorescence correlation spectroscopy 
FDA (United States) Food and Drug Administration 
FIB-SEM focused ion beam scanning electron microscopy 
GFP green fluorescent protein 
HBV Hepatitis B Virus 
hpf hours post fertilization 
hpi hours post injection 
HRP Horseradish peroxidase 
H2O2 hydrogen peroxide 
LSECs liver sinusoidal endothelial cells 
MPS mononuclear phagocytic system 
Nanomedicines drug or therapeutic agent loaded nanoparticles 
NTCP sodium-taurocholate cotransporting polypeptide 
PEG polyethylenglycol 
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PEG2000 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000] 
PEG350 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-350] 
PEG5000 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-5000] 
PEG750 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-750] 
PEI polyethylenimine 
PIB polyisobutylene 
PLGA poly(lactide-co-glycolide) 
POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
RES reticuloendothelial system 
RLP resorufin-like product 
SECs scavenger endothelial cells 
Tm transition temperature 
t1/2 half-life 
VEGF Vascular Endothelial Growth Factor 
179
BIBLIOGRAPHY 
[1] P. Ehrlich, Experimental Researches on Specific Therapy, on Immunity with Special Relationship
between Distribution and Action of Antigens, (1908).
[2] P. Grossen, D. Witzigmann, S. Sieber, J. Huwyler, PEG-PCL-based nanomedicines: A biodegradable
drug delivery system and its application, J. Control. Release Off. J. Control. Release Soc. 260
(2017) 46–60. doi:10.1016/j.jconrel.2017.05.028.
[3] D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as an emerging
platform for cancer therapy, Nat. Nanotechnol. 2 (2007) 751–760. doi:10.1038/nnano.2007.387.
[4] H. Ragelle, F. Danhier, V. Préat, R. Langer, D.G. Anderson, Nanoparticle-based drug delivery
systems: a commercial and regulatory outlook as the field matures, Expert Opin. Drug Deliv. 14
(2017) 851–864. doi:10.1080/17425247.2016.1244187.
[5] A. Wicki, D. Witzigmann, V. Balasubramanian, J. Huwyler, Nanomedicine in cancer therapy:
challenges, opportunities, and clinical applications, J Control Release. 200 (2015) 138–157.
doi:10.1016/j.jconrel.2014.12.030.
[6] J. Shi, P.W. Kantoff, R. Wooster, O.C. Farokhzad, Cancer nanomedicine: progress, challenges and
opportunities, Nat. Rev. Cancer. 17 (2017) 20–37. doi:10.1038/nrc.2016.108.
[7] A.D. Bangham, R.W. Horne, NEGATIVE STAINING OF PHOSPHOLIPIDS AND THEIR STRUCTURAL
MODIFICATION BY SURFACE-ACTIVE AGENTS AS OBSERVED IN THE ELECTRON MICROSCOPE, J.
Mol. Biol. 8 (1964) 660–668.
[8] Y. Barenholz, Doxil®–the first FDA-approved nano-drug: lessons learned, J. Control. Release Off.
J. Control. Release Soc. 160 (2012) 117–134. doi:10.1016/j.jconrel.2012.03.020.
[9] J.-C. Leroux, Editorial: Drug Delivery: Too Much Complexity, Not Enough Reproducibility?, Angew.
Chem. Int. Ed. 56 (2017) 15170–15171. doi:10.1002/anie.201709002.
[10] F. Danhier, To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what
is the future of nanomedicine?, J. Control. Release Off. J. Control. Release Soc. 244 (2016) 108–
121. doi:10.1016/j.jconrel.2016.11.015.
[11] J.I. Hare, T. Lammers, M.B. Ashford, S. Puri, G. Storm, S.T. Barry, Challenges and strategies in anti-
cancer nanomedicine development: An industry perspective, Adv. Drug Deliv. Rev. 108 (2017)
25–38. doi:10.1016/j.addr.2016.04.025.
[12] L. Belfiore, D.N. Saunders, M. Ranson, K.J. Thurecht, G. Storm, K.L. Vine, Towards clinical
translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and
opportunities, J. Controlled Release. 277 (2018) 1–13. doi:10.1016/j.jconrel.2018.02.040.
[13] S. Wilhelm, A.J. Tavares, Q. Dai, S. Ohta, J. Audet, H.F. Dvorak, W.C.W. Chan, Analysis of
nanoparticle delivery to tumours, Nat. Rev. Mater. 1 (2016) 16014.
doi:10.1038/natrevmats.2016.14.
[14] A.P. Blum, J.K. Kammeyer, A.M. Rush, C.E. Callmann, M.E. Hahn, N.C. Gianneschi, Stimuli-
Responsive Nanomaterials for Biomedical Applications, J. Am. Chem. Soc. 137 (2015) 2140–2154.
doi:10.1021/ja510147n.
[15] V.P. Torchilin, Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery, Nat.
Rev. Drug Discov. 13 (2014) 813–827. doi:10.1038/nrd4333.
[16] M.V. Yezhelyev, X. Gao, Y. Xing, A. Al-Hajj, S. Nie, R.M. O’Regan, Emerging use of nanoparticles in
diagnosis and treatment of breast cancer, Lancet Oncol. 7 (2006) 657–667. doi:10.1016/S1470-
2045(06)70793-8.
[17] J.H. Ryu, S. Lee, S. Son, S.H. Kim, J.F. Leary, K. Choi, I.C. Kwon, Theranostic nanoparticles for future
personalized medicine, J. Controlled Release. 190 (2014) 477–484.
doi:10.1016/j.jconrel.2014.04.027.
[18] T. Lammers, F. Kiessling, M. Ashford, W. Hennink, D. Crommelin, G. Storm, Cancer nanomedicine:
Is targeting our target?, Nat. Rev. Mater. 1 (2016). doi:10.1038/natrevmats.2016.69.
[19] D. Bobo, K.J. Robinson, J. Islam, K.J. Thurecht, S.R. Corrie, Nanoparticle-Based Medicines: A
Review of FDA-Approved Materials and Clinical Trials to Date, Pharm. Res. 33 (2016) 2373–2387.
doi:10.1007/s11095-016-1958-5.
180
[20] S. Behzadi, V. Serpooshan, W. Tao, M.A. Hamaly, M.Y. Alkawareek, E.C. Dreaden, D. Brown, A.M.
Alkilany, O.C. Farokhzad, M. Mahmoudi, Cellular uptake of nanoparticles: journey inside the cell,
Chem. Soc. Rev. 46 (2017) 4218–4244. doi:10.1039/c6cs00636a.
[21] S. Mitragotri, T. Lammers, Y.H. Bae, S. Schwendeman, S. De Smedt, J.-C. Leroux, D. Peer, I.C.
Kwon, H. Harashima, A. Kikuchi, Y.-K. Oh, V. Torchilin, W. Hennink, J. Hanes, K. Park, Drug Delivery
Research for the Future: Expanding the Nano Horizons and Beyond, J. Control. Release Off. J.
Control. Release Soc. 246 (2017) 183–184. doi:10.1016/j.jconrel.2017.01.011.
[22] K. Paunovska, C.D. Sago, C.M. Monaco, W.H. Hudson, M.G. Castro, T.G. Rudoltz, S. Kalathoor,
D.A. Vanover, P.J. Santangelo, R. Ahmed, A.V. Bryksin, J.E. Dahlman, A Direct Comparison of in
Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak
Correlation, Nano Lett. (2018). doi:10.1021/acs.nanolett.8b00432.
[23] C. Nüsslein-Volhard, The Identification of Genes Controlling Development in Flies and Fishes
(Nobel Lecture), Angew. Chem. Int. Ed. Engl. 35 (1996) 2176–2187. doi:10.1002/anie.199621761.
[24] C. Nüsslein-Volhard, The zebrafish issue of Development, Dev. Camb. Engl. 139 (2012) 4099–
4103. doi:10.1242/dev.085217.
[25] D. Ribatti, The chick embryo chorioallantoic membrane (CAM). A multifaceted experimental
model, Mech. Dev. 141 (2016) 70–77. doi:10.1016/j.mod.2016.05.003.
[26] R. Swadi, G. Mather, B.L. Pizer, P.D. Losty, V. See, D. Moss, Optimising the chick chorioallantoic
membrane xenograft model of neuroblastoma for drug delivery, BMC Cancer. 18 (2018) 28.
doi:10.1186/s12885-017-3978-x.
[27] C.S. Kue, K.Y. Tan, M.L. Lam, H.B. Lee, Chick embryo chorioallantoic membrane (CAM): an
alternative predictive model in acute toxicological studies for anti-cancer drugs, Exp. Anim. 64
(2015) 129–138. doi:10.1538/expanim.14-0059.
[28] W.A. Sassen, R.W. Köster, A molecular toolbox for genetic manipulation of zebrafish, Adv.
Genomics Genet. (2015). doi:10.2147/AGG.S57585.
[29] C.A. MacRae, R.T. Peterson, Zebrafish as tools for drug discovery, Nat. Rev. Drug Discov. 14 (2015)
721–731. doi:10.1038/nrd4627.
[30] R. White, K. Rose, L. Zon, Zebrafish cancer: the state of the art and the path forward, Nat. Rev.
Cancer. 13 (2013) 624–636. doi:10.1038/nrc3589.
[31] G.J. Lieschke, P.D. Currie, Animal models of human disease: zebrafish swim into view, Nat. Rev.
Genet. 8 (2007) 353–367. doi:10.1038/nrg2091.
[32] L. Evensen, P.L. Johansen, G. Koster, K. Zhu, L. Herfindal, M. Speth, F. Fenaroli, J. Hildahl, S.
Bagherifam, C. Tulotta, L. Prasmickaite, G.M. Mælandsmo, E. Snaar-Jagalska, G. Griffiths,
Zebrafish as a model system for characterization of nanoparticles against cancer, Nanoscale. 8
(2016) 862–877. doi:10.1039/c5nr07289a.
[33] L.D. Mayer, L.C.L. Tai, D.S.C. Ko, D. Masin, R.S. Ginsberg, P.R. Cullis, M.B. Bally, Influence of Vesicle
Size, Lipid Composition, and Drug-to-Lipid Ratio on the Biological Activity of Liposomal
Doxorubicin in Mice, Cancer Res. 49 (1989) 5922–5930.
[34] M.C. Woodle, K.K. Matthay, M.S. Newman, J.E. Hidayat, L.R. Collins, C. Redemann, F.J. Martin, D.
Papahadjopoulos, Versatility in lipid compositions showing prolonged circulation with sterically
stabilized liposomes, Biochim. Biophys. Acta. 1105 (1992) 193–200.
[35] A.A. Gabizon, Y. Barenholz, M. Bialer, Prolongation of the Circulation Time of Doxorubicin
Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid:
Pharmacokinetic Studies in Rodents and Dogs, Pharm. Res. 10 (1993) 703–708.
doi:10.1023/A:1018907715905.
[36] C. Kirby, J. Clarke, G. Gregoriadis, Effect of the cholesterol content of small unilamellar liposomes
on their stability in vivo and in vitro, Biochem. J. 186 (1980) 591–598. doi:10.1042/bj1860591.
[37] C.D. Oja, S.C. Semple, A. Chonn, P.R. Cullis, Influence of dose on liposome clearance: critical role
of blood proteins, Biochim. Biophys. Acta BBA - Biomembr. 1281 (1996) 31–37.
doi:10.1016/0005-2736(96)00003-X.
[38] T.M. Allen, C.B. Hansen, D.E.L. de Menezes, Pharmacokinetics of long-circulating liposomes, Adv.
Drug Deliv. Rev. 16 (1995) 267–284. doi:10.1016/0169-409X(95)00029-7.
181
[39] S. Sieber, P. Grossen, J. Bussmann, F. Campbell, A. Kros, D. Witzigmann, J. Huwyler, Zebrafish as 
a Preclinical In Vivo Screening Model for Nanomedicines, Adv. Drug Deliv. Rev. (2019). 
doi:10.1016/j.addr.2019.01.001. 
[40] S. Sieber, P. Grossen, P. Uhl, P. Detampel, W. Mier, D. Witzigmann, J. Huwyler, Zebrafish as a 
predictive screening model to assess macrophage clearance of liposomes in vivo, Nanomedicine 
Nanotechnol. Biol. Med. (2019). doi:10.1016/j.nano.2018.11.017. 
[41] S. Sieber, P. Grossen, P. Detampel, S. Siegfried, D. Witzigmann, J. Huwyler, Zebrafish as an early 
stage screening tool to study the systemic circulation of nanoparticulate drug delivery systems 
in vivo, J Control Release. 264 (2017) 180–191. doi:10.1016/j.jconrel.2017.08.023. 
[42] F. Campbell, F.L. Bos, S. Sieber, G. Arias-Alpizar, B.E. Koch, J. Huwyler, A. Kros, J. Bussmann, 
Directing Nanoparticle Biodistribution Through Evasion and Exploitation of Stab2-Dependent 
Nanoparticle Uptake, ACS Nano. (2018). doi:10.1021/acsnano.7b06995. 
[43] S. Sieber, S. Siegrist, S. Schwarz, F. Porta, S.H. Schenk, J. Huwyler, Immobilization of Enzymes on 
PLGA Sub-Micrometer Particles by Crosslinked Layer-by-Layer Deposition, Macromol. Biosci. 17 
(2017). doi:10.1002/mabi.201700015. 
[44] T. Einfalt, D. Witzigmann, C. Edlinger, S. Sieber, R. Goers, A. Najer, M. Spulber, O. Onaca-Fischer, 
J. Huwyler, C.G. Palivan, Biomimetic artificial organelles with in vitro and in vivo activity triggered 
by reduction in microenvironment, Nat. Commun. 9 (2018) 1127. doi:10.1038/s41467-018-
03560-x. 
[45] H.H. Gustafson, D. Holt-Casper, D.W. Grainger, H. Ghandehari, Nanoparticle uptake: The 
phagocyte problem, Nano Today. 10 (2015) 487–510. doi:10.1016/j.nantod.2015.06.006. 
[46] M. Mahmoudi, N. Bertrand, H. Zope, O.C. Farokhzad, Emerging understanding of the protein 
corona at the nano-bio interfaces, Nano Today. 11 (2016) 817–832. 
doi:10.1016/j.nantod.2016.10.005. 
[47] C.D. Walkey, J.B. Olsen, H. Guo, A. Emili, W.C.W. Chan, Nanoparticle Size and Surface Chemistry 
Determine Serum Protein Adsorption and Macrophage Uptake, J. Am. Chem. Soc. 134 (2012) 
2139–2147. doi:10.1021/ja2084338. 
[48] M.C. Woodle, Sterically stabilized liposome therapeutics, Adv. Drug Deliv. Rev. 16 (1995) 249–
265. doi:10.1016/0169-409X(95)00028-6. 
[49] F. Ellett, L. Pase, J.W. Hayman, A. Andrianopoulos, G.J. Lieschke, mpeg1 promoter transgenes 
direct macrophage-lineage expression in zebrafish, Blood. 117 (2011) e49-56. 
doi:10.1182/blood-2010-10-314120. 
[50] S.A. MacParland, K.M. Tsoi, B. Ouyang, X.-Z. Ma, J. Manuel, A. Fawaz, M.A. Ostrowski, B.A. Alman, 
A. Zilman, W.C.W. Chan, I.D. McGilvray, Phenotype Determines Nanoparticle Uptake by Human 
Macrophages from Liver and Blood, ACS Nano. 11 (2017) 2428–2443. 
doi:10.1021/acsnano.6b06245. 
[51] M. Nguyen-Chi, B. Laplace-Builhe, J. Travnickova, P. Luz-Crawford, G. Tejedor, Q.T. Phan, I. 
Duroux-Richard, J.-P. Levraud, K. Kissa, G. Lutfalla, C. Jorgensen, F. Djouad, Identification of 
polarized macrophage subsets in zebrafish, ELife. 4 (2015) e07288. doi:10.7554/eLife.07288. 
[52] S. Schöttler, G. Becker, S. Winzen, T. Steinbach, K. Mohr, K. Landfester, V. Mailänder, F.R. Wurm, 
Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-
coated nanocarriers, Nat. Nanotechnol. 11 (2016) 372–377. doi:10.1038/nnano.2015.330. 
[53] L.K. Müller, J. Simon, C. Rosenauer, V. Mailänder, S. Morsbach, K. Landfester, The Transferability 
from Animal Models to Humans: Challenges Regarding Aggregation and Protein Corona 
Formation of Nanoparticles, Biomacromolecules. (2017). doi:10.1021/acs.biomac.7b01472. 
[54] C. Li, X.F. Tan, T.K. Lim, Q. Lin, Z. Gong, Comprehensive and quantitative proteomic analyses of 
zebrafish plasma reveals conserved protein profiles between genders and between zebrafish and 
human, Sci. Rep. 6 (2016) 24329. doi:10.1038/srep24329. 
[55] M. Hadjidemetriou, Z. Al-Ahmady, M. Mazza, R.F. Collins, K. Dawson, K. Kostarelos, In Vivo 
Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid 
Bilayer Nanoscale Vesicles, ACS Nano. 9 (2015) 8142–8156. doi:10.1021/acsnano.5b03300. 
182
[56] P. Laverman, M.G. Carstens, O.C. Boerman, E.T.M. Dams, W.J.G. Oyen, N. van Rooijen, F.H.M.
Corstens, G. Storm, Factors Affecting the Accelerated Blood Clearance of Polyethylene Glycol-
Liposomes upon Repeated Injection, J. Pharmacol. Exp. Ther. 298 (2001) 607–612.
[57] J. Szebeni, Complement activation-related pseudoallergy: A stress reaction in blood triggered by
nanomedicines and biologicals, Mol. Immunol. 61 (2014) 163–173.
doi:10.1016/j.molimm.2014.06.038.
[58] A.M. Cadena, S.M. Fortune, J.L. Flynn, Heterogeneity in tuberculosis, Nat. Rev. Immunol. 17
(2017) 691–702. doi:10.1038/nri.2017.69.
[59] J.R. Kurtz, J.A. Goggins, J.B. McLachlan, Salmonella infection: Interplay between the bacteria and
host immune system, Immunol. Lett. 190 (2017) 42–50. doi:10.1016/j.imlet.2017.07.006.
[60] J.A. Crump, M. Sjölund-Karlsson, M.A. Gordon, C.M. Parry, Epidemiology, Clinical Presentation,
Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive
Salmonella Infections, Clin. Microbiol. Rev. 28 (2015) 901–937. doi:10.1128/CMR.00002-15.
[61] R.S. Santos, C. Figueiredo, N.F. Azevedo, K. Braeckmans, S.C. De Smedt, Nanomaterials and
molecular transporters to overcome the bacterial envelope barrier: Towards advanced delivery
of antibiotics, Adv. Drug Deliv. Rev. (2017). doi:10.1016/j.addr.2017.12.010.
[62] M. Varas, A. Fariña, F. Díaz-Pascual, J. Ortíz-Severín, A.E. Marcoleta, M.L. Allende, C.A. Santiviago,
F.P. Chávez, Live-cell imaging of Salmonella Typhimurium interaction with zebrafish larvae after
injection and immersion delivery methods, J. Microbiol. Methods. 135 (2017) 20–25.
doi:10.1016/j.mimet.2017.01.020.
[63] S.-W. Jin, D. Beis, T. Mitchell, J.-N. Chen, D.Y.R. Stainier, Cellular and molecular analyses of
vascular tube and lumen formation in zebrafish, Development. 132 (2005) 5199–5209.
doi:10.1242/dev.02087.
[64] S.C. Semple, A. Chonn, P.R. Cullis, Influence of cholesterol on the association of plasma proteins
with liposomes, Biochemistry (Mosc.). 35 (1996) 2521–2525. doi:10.1021/bi950414i.
[65] E. Ellertsdóttir, A. Lenard, Y. Blum, A. Krudewig, L. Herwig, M. Affolter, H.-G. Belting, Vascular
morphogenesis in the zebrafish embryo, Dev. Biol. 341 (2010) 56–65.
doi:10.1016/j.ydbio.2009.10.035.
[66] L. Herwig, Y. Blum, A. Krudewig, E. Ellertsdottir, A. Lenard, H.-G. Belting, M. Affolter, Distinct
Cellular Mechanisms of Blood Vessel Fusion in the Zebrafish Embryo, Curr. Biol. 21 (2011) 1942–
1948. doi:10.1016/j.cub.2011.10.016.
[67] L. Aschoff, Das reticulo-endotheliale System, in: Ergeb. Inn. Med. Kinderheilkd., Springer, Berlin,
Heidelberg, 1924: pp. 1–118. doi:10.1007/978-3-642-90639-8_1.
[68] Y. Kawai, B. Smedsrød, K. Elvevold, K. Wake, Uptake of lithium carmine by sinusoidal endothelial
and Kupffer cells of the rat liver: new insights into the classical vital staining and the reticulo-
endothelial system, Cell Tissue Res. 292 (1998) 395–410. doi:10.1007/s004410051069.
[69] B. Zhou, J.A. Weigel, L. Fauss, P.H. Weigel, Identification of the Hyaluronan Receptor for
Endocytosis (HARE), J. Biol. Chem. 275 (2000) 37733–37741. doi:10.1074/jbc.M003030200.
[70] E.N. Harris, P.H. Weigel, The ligand-binding profile of HARE: hyaluronan and chondroitin sulfates
A, C, and D bind to overlapping sites distinct from the sites for heparin, acetylated low-density
lipoprotein, dermatan sulfate, and CS-E, Glycobiology. 18 (2008) 638–648.
doi:10.1093/glycob/cwn045.
[71] B. Yin, K.H.K. Li, L.W.C. Ho, C.K.W. Chan, C.H.J. Choi, Toward Understanding in Vivo Sequestration
of Nanoparticles at the Molecular Level, ACS Nano. (2018). doi:10.1021/acsnano.8b00141.
[72] E. Keles, Y. Song, D. Du, W.-J. Dong, Y. Lin, Recent progress in nanomaterials for gene delivery
applications, Biomater. Sci. 4 (2016) 1291–1309. doi:10.1039/C6BM00441E.
[73] H. Hatakeyama, H. Akita, H. Harashima, A multifunctional envelope type nano device (MEND) for
gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma,
Adv. Drug Deliv. Rev. 63 (2011) 152–160. doi:10.1016/j.addr.2010.09.001.
[74] P.R. Cullis, M.J. Hope, Lipid Nanoparticle Systems for Enabling Gene Therapies, Mol. Ther. 25
(2017) 1467–1475. doi:10.1016/j.ymthe.2017.03.013.
183
[75] B.S. Clark, M. Winter, A.R. Cohen, B.A. Link, Generation of Rab‐based transgenic lines for in vivo
studies of endosome biology in zebrafish, Dev. Dyn. 240 (2011) 2452–2465.
doi:10.1002/dvdy.22758.
[76] K. Ellis, J. Bagwell, M. Bagnat, Notochord vacuoles are lysosome-related organelles that function
in axis and spine morphogenesis, J Cell Biol. 200 (2013) 667–679. doi:10.1083/jcb.201212095.
[77] J. Silvent, A. Akiva, V. Brumfeld, N. Reznikov, K. Rechav, K. Yaniv, L. Addadi, S. Weiner, Zebrafish
skeleton development: High resolution micro-CT and FIB-SEM block surface serial imaging for
phenotype identification, PLOS ONE. 12 (2017) e0177731. doi:10.1371/journal.pone.0177731.
[78] N.L. Schieber, P. Machado, S.M. Markert, C. Stigloher, Y. Schwab, A.M. Steyer, Chapter 4 -
Minimal resin embedding of multicellular specimens for targeted FIB-SEM imaging, in: T. Müller-
Reichert, P. Verkade (Eds.), Methods Cell Biol., Academic Press, 2017: pp. 69–83.
doi:10.1016/bs.mcb.2017.03.005.
[79] D. Witzigmann, S. Sieber, F. Porta, P. Grossen, A. Bieri, N. Strelnikova, T. Pfohl, C. Prescianotto-
Baschong, J. Huwyler, Formation of lipid and polymer based gold nanohybrids using a
nanoreactor approach, 5 (2015) 74320–74328. doi:10.1039/C5RA13967H.
[80] N. Bertrand, J. Wu, X. Xu, N. Kamaly, O.C. Farokhzad, Cancer nanotechnology: The impact of
passive and active targeting in the era of modern cancer biology, Adv. Drug Deliv. Rev. 66 (2014)
2–25. doi:10.1016/j.addr.2013.11.009.
[81] J. Reineke, Terminology matters: There is no targeting, but retention, J. Controlled Release. 273
(2018) 180–183. doi:10.1016/j.jconrel.2018.01.016.
[82] D. Shan, J. Li, P. Cai, P. Prasad, F. Liu, A.M. Rauth, X.Y. Wu, RGD-conjugated solid lipid
nanoparticles inhibit adhesion and invasion of
α<Subscript>v</Subscript>β<Subscript>3</Subscript> integrin-overexpressing breast cancer
cells, Drug Deliv. Transl. Res. 5 (2015) 15–26. doi:10.1007/s13346-014-0210-2.
[83] J. Yang, Y. Shimada, R.C.L. Olsthoorn, B.E. Snaar-Jagalska, H.P. Spaink, A. Kros, Application of
Coiled Coil Peptides in Liposomal Anticancer Drug Delivery Using a Zebrafish Xenograft Model,
ACS Nano. 10 (2016) 7428–7435. doi:10.1021/acsnano.6b01410.
[84] K. Stoletov, V. Montel, R.D. Lester, S.L. Gonias, R. Klemke, High-resolution imaging of the dynamic
tumor cell vascular interface in transparent zebrafish, Proc. Natl. Acad. Sci. U. S. A. 104 (2007)
17406–17411. doi:10.1073/pnas.0703446104.
[85] S. Nicoli, M. Presta, The zebrafish/tumor xenograft angiogenesis assay, Nat. Protoc. 2 (2007)
2918–2923. doi:10.1038/nprot.2007.412.
[86] M. Gaumet, A. Vargas, R. Gurny, F. Delie, Nanoparticles for drug delivery: The need for precision
in reporting particle size parameters, Eur. J. Pharm. Biopharm. 69 (2008) 1–9.
doi:10.1016/j.ejpb.2007.08.001.
[87] R. Cao, A. Eriksson, H. Kubo, K. Alitalo, Y. Cao, J. Thyberg, Comparative Evaluation of FGF-2–,
VEGF-A–, and VEGF-C–Induced Angiogenesis, Lymphangiogenesis, Vascular Fenestrations, and
Permeability, Circ. Res. 94 (2004) 664–670. doi:10.1161/01.RES.0000118600.91698.BB.
[88] V.E. Bosio, G.A. Islan, Y.N. Martinez, N. Duran, G.R. Castro, Nanodevices for the immobilization
of therapeutic enzymes, Crit. Rev. Biotechnol. 36 (2016) 447–464.
doi:10.3109/07388551.2014.990414.
[89] R.J.R. W. Peters, I. Louzao, J.C.M. van Hest, From polymeric nanoreactors to artificial organelles,
Chem. Sci. 3 (2012) 335–342. doi:10.1039/C2SC00803C.
[90] T.M.S. Chang, Therapeutic applications of polymeric artificial cells, Nat. Rev. Drug Discov. 4 (2005)
221–235. doi:10.1038/nrd1659.
[91] Tanner Pascal, Egli Stefan, Balasubramanian Vimalkumar, Onaca Ozana, Palivan Cornelia G.,
Meier Wolfgang, Can polymeric vesicles that confine enzymatic reactions act as simplified
organelles?, FEBS Lett. 585 (2011) 1699–1706. doi:10.1016/j.febslet.2011.05.003.
[92] E. Le Moal, G. Juban, A.S. Bernard, T. Varga, C. Policar, B. Chazaud, R. Mounier, Macrophage-
derived superoxide production and antioxidant response following skeletal muscle injury, Free
Radic. Biol. Med. 120 (2018) 33–40. doi:10.1016/j.freeradbiomed.2018.02.024.
184
ACKNOWLEDGMENT 
I would like to begin with my doctoral advisor Prof. Dr. Jörg Huwyler. He always had time to answer 
my questions, was open for many project ideas, and was supportive far beyond what you can expect 
of a PhD supervisor. His enthusiasm for science was contagious and motivating which altogether 
turned my PhD more into a hobby than a profession. I am looking forward to my PostDoc in his lab 
tackling further scientific challenges together with him. 
I would like to thank Prof. Dr. Markus Affolter for his co-referee and for unselfishly sharing his 
zebrafish facility with our group. In this context I would also like to thank Dr. Heinz Georg Belting and 
the whole Fish Club for sharing their enormous knowledge and giving me inspiring insights into their 
research. 
I would like to thank the Stiftung zur Förderung des pharmazeutischen Nachwuchses in Basel and the 
Freiwilligen Akademischen Gesellschaft Basel (FAG) for their generous financial support of this PhD 
project. 
Furthermore, a great “thank you” goes to Prof. Dr. Alexander Kros, Dr. Jeroen Bussmann, and Dr. Fred 
Campbell and their whole group for welcoming me as a guest at the University of Leiden. Their 
hospitality allowed me to start my work with the zebrafish, which has been crucial for the further 
development of my PhD. 
I would like to thank all collaborators who contributed to any part of this thesis. In particular, I would 
like to thank my initial supervisor Dr. Fabiola Porta, my master students Stéphanie Schwarz and 
Salome Siegfried, Dr. Tomaz Einfalt, Prof. Dr. Cornelia G. Palivan, Dr. Pascal Detampel, Prof. Dr. 
Walter Mier, Dr. Philipp Uhl, Matthias Voigt, Prof. Dr. Mark Helm, Etienne Schmelzer, and Niels 
Schellinx. 
I would like to thank Dr. Dominik Witzigmann, who has always been a role model in and outside the 
lab. Already during my master thesis, he started supervising my projects which turned out to be a 
stroke of luck. He was always willing to share his enormous knowledge, and his passion for science 
185
motivated me to do this PhD. His guidance and experience resulted in many excellent publications and 
I am looking forward to further fruitful collaboration. I am sure and hope he will get rewarded for all 
he has done so far for many young scientists. I would also like to thank Dr. Philip Grossen and 
Dr. Stefan Siegrist, who have been in the lab during my whole PhD. Their open minds and willingness 
to collaborate created a great working environment. Furthermore, I really appreciated their mental 
support during all the usual up and downs and their shared enthusiasm for after work activities. 
I would like to thank Dr. Susanne Schenk for her honest and valuable scientific inputs and for always 
supporting me. Of course I would also like to thank the whole group of Pharmaceutical Technology for 
so much support and the great working environment which allowed me to enjoy being at work. It has 
been a pleasure to collaborate and/or talk about science and private stuff. A special thanks to my 
colleagues teaching the practical course of solid dosage forms for having so much fun together during 
practicals. I am looking forward to further occasions “abusing” the lab equipment. 
I would like to thank all my friends from home and Basel for always being there even if I did not always 
have a lot of time for them. I hope you know how much I appreciate each of you! I would especially 
like to thank my two roommates Selim and Ben with whom I have shared a flat for the past nine years. 
Their personal way of doing or seeing things differently often inspired me and helped me to relax in 
stressful situations. Thanks for the great time and the unforgettable moments! 
A great thank goes to my parents Hansjörg and Bea Sieber. They always supported me in what I have 
been doing and backed me up whenever I needed it. Without their steady support, it would not have 
been possible to pursue my dreams in such a lighthearted manner. Furthermore, I would like to thank 
Dario Sieber for not only being a brother but also a friend, which means a lot to me. 
Finally, I would like to thank my girlfriend Melanie Haag. She had to stand all my moods, flaws, and 
little “neuroses” to the greatest extend and did it with almost endless patience. I am extremely 
thankful for her tolerance and support during the whole time and for having her by my side. I am 
looking forward to many years to come. 
186
Sandro Sieber 
St.Alban-Anlage 19, 4052 Basel, Switzerland 
M: sandro.sieber@hotmail.de T: +41 79 946 75 74 
As a scientist and skydiver, I am fascinated by new challenges 
and used to perform in demanding situations. 
Professional Experience 
2014 - present Scientist, University of Basel 
 Implementing and validating the zebrafish experimental facility
in the group of Pharmaceutical Technology including evaluation
an acquisition of the required equipment
 Design and development of nanomaterial based drug delivery
systems including the optimization of manufacturing processes
with respect to up-scaling
 Organizing and guiding international collaborations with
academic and industrial partners (Universities of Mainz, Freiburg,
and Leiden, Hoffmann La-Roche)
 Publishing in peer-reviewed journals and presenting scientific
results at international conferences (e.g. CLINAM Basel, ILS/LRD
Athens)
 Active contribution to patenting processes and marketing of
generated intellectual property
 Supervising practical courses for bachelor students and
representing the university and the department at public events
(Maturandeninfotag, Masterinfoabend, Schülerbesuche)
07 2018 Visiting scientist, Mount Desert Island Biological Laboratory 
 Evaluating the killifish as a model for renal drug clearance
2016 - 2018 Member of the AVUBA association board 
 Representing PhD’s and Postdoc’s interests at the university
senate
 Negotiating new job descriptions for university assistants
08 2015 - 10 2015 Visiting scientist, University of Leiden 
 Acquiring technical and practical know-how working with zebrafish
05 2013 - 10 2013 Internship Manufacturing Science and Technology, Hoffmann-La Roche 
 Supporting the daily business of the GMP subunit in the
production of solid dosage forms focusing on cleaning
validation
 Identifying and weighing risk factors for cross contamination by
performing a Multi-Product Risk Assessment
 Troubleshooting of an in-process product loss by performing a
Root Cause Analysis
187
Trainings and Qualifications 
 
Software Microsoft Office, Stavex, Origin Pro, Adobe Illustrator, ImageJ, GIMP 
 
Languages German (native), English (C1/C2), French (A2/B1) 
 
Additional courses Project Management for new PhDs 
Leadership Basics 
LTK Module 20 Course in Laboratory Animal Science 
Creating Scientific Posters 
 
Education 
 
2014 - 2018 PhD Pharmaceutical Sciences, University of Basel 
 
2012 - 2014 Master of Pharmaceutical Sciences, University of Basel 
 
2009 - 2012 Bachelor of Pharmaceutical Sciences, University of Basel 
 
2004 - 2008 Matura with a major in economics and law, Kantonsschule Heerbrugg (SG) 
 
Honors and Awards 
 
Research Grant Grant supporting my PhD project (CHF 72’000) awarded by the  
 Stiftung zur Förderung des pharmazeutischen Nachwuchses in Basel 
 
Travel Grant Grant for staying at the University of Leiden (CHF 7’600) 
awarded by the Freiwilligen Akademischen Gesellschaft (FAG) Basel 
 
Cover Story Selected for the cover story of the Journal of Controlled  
 Release (October 2017) including an editorial by the editor in chief 
 
Invited Speaker Presenting our zebrafish model at the Leiden Cell Symposium 2018 
 
Presentation Award 3rd best Talk during the PhD Retreat 2016 
 
Activities and Interests 
 
Handball JS licensed U9 handball coach HBBB Binningen 
 
Skydiving 
  
188
Bibliography of Publications [1–9] 
 D. Witzigmann, S. Sieber, F. Porta, P. Grossen, A. Bieri, N. Strelnikova, T. Pfohl, C. Prescianotto-
Baschong, J. Huwyler, Formation of lipid and polymer based gold nanohybrids using a
nanoreactor approach, RSC Advances (2015)
 S. Sieber, S. Siegrist, S. Schwarz, F. Porta, S.H. Schenk, J. Huwyler, Immobilization of Enzymes
on PLGA Sub-Micrometer Particles by Crosslinked Layer-by-Layer Deposition, Macromol Biosci.
(2017)
 P. Grossen, D. Witzigmann, S. Sieber, J. Huwyler, PEG-PCL-based nanomedicines: A
biodegradable drug delivery system and its application, J Control Release. (2017)
 S. Sieber, P. Grossen, P. Detampel, S. Siegfried, D. Witzigmann, J. Huwyler, Zebrafish as an early
stage screening tool to study the systemic circulation of nanoparticulate drug delivery systems
in vivo, J Control Release. (2017)
 F. Campbell, F.L. Bos, S. Sieber, G. Arias-Alpizar, B.E. Koch, J. Huwyler, A. Kros, J. Bussmann,
Directing Nanoparticle Biodistribution through Evasion and Exploitation of Stab2-Dependent
Nanoparticle Uptake, ACS Nano  (2018)
 T. Einfalt, D. Witzigmann, C. Edlinger, S. Sieber, R. Goers, A. Najer, M. Spulber, O. Onaca-
Fischer, J. Huwyler, C.G. Palivan, Biomimetic artificial organelles with in vitro and in vivo
activity triggered by reduction in microenvironment, Nat Commun. (2018)
 S. Sieber, P. Grossen, J. Bussmann, F. Campbell, A. Kros, D. Witzigmann, J. Huwyler, Zebrafish
as a Preclinical In Vivo Screening Model for Nanomedicines, Advanced Drug Delivery Reviews
(2019)
 S. Sieber, P. Grossen, P. Uhl, P. Detampel, W. Mier, D. Witzigmann, J. Huwyler, Zebrafish as a
predictive screening model to assess macrophage clearance of liposomes in vivo,
Nanomedicine: Nanotechnology, Biology and Medicine (2019)
 M. Sedighi, S. Sieber, F. Rahimi, M.-A. Shahbazi, A.H. Rezayan, J. Huwyler, D. Witzigmann, Rapid
optimization of liposome characteristics using a combined microfluidics and design-of-
experiment approach, Drug Delivery and Translational Research (2019)
189
